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The emerging role of the multifunctional enzyme, Transglutaminase 2 (TG2) in Cystic 
Fibrosis (CF) has been linked to its increased expression and intracellular transamidating 
activity. However, a full understanding of the molecular mechanisms involved still remains 
unclear despite numerous studies that have attempted to delineate this process. These 
mechanisms include the NFκB and TGFβ1 pathway amongst others. This study reveals for 
the first time that the development of fibrosis in CF is due to a TG2-driven epithelial to 
mesenchymal transition (EMT) via a mechanism involving the activation of the pro-fibrotic 
cytokine TGFβ1. Using a human ΔF508/W1282X CFTR CF mutant bronchial cell (IB3-1), 
its CFTR corrected “add-back” cell (C38) as well as a primary human bronchial epithelial 
cell (HBEC), elevated TG2 levels in the CFTR mutant IB3 cell were shown to activate latent 
TGFβ1 leading to increased levels found in the culture medium. This activation process 
was blocked by the presence of cell-permeable and impermeable TG2 inhibitors while 
inhibition of TGFβ1 receptors blocked TG2 expression. This demonstrates the direct link 
between TG2 and TGFβ1 in CF. The presence of active cell surface TG2 correlated with an 
increase in the expression of EMT markers, associated with the CF mutant cells, which 
could be blocked by the presence of TG2 inhibitors. This was mimicked using the “add-
back” C38 cell and the primary human bronchial epithelial cell, HBEC, where an increase in 
TG2 expression and activity in the presence of TGFβ1 concurred with a change in cell 
morphology and an elevation in EMT marker expression. Conversely, a knockdown of TG2 
in the CF mutant IB3 cells illustrated that an inhibition of TG2 blocks the increase in EMT 
marker expression as well as causing an increase in TEER measurement. This together 
with an increase in the migration profile of the CF mutant IB3 cell against the “add-back” 
C38 cell suggests that TG2 drives a mesenchymal phenotype in CF. The involvement of 
TG2 activated TGFβ1 in CF was further demonstrated with an elevation/inhibition of p-
SMAD 2 and 3 activation in the presence of TGFβ1/TG2 cell-permeable/impermeable 
inhibitors respectively. The use of a comparative airway cell model where bronchial 
epithelial cells were cultured at the air liquid interface (ALI) confirmed the observations in 
submerged culture depicting the robustness of the model and reiterated the importance of 
TG2 in CF. Using a CFTR corrector combined with TG2 inhibitors, this study showed that 
the correction and stabilisation of the ΔF508 CFTR mutation in the mutant cell forged an 
increase in matured CFTR copies trafficking to the apical surface by circumventing 
proteosomal degradation. Thus the results presented here suggests that TG2 expression is 
elevated in the CFTR mutant bronchial cell via a TGFβ1 driven positive feedback cycle 
whereby activation of latent TGFβ1 by TG2 leads in turn to an elevation in its own 
expression by TGFβ1. This vicious cycle then drives EMT in CF ultimately leading to lung 
remodelling and fibrosis. Importantly, TG2 inhibition blocks TGFβ1 activation leading to an 
inhibition of EMT and further blocks the emerging fibrosis, thus stabilizing and supporting 
the maturation, trafficking and conductance of CFTR channels at the apical surface.  
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1.1 INTRODUCTION 
!
Transglutaminases, (EC 2.3.2.13: TGases), are a group of enzymes that are 
structurally related and responsible for the post-translational modification of proteins 
(Iismaa et al., 2009). These enzymes are implicated in the crosslinking of proteins 
involving an acyl transfer reaction between the γ-carboxamide chain of glutamine and 
the ε-amino chain of lysine or any primary amino group of a polyamine serving as the 
acyl acceptor and if the primary amine is that from a peptide bound lysine, Nε (γ-
glutamyl) lysine bonds are formed (Greenberg et al., 1991, Folk and Finlayson, 1977, 
Griffin et al., 2002). The reaction is Ca2+-dependent as the binding of Ca2+ -reconfigures 
TGases from a quiescent, closed conformation into an open conformation, which 
exposes the active catalytic site to its substrates (Bergamini, 1988, Bergamini and 
Signorini, 1993, Tanfani et al., 1993). Paradoxically one particular TGase, tissue 
transglutaminase (TG2) is also involved in Ca2+ independent reactions, where the 
structure is maintained in a closed conformation by GTP/GDP, blocking its crosslinking 
activity but acting as a high molecular weight GTP binding protein and GTPase (Lee et 
al., 1993). In the case of TG2, its transamidating activity is synonymous with the 
prevailing environment since low levels of Ca2+ intracellularly maintains its GTPase 
functions whereas extracellularly as Ca2+ levels increase, extracellular TG2 and Factor 
XIII assume either a transamidation or a cell adhesion related function (Belkin, 2011, 
Komaromi et al., 2011, Wang et al., 2010). 
 
 
Cystic Fibrosis (CF) is an autosomal recessive inherited disease which is characterized 
by abnormal chloride secretion due to a defect in the gene encoding the chloride 
channel, the Cystic Fibrosis Transmembrane Regulator Conductance (CFTR) gene 
(Riordan et al., 1989). There are over 1900 mutations recognised with defects varying 
from an absolute loss of the synthesis of the channel, defective processing, defective 
regulation of the channels to partial processing and production defects 
(Vankeerberghen et al., 2002, Bobadilla et al., 2002). Mutations associated with 
defective processing have been linked to the deletion of phenylalanine at position 508 
(ΔF508), which has been discovered to be the most predominant mutation in the world 
accounting for more than 70% of mutations (Dalemans et al., 1991, Lukacs et al., 
1993). However, studies have shown variations in the phenotypic expression of 
heterozygous and homozygous mutations of ΔF508 (Shoshani et al., 1992, 1993)( 
Anon., 1993). 
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Recent studies have centred on TG2 due to its pleiotropic and ubiquitous nature and 
the role it plays in the pathogenesis of certain diseases with underlying fibrosis, where 
via its crosslinking activity, it can directly increase the deposition of matrix proteins like 
collagen and fibronectin making them resistant to proteolysis (Verderio et al.,2004, 
Verderio et al., 2005; Collighan and Griffin, 2009). Under pathological conditions when 
intracellular Ca2+ is raised, TG2 can also activate NFKB by a non-canonical pathway 
(Mirza et al., 1997, Kim et al., 2006).  In addition, activation of latent TGFβ1 has been 
linked to TG2 and in turn to the progression of fibrosis which is associated with the 
activation of the latent cytokine in the extracellular matrix (ECM) (Sheppard, 2006b, 
Johnson et al., 2007, Nunes et al., 1997). Along with some other TGases, TG2 exhibits 
diverse roles in the pathology of neurodegenerative diseases (Kim et al., 1999), 
inflammatory diseases, cardiac and kidney disease and neoplasms, either directly by 
covalently crosslinking proteins or indirectly by activation of pro-inflammatory cytokines 
eg TGFβ1. 
 
Consequently, this study will attempt to understand the link between TG2 and cystic 
fibrosis (CF). It correlates the induction of the fibrotic cascade involving the 
dysfunctional changes caused by the mutated CFTR chloride channel which causes 
loss of epithelial cell integrity to the expression and activity of TG2 and its partner 
proteins ultimately leading to the proposal of a mechanism by which TG2 is involved in 
the EMT process. 
 
1.2   TRANSGLUTAMINASES (TGases) 
1.2.1   Functional domains of TGases  
 
Currently, 9 mammalian TGases have been characterised as shown in table 1. All the 
enzymes have 4 domains: an amino N-β sandwich terminal, a Tryptophan-Cysteine-
Histidine-Aspartate catalytic centre and two carboxylic acid C-β barrel domains (Iismaa 
et al., 2009). 
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Table 1.1: Different Transglutaminases and their function (adapted from 
Griffin et al., 2002) 
Transglutaminases Synonyms Function 
Transglutaminase 1 Keratinocyte TGase, TG1 Differentiation of 
keratinocytes 
Transglutaminase 2 Tissue TGase, TG2 Cell differentiation, cell 
adhesion, cell death 
Transglutaminase 3 Epidermal TGase, TG3 Cell envelope formation  
Transglutaminase 4 Prostate TGase, TG4 Spermatogenesis 
Transglutaminase 5 TGase X Epidermal differentiation 
Transglutaminase 6 TGase Y      - 
Transglutaminase 7 Tgase Z     - 
Plasma 
Transglutaminase 
FX IIIa Wound healing and blood 
clotting 
Protein 4.2 Erythrocyte Protein Band 4.2 Inactive TGase (loss of 
Cysteine at catalytic site) 
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Figure 1.1: Ribbon diagrams of TG structure and linear domain configuration. A1. 
Ribbon diagram of GTP bound, closed inactive conformation showing amino, N (blue), 
and carboxylic, C (yellow and red), domains (arrow indicates GTP binding site). A2 
Ribbon diagram of TG2 inhibitor bound open conformation. B showing the 4 domains 
of the protein (βS, core and barrel 1&2) with the exons encoding the different domains 
indicated underneath. The active site (green), shown to carry the catalytic triad; 
Cysteine (Cys), Histidine (His) and Aspartate (Asp) with a conserved Tryptophan (Trp), 
that stabilizes the transition state. FXIII and TG1 have 15 exons and 14 introns with 
exon 1 and 2 been non-coding and amino terminal pro-peptide respectively while TG2-
7 and Erythrocyte Protein 4.2 have 13 exons and 12 introns with exon 10 and 11 
separated by one intron. Dotted lines represent the exons encoding the different 
structural domains of protein (Iismaa et al., 2009). 
A1#
B#
A2#
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The thrombin activated form of plasma transglutaminase, Factor XIII (Factor XIIIa) and 
TG1 have in addition to the thirteen exons and twelve introns present in the other 
TGases, two exons; a non coding exon one and exon two that codes for the transitional 
N- terminal pro-peptide which is cleaved on activation of the TGases. As indicated from 
Figure 1.1 above, TGases 2-7 and Band 4.2 protein do not have the intron present 
between exon 10 and eleven as found in Factor XIIIa and TG1.The presence of the 
catalytic triad, Cysteine, Histidine and Aspartate represent the core of the catalytic 
activity of the enzyme, however, the presence of tryptophan helps to stabilise the 
transition state (Iismaa, 2003). 
Although, the activity at the catalytic core revolves around the four domains on the 
catalytic core, studies have shown that this is the region conserved within different 
TGases (FXIIIa, TG1 &2) with minor differences in TG3 (Kim, 2001). For TG2, the four 
domains span amino acids 1-687, with the domains having amino acids from 1-139 
(1st), 140-454 (2nd) (Small et al.1999), 479-585 (3rd) and 586-687(4th) respectively 
(Casadio et al., 1999). Using TG2 constructs generated with a domain deleting 
approach, Iismaa et al., (1997), showed that domains one and two were essential for 
the transamidating activity of TGases, the initial 47 residues of domain two are 
responsible for the GTPase and ATPase activity and domain four aids in maintaining 
the integrity of the active GTPase conformation (Monsonego et al., 1998).  
Domain one has been shown to contain 7 of the 10 short β-structures, having β1 as the 
isolated strand, tightly packed anti-parallel β2-6 strand interacting with a β-sandwich 
motif and leaving at the lower β-sandwich end, a short β7 strand that interacts with the 
β1 strand (Griffin et al., 2002). Domain two contains peptide chains running along its 
surface, upwards and downwards, β-strands β8 and 9 contain the amino acid residues 
Ser171 and Lys173 which embeds the GTPase activity. Domain two also has an 
additional β-strand β10-13 as well as four α-helices, with three of these arranged 
triangularly in the direction of the active site, Cys277, His335 and Asp358 and the last α-
helix sheltering the amino acids (Ser449, Glu451 and Glu452) involved in Ca2+ binding 
(Griffin et al., 2002). The residues in the active site harbouring amino acids 454-478, 
importantly are functionally involved in the TGase activity of the enzyme as they 
essentially remain exposed to substrates, however, this active site residue has different 
functions in other TGases (TG1, TG3 and FXIII). The double barrel C-domains three 
and four have β-anti-parallel strands with domain three having six β-barrels and one β- 
barrel turn and domain four having seven anti-parallel β-strands that have been shown 
to control both GTPase and ATPase activity (Lai et al., 1996). 
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1.2.2   Mechanism of activity of TGases 
 
Transglutaminases have been shown to be involved in the post-translational 
modification of proteins either by covalently crosslinking them via a transamidation 
reaction or by their esterification and/or hydrolysis. The crosslinking reaction involves 
the formation of an acyl enzyme intermediate, glutamyl thioester, which is a product of 
the interaction between the active site cysteine (Cys277 for TG2) with an acyl acceptor 
protein containing glutamine and release of ammonia as a by product. 
!
 
Figure 1.2: Schematic representation of TGase catalysed reaction. Calcium 
stabilised Transglutaminase 2 (TG2; green circle) is involved in the catalysis of 
glutamine side chain of a protein using its active thiol group (SH), which forms an 
intermediate thiolester (middle figure). This subsequently reacts either with a primary 
amine substrate (R-NH2) to transfer the acyl side chain (transamidation) to form a 
simple amine isopeptidyl adduct or a ε-(γ-glutamyl lysine) protein (transamidated 
protein) or unfavourably with water where it undergoes a deamidation/hydrolysis 
reaction where the glutamine is converted to a glutamic acid (adapted from Pinkas et 
al., 2007)  
 
Although, the conformation of TGases is conserved amongst them, two different 
conformations, open and close conformation, which delineates the functional roles for 
some of the family members (Collighan and Griffin, 2009). The intracellular milieu 
supports a low Ca2+ concentration (100-200nM) and high GTP (50-300µM) which 
studies have shown supports a compact TG2 conformation of which the core catalytic 
site is not exposed and the enzyme is normally inactive (Greenberg et al., 1991). The 
conformational change observed with TG2 as shown by Pinkas et al. (2007), indicates 
that, although intracellularly TG2 exists in a GTP bound form, when secreted to the 
extracellular environment (Gaudry et al., 1999b) through an unknown mechanism, 
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because of the increase in calcium, the enzyme changes its conformation and 
assumes an open conformation that exposes the active catalytic core to its substrates. 
In addition to TG2’s intracellular and GTPase activity (Mian et al., 1995), it may also 
have protein disulfide isomerase activity (Hasegawa et al., 2003).  
 
1.2.3   Different Types of TGases 
!
Currently, there are 9 different types of TGases that have been characterised: TG1-7, 
Factor XIIIa and the inactive TGase, protein band 4.2. As earlier mentioned, all the 
TGases share a similar homology in terms of conformation and domains which is 
conserved from species to species with slight variations in functionality of enzyme, 
even band 4.2 found in red blood cells has 37-51% homology with other TGases 
(Candi et al., 1998; Casadio et al., 1999; Noguochi et al., 2001; IIsmaa et al., 2009). 
Whilst, the catalytic site of TG have the Cys-His-Asp triad which requires Ca2+ ions for 
enzymatic activity, band 4.2 has an Ala-His-Arg triad which accounts for its loss of 
activity due to an exchange of alanine for cysteine (Carsadio et al., 1999; Korsgren et 
al., 1990). Greenberg et al. (1991) described the structural homology existing between 
TGase active sites and the calcium binding site, hypothesising that different substrates 
would aid in identifying different TGases.  
 
1.2.3.1    Factor XIII (Plasma Transglutaminase) 
!
The tetramer exists either as an intracellular cytoplasmic or extracellular plasma Factor 
XIII zymogen, with two subunits; A2B2 subunits, however the B2 subunit does not exist 
for cellular Factor XIII. Plasma FXIII has an A2 subunit, which is an 83kDa active 
transglutaminase subunit coded for by the FXIIIA gene on chromosome 6p 24-25 and 
the B2 80kDa regulatory subunit coded for by the FXIIIB gene on 1q 31-32.1, which is 
the carrier of the A2 subunit (Iismaa et al., 2009). The activation of the zymogen 
associated with blood coagulation is orchestrated by thrombin, which converts FXIII to 
its active form. In the presence of calcium and fibronectin, FXIII activity forms ε-(γ-
glutamyl) lysine bonds between fibronectin monomers ultimately leading to the 
formation of stabilised clots (Ichinose and Davie, 1988). Furthermore, the central role 
FXIII plays in wound healing involves platelet activation and laying down of granulation 
tissues which marks the beginning of tissue adhesion (Griffin et al., 2002). 
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Studies have shown that, in patients with fibrosing alveolitis and wheezy bronchitis, 
activated FXIIIa is present in bronchoalveolar lavage liquid (BALF). This has been 
linked to increased capillary permeability, favouring increased plasma leakage. These 
conditions have been associated with chronic inflammation where FXIII A2 is up 
regulated four to five times and alveolar macrophages have been put forward as a 
possible source of the enzyme (Katona et al., 2005). 
 
1.2.3.2   Transglutaminase 1 (Keratinocyte transglutaminase) 
!
Transglutaminase 1,TG1, is a membrane bound and soluble transglutaminase which is 
involved in the terminal differentiation of the cornified envelope (CE) in keratinocytes 
(Sturniolo et al., 2005). Like FXIII, TG1 exists as a zymogen, (106 kDa) and 
subsequently becomes activated during terminal differentiation of keratinocytes to form 
the CE (Iismaa et al., 2009). The cleaved membrane bound form of TG1 is embedded 
in the plasma membrane by myristic and/or palmitic fatty acid side chains (Eckert, 
1989). In this form, it is found distributed between proliferating and differentiating cells. 
The active form of the enzyme is a complex of 67/33/10kDa, which has been 
associated with the activity of TG1 (Hiiragi et al., 1999). The expression of TG1 has 
also been found in cell-cell adheren junctions in lung, liver and kidney epithelial cells 
where it has been shown to co localize with E-Cadherin and zonula occludens, which 
are markers of cell-cell adheren junctions (Hiiragi et al., 1999).  
Using immunohistochemistry, IHC, Martinet et al. (2003) showed that all cell types 
found in normal airway epithelium expressed TG1 except basal cells, which are 
regulated by extrinsic and intrinsic factors like growth factors, hormones and 
extracellular mediators (Eckert, 1989, Martinet, 2003). In TGase 1 null mice, it was 
observed that the anomalous skin function phenotype caused by the distortion of the 
keratinization process showed the importance of TG1 in epidermal development and 
the non compensatory role of TG2 and TG3 as mice died due to dehydration (Martinet, 
2003). In concert, Eckert et al. (1989) suggested that TG1 levels increase as cells 
differentiate from the basal layer. High extracellular calcium has been shown to be 
important for the activation of TG1 as concentrations less than 1.2mM supported 
proliferation and concentrations above that initiated the formation of stratified layers 
and expression of differentiation markers (Eckert, 1989). As the level of calcium influx 
into the cell increases, it orchestrates the terminal crosslinking of involucrin by TG1, 
which is a soluble constituent of CE. The disruption of this process leads to the 
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introduction of an abnormality which may be linked to the cause of epithelial related 
diseases like cancers, hyper proliferative diseases and viral infections (Eckert, 1989). 
 
1.2.3.3   Transglutaminase 3 
 
Transglutaminase 3, TG3, exists as a zymogen, which undergoes proteolytic activation 
into its active complex of 50/27 kDa transglutaminase. Its 77kDa inactive form 
undergoes cathepsin L mediated activation to form the active form found expressed in 
the inner root sheath (IRS) of the hair canal (Shah et al.1999) and the distal end of the 
outer root sheath (Thibaut et al., 2008, Iismaa et al., 2009). TG3 has been shown to be 
responsible for the crosslinking of trichohyalin and keratin intermediate filaments, 
which are the proteins that make up the structure of the hair follicle, giving the hair 
tensile strength and shape (Lee et al., 1996). 
 
Studies have been performed to determine the activity of TG3 and using 
monodansylcadaverine incorporation, activity was found to be confined to the IRS and 
hair shaft (Thibaut et al., 2008). The role of TG3 was however concluded to be 
embedded in the hair shaft where it is responsible for scaffolding which serves a 
protective function. 
 
1.2.3.4   Transglutaminase 4 
 
Transglutaminase 4, prostate transglutaminase, TG4, is a 77kDa protein, which has 
684 amino acids. TG4 enzyme expression has been limited to the prostate where it is 
stimulated by androgens (Dubbink et al., 1996). Not until recently, expression was 
limited to rodents where it has been shown that the enzyme is implicated in the female 
reproductive tract as a copulatory plug after intercourse and as a protective regulator of 
the immune system preventing against the destruction of sperms as antigens in the 
female reproductive system (Cho et al., 2010). The dorsal prostate protein, DP1, which 
makes up 25% of the dorsal rat prostate and coagulating gland, has 53% similarity to 
human TGase. Dot blots for DP-1 have been used to show that the expression is 
limited to the rat prostate (Dubbink et al., 1998). However, Northern blot analysis of 
different human tissues did not reveal TG4 expression (Dubbink et al., 1996). 
 
Although, there has not been a link to TG4 activity in human semen (Lilja and Laurell, 
1985), TG4 has been implicated to be active in seminal plasma (Porta et al., 1986). For 
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example castrated infertile male guinea pig with extended seminal liquefaction as 
shown by immunohistochemical staining (Seitz et al., 1990) and masked antigenicity of 
sperms in the female reproductive system thus modifying its maturation process (Cho 
et al., 2010). 
 
1.2.3.5   Transglutaminase 5 
 
Analogous to TG1 and TG3, TG5, is an 81kDa protein, which stands as the most 
recently discovered and uncharacterised TGase. Activation of TG5 has been 
associated with terminal differentiation of the cornified cell envelope (CE) and hair 
follicle (Candi et al., 2001). In keratinocytes, TG5 has been found to be deposited in 
the cytosol and localized perinuclearly (Candi et al., 2001). In relation to Epithelial - 
Mesenchymal Transition (EMT), TG5 has been found to co-localise with the vimentin 
intracellular filament network in fibroblasts where vimentin serves as an acyl donor 
substrate (Candi et al., 2001, Iismaa et al., 2009). 
!
1.2.3.6   Transglutaminase 2 (TG2) 
 
Tissue transglutaminase, TG2, is a ubiquitous transglutaminase enzyme found 
distributed in various cells in vivo and in vitro where it has been shown to be involved in 
both calcium-dependent and independent activity (Greenberg et al., 1991). The 
enzyme was originally discovered in liver (and thus referred to as Liver 
transglutaminases) but its distribution in many other tissues has implicated its role in 
the pathogenesis of many diseases (Piacentini et al., 1991, Mirza et al., 1997, Small et 
al., 1999, Griffin et al., 1979). As an enzyme, TG2 has been suggested to play roles in 
cell differentiation, cell survival, acting via receptors in endocytosis, apoptosis and 
tumour metastasis (Fesus et al., 1989, Aeschlimann et al., 1993, Johnson et al., 1994). 
However, extracellularly, TG2 has been shown to play a vital role in cell adhesion and 
maintenance of the extracellular matrix (Martinez et al., 1994). 
 
Intracellularly, transglutaminases are normally inactive due to the low levels of Ca2+ 
and increased GTP binding which maintains the closed inactive conformation 
(Bergamini and Signorini, 1993, Bergamini, 1988, Tanfani et al., 1993, Iismaa et al., 
2009). However, following trafficking and secretion into the extracellular matrix by an 
undefined mechanism, TG2 assumes an open active conformation. Kawai et al. (2008) 
suggested cell damage as a method of TG2 externalisation in response to membrane 
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repair. Increased Ca2+ levels open up the compact state of TG2. This then exposes the 
catalytic site rendering it active and exposes it to protein substrates, which becomes 
modified. Wang et al. (2012) demonstrated using stably transfected Swiss 3T3 cells 
under the control of a tet-inducible promoter that syndecan shedding was involved in 
the rapid translocation of TG2 into the ECM.  However, binding to fibronectin and 
subsequent oxidation of the active site thiol can render the catalytic transamidation site 
inactive. In this state, the enzyme acts as a cell adhesion protein via its binding to 
fibronectin, integrins β1, β3, β5 and the heparan sulphate receptor, syndecan 4 and the 
G-protein coupled cell adhesion receptor GPR56 (Iismaa et al., 2009, Verderio et al., 
2003, Telci et al., 2008, Wang et al., 2010). This adhesion property is independent of 
the transamidating property of TG2. 
 
TG2 is essentially located intracellularly within the cytosol, plasma membrane or 
nucleus, although it is found extracellularly within the extracellular matrix. Studies have 
shown that TG2 possesses no ER/Golgi signalling tags which has been attributed to an 
unglycosylated enzyme even though it might have glycosylation sites (Folk and 
Finlayson, 1977). 
 
Studies by Griffin et al. (1979), showed that pulmonary fibrosis induced in rats by 
paraquat treatment could be attributed to a protein found in the "nuclear/membrane 
pellet" which was suggested to be membrane bound transglutaminase. In parallel, TG2 
has been implicated in scarring in liver, lungs and kidney, of which in the latter, TG2 
has been extensively studied where it has been shown to be a major player in the 
pathogenesis of Chronic Kidney Disease (CKD). Here, TG2’s externalisation and 
crosslinking of ECM matrix in the presence of high calcium concentration, prevents 
ECM degradation by matrix metalloproteinases (MMP) (Johnson et al., 1999, Johnson 
et al., 2007). Paradoxically, intracellular TG2 activated by changes in intracellular 
milieu in traumatised cells leads to an increase in calcium concentration ultimately 
leading to rapid cell death as a means of averting cell necrosis and cell disruption 
(Verderio et al., 1998).  
 
1.3 TRANSGLUTAMINASE 2 AND ASSOCIATED 
PATHOLOGIES 
 
In a review of the involvement of TGases in chronic diseases, much attention has been 
focused on the role the enzyme plays in wound healing and inflammatory diseases 
such as fibrosis and autoimmune diseases, degenerative diseases and 
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neurodegenerative diseases e.g. Alzheimer’s, Parkinson’s, arthritis, atherosclerosis 
and neoplasms. A myriad of TGases function by reinstating the integrity of the tissue 
during wound healing. Notably, FXIIIa, which, by crosslinking fibronectin and activating 
platelets, orchestrates the wound healing process and lays down the tissues essential 
for repair. TG2 chiefly has been implicated in inflammatory conditions like fibrosis (liver, 
kidney and lung) and cirrhosis (liver) where the enzyme has been suggested to 
crosslink proteins in the matrix due to enhanced expression as a result of progressive 
deterioration from fibrogenesis to fibrosis (Richards et al., 1991). This in turn might be 
linked to the concomitant dedifferentiation of precursor epithelial or other cells. Also 
cytokines, growth factors and chronic stress have been shown to regulate the 
expression of TG2 in inflammation (Iismaa et al., 2009, Johnson et al., 1999, Richards 
et al., 1991). In the liver, TNF-α induces the activation of Inhibitor of κB kinase (IκK). 
This in turn phosphorylates IκB (IκBα and IκBβ), which unblocks sequestered NFκB 
and uncovers the nuclear localisation signal (NLS) of NFκB. This phosphorylation 
allows the dissociation and translocation of NFκB into the nucleus and the activation of 
various genes including TG2 which has a binding motif for NFκB on its promoter site 
(Kuncio et al., 1998). In addition, TGFβ1 is up regulated in inflammation where TG2 is 
thought to cross link the large latent TGFβ1 binding protein (LTBP1) to extracellular 
matrix proteins i.e. fibronectin and collagen leading to the subsequent activation of 
TGFβ1. This together with matrix crosslinking by the enzyme leads to increased 
deposition and stabilisation of matrix proteins (Verderio et al., 1999, Nunes et al., 1997, 
Griffin et al., 2002). TG2 expression is elevated in diseases such as arthritis and 
certain neurodegenerative diseases like Parkinson’s and Alzheimer’s disease, which 
are characterised by increased mineralization at diseased joints or deposition of 
insoluble protein plaques respectively (Johnson et al., 1997a, Plenz et al., 1996). Other 
diseases in which TG2 has been implicated include coeliac disease, type 1 diabetes 
and Sjögren’s syndrome (Villalta et al., 2002, Seissler et al., 1999, Arentz-Hansen et 
al., 2000) and recently CF (Maiuri et al., 2008). 
 
 
1.4   CYSTIC FIBROSIS (CF) 
 
CF is an autosomal recessive disease characterized by a defective chloride channel, 
which is coded by a 230kb gene found on chromosome 7. The CFTR gene encodes 
the 1480 amino acid polypeptide, the cystic fibrosis transmembrane conductance 
regulator (CFTR)(Rommens et al., 1989; Riordan et al., 1989; Kerem et al., 1989). The 
channel functions as a cAMP regulated chloride channel found apically in many 
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epithelial cells including sweat glands, salivary glands, pancreas, vas deferens in 
males and airway epithelium. Anderson first made the description of the salty skin in 
children with CF in 1938 and this led to the first description of the disease as "Cystic 
Fibrosis” (Anderson, 1938). Studies thereafter showed that the disease was 
characterized by high salt content in sweat due to abnormal reabsorption of chloride 
ions (Di sant Agnese et al., 1953). Notable symptoms of the disease include high salt 
content in sweat, nasal polyps, infertility in men and reduced fertility in women, liver 
disease, diabetes and chronic sinusitis (Bombieri et al., 2011, Mak et al., 2000, 
Zielenski, 2000). 
 
The disease is rare affecting 70,000 worldwide with over 1900 mutations defined 
(Bobadilla, 2002, Sparbel and Tluczek, 2011) and defects vary from an absolute loss of 
synthesis of channel, defective processing, defective regulation of ion channels to 
partial processing, defective conductance, defective regulation of affiliated channels 
and production defects (Vankeerberghen et al., 2002). Typically, pancreatic 
insufficiency is associated with the first three classes of defects (section 1.4.1), which 
accounts for the highest incidence of CF defects. The other classes have a lower 
incidence of pancreatic insufficiency (Ratjen and Doring, 2003). 
 
Bobadilla et al. (2002) studied the variation of CFTR mutation worldwide and 
concluded that there was a wide heterogeneity to CFTR gene mutations but the 
mutation at position 508 on the gene correlated with a high incidence of the disease. 
This mutation, ΔF508, accounts for 70% of the disease occurrence involves the 
deletion of 3 base pairs at position 508 coding for phenylalanine. It is associated with 
defective processing, defectively glycosylated CFTR is translated but loses its 
resistance to degradation proteases. Hence, it is ultimately tagged for ubiquination in 
the cytosol (Jilling and Kirk, 1997). However, there are other mutations, one is 
characterised by a substitution of G for A at position 3978 on the base pairs of exon 20 
of CFTR causing tryptophan to become a stop codon at position 1282 (W1282X) 
(Shoshani et al., 1992). Kerem et al. (1990) showed that patients homozygous for the 
W1282X mutation showed the same disease severity to that heterozygous for ∆F508 
/W1282X. This phenotype, which occurs mainly as a heterozygote, ∆F508 /W1282X, 
was shown to be associated with increased CFTR degradation in the ER due to rapid 
misfolding of the ∆F508 protein and such that 99% of the channel is lost with very little 
getting apically expressed (Vankeerberghen et al., 2002). Interestingly, studies have 
shown that the expression of CFTR is tissue specific for homozygous ∆F508 and 
expression of the ∆F508 mutation in respiratory tract and intestinal tissue was the 
same as that found in non-CF wild type cells (Kalin et al., 1999). 
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1.4.1 Classes of CFTR mutation  
 
The mutational defect on the CFTR gene has been classified into 6 different classes 
according to the dysfunctional effect of the mutation on CFTR.  They are:  
! Class I: Defective protein synthesis 
! Class II: Defective protein processing 
! Class III: Defective protein regulation  
! Class IV: Defective or altered protein conductance 
! Class V: Reduced CFTR level 
! Class VI: Reduce CFTR stability 
 
1.4.1.1    Class I: Defective protein synthesis 
!
Mutations of this type are characterized by premature termination codons (PTCs) due 
to frameshifts and nonsense codons. This introduces an interference ultimately leading 
to the formation of truncated proteins with diminished mRNA half-lives which impedes 
protein synthesis due to nonsense-mediated RNA decay (NMRD) (Frischmeyer and 
Dietz, 1999). One of the foremost-discovered mutations belonging to this class is the 
W1282X mutation which involves a change in the nucleotide G−A at position 3978, 
which introduces a tryptophan stop codon at position 1282 (Shoshani et al., 1992). This 
imparts on the severity of the disease as mutations of this class produce deleterious 
phenotypes. The use of the aminoglycoside antibiotic, gentamicin has been shown to 
aid with the read-through of PTCs in CF cells with an expression of full length CFTR in 
patients administered intranasal gentamicin (Wilschanski et al., 2003). Similarly, using 
the orally bioactive molecule, Ataluren (PTC124), studies have shown that in patients 
with at least one nonsense mutation, PTC124 alleviates electrophysiological 
aberrations associated with CFTR mutations (Kerem et al., 2008, Wilschanski et al., 
2011).
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1.4.1.2    Class II: Defective protein processing 
   
Under normal physiological conditions, CFTR protein undergoes a series of post-
translational modifications in the endoplasmic reticulum (ER) and the Golgi where the 
protein becomes glycosylated and is folded with the aid of chaperone proteins 
supporting its trafficking to the apical membrane. This process is impaired in class II 
mutations with processing defects. Hence CFTR proteins are susceptible to an 
abnormally high (>99%) early degradation by ER-associated protein degradation 
(ERAD) systems (Ward et al., 1995). The ΔF508 mutation is the most common class II 
mutation, characterised by the deletion of phenylalanine on position 508 of the gene 
(Riordan et al., 1989). However, aside from the premature degradation the protein 
undergoes by ERAD, the minute amount of protein that gets to the plasma membrane 
post-Golgi further undergoes exocytosis where abnormal recycling reduces the copies 
of the channel on the apical membrane (Sharma et al., 2004). Studies have shown that 
the ΔF508 mutation is found on the nuclear binding domain 1 (NBD-1) of the protein 
(Thomas et al., 1991). Recent studies have shown that in the presence of “CFTR 
correctors”, conformational correction of membrane spanning domain 1(MSD-1) can 
impact on the stabilisation of the NBD-1 and allow the processing of CFTR in patients 
carrying the ΔF508 mutation (Ren et al., 2013). Corrector compounds like VX-809, are 
currently under clinical trials as lead compounds to modify ΔF508 CFTR function. 
Clinical trials have attempted using combinatorial therapy of CFTR correctors and 
CFTR potentiators in ΔF508 mutation to alleviate the trafficking and conductance of 
chloride ions (Clancy et al., 2012, Rowe and Verkman, 2013). Similarly, the histone 
deacetylase inhibitor, sodium 4-phenyl butyrate, 4-PBA, has been found to increase 
CFTR trafficking by up regulating chaperone proteins like heat shock protein, Hsp70, 
involved in folding the N-terminal NBD-1 of CFTR (Choo-Kang and Zeitlin, 2001). 
 
1.4.1.3    Class III: Defective protein regulation  
!
This class of mutations is characterised by a default either in phosphorylation or 
dephosphorylation of CFTR, hence the channel loses the ability to be regulated by 
cAMP. The gating route, which requires ATP to regulate the opening and closing of the 
gate is faulty thus CFTR trafficked to the plasma membrane is impaired. Examples of 
this class include G551D and Y569D. The G551D mutation is linked with severe 
phenotype depicted by severe pulmonary dysfunction and pancreatic insufficiency 
(Cutting et al., 1990).  Also the G551D mutated CFTR channel has little or no ATP-
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dependent gating traits (Bompadre et al., 2007). However, certain compounds known 
as “CFTR potentiators” have been shown to enhance the gating properties of class III 
mutations (Pasyk et al., 2009, Yu et al., 2012, Accurso et al., 2010).  
 
1.4.1.4    Class IV: Defective or altered protein conductance 
 
This class of CFTR mutations are synonymous to class III however the rate of chloride 
efflux is distorted. Examples of mutations in this group include R117H and D1152H. 
R117H mutations possess intragenic mutations where its disease causing ability lies 
within the poly-T tract region of the gene. This dictates the severity of the phenotype, 
with 5T poly-T tract characterized by elevated sweat chloride and increased male 
infertility risk whilst 7T poly-T patients have the contrary. In addition, studies have 
shown that R117H mutation are diagnosed late compared to ΔF508 mutations 
(Anon.,(1993).  
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Figure 1.3: The classification of CFTR mutations. The 6 different classes of 
mutation in CFTR ranging from class I (synthesis), class II (processional), class III 
(regulation), class IV (defective conductance), class V (reduced CFTR levels) to class 
VI (reduced CFTR stability). The different mutations ultimately lead to the production of 
defective, inactive, normal or reduced copies of CFTR at the apical surface. Each 
classification overtly determines the number of CFTR copies on the apical membrane 
of the cell, hence differences in their phenotypic expressions (Adapted Rowe and 
Verkman (2013) 
!
1.4.1.5    Class V: Reduced CFTR level 
!
Class IV mutation account for <1% of CFTR mutations and are characterised by the 
aberration in normal protein transcription hence reduces the amount of channel present 
at the apical membrane (Proesmans et al., 2008). This consequently leads to the 
production of abnormal mRNA splicing including exon skipping or intron inclusions, 
which ultimately disrupts exon recognition. This leads to a dissimilarity in correctly and 
aberrant mRNA transcripts in different organs within a patient as well as amongst 
different patients (Ramalho et al., 2002). An example is the 3272-26 A-G mutation, a 
splicing mutation which has been demonstrated to show less severity of CF phenotype 
in terms of pancreatic sufficiency, airway disease and presence of Pseudomonas 
aeruginosa as compared to patients with the ΔF508 mutation (Amaral et al., 2001). 
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1.4.1.6   Class VI:  Reduced CFTR stability 
!
This is a new class characterised with a high turn over of CFTR at the apical surface. 
However due to a C-terminal truncation, the CFTR channels becomes highly unstable 
(Haardt et al., 1999). As a consequence of a frameshift or a nonsense codon, up to 
100 base pairs could be truncated at the C-terminus. eg 4326delTC.   
!
!
!
!
!
!
!
!
!
!
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Table 1.2: CFTR classes and their mutational defects 
 Class I Class II Class III Class IV Class V Class VI 
CFTR 
defect 
Defective 
protein 
synthesis 
Defective 
protein 
processing 
Defective 
protein 
regulation 
Defective or 
altered 
channel 
conductance 
Reduced 
protein 
level 
Reduced 
protein 
stability 
Type of 
mutation 
Nonsense;  
Frameshift 
Missense; 
Deletion of 
amino acid 
Missense; 
Change of 
amino acid 
Missense; 
Change of 
amino acid 
Missense; 
Splicing 
defect 
Missense; 
Change of 
amino acid 
Mutation 
example 
W1282X ∆F508 G551D R117H 3272-
26A-G 
4326delTC 
 
!
!
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1.4.2   The Chloride Channel: CFTR 
 
The CFTR protein is an ATP Binding cassette (ABC) transporter which has a central 
hydrophilic regulatory domain (R), two nucleotide binding domains (NBD) and six 
membrane spanning helices /domains (MSD). The mRNA exits the nucleus where 
tRNA transcribes it on the endoplasmic reticulum (ER). A series of convoluted 
processes ensue and the protein is N-glycosylated. This leads to an increase the 
molecular weight from 130kDa to 150kDa and subsequently folded, which renders it 
resistant to protease degradation in the endoplasmic reticulum, thus transported to the 
Golgi apparatus. The folding process is overtly inefficient leading to the formation of 
misfolded protein in one half of wild type CFTR (Lukacs et al., 1994). The ER retains 
within it chaperones such as calnexin and calreticulin that regulate folding of CFTR and 
function in concert with ER proteins including Heat shock proteins, Hsp 70, to redirect 
misfolded proteins to be degraded. In addition, these chaperones coordinate the 
transfer of CFTR to the Golgi (Sun et al., 2008, Rosser et al., 2008).  In the Golgi, 
further glycosylation occurs where the mannose core glycosylated form is converted to 
a matured protein with an oligosaccharide side chain attached to the fourth 
extracellular loop of the MSD-1 bearing the asparagine residue (Lukacs et al., 1994). 
The matured band C protein, 170kDa is then clathrin-transported in vesicles and 
apically expressed in the cell membrane as a chloride channel, which functionally 
undergoes endocytosis and recycles itself to the apical membrane (Jilling and Kirk, 
1997). The protein has a half-life of 16h, where cAMP drives its recycling process until 
such time when the protein is tagged for proteosomal degradation (Lukacs et al., 
1993). 
 
Essentially, the folding process within the ER is not robust and about 75% of wild type 
CFTR is degraded and ∼ 25% of the protease resistant translational product gets to the 
Golgi (Varga et al., 2004). This infers that a significant amount of the protein is not 
folded properly and ultimately, gets degraded as it is tagged for the ubiquitin pathway 
(Vankeerberghen et al., 2002). 
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Figure 1.4: The CFTR channel structure. The cartoon shows the 3 domains of 
mature CFTR: Regulatory domain, R, Nucleotide binding domains 1 and 2, NBD1&2 
and membrane spanning domains,1 and 2 MSD1&2. The two-glycosylation sites on the 
fourth extracellular loop are indicated. Phosphorylation of the R domain induces the 
hydrolysis of ATP on NBD1, which in turn causes the partial opening of the MSD1 and 
this then allows the flow of anions in the direction of the electrochemical current. As 
more ATP is hydrolysed on NBD2, MSD2 is open and now the channel is fully open. As 
the R domain becomes dephosphorylated by phosphatases, the channel closes 
(Vankeerberghen et al., 2002).  
 
1.4.2.1   Mechanism of action 
 
The CFTR channel has been described as a chloride channel with regulatory functions 
on other channels. Studies have reported that CFTR regulates the epithelial sodium 
channel (ENaC) by negatively regulating its function via down regulating its production 
(Stutts, 1997; Mall et al, 1996). On the contrary, Reddy et al., (1999) showed that 
CFTR is essential for the activation of ENaC and a mutation of the CFTR channel 
would lead to loss of activity of the ENaC. 
 
The CFTR channel functions with the R domain, being phosphorylated by activated 
protein kinase A (PKA), which is dependent on cAMP (Winter and Welsh, 1997, 
Hegedus et al., 2009). The response would be NBD1 binding and hydrolysis of 
adenosine triphosphate (ATP). This causes the channel to open through the pore in the 
MSD1 as against the gradient and allows anions to flow through it (Vergani et al., 
2005). The continuous phosphorylation of the R domain causes the second NBD2 to 
bind and further hydrolysing ATP and this further opens the pore of MSD2, which 
stabilises the open state. At a point when the R domain becomes dephosphorylated as 
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a consequence of protein phosphatases, PP2A or PP2C, it inhibits the ability of the 
NBDs to bind ATP, the channel closes (Travis et al., 1997, Luo et al., 1998).   
 
1.4.3   CFTR mutational phenotype 
 
In CF, the CFTR channel which carries the mutation loses its ability to escape the 
Endoplasmic Reticulum Quality Control (ERQC) system because of it being 
enormously misfolded and becomes susceptible to degradation and it is rapidly cleared 
with a significant reduction in the amount of the channel been trafficked to the apical 
membrane (Grove et al., 2009, Jacquot et al., 2008). Ribeiro et al. (2005) showed that 
CFTR hyper-inflammatory phenotype favours an increase in secretion of cytokines and 
a consequent up regulation in the level of ER calcium, Ca2+, stores. This enhances 
interleukin-8, IL-8, production beyond basal levels and thus increases inflammation. 
However, because of the variation in tissue expression of mutant ∆F508 CFTR (Kalin 
et al., 1999) and possibly other mutations of the channel, the phenotypic expression 
differs between patients with mutations having pronounced defective expression of the 
mutant channel than the other i.e. in patients with the R117H allele, where the mutation 
is a missense mutation, sufferers are affected with high incidence of pancreatic 
insufficiency compared to ∆F508 with a contrary phenotype (Anon,1993).The ∆F508 
mutation has been seemly linked with an upsurge of sodium, sodium ion absorption 
with a consequent reduction in airway surface liquid volume (ASL), which creates a 
viscid mucus on the surface of the airway epithelium (Konstan et al., 1994). The viscid 
mucus truncates defensin, which protects the airway against bacterial attack leading to 
a myriad of infections found in CF patients (Ratjen and Doring, 2003). The disease has 
been characterised with high salt content in sweat, other pathogenic symptoms include 
meconium ileus, pancreatic insufficiency, chronic cough, recurrent lower tract 
infections, mucoid sputum, biliary cirrhosis, nasal polyps, azoospermia, infertility and 
other rare symptoms (Davis and di Sant'Agnese, 1984). In concert, studies have shown 
that patients with class I-III mutations suffer a spontaneous deterioration of lung 
function with minimal survival rates (de Gracia et al., 2005). This is due to a near loss 
or complete loss of CFTR function (<3% of functional CFTR) in these patients (Welsh 
and Smith, 1993). Kerem et al. (1989) also showed that these mutations were 
associated with a rapid increase in pancreatic insufficiency. Also it was observed that 
male patients carrying the R117H-7T/ΔF508 mutations were infertile due to the 
absence of vas deferens, however, they may show normal lung function but present 
with disease phenotype consistent with CF patients (Colin et al., 1996, Castellani et al., 
1999). Dumar et al., (1990) further showed that the loss of vas deferens, congenital 
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bilateral absence of vas deferens (CBAVD) was associated with 9/17 infertile CF men, 
which were associated with meconium ileus, a condition characterised by an 
obstruction of the intestine. This was related to patients with pancreatic insufficiency 
across class I to class III mutations (Feingold and Guilloud-Bataille, 1999, Hamosh et 
al., 1992). Studies have pointed out the variations in CF phenotype amongst patients is 
largely influenced by environmental and genetic modifiers (Ferec and Cutting, 2012, 
Drumm et al., 2005). Consequently, studies have linked the occurrence of certain 
diseases to mutations of CF and termed them collectively as “CF-related diseases”, 
CF-RD (Bombieri et al., 2011). Some examples of CF-RD are idiopathic chronic 
pancreatitis and disseminated bronchiectasis. In all, these findings continue to improve 
on the therapy regimen for CF patients and provide insights into potential targets for 
patients based on their mutations.       
 
 
1.5 TG2 and Fibrosis in the lungs  
!
The multiplicity of functions of TG2 surrounds its ubiquitous nature and its involvement 
in the pathology of various diseases. Its role in tissue damage and cell stress has been 
elaborated in various studies where an increase in its transamidation activity has been 
observed (Upchurch et al., 1991, Johnson et al., 1999). Wound healing is made up of 5 
basic phases; haemostasis, inflammation, proliferation, remodelling and scar formation 
and scar maturation phases (Enoch and Leaper, 2008). From the inflammatory to the 
remodelling phase, high levels of cytokines and growth factors are secreted which 
include VEGF, IL-1, TGFβ and TNFα. The proliferative phase includes fibroblast 
migration with TGFβ implicated, formation of the extracellular matrix with the deposition 
of collagens and fibronectin, formation of granulation tissue and reepithelialisation. 
With scar formation, the wound begins to contract and collagen turnover ensues via 
metalloproteinases, which are tightly controlled to prevent untoward distortion of the 
healing process. Remodelling further inactivates metalloproteinases, reduces 
macrophages and fibroblasts whilst allowing scars to mature. In chronic wounds, 
various proteases and inflammatory cytokines remain elevated and this forges the 
development of fibrotic tissues.   
Increased expression of TG2 in wound healing is important as it regulates the 
inflammatory responses and modulates ECM deposition and remodelling (Shah et al., 
1999). Its complex interaction with fibronectin (FN), which is important in cell adhesion 
and migration, requires an intact N-terminal FN binding site (Gaudry et al., 1999a). In 
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concert, using Swiss 3T3 fibroblast cells under the Tet-regulated system, studies have 
linked an increase in fibronectin fibrils with an increase in TG2 expression in TG2-
induced cells compared to control and have suggested the crosslinking activity of TG2 
to be important in the stabilisation of the matrix (Verderio et al., 1998). However, it was 
concluded in these studies that TG2 activity was independent of cell motility. Albeit, in 
a related study, cell surface TG2 was implicated in migration as TG2 targeting 
monoclonal antibody was shown to block the migration of 3T3 Swiss fibroblasts 
(Balklava et al., 2002). In this study 3T3 Swiss fibroblasts were transfected with 
catalytically active and inactive (Cys277Ser mutant) under the tet-inducible system, 
which showed increased activity in homogenates and cell surface as well as 
comparable activity to wild type protein. Increased TG2 activity sustained an elevation 
in TG2 externalisation. These results demonstrated that on fibronectin, migration was 
decreased in both active and inactive TG2 mutants transfected into fibroblasts 
suggesting that TG2 acts independently of its transamidating activity during migration. 
Interestingly, in all, TG2 was demonstrated to be important in wound healing as the 
TG2 deficient mouse (Tgm2-/-) was shown to have delayed wound healing and delayed 
fibrosis compared to wild type (C57BL/6) after 21 days of administering bleomycin (2.5 
U/kg) (Olsen et al., 2011). At the epicentre of TG2’s involvement with fibrosis is the 
study made by Griffin et al. (1978) showing that when rats were treated with bleomycin, 
TG2 expression and activity was elevated and this was illustrated to be associated with 
an increase in fibronectin deposition as well as the mesenchymal collagen synthesizing 
fibroblasts. Similarly, Mirza et al. (1997) showed in rats treated with carbon 
tetrachloride (CCl4) that TG2 expression and activity increase in liver corresponding 
with the development of hepatic fibrosis. This was in concert with studies in renal 
fibrosis in rats having undergone subtotal nephrectomy and where extracellular TG2 
levels were shown to be elevated and active within the ECM (Johnson et al., 1997b). 
Nunes et al. (1997) demonstrated the link between TG2 and TGFβ1 where latent TGFβ 
binding protein 1 (LTBP1) was shown to be a substrate of TG2, hence TG2 was 
suggested to be involved in the storage and activation of latent TGFβ1 in the ECM. 
Olsen et al., (2011) showed that TGFβ1 treatment of Human Lung Fibroblasts (HLF) 
caused an increase in extracellular TG2 expression and activity, which was 
commensurate to the progression of Idiopathic pulmonary fibrosis (IPF). These results 
were in agreement with that of Shweke et al. (2008) where TG2 knockout mice showed 
amelioration of collagen deposition, renal inflammation and myofibroblast infiltration 
corresponding to a reduction in TGFβ1 secretion. Also, the up-regulation of TG2 in 3T3 
Swiss fibroblasts regulated by the tet inducible system was shown to significantly 
elevate the secretion of TGFβ1 and as well as deposition of collagen I, III, IV and 
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fibronectin in the ECM (Telci et al., 2009). Together, all these findings support the role 
TG2 plays in wound healing, migration, and activation of TGFβ1, which ultimately 
fosters the progression of fibrosis. 
 
1.6 TGFβ1: A pleiotropic cytokine activated by TG2 in 
Fibrosis 
1.6.1 Activation of TGFβ1 and induction of TG2 expression 
 
TGFβ1, a pleiotropic cytokine, has been shown to be involved in fibrosis in various 
pulmonary diseases like asthma (Hackett et al., 2009), IPF (Kasai et al., 2005), acute 
lung injury (Pittet et al., 2001) and CF (Eickmeier et al., 2013, Drumm et al., 2005). It is 
secreted as part of an inactive complex of latent TGFβ bound non-covalently to its 
propeptide, latency associated protein (LAP) forming the small latent complex (SLC). In 
turn, the SLC is bound covalently to a large TGFβ binding protein (LTBP) to form the 
large latent complex (LLC) (Munger et al., 1997). Its activity has been linked to its 
activation from its inactive latency complex (LLC), where LTBP-1 is cross linked to the 
ECM by TG2 (Nunes et al., 1997) and LAP bound to TGFβ dissociates from the LLC 
due to temperature and pH changes and becomes proteolytically activated to release 
the active TGFβ. Thus the presence of LAP inhibits the activation of TGFβ. Free active 
TGFβ can then bind to serine-threonine TGFβ receptors, Type RI and RII (Massaous 
and Hata, 1997). The phosphorylation and activation of RI recruits RII which activates 
the receptor where a complex is formed which binds to certain transcriptional factors 
intracellularly for signal transduction, either through the SMAD or non-SMAD pathway 
(Heldin et al., 1997). TG2 has been shown to be involved in the activation of TGFβ1 by 
crosslinking the LLC via LTBP-1 to the extracellular matrix and releasing the small 
latency complex comprising the inactive TGFβ bound to latency associated peptide 
(LAP) (Nunes et al., 1997, Telci et al., 2009). This has been suggested as the rate-
limiting step in the activation of TGFβ1. 
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Figure 1.5: Activation of TGFβ1 by TG2. The latent TGFβ complex is secreted from 
the cell where TG2 activity crosslinks LTBP-1 to the matrix, releasing SLC with TGFβ 
and LAP. TGFβ is activated proteolytically dissociating LAP, with TGFβ binding to the 
receptor, RII, which recruits RI and the complex is phosphorylated hence activating 
intracellular SMADs 2 and 3 which are phosphorylated subsequently and form a 
complex with SMAD-4. This complex is translocated into the nucleus. The complex is 
then responsible for the activation of target genes which may include TG2 [Adapted 
from Bartram,(2004)] 
 
Studies have also shown a marked up regulation of TG2 mRNA and activity levels in 
normal human epidermal keratinocytes (NHEK) treated with TGFβ1 within 4h of 
treatment (George et al., 1990). Ritter and Davies (1998) subsequently showed that 
the increase in TG2 expressional levels could be attributed to a the presence of a 
composite TGFβ1 or bone morphogenetic protein-4, TGFβ1/BMP-4 response element, 
868 base pairs from the transcription start site on the TG2 promoter. However, other 
studies have correlated the activation of TGFβ1 to the presence of αVβ6 and αVβ1 
integrins and to a lesser extent αVβ5, where the avidity of the integrin for TGFβ1 via 
the RGD binding site on LAP induces an activation of TGFβ1 in a paracrine manner 
(Ritter and Davies, 1998, Sheppard, 2005, Munger et al., 1998). This has led to the 
suggestion that TGFβ1 activation by αVβ6 requires cell-to-cell contact, as activation 
does not release active TGFβ1. Similarly, αVβ8 integrin was shown to activate TGFβ1 
by promoting the degradation of LAP on presenting latent complexes to 
metalloproteinases i.e. MMP-14 thus releasing the active TGFβ1 (Mu et al., 2002). In 
all, TG2 has been demonstrated to be involved in binding tightly fibronectin and other 
matrix proteins, thus aiding the incorporation of LTBP-1 into the matrix and increasing 
cell to cell contact which ultimately activates TGFβ1 (Verderio et al., 1999). In concert, 
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αVβ6 integrin has been shown to require fibronectin for the activation of latent TGFβ1 
(Fontana et al., 2005). Also, studies have suggested other cytoplasmic proteins might 
be involved in αVβ6 dependent TGFβ1 activation as mutational deletion of β6 subunit 
blocks the ability of αVβ6 to activate TGFβ1 but not its adhesion to LAP (Sheppard, 
2005). This suggests that TG2 and αVβ6 integrin might be working simultaneously in 
the activation of TGFβ1.  
In a myriad of fibrotic conditions, TG2 and TGFβ1 have been illustrated to be elevated 
corresponding to the progression of the disease process. Various pathways have been 
postulated with these conditions. Notably is the NFκB pathway (Telci et al., 2009, 
Venkatakrishnan et al., 2000, Vij et al., 2009, Luciani et al., 2009a) and more recently 
the Epithelial to Mesenchymal pathway (EMT) (Heldin et al., 2012, Kasai et al., 2005, 
Olsen et al., 2011, Miettinen et al., 1994).  
!
1.6.2 TG2 and NFκB 
 
In CF, studies have attempted to show the involvement of the NFκB inflammatory 
pathway in the initiation of inflammation and progression of fibrosis. A mutational 
destabilisation of the internal cellular milieu in CF has been shown to account for an 
elevated level of calcium in the cell, which together with ERAD stress supports the 
activation of NFκB. 
Pahl et al. (1996) proposed that for homozygous ∆F508, the mutation was associated 
with an increase in calcium levels and reactive oxygen species (ROS) and subsequent 
activation of NFκB. However, in a related study the mutant, G551D, with defective 
regulation, showed CFTR getting past the ER without being degraded and trafficking to 
the apical membrane with complete loss of CFTR protein function, but did not stimulate 
NFκB (Comer et al., 2009, Fulmer et al., 1995). Hudson (2004) also proposed that the 
∆F508 mutation induces an imbalance in the physiological levels of anions of which 
glutathione, which protects against oxidants in the lungs is significantly reduced and 
this leads to a consequent increase in Ca2+ release from intracellular stores. Vij et al. 
(2009), described CFTR as a negative regulator of the NFκB mediated innate response 
with a decrease in IL-8 expression in wild type cells and a reversal in overexpressed 
CFBE41o- cells. Studies have also shown that high levels of ROS were associated with 
increases in TG2 activity (Luciani et al., 2009). Consequently, because TG2 activity 
(transamidating) is associated with high calcium levels, it could be inferred that as a 
consequence, TG2 activity could be linked to a high levels of calcium within the cell 
Chapter!One:!Introduction!
!
! 45!
due to the high levels of ROS in cell. However, the effects of intracellular Ca2+ depends 
on the levels of GTP in the cells as GTP alters the binding of TG2 to Ca2+ thus 
impeding the activation of the enzyme intracellularly (Bergamini, 1988). Studies have 
shown in IB3 cells, a CF cell with an heterozygous mutation, ∆F508 /W1282X and C38 
cell, the corrected “add-back” CFTR cell line with a truncated but functional CFTR, that 
basal calcium levels were shown to be higher in IB3 cells and attributed to cell stress 
(Weber et al., 2001, Tabary et al., 2006). As a result, using immunofluorescence, basal 
NFκB activation was illustrated as seen with the translocation of p65, NFκB homodimer 
into the nucleus in IB3 cells but minimal p65 was found in C38 (DiMango et al., 1998). 
Luciani et al., (2009) suggested that SUMOylation, which is a process whereby 
proteins are modified post-translationally at their C-terminal and which alters binding 
and transport, accounts for the non-ubiquitination of TG2 for degradation thus 
prolonging its half-life. As a consequence, activated TG2 has been suggested to 
activate NFκB through a constitutive polymerisation of IκB-α, releasing NFκB for 
translocation into the nucleus where it acts as a transcriptional activator which then 
induces the transcription of TG2, CFTR (Trezise and Buchwald, 1991) and 
inflammatory cytokines, IL-8  (Bonfield et al., 1999), IL-1β, TNF-α and IL-6 (Osika et al., 
1999). These cytokines orchestrate infiltration, serving as chemoattractants of 
polymorphonuclear cells (PMN), neutrophils into the lungs. The untoward effect is the 
production of elastase which damages lung tissue and truncates the mechanisms 
involved in the ingestion of bacteria thus allowing bacteria to thrive (Chmiel and Davis, 
2003). This ultimately favours chronic inflammation. 
 
1.6.3 TG2 and Epithelial to Mesenchymal transition (EMT) 
 
The foremost role of EMT is in organogenesis where it coordinates cellular 
development via its ability to stimulate mesoderm synthesis from the epithelium during 
gastrulation and heart development (Hay, 1995, Boyer et al., 1999). However in effect, 
EMT is a phenomenon where epithelial cells transcend into mesenchymal cells with a 
change in phenotype thus acquiring a motile myofibroblast-like morphology and loss of 
the characteristic cobblestone like structure and cell polarity (Miettinen et al., 1994). 
This is accompanied by the acquisition of EMT markers, N-cadherin, fibronectin, α-
smooth muscle actin, α-SMA and loss of the tight junction marker, E-cadherin (Lee et 
al., 2006, Willis and Borok, 2007).    
Tight junctional proteins have been shown to provide a sealing on the lateral side of the 
cell where they function to impede paracellular diffusion providing a distinction between 
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apical and basolateral surfaces with proteins including occludin and zonula occludens 
(Tsukita et al., 2001). Par proteins (3 and 6) are involved in maintaining the polarity 
complex on the apical surface of the cell as well as junction integrity (Assemat et al., 
2008). 
The development of EMT is associated with elevated levels of cytokines which have 
been shown to elicit a proteolytic breakdown of the basal epithelial membrane thus 
supporting the invasive nature of the process (Kalluri and Neilson, 2003). TGFβ1, EGF, 
IGF-2 and other cytokines have been shown to be involved in promoting this process. 
TGFβ1 via SMAD-dependent or SMAD-independent pathways i.e. MAP kinase 
pathway enhances this process, causing an elevation in the expression and 
stabilisation of matrix proteins as well as TG2.  
 
Figure 1.6: Schematic illustration of the process of EMT. An initial loss of tight 
junctional /adhesion markers (left of image) is followed by the loss of cell polarity and 
actin skeleton reorganisation leading to cell migration and basal cell membrane 
degradation. This is commensurate with loss of epithelial markers; E-cadherin, claudins 
and occludins and an increase in the EMT markers N-cadherin, fibronectin, collagen I/II 
and vimentin (from left to right of image). The cells lose their pseudostratified structure, 
with simultaneous loss of apical cilia and assume a fibroblast-like structure with 
migratory character (Adapted from Aroeira et al., 2007). 
 
Studies have shown that TG2 is involved in mediating EMT in tumour epithelial cells 
(Kumar et al., 2010). The induction of EMT was shown to progress with an increase in 
the expression of transcriptional repressors like Snail, Slug, Twist and Zeb, where the 
expression of vital proteins like Par, Crumbs and Scribble, involved in maintaining 
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apicobasal polarity and junctional integrity, are disrupted by the expression of these 
transcription repressors (Thiery, 2002).  
The increased development of myofibroblasts cells, intermediate specialised fibroblast 
cells with both fibroblast and smooth muscle cell characteristics, serves as a hallmark 
of EMT as these cells have been shown to express α-smooth muscle actin (α-SMA), a 
marker of smooth muscle thickening and are stimulated to differentiate by TGFβ1 
(Kasai et al., 2005, Willis and Borok, 2007).  
Studies have shown that when human lung fibroblast cells, expressing low levels of 
TG2, were transduced with viral TG2 plasmid and treated with 5ng/ml of TGFβ1, TG2 
protein expression was significantly elevated (Olsen et al., 2011, Kelley et al., 1991). 
Likewise, when primary Human Bronchial Epithelial cells (HBEC) were treated with 
5ng/ml of TGFβ1, an increase in N-cadherin, vimentin, α-SMA, p-SMAD2 and MMP-2 
was observed with a reciprocal decrease in E-cadherin expression (Camara and Jarai, 
2010). With these findings, it can be postulated that elevated levels of TG2 might be 
involved in driving EMT progression via TGFβ1 in epithelial cells.      
  
1.6.3.1 SMAD dependent EMT 
 
The intricate processes involved in the activation of TGFβ1 are followed by a 
sequential course of events required for its intracellular signalling. SMADs, which are a 
subclass of a closely related gene, mothers against decephapentaplegic (MAD) found 
in Drosophila. They were discovered in nematodes and have been shown to be an 
important transcriptional regulator involved downstream in the control of intracellular 
signalling for TGFβ in the cell (Kretzschmar and Massague, 1998, Massague, 1996). 
SMADs are subdivided into 3 classes based on structural and functional characteristics 
and includes; receptor/regulator SMADs, R-SMADs (SMAD 1,2,3,5 and 8), 
collaborating SMAD, Co-SMAD (SMAD 4) and Inhibitory SMADs (SMAD 6 and 7). R-
SMADs are direct substrates for TGFβ with SMADs 1, 5 and 8 being BMP receptor 
substrates and SMADs 2 and 3 in addition to being substrates for TGFβ are substrates 
of activins (Graff et al., 1996). Hence, R-SMADs have been demonstrated to 
translocate into the nucleus where they are involved in transcriptional activation of 
genes (Hoodless et al., 1996). In concert, R-SMADs require co-SMAD 4, which 
constantly undergoes nucleocytoplasmic shuttling for signalling functions (Zhang et al., 
1996). Conversely, inhibitory SMADs, 6 and 7 act by blocking the binding of activated 
R-SMADs to SMAD 4 (Hata et al., 1998).  
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In the resting cell, basal R-SMADs are located in the cytoplasm however, on 
phosphorylation which occurs within 15 min of TGFβ binding to its receptors and lasts 
for hours, they undergo nucleocytoplasmic shuttling where co-SMAD 4 binds to the c-
terminus of R-SMADs to form complexes involved in activating target genes until their 
dephosphorylation occurs which causes R-SMADs to return to the cytoplasm 
(Massague et al., 2005, Chacko et al., 2004, Xu et al., 2009).  
With regards to EMT, elevation of R-SMADs 2 and 3 together with co-SMAD 4 has 
been shown in murine mammary epithelial cells, NMuMG, treated with TGFβ to 
correspond to EMT and TGFβ inhibition has been shown to reverse the process (Piek 
et al., 1999). Interestingly, it was shown that while SMAD 3 expression was elevated in 
the presence of TGFβ, which causes renal tubular cells to undergo EMT, loss of SMAD 
2 reciprocally promoted EMT in keratinocytes (Sato et al., 2003).  Research has shown 
that 3 transcriptional families transitionally regulate induction of EMT by SMADs 
namely; Snail, Zeb and Helix-loop-helix family (Xu et al., 2009). 
 
1.6.3.1.1 Snail 
 
The snail transcriptional group function as transcriptional repressors, where their 
activity has been shown to be mediated by 3 distinct members, snail1, snail2 (slug) and 
snail 3 (Xu et al., 2009). Expression of snail 1 and 2 has been associated with TGFβ 
induced EMT (Barrallo-Gimeno and Nieto, 2005, Zavadil and Bottinger, 2005). SMADs 
2 and 3 have been shown to be involved in mediating snail expression on binding to 
the promoter sites after TGFβ activation (Cho et al., 2007, Hoot et al., 2008). Thus an 
induction of EMT correlates with an increase in expression of EMT markers, N-
cadherin, fibronectin, vitronectin and collagen V as well as with the repression of E-
cadherin, junctional proteins and the cell polarity protein, Crumb 3 expression 
(Ikenouchi et al., 2003, Wang et al., 2007, Moreno-Bueno et al., 2006, Cano et al., 
2000).  
1.6.3.1.2  Zeb 
 
This group of transcriptional repressors are made up of 2 members; Zeb 1 and Zeb 2 
which have been shown to have SMAD interaction domains. TGFβ induced EMT 
increases Zeb expression via SMAD-3, where repression of proteins involved in 
maintaining epithelial cell integrity have been observed (Postigo et al., 2003). Again, 
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Comijn et al. (2001) linked Zeb 1 induction to the decreased expression of E-cadherin 
ultimately supporting cell invasiveness. 
 
1.6.3.1.3 Helix-loop-helix  
 
Amongst the members of the helix-loop-helix transcriptional repressors, Twist 1 and 2 
as well as E12 and E47 are the most well known. The down regulation of E-cadherin, 
occludin and claudin has been linked to the up regulation of Twist 1 and 2 which 
studies have shown to always heterodimerise with E12 and E47proteins and EMT 
markers, N-cadherin and vimentin (Yang et al., 2004, Comijn et al., 2001) 
 
1.6.3.2 SMAD independent EMT 
 
The induction of non-SMAD pathway signalling occurs via TGFβ RII or RI through 
adaptor proteins like TNF-receptor associated factor, TRAF-6, Par-6 and PI3K and this 
occurs independently of SMAD signalling, thus blockage of TGFβ receptors abrogate 
signalling through this pathway (Xu et al., 2009). Research has shown that the non-
SMAD pathways are linked to TGFβ-induced EMT as they have been shown to 
regulate cellular processes involved in EMT like actin organisation, cell migration, 
growth and invasion (Derynck and Zhang, 2003). Together with the SMAD dependent 
pathway, non-SMAD pathways are involved in EMT progression as inhibition of this 
pathway abolishes EMT. Three downstream pathways have been classified namely; 
Erk MAP Kinase, Rho GTPase and PI3 Kinase/Akt pathway. 
 
 
1.6.3.2.1 Mitogen activated protein kinase (MAPK) pathway 
 
The MAPK pathway have been shown to be activated via tyrosine kinase receptors on 
binding of growth factors, which studies have linked to elevated pathway activity 
compared to MAPK activation by TGFβ (Derynck and Zhang, 2003). R-SMADs 
signalling is likewise blocked by the Erk-MAPK pathway by phosphorylation of the 
linker regions thus impeding their transcriptional activity (Xu et al., 2009). Studies have 
shown using rat intestinal epithelial cells that a synergy between Ras-Erk-MAPK 
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pathway and TGFβ is driving EMT as E-cadherin expression was inhibited (Uttamsingh 
et al., 2008). Similarly, an up regulation and stabilisation of Snail 1 was linked to an 
activation of the Ras-Erk-MAPK pathway, which was similar to a TGFβ induced 
elevation of N-cadherin and matrix MMP in pig thyroid epithelial cells (Grande et al., 
2002, Marchetti et al., 2008).  
 
1.6.3.2.2 Rho-GTPases 
 
In accord with EMT progression, an elevation of Rho-GTPases has been linked to the 
increase in expression of its effector kinase, ROCK, leading to increased cell migration 
and development of stress fibres (Pellegrin and Mellor, 2007). The complex formed by 
TGFβ RI / Par 6 which allows the phosphorylation of Par 6 by TGFβ RII recruiting 
Smurf-1, an E3 ubiquitin ligase, which activates the ubiquitination of Rho-A, leading to 
the degradation of tight junction proteins (Ozdamar et al., 2005). 
 
1.6.3.2.3 PI3 Kinase/Akt pathway 
 
Unlike the marginal effect of TGFβ observed on tyrosine kinase receptors in stimulating 
the activation of MAPK pathway, TGFβ rapidly activates PI3 kinase activity, which 
regulates cell survival and cell migration (Yi et al., 2005). Cho et al., (2007) showed in 
primary lens epithelial cells that activation of R-SMADs 2 and 3 by TGFβ leads to the 
down-stream activation of Snail and this was linked to the activation of Akt signalling in 
these cells (Cho et al., 2007). Also, blocking of the PI3 kinase /Akt pathway reverses 
SMAD 2 phosphorylation in NMuMG mammary gland epithelial cells induced by TGFβ1 
(Bakin et al., 2000). This implies a possible interaction between the SMAD and PI3 
kinase/Akt pathway.  
In all, these studies have been able to link TGFβ activation and signalling via its 
receptors to the phosphorylation of SMADs and activation of non SMADs pathways in 
epithelial cells ultimately leading to the progression of EMT. However, recent studies 
have linked the elevation of TG2 in mammary epithelial cell lines to the activation of 
TGFβ, which in turn down regulates E-cadherin expression and up regulates 
fibronectin, N-cadherin and transcriptional repressors, Snail 1, Zeb 1, Zeb 2 and Twist 
1 (Kumar et al., 2010). In a related study using ovarian cancer cells, elevation of TG2 
by TGFβ caused an activation of the canonical SMAD pathway inducing EMT by the 
formation of spheroids and cell metastasis (Cao et al., 2012). Also in the study by 
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Tovar-Vidales et al., (2011) using non-transformed primary human tubercular 
meshwork cells treated with TGFβ, results showed an elevation of TG2 protein and 
activity corresponding to the phosphorylation of SMAD-3 (Tovar-Vidales et al., 2011). 
This all supports the hypothesis that TG2 is involved in driving EMT in epithelial cells. 
 
1.7   Culturing of airway epithelial cells in air liquid 
interface (ALI) 
 
Traditionally, submerged cultures have been long established for culturing cells of all 
types. The in vitro technique is quite robust and allows for easy manipulations of cells 
to obtain reproducible results. In submerged cultures, cells are grown on plastic plates, 
which allows the dispersed and isolated cells to adhere and proliferate under 
appropriate conditions (Yankaskas et al., 1985). Typically, epithelial cells in vivo 
assume a pseudo-stratified columnar structure comprising of basal cells, secretory 
(mucus, goblet or serous) cells and apical ciliated cells, which make up about 50% of 
the cell population (BeruBe et al., 2009). Studies have shown that epithelial cells in 
submerged culture grown in monolayers were flattened, with significant loss of cilia, 
which is a characteristic of epithelial cells in vivo and low electrical currents (de Jong et 
al., 1994, Yamaya et al., 1992). Paradoxically, cells cultured and induced to 
differentiate at Air Liquid Interface (ALI) using appropriate medium and growth 
conditions, which include substrate, simulated in vivo epithelial ultrastructure and this 
has been shown to be reproducible (Lee et al., 1996). At ALI, epithelial cells are grown 
on a membrane with high pore density and porosity which allows for the exchange of 
nutrients from the lower basolateral compartment with medium to the apical surface of 
the cells (Gruenert et al., 1995).  
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Figure 1.7: Schematic illustration of the ALI cell culture system. Transwell® inserts 
are placed into companion plates; the inserts have PET etched membrane with an area 
of 0.33cm2 and a pore size of 0.4µm. The membrane has 100% porosity, which allows 
for the exchange of nutrients from medium and biologic waste from cells. Insert 
membranes are coated with collagen IV before cells are allowed to attach, after which 
the medium on the apical cell surface is removed and cells are presented in an air 
liquid interface. 
 
Studies have shown that the three basic requirements for cells to undergo 
differentiation at ALI is the presence of retinoic acid (Ann et al., 1988, Chopra et al., 
1989) collagen gel and ALI (Wu et al., 1990). Yamaya et al. (1992) suggested that at a 
plating density of 3 x 105cells/cm2, differentiated cultures could be maintained at ALI for 
one month. It has also been shown from studies (Yankaskas et al., 1985, Wu et al., 
1985, Gruenert et al., 1995) that culturing of airway epithelial cells on collagen 
substratum increases ciliogenesis and hence mucus production which, in vivo serves 
as an artificial sieve that traps and prevents inhaled particles from getting to the 
epithelium .The growth of the cells on suitable substratum like collagen IV has been 
proven to support the activation of cell surface receptors and allows the cells to attach 
so as to form cuboidal  epithelium by providing the suitable extracellular matrix 
(Robinson and Wu, 1993). In concert, this model favours higher aeration of cells which 
enhances differentiation (Johnson et al., 1993).  
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1.8   Overall Aims 
!
This project is chiefly aimed at finding the relationship between the expression and 
activation of TG2 and the development and progression of fibrosis in CF. The 
objectives include examining the link between TG2 activity and TGFβ1 activation and 
the effect on epithelial cell migration as well as regulation of EMT. In addition, by using 
TG2 knockdown cells, observe the effect of reduced TG2 expression on EMT 
progression. Conversely, using TG2 transduced cells to observe the effect of TG2 
elevation on EMT progression. Finally, using CFTR correctors and TG2 inhibitors, to 
correct the maturation of CFTR protein and improve its trafficking to the apical surface 
where chloride could be evaluated.   
!!
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2.0 Materials and Methods:  
2.1 Materials 
2.1.1 Antibodies: 
ANTIBODY COMPANY ISOTYPE APPLICATION 
Transglutaminase 2 
(CUB7402 + TG100)( 
MA5-12989) 
THERMO 
SCIENTIFIC 
Mouse ICC, WB 
Transglutaminase 
2(SAB4200072) 
SIGMA ALDRICH Rabbit WB, ICC, C0-IP 
Transglutaminase 
1(B.C.1) 
ABCAM,UK Mouse  WB 
E-Cadherin (H-108) SANTA CRUZ,UK Rabbit WB, ICC 
N-Cadherin (13A9) SANTA CRUZ,UK Mouse WB, ICC 
α-SMA (B4) SANTA CRUZ,UK Mouse ICC 
CFTR (A3) SANTA CRUZ,UK Mouse WB, ICC 
Na+- K+ ATPase (H3) SANTA CRUZ,UK Mouse WB 
Slug (H-140) SANTA CRUZ,UK Rabbit WB 
GAPDH (H-12) SANTA CRUZ,UK Mouse WB 
αv-Integrin (H-2) SANTA CRUZ,UK Mouse WB, CO-IP 
Β-6 (H-110) SANTA CRUZ,UK Rabbit WB, CO-IP 
Β-1 SANTA CRUZ,UK Mouse WB 
Β-3 (SAP) SANTA CRUZ,UK Mouse WB 
Twist (H-81) SANTA CRUZ,UK Rabbit WB 
Snail-1 (G-7) SANTA CRUZ,UK Rabbit WB 
fibronectin (F3648) SIGMA 
ALDRICH,UK 
Rabbit WB, ICC 
Cytokeratin 8 (M20) ABCAM, UK Mouse WB 
TGFβ-1 RI (R-20) SANTA CRUZ,UK Rabbit WB 
TGFβ-1 RII (C-16) SANTA CRUZ,UK Rabbit WB 
SMAD 2 SANTA CRUZ,UK Mouse WB 
P-SMAD 2 SANTA CRUZ,UK Rabbit WB 
SMAD 3 SANTA CRUZ,UK Mouse WB 
P-SMAD 3 SANTA CRUZ,UK Rabbit WB 
TGFβ1 Pan specific 
(AB-100NA) 
R&D SYSTEMS Rabbit WB 
Secondary antibodies 
FITC DAKO, DENMARK Mouse ICC 
TRITC DAKO, DENMARK Rabbit ICC 
Swine anti-rabbit 
HRP conjugated 
DAKO, DENMARK Rabbit ICC 
Goat anti-mouse 
HRP conjugated 
DAKO, DENMARK Mouse ICC 
ICC-immunocytochemistry WB- Western blotting CO-IP@Co-Immunoprecipitation 
 
!
!
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2.1.2 Chemicals: 
!
All lab reagents were purchased from PAA Laboratories, Yeovil, Somerset, UK unless 
otherwise specified. 
Promocell® (Heidelberg, Germany) 
Airway Epithelial Cell Media, AEM, (C-21260) with supplement mix: Insulin,hEGF-5, 
Hydrocortisone, Epinephrine, Triiodothyronine, Transferrin, Retinoic acid and Bovine 
pituitary extract BPE. 
Sigma Aldrich, (UK) 
• Insulin, Transferrin, Sodium Selenite (Sermet-Gaudelus et al.) medium, 10X 
• Diethyl pyrocarbonate (DEPC) (159220) 
• SIGMAFAST® OPD tablets (P9187) 
• Cycloheximide (C7698) 
• Valinomycin (V0627) 
• Fibronectin (F0895) 
• N-(Ethoxycarbonylmethyl)-6-Methoxyquinolium Bromide (MQAE) (46123) 
• Forskolin (F6886) 
• Dimethyl Sulfoxide (DMSO) (D2438) 
• Cystamine (30050-25) 
• Protein G Sepharose beads (P3296) 
• Monodansylcadaverine (30402) 
• Ponceau S stain (P7170): 0.1%(w/v) Ponceau S and 5%(w/v) acetic acid ready 
to use.  
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Melford (UK) 
• Acrylamide (29:1) (A2455) 
Selleckchem (UK) 
• VX-809 (S1565) 
• VX-770 (S1144) 
Tocris Bioscience (UK) 
• Dibutyryl cyclic AMP (1141) 
Life Technologies Ltd (UK) 
• Lipofectamine® 2000 
• TRIzol ® (15596-026) 
Qiagen (UK) 
• Sensiscript® Reverse Transcriptase, Qiagen 
• Qiagen Quantitect® SYBR® Green PCR kit 
• RT2 First strand Kit 
Pierce (UK) 
• Sulfo-NHS-LC-Biotin 
Zedira (Germany) 
• N-(Biotinyl) Cadaverine 
• Z-DON-Val-Pro-Leu-OMe (Z-DON) 
Roche (UK) 
• 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) 
Vector Laboratories (UK) 
• Vectashield hard set mounting medium with DAPI (4',6-diamidino-2-
phenylindole) 
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Aston University (Prof Martin Griffin’s Lab) 
• R281: (N-benzyloxycarbonyl(CBZ)-L-phenylalanyl-6-dimethylsulfonium-5-oxo-L-
norleucine) (Jones et al., 2006) 
• R283: (1,3-dimethyl-2-[(oxopropyl)thio] imidazolium. (Jones et al., 2006) 
• R294: cell impermeable TG2 inhibitor (Griffin et al., 2008) 
• 1-133: Peptido-mimetic cell impermeable TG2 inhibitor  
• 1-155: Peptido-mimetic cell-permeable TG2 inhibitor 
 
4x Tris-Cl/SDS, pH 6.8 (0.5M): 
To make 100ml of solution, 6.05g of Tris base was dissolved in 40ml of distilled water 
with pH adjusted to 6.8. 0.4g of SDS was added and placed on a stirrer to dissolve 
completely. Solution was then stored at 4oC.  
 
4x Tris-Cl/SDS, pH 8.8 (1.5M): 
To make 500ml of solution, 91g of Tris base was dissolved in 300ml of distilled water 
with pH adjusted to 8.8. Solution was made up to 500mls with distilled water. 2g of 
SDS was added and placed on a stirrer to dissolve completely. Solution was then 
stored at 4oC.  
 
*10x Transfer buffer: 
Transfer buffer (10x) (w/v) 
Tris base 3.03 
Glycine 14.42 
• *Methanol added when buffer is ready to be used 
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10x TBS-Tween buffer: 
TBS-Tween (10x), pH 7.4 To make up 1L 
Tris base 121.14g 
NaCl 90g 
Tween-20 5mls 
 
Stripping buffer: 
Buffer Amount required to make up 
Tris-Cl (pH 6.8) 62.5mM 
SDS 2%(w/v) 
2-β-Mecaptoethanol 100mM* 
* To add freshly before use 
 
2.1.3 Equipment: 
 
Leica Microsystem (Milton Keynes, UK) 
• Leica TCS SP5 II Broadband Confocal Microscope 
MWG  (USA) 
• Primus 96 thermal cycler 
Stratagene  (UK) 
• MX-3000P® Real-Time PCR machine 
Worldwide Precision (USA) 
• EVOM Epithelial Voltohmmeter   
Syngene (UK) 
• GEL box (G:BOX F3) 
 
 
 
Chapter!Two:!Materials!and!Methods!
!
! 60!
2.2    Methods: 
 
2.2.1 Cell culturing: 
 
2.2.1.1 Cell lines 
 
IB3-1 (mutant tracheal epithelial cell line with a heterozygote mutation, 
∆F508/W1282X, leading to the loss of CFTR channel function and immortalized by SV-
40 transfection), C38 (“add back” IB3-1 cell line which has a truncated CFTR channel 
with 119 residues missing but functional with elevated basal Cl- ion efflux) and Human 
Bronchial Epithelial cell (HBEC) (isolated from surface epithelium of human bronchi) 
obtained as a gift from Dr Lindsay Marshall (Aston University, Birmingham, UK). 
 
2.2.1.2 Culturing of cells in submerged medium 
 
IB3-1 and C38 cells were cultured in airway epithelial medium, AEM, substituted with 
supplements; 5%(v/v) Foetal Calf Serum (FCS), 1% (v/v) Penicillin/Streptomycin and 
1%(w/v) L-Glutamine (GE Healthcare). The cells were cultured in plastic flasks to attain 
a confluency of 70% to 90%.  
 
2.2.1.2.1. To determine TGFβ1 levels in cells cultured in submerged conditions 
 
5 x 105 C38 or HBEC cells were cultured in complete medium to attach and spread for 
6h then medium was changed to serum-free medium supplemented with 1x ITS and 
rTGFβ1 (3ng/ml) alone or in combination with TG2 inhibitor for 48 h. 
 
2.2.1.3.  Passaging of cells (submerged medium) 
 
The cells were rinsed with 1x PBS pH 7.4 and then treated with 0.25%(v/v) trypsin (GE 
Healthcare) in 2mM EDTA in 1x PBS at pH 7.4 kept at 37oC for 3-5 min. Cells were 
collected in fresh medium with serum to neutralise the trypsin and centrifuged at 250g 
for 5 min. Subsequently, cells were re-suspended in fresh complete medium. 
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2.2.1.4 Culturing of cells at Air Liquid Interface (ALI) 
 
In order to culture airway epithelial cells to assume a pseudo-stratified structure,  
Transwell® (Corning Lifesciences, Amsterdam) inserts with an area of 0.33cm2 and 
0.4µm pore size were inserted in Transwell® companion plates. 33µl of 100µg/ml 
solution of collagen IV in 3%(v/v) acetic acid was added to each insert membrane and 
allowed to attach for 45 min at room temperature. Medium was used to rinse inserts to 
neutralise the acidity of the solution.  3 x 104 cells in 300µl of airway epithelial medium, 
AEM, were added to each insert apically and 600µl of complete medium added basally 
to each well underneath each insert. The cells were cultured for 4 days after which 
medium was removed from inserts and the cells were exposed to air. Medium in basal 
companion Transwell® plates was replaced and cells were cultured for 14 days during 
which basal medium was changed on alternate days. Afterwards, the TEER was 
measured.  
 
2.2.1.5 Trans-Epithelial Electrical Resistance (TEER) of airway epithelial cells 
cultured at ALI.  
 
In order to ensure airway integrity, Trans-Epithelial Electrical Resistance, TEER, was 
measured. Using electrodes, 300µl medium was carefully added to each insert not to 
distort cells. The electrodes attached to the voltohmmeter were then inserted into each 
insert with the longer arm extending into the basal compartment and the shorter arm 
inserted apically above the cells (EVOM Epithelial voltohmmeter). Caution was taken 
not to disrupt cells. The measurement was done passing AC current through the cells 
consequently, taking the resistance (in ohms) as the current passes through. This was 
done in triplicate with electrodes dipped intermittently in 70%(v/v) Industrial Methylated 
Spirit (IMS) and air dried before each use to keep electrodes sterile. As resistance 
attains 300Ω, the apical medium was removed from the surface of cells in inserts and 
inserts placed into basal medium in Transwell® with cells cultured at 37oC.  
 
TEER 
(Ωcm2)=!
!
!
Mean of resistance 
measured across each 
membrane (Ω)!
Area of  
Membrane (cm2)  
!
X 
Mean of resistance 
measured across 
empty control 
membrane (Ωcm2)!
- 
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2.2.2 Lysing of cells  
 
2.2.2.1 Lysing of cells cultured in submerged medium 
 
The cells were washed with ice-cold 1x PBS, pH 7.4 twice and lysis buffer (5mM DTT, 
50mM Tris-Cl, 150mM NaCl, 1mM EGTA, 1mM PMSF, 1%(V/V) protein Inhibitor 
cocktail and 1mM Sodium orthovanadate) was added to cells and scrapped into pre-
cooled eppendorf tubes. The cells were incubated for 30min and centrifuged at 300g 
for 5 min. Supernatant was collected into fresh tube and protein was quantified by the 
Lowry method. For cell and matrix proteins, cells were rinsed with 1x PBS, pH 7.4 
twice, collected in 2mM EDTA in 1x PBS, pH 7.4 which were lysed on ice for 30 min 
prior to centrifugation at 300g for 5 min. To the matrix, 40µl of 2x Laemilli buffer was 
added and scrapped into pre-cooled eppendorf tubes, which were boiled for 5 min 
before loading on polyacrylamide gels. 
 
2.2.2.2 Lysing of cells (ALI) 
 
Using a scalpel, membrane inserts rinsed with 1x PBS, pH 7.4, were carefully cut to 
avoid distorting the attached cells. The membrane was placed in eppendorf tubes with 
lysis buffer on ice and vortex to aid in detaching the cells from membrane. The cells 
are incubated on ice for 30min and centrifuged at 300g for 6min. The supernatant was 
collected into fresh tubes on ice and the membrane viewed to ensure cells were 
detached.   
 
2.2.3 Sodium Dodecyl Sulphate Polyacrylamide gel Electrophoresis 
(SDS-PAGE) of lysates of airway epithelial cells 
 
Protein homogenates were added to either 2x laemmli (125mM Tris- Cl, pH 6.8, 20% 
(v/v) glycerol, 10% 2-β mercaptoethanol, 4%(w/v) SDS and 0.01% bromophenol blue) 
or 6x laemmli buffer (5.91 g Tris-HCl, 6 %(w/v) SDS, 48%(v/v) glycerol, 9 ml 14.7 M 2-
Mercaptoethanol, and 30 mg bromophenol blue and distilled water to make up volume 
to 100ml) (Laemmli, 1970) (1:1) and mixed prior to boiling for 5min. SDS gels were 
made depending on the proteins to be separated.  
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For 15ml of resolving gel; 
Resolving solutions (w/v)  6% 8% 12% 
30% (w/v) 2.25 3 4.5 
4x Tris-Cl/SDS, pH8.8 3.75 3.75 3.75 
Distilled water 9 8.25 6.75 
10% ammonium persulphate 0.05 0.05 0.05     
TEMED 0.01 0.01 0.01 
Total volume (ml) 15 15 15 
 
5ml of stacking gel: 
Stacking solutions (w/v) (ml) 
30% (w/v) 0.4875 
4x Tris-Cl/SDS, pH6.8 1.25 
Distilled water 3.21 
10% ammonium persulphate 0.025 
TEMED 0.005 
Total volume (ml) 5 
 
The gels were allowed to polymerise at room temperature for 45min to 60min. The 
wells on stacking gel were washed with 1x running buffer (10x running buffer; 25.01mM 
Tris base, 190mM glycine and 0.1%(w/v) SDS with pH adjusted to 8.3. The solution 
was made up to 1000ml) placed in glass-plate chamber. Excess amount of running 
buffer was added to fill the chamber and protein homogenates boiled for 5 min in 2x 
laemmli and vortex gently to mix protein and loaded on the gels.  Electrophoresis was 
conducted at 90mA through the stacking gel. As the protein front approached the end 
of stacking gel, the voltage was increased to 120mA and further ran for 30min to 45 
min.     
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2.2.4 Western Blotting to detect separated proteins from lysates of 
airway epithelial cells 
 
Western blotting was carried out according to the method as described by Towbin et al. 
(1979). The separated protein on the gel were transferred to nitrocellulose membrane 
using pre-cooled 1x transfer buffer [25.01mM Tris-base and 192mM glycine, pH 8.3] 
made up with methanol and distilled water (1:7:2). Transfer was carried out at 200mA 
for 2 h. A sandwich was made of cushions, gel, nitrocellulose membrane, packaged in 
a fitted cassette, which was degassed to remove any interfering bubbles and the 
assembly placed in a transfer rack where current passes and transfers protein to the 
membrane. The transfer was carried out under low temperatures as ice packs were 
placed in adjacent transfer rack. After 2 h, the assembly was dismantled and 
membrane was assessed for transferred proteins by staining them with Ponceau S 
stain (add stain to membrane and stain for 5 min. To destain membrane, wash with 1x 
PBS, pH 7.4). The membrane was then blocked with blocking buffer [5%(w/v) skimmed 
milk in 1x TBS-Tween, pH 7.4] for an hour. Thereafter, membrane was blotted with 
primary antibody in blocking buffer and incubated overnight at 4oC on a rocking stirrer. 
Subsequently, the membrane was washed in wash buffer (1x TBS-Tween, pH 7.4) four 
times and incubated with HRP-conjugated secondary antibody for 2 h at room 
temperature. After incubation, the membrane was washed four times with washing 
buffer every 15min. Membrane was gently rinsed in 1x PBS, pH 7.4 and luminescence 
determined using ECL® chemiluminescent reagents (1:1 dilution) and images captured 
using the G-box system (Syngene®). 
2.2.5 Membrane stripping: 
 
Membrane stripping was performed to free the membrane of bound primary and 
secondary antibodies and reassess membrane other proteins or evaluate the amount 
of protein loaded on the gel at the same time. The membranes were rinsed with 1x 
TBS-Tween, pH 7.4 and placed in stripping buffer. The buffer was then placed in a 
heating chamber at 50oC for 20 min and intermittently mixed to aid stripping of the 
membrane. The membrane was carefully removed from buffer in a HEPA filtered hood 
into 1x TBS-Tween, pH 7.4 and placed on a rotatory shaker to wash. The stripping 
buffer was aseptically discarded. The membranes were washed for an hour with 
washing buffer and changed every 15 min. The membranes were blocked as described 
in the section above and assessed for proteins as described. 
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2.2.6 Determination of protein expressed in whole cell lysates of 
airway epithelial cells 
 
To detect total protein expressed by cells, whole cell lysates (WCL) were obtained as 
described below. Cells were cultured to a confluency of between 70% to 90%. Cells 
were then washed with ice- cold 1x PBS, pH 7.4 twice. To lyse the cells, lysis buffer 
was added and cells were placed on ice for 5 min. Using a scraper, cells were gently 
detached, collected into eppendorf tubes and placed on ice for 30 min. Subsequently, 
cell lysates were centrifuged at 300g for 5 min. The protein supernatant was collected 
into fresh tubes. Quantification was done using the Lowry protein quantification method 
(Lowry et al., 1951).  
 
2.2.7 TG2 Activity assay using the Biotin Cadaverine Incorporation 
assay 
2.2.7.1 TG2 activity in whole cell lysates (WCL) of cells cultured in submerged 
conditions or at ALI: 
!
Activity assays were carried out using biotin cadaverine incorporation into fibronectin 
(FN). 5 x105 cells were cultured in 6-well plates for 6 h to attach and medium was 
changed and replaced with fresh medium. For treated groups, medium was 
supplemented with inhibitors, antibodies or chemical compounds. Whole cell lysates 
were obtained as described in section 2.2.6. TG2 activity assay was carried out in 96-
well plates, coated with 50µl of a 5µg/ml fibronectin solution overnight at 4oC. 50µg of 
WCL were pre-incubated on FN coated plates in the presence of 10mM calcium, 1mM 
DTT, 0.1mM biotin cadaverine (BCD) and made up to a final volume of 100µl/well (96 
well plate) using 50mM Tris-Cl, pH 7.4. The positive and negative control were with 
purified 50µg of guinea pig liver TG2 (gplTG2) with the substitution of calcium for 10 
mM EDTA in the negative control. The samples were done in triplicates. The plate was 
incubated at 37oC, 5% CO2 for 2 h. Thereafter, 2mM EDTA in 1 x PBS, pH 7.4 was 
added to wells to stop the reaction and the wells washed three times with the same 
buffer. The wells were washed with 50mM Tris-Cl, pH 7.4 three times then blocked with 
blocking buffer, heat inactivated 3%(w/v) Bovine Serum Albumin, BSA, in 50mM Tris-
Cl, pH 7.4 for 30 min at 37 oC. The wells were washed with blocking buffer and then 
incubated with 100µl of 1:1000 dilution of Extravidin® peroxidise conjugate for 1 h at 
37oC. The wells were washed again with 50mM Tris- Cl, pH 7.4 three times. 100µl of 
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SigmaFast® OPD tablets dissolved (1:1) in 20ml of distilled water was added to the 
plates and the reaction was stopped by adding 50µl of 3M HCl. Absorbance was 
detected at 490nm. 
Similarly, 3 x 104 cells were cultured at ALI as described in section 2.2.1.4. The cells 
were carefully rinsed with 1x PBS, pH 7.4 twice and membrane was cut out carefully 
with a scalpel into eppendorf tubes as described in section 2.2.2.2. 50µg of protein was 
used for TG2 activity assay as described above.   
 
2.2.7.2 Detection of cell surface TG2 activity in airway epithelial cells cultured in 
submerged conditions. 
 
Using T25 flasks, cells were cultured overnight to attain confluency of between 80%-
90%. The cells were rinsed with 1x PBS, pH 7.4 twice and detached using 0.5mM 
EDTA in 1x PBS, pH 7.4, incubated at 37oC for 5 min. The cells were centrifuged for 
5min at 300g and supernatant discarded. The pellets were re-suspended in AEM 
without serum. 2 x 104 cells were counted and re-suspended in 400µl of medium 
containing 0.1mM biotin cadaverine. The mixture was added to a 96-well plate coated 
with 50µl of 5µg/ml fibronectin and incubated at 37oC for 2 h. To treated groups, 
inhibitors, antibodies or chemical compounds were added and incubated with cells 
prior to the addition of 0.1mM biotin cadaverine. The reaction was stopped by addition 
and further washing wells with 2mM EDTA in 1x PBS, pH 7.4. 100µl of 0.1%(w/v) 
sodium deoxycholate in 2mM EDTA in 1x PBS, pH 7.4 was added to each well and 
incubated on a slow shaker for 10 min at room temperature. On discarding the mixture 
from the wells, the well were washed thrice with 50mM Tris-Cl, pH 7.4 and blocked with 
heat inactivated 3% (w/v) Bovine Serum Albumin, BSA, in 50mM Tris-Cl, pH 7.4 at 
37oC for 30 min. The wells were washed and the immunoassay detecting the 
incorporation of biotin cadaverine by cell surface TG2 into fibronectin was determined 
using a 1:1000 dilution of Extravidin® peroxidase conjugate incubated at 37oC for 1h. 
On washing the wells with 50mM Tris-Cl, pH 7.4, 100µl of OPD tablets (1:1) dissolved 
in 20mls of distilled water was added to wells and the reaction stopped using 50µl of 
HCl (3M) and the absorbance determined at 490nm.  
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2.2.7 Migration studies of iB3 and C38 cells using wound/scratch 
assay: 
To evaluate the in vitro migratory profile of epithelial cells, 1 x 105 cells were sub 
cultured into 96 well plates and allowed to grow to confluence over 16 h in complete 
medium with supplements. Cells were cultured in AEM with supplement mix and 5% 
(v/v) FBS and 1X L-glutamine. After 4 h, medium was changed and replaced with 
medium without FBS but supplemented with 1x ITS (Insulin, Transferrin and Sodium 
Selenite). The cells were cultured overnight in serum free medium. Thereafter, using 
the wound maker® device or a 10µl pipette tip, a scratch was made across each well 
for each cell line. Each cell line was divided into two groups: treated and untreated 
groups and then after medium change cultured in 2% (v/v) serum supplemented AEM. 
The cells were incubated in an Innocyte FLR® incubator at 37oC for 24 h over which 
images were taken every hour in both treated and untreated groups at 37oC in 
humidified incubator with 5% CO2. The percentage relative wound closure i.e relative 
comparison between total area of scratch between cell migration front and space 
uncovered between migration fronts on both sides of the scratch over time. 
2.2.8  Biotinylation, as a measure of the presence of cell surface 
TG2. 
The biotinylation assay was carried out to selectively label proteins on basal or apical 
surface of cells. IB3 and C38 cells were cultured in submerged culture to determine cell 
surface TG2. Briefly, 5 x 105 cells where cultured on 10cm plates to attain a confluency 
of between 80-90% cells. The cells were washed with ice cold 1 x PBS, pH 7.4 twice. 
Cells were incubated with 80mM EZ Sulfo –NHS-LC-biotin dissolved in 1 x PBS, pH 
7.4 on ice for 20min. Excess biotin solution was removed and washed three times with 
50mM Tris-Cl, pH 8.0 and lysed in 1%(w/v) SDS in 1 x PBS, pH7.4. Cells were scraped 
off plates. A 1:1000 dilution of benzonase was then added. Following the incubation on 
ice for 30 min, the lysates were warmed up briefly and centrifuged at 300g for 5 min at 
room temperature. Protein concentration was determined using the Lowry 
quantification method. Supernatants containing 0.5mg-1mg of protein were added to 
Neutravidin® agarose beads rinsed with 1 x PBS, pH 7.4 and left overnight on a shaker 
at 4oC. The lysates were centrifuged at 1,000g for 1min at room temperature and 
supernatant discarded. The beads were washed thrice with 1x PBS, pH 7.4 discarding 
supernatant after each wash. 40µl of 2x Laemmli sample buffer was then added and 
boiled for 5 min. The beads were pelleted at 1000g for 1 min. Supernatant was used 
for SDS-PAGE and Western Blots as described in section in 2.2.3 and 2.2.4. GAPDH 
was used to check for cytoplasmic contamination.  
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2.2.9 Determination of total TGFβ1 levels secreted from airway 
epithelial cells using Human/Mouse TGFβ1 ELISA Ready-SET-Go! 
(2nd Generation) 
  
2.5 x 105 cells were cultured in complete AEM on 6-well plates. After the cells had 
attached to the plates, the medium was taken off and replaced with AEM with 1x ITS 
(Insulin, Transferrin and Sodium Selenite). Each cell line was assayed in duplicate and 
in groups with cells pre-treated with inhibitors, antibodies or chemical agents prior to 
the collection of medium. Plates were incubated for 24 h. Media was then taken off and 
centrifuged down at 300g for 5 min. The supernatant was then taken off and assayed 
for TGFβ1.  
The assay was undertaken in 96-well plates pre-coated overnight with capture antibody 
(Ab) (1:250 dilution of capture Ab in coating buffer (1x: made from 10x buffer diluted 
with water). The wells were coated with 100µl /well and incubated at 4oC overnight. 
Wells were aspirated and washed 5x with wash buffer (1x PBS, pH 7.4 with 0.05%(v/v) 
Tween-20) allowing soaking for 1 min between washes. The plates were then blotted to 
remove excess buffer. 200µl of assay diluent (5x assay diluent was diluted to 1x diluent 
with distilled water) was then used to block the wells, which were incubated at room 
temperature for 1 h. The wells were aspirated and washed with wash buffer, 5x. To the 
test samples collected from the cells, TGFβ1 was activated using 20µl of 1M HCl per 
100µl of sample and incubated at room temperature for 10 min. The samples were 
then neutralized with 1M NaOH. Standard samples were prepared from a standard 
solution of 8000pg/ml with serial dilutions made using 1x assay diluent ie 1000, 500, 
250, 125, 62.5 and 0pg/ml. 100µl of standard sample and test sample were added to 
the appropriate wells in a Nunc Maxisorp® ELISA plate in triplicates. The plates were 
covered and incubated overnight at 4oC. Plates were washed 5x with wash buffer. 
100µl of detection Ab in 1x assay buffer (1:250 dilution) was added to the treated wells 
and incubated at room temperature for 1 h. A repeat wash with wash buffer (5x) was 
done. 100µl of Avidin-HRP in 1x assay diluent (1:250 dilution) was added to each well 
and incubated at room temperature for 30 min. Wells were aspirated and washed with 
washing buffer (7x). 100µl of substrate solution (1x 3,3’,5,5’-
Tetramethylbenzidine,TMB, solution) was added to each well and incubated for 15 min. 
After a colour change was observed within 15min, 50µl of stop solution (2N H2SO4) 
was added to each well and plate absorbance was read at 450nm. 
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2.2.10 Cell viability assay for airway epithelial cells  
 
Using XTT assays, cell viability is determined with the change in the soluble yellow 
tetrazolium derivative of XTT to an insoluble orange formazan derivative by 
mitochondrial dehydrogenases. 7 X 104 cells were counted and sub-cultured into 96 
well plates and allowed to attach to the plates in complete medium at 37oC. To 
medium, 40µl of XTT reagent (1ml of XTT labelling reagent and 40µl of electron 
coupling reagent were added together and mixed to get a homogenous mixture) was 
added and allowed to incubate with cells for 4 h at 370C, 5% CO2. The assay was 
carried out at every 4h for 24h then every 24 h for 48 h ie 0, 4,8,12,18,20,24 and 48h. 
The absorbance was measured at 490nm. Assays were carried out in triplicate. 
 
2.2.11 siRNA gene silencing of TG2 in airway epithelial cells 
 
5 x 105 cells were seeded into 6-well plates in 2300µl of complete AEM with L-
glutamine, 5%(v/v) serum. The cells were incubated overnight for 18-24 h. Cells were 
divided into six groups; untreated, TG2 plasmids TG2 #1, TG2 #5, TG2 #6, TG2 #7 
(sequence of each siRNA plasmid shown in table 2.1 below) and global negative 
control. Using 100µl of serum free medium, 10nM of each siRNA was added to serum 
free medium. This was gently mixed with 12 µl of Hiperfect® Transfection reagent. The 
mixture was allowed to stand for 5-10 min and reagent added in a drop-wise manner to 
2300µl of medium with serum in each well labelled according to the plasmid used. The 
plates were gently swirled around and incubated for 24 h at 370C, 5% CO2. The cells 
were washed with ice-cold 1x PBS, pH 7.4 twice and lysed with lysis buffer for 
SDS/PAGE and Western Blotting according to the protocols described in section 2.2.3 
and 2.2.4 respectively.  
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Table 2.1: siRNA sequences for TG2: 
siRNA         CAT NO                                   SEQUENCE Base pairs 
    
TG2  #1   
 
TG2  #5     
 
TG2  #6   
 
TG2  #7 
 
     
       SI00743715 
 
       SI03020927 
 
       SI03055465   
 
       SI03101966 
CCGCGTCGTGACCAACTACAA 
 
TGGGCTGAAGATCAGCACTAA 
 
CACAAGGGCGAACCACCTGAA 
 
GACGATGGGTCTGTGCACAAA 
21 
 
21 
 
21 
 
21 
 
2.2.12.  RNA isolation from IB3 and C38 cells  
!
5 x105 cells were cultured on 60mm petri dishes in submerged medium to a confluent 
count of 80-90%. RNA was extracted using the TRIzol® method. Briefly, using a cell 
scraper, 1ml of TRIzol® reagent was added to each plate and cells were scraped from 
the petri dishes into 1ml eppendoff tubes on ice. To all the tubes, 0.2ml of chloroform 
was added, vortex for 20 seconds and incubated at room temperature for 3 min. 
Subsequently, the tubes were centrifuged at 12,000g for 15 min at 4oC. The 
supernatant from each tube was then transferred into fresh tubes and 500µl of 
Isopropyl alcohol was added to samples, which were incubated at room temperature 
for 15 min.  The samples where centrifuged at 12,000g for 10 min at 4oC.  The 
supernatant was removed completely and 1ml of 75%(v/v) ethanol was added to each 
tube, vortex and centrifuged at 7,500g for 5 min at 4oC. This was done twice. 
Thereafter the RNA pellets were allowed to dry and re-suspended in RNAse free water. 
The samples were placed on ice and subsequently quantified using the Nanodrop® 
spectrophotometer. 
 
2.2.13 Reverse Transcription of RNA to cDNA 
 
Using the Qiagen® RT2 First Strand Kit, RNA fragments from cells were transcribed into 
cDNA. 5ng of RNA template from each cell line was added to the master mix of 
genomic elimination mixture (2µl of 5x gDNA elimination buffer) to get rid of any 
genomic contaminants. 10µl of RNAse free water was added and gently mixed prior to 
incubation at 42oC for 5 min. The tube was chilled on ice for a min and for each 
reaction a reverse transcription (RT) cocktail was made containing 4µl of 5x RT buffer 
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mix, 1µl of a primer and external control mix, 2µl of a RT enzyme mix and RNAse free 
water to make up a total volume of 10µl per reaction. This was added to 10µl of the 
genomic DNA elimination mix and mixed gently pipetting up and down. The mixture 
was incubated for 15 min at 42oC and heating the tube to 95oC for 5 min stopped 
reaction. To each mix of 20µl, 91µl of RNAse free water was added and mixed. This 
mix containing the cDNA was then used for PCR. 
 
2.2.14 PCR using Qiagen® Taq polymerase Core Kit 
 
The PCR was performed to determine the amount of TG1, TG2 and FX III in IB3 and 
C38 cells cultured in submerged conditions. Using annealing temperatures derived 
from the primers for Transglutaminases (TG); TG1-2 & FX III, the PCR was performed 
using a master mix containing: 10x PCR buffer, 10mM dNTP mix, 0.3uM of forward 
and reverse primers for TG1-2 and FX III, Taq polymerase and distilled water to make 
up the volume to 50µl. To aliquots of this mix, approximately 1µg of the cDNA was 
added mixed and the tubes were placed in the block wells of a Thermal Lightcycler 
machine. According to the most appropriate temperatures, the PCR was run: 
Denaturation 1min at 94oC, Annealing at 62oC for TG1-2 and FXIII and Extension for 
1min at 72 oC. This was run for 35 cycles. A final extension for 10min at 72 oC was 
finally carried out. cDNA amplicons were run on Agarose gels (2%w/v) and gel pictures 
taken on a UV transluminator. The primer sequences of the genes used are: 
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Table 2.2: Forward and reverse primer sequence for genes used:  
Primers Forward Reverse 
TG1 5’-accgtgtgaccatgccagtg-3’ 5’-gctgctcccagtaacgtgagg-3’ 
TG2 5’-atgagaaataccgtgactgccttac-3’ 5’-cagcttgcgtttctgcttgg-3’ 
FX III 
fibronectin 
E-cadherin 
N-cadherin 
Slug 
Twist 
Zeb2 
TGFβ1 
GAPDH 
5’-gaccaatgaagaagatgttccgt -3’ 
5-’ggatgacaaggaaagtgtcccta-3’ 
5’-cctgggactccacctacaga-3’ 
5’-aacagcaacgacgggttagt-3’ 
5’-acgcctccaaaaagccaaac-3’ 
5’-agctgagcaagattcagaccctc-3’ 
5’-caagcctctgtagatggtcc-3’ 
5’-tgcggcagtggttgagccgt-3’ 
5’-tgcaccaccaacttgcttagc-3’ 
5’-gaaggtcgtctttgaatctgcac -3’ 
5’-ggtggaagagtttagcggggt-3’ 
5’-tggattccagaaacggaggc-3’ 
5’-cagacacggttgcagttgac-3’ 
5’-acagtgatggggctgtatgc-3’ 
5’-ccgtctgggaatcactgtc-3’ 
5’-atcgcgttcctccagttttct-3’ 
5’-acctcggcggccggtagtga-3’ 
5’-ggcatggactgtggtcatgag-3’ 
 
2.2.15 Real Time Polymerase Chain Reaction (RT-PCR) to determine 
relative gene expression of TG2 and EMT markers in airway 
epithelial cells 
 
This was performed according to the conditions on the Stratagene® MX-3000P real-
time PCR machine of which the annealing temperature was updated to accommodate 
the primers used for the RT-PCR. RT-PCR was carried out incorporating the labels and 
dyes in each well with the PCR master mix and primers for TG1-2. The Qiagen 
Quantitect® SYBR® Green PCR kit was used which contains a 2x Quantitect SYBR® 
Green PCR Master mix with 2.5mM MgCl2, 0.3µM of forward and reverse primers for 
TG1-2 and RNAse free water. The optimum temperatures for amplifying cDNA in 40 
cycles are; activation 95oC for 15 min, denaturation 94oC for 15 sec, annealing 62oC for 
30 sec and extension 72oC for 30 sec. This was followed by a dissociation curve, which 
began with 60 sec incubation at 95oC, 30 sec at 55oC and a final temperature ramp to 
95oC when the results are collected.  After the experiments, the results were collected 
and analysed for amplification and dissociation curves. The housekeeping gene was 
GAPDH and relative level of expression was determined in relation to GAPDH 
expression. 
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2.2.16 Cell localisation studies (Immuno-fluorescence staining)  
2.2.16.1 Submerged culture: 
 
5 x 105 cells were cultured on 60mm petri dishes. The cells were cultured to conflueny 
of about 70-90%. The cells were washed three times with 1x PBS, pH 7.4 for 3 min 
each. 200µl of 3.7% (v/v) paraformaldehyde in 1 x PBS, pH 7.4 was added to each well 
for 20min at 37oC. Cells were washed 3 times with 1x PBS, pH 7.4 for 3 min each. To 
each petri dish, 200µl of primary antibody (Ab) in complete medium was added and 
incubated for 1h at 37oC. The cells were washed 3 times with 1x PBS, pH 7.4 with 3 
min for each wash. Subsequently, the cells were incubated with 200µl/petri dish with 
Fluorescein isothiocyanate, FITC (green) or Tetramethylrhodamine, TRITC (red) 
conjugated secondary antibody at 37oC for 1h. Wells were then washed 3 times with 1 
x PBS, pH 7.4 with 3 min for each wash. A repeat was done with primary and 
secondary Ab for co-localisation studies. The petri dishes were dabbed to remove 
excess liquid and a drop of 4’,6 –diamidino- 2-phenylindole (DAPI) in mounting solution 
was added and cover slips placed on them. The petri dishes were wrapped and stored 
at 4oC prior to imaging. The petri dishes were viewed using the Leica® SP5 confocal 
microscope.  
 
2.2.16.2 ALI culture 
 
The cells at air liquid interface (ALI) were used for immunocytochemistry after 28 days. 
The membranes were carefully cut out of inserts and placed cell uppermost in 12-well 
plates using a scalpel. Using 200µl of 1x PBS, pH 7.4, cells were carefully rinsed twice. 
150µl of 3.7% (v/v) paraformaldehyde in 1x PBS, pH 7.4 was added to each insert for 
20min at 37oC. Cells were washed 3 times with 1x PBS, pH 7.4 for 3 min each. To 
each insert, 150µl of primary antibody (Ab) in complete medium was added and 
incubated for 1h at 37oC. The cells were washed 3 times with 1x PBS, pH 7.4 with 3 
min for each wash. Subsequently, the cells were incubated with 200µl of Fluorescein 
isothiocyanate, FITC (green) or Tetramethylrhodamine, TRITC (red) conjugated 
secondary antibody at 37oC for 1h. Wells were then washed 3 times with PBS, pH 7.4 
with 3 min for each wash. Samples were dabbed to remove excess fluid. The 
membranes were transferred to slides and a drop of DAPI in mounting solution was 
added to each membrane and covered with a cover slip. The slides were stored at 4oC. 
Slides were visualised under Leica® SP5 confocal microscope. 
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2.2.17 Membrane fractionation 
2.2.17.1 Submerged culture 
 
5 x 105 IB3 cells were sub cultured into 60mm petri dishes and allowed to attach for 4h. 
Medium was discarded and replaced with treated medium with VX-809 (Selleckchem®) 
(10µM), R283 (500µM), a combination of VX-809 and R283 and with DMSO as control. 
The cells were cultured for 72 h with medium changed every 24 h. Cells were washed 
with ice cold 1x PBS, p.H 7.4 twice and lysed using a homogenization buffer (75mM 
Tris-Cl, p.H 7.4, 200mM NaCl, 15mM NaF, 1.5mM Na3VO4, 7.5mM EGTA, 7.5 mM 
EDTA, 1.5% Triton X-100, 0.75%(v/v) Igepal CA-630, Protease inhibitor cocktail). Cells 
were scraped into pre-cooled eppendorff tubes and place on ice for 30 min. The 
lysates were centrifuged at 300g for 10 min and supernatant transferred into fresh 
tubes. Protein was quantified using Lowry method and 250µg of protein was 
transferred into fresh tubes and centrifuged at 17,500g for 15 min. The supernatant 
was transferred into another fresh tube and the pellets were washed with 1x PBS, p.H 
7.4 twice. 35µl of 2x Laemmli buffer was added to pellet and boiled. Western blotting 
was carried using the pellets as described in section 2.2.4. 
 
2.2.17.2 ALI culture 
 
3 x 104 IB3 cells were sub cultured into 0.33µm transwell® insert membrane coated 
with collagen IV (100µg/ml). The cells were allowed to attach for 6 h. The medium was 
changed in Transwell® inserts as well as in the companion plates. 300µl of complete 
medium was inserted into the Transwell® inserts supplemented with VX-809 (10µM), 
R283 (500µM), a combination of VX- 809 and R283 and with DMSO as control 
(1:1000). The groups were cultured in duplicates. The basal medium was changed 
daily for the first 4 days i.e. time required to attain basal ALI status. The medium was 
subsequently removed from the inserts and cells were then subject to ALI. The cells 
were treated afterwards every 2 days for another 14 days. TEER was measured using 
the voltohmmeter across the PET-itched polyethylene membrane. On attaining a TEER 
value of ≥300Ωm-1, the cells were then subject to Western blotting or 
immunocytochemistry as described above in section 2.2.4 and 2.2.16.2. 
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2.2.18 Chloride channel activity assay in IB3 cells cultured in 
submerged conditions. 
 
To determine CFTR chloride channel activity in IB3 cells, the assay was carried out as 
described by West and Molloy (1996). Briefly, 1 x 105 IB3 cells were sub cultured into 
100µl in 96-well plates and allowed to attach for 6 h. The medium was changed and 
replaced with medium supplemented with TG2 inhibitors with or without the CFTR 
corrector, VX-809 (10µM). The TG2 inhibitors used were R283 (500µM), cystamine 
(250 µM) or 1-33 (50 µM). DMSO (1:1000) was used as a vehicle control. In order to 
load the cells with a chloride sensitive indicator, 10 mM MQAE was added to 100µl/well 
according to the previously published method (West and Molloy, 1996) and cells were 
incubated at 37oC for 16-18 h. The cells were washed with chloride buffer (126mM 
NaCl, 5mM KCl, 1.5mM CaCl2, 1.0mM MgCl2, 20mM HEPES, 0.1%(w/v) BSA and 
0.1%(w/v) D-Glucose; pH 7.2) and chloride free buffer (126mM NaNO3, 5mM KNO3, 
1.0mM Mg (NO3)2, 1.5mM Ca(NO3)2, 20mM HEPES, 0.1%(w/v) BSA and 0.1%(w/v) D-
Glucose; pH 7.2) twice and incubated with either Foskolin (10 µM) or Dibutyryl Cyclic 
Adenosine Monophosphate (dbcAMP) (1mM). The fluorescence was measured in a 
SpectraMax® Multi-mode microplate reader (Molecular Devices) with excitation at 
350nm and emission at 450nm wavelengths. The fluorescence was measured for 8 
min with readings taken every 25 sec. After this, the assay buffer was replaced with 
fluorescence quenching buffer containing potassium thiocyanate and 10mM 
valinomycin and fluorescence was measured for another 8 min.  
 
2.2.19  Lentiviral Transduction of TG2 plasmids into IB3, C38 and 
HBE cells 
 
2.2.19.1 Culturing of packaging cells, HEK293FT 
 
Packaging cells, HEK293FT cells were cultured in T150 flask to 80% confluency in 
DMEM medium supplemented with 1x L-glutamine, 10%(v/v) FBS, 1mM sodium 
pyruvate, 400µg/ml G418 (the antibiotic is omitted immediately after defrosting and 
prior to transfection) and 1x Non- essential amino acids (NEAA). The cells were then 
trypsinised and sub cultured into T75 flasks prior to transfection. The cells were 
allowed to attach and proliferate overnight. The medium was changed and cells were 
then transfected with viral packaging mix and plasmids of interest TG2 shRNA (to 
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knockdown TG2 expression) and TG2 wild type with the conserved mutation to prevent 
shRNA inhibition (to over express TG2), W241A mutant (where tryptophan was 
replaced with alanine), R580A (where arginine is replaced with alanine) and C277S 
(where cysteine is been replaced with serine at position 277 at the catalytic site). 
 
2.2.19.2 Viral production of TG2 plasmids 
 
To the HEK293FT cells in T75 flasks, a transfection mix of packaging plasmid, pPAX, 
viral envelop, VSV-G and DNA of interest where mixed in a 9µg: 4.5 µg: 6µg ratio with 
Lipofectamine® 2000. The mixture was allowed to stand for 20 min to form the 
complex, which was added to the packaging cells in a drop wise manner. The mixture 
on the cells was swirled around gently to obtain a homogenous mix. The cells were 
allowed to transfect for 72 h within which viral particle were released into the medium. 
After this incubation period, the infectious medium was carefully collected. The medium 
was centrifuged at 500g for 10min to remove cell debris and viral aggregates. The 
supernatant was discarded aseptically. 
 
2.2.19.3 Lenti-X viral concentration 
 
The clarified supernatant was transferred into fresh tubes and to three volumes of 
clarified supernatant, one volume of Lenti-X virus concentrator was added (3:1) and 
gently inverted to mix. The mixture was incubated for 3-4 h at 4oC or overnight.  Virus 
was pelleted at 1,500g for 45min at 4oC. The supernatant was discarded carefully 
without disturbing the pellet. The viral pellet was re-suspended in DMEM medium 
carefully with 1/10th of the original volume used. Aliquots were made in 250µl -300µl 
and stored at -80oC. 
  
2.2.19.4 Lentiviral Titre value 
 
Lentiviral titre was determined using the Lenti-X® Go-stix. Using 20µl of the 
concentrated viral mix, this was added to the Lenti-X® Go-stix kit and 4 drops of Lenti-
X® concentrator buffer was added. This was allowed to stand for 15 min. The presence 
of two visible bands indicates viruses present in them as well as the intensity predict 
the density of the viral particles collected. 
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2.2.19.5. Viral transduction for airway epithelial cells cultured in submerged 
culture or at ALI 
 
To transduce cells with viral particles, 5 x 105 cells were sub cultured onto 6-well plates 
in complete medium and cultured overnight for 16-18 h. Media was changed and 
replaced with fresh medium. An aliquot of viral particle for the TG2 mutant of interest 
was added to wells in a drop-wise manner and plates were gently swirled to mix the 
viral particle and medium gently. The cells were then incubated at 37oC for 48 h with 
re-infection (addition of fresh aliquot of viral particle to wells) carried out every 24 h. 
The cells were viewed under the Leica® DMI 4000 inverted wide field fluorescence 
microscope for GFP green expression. The medium was aseptically discarded and 
cells were rinsed with 1x PBS, pH 7.4 twice and cells were lysed and SDS/PAGE and 
Western blotting carried out as described in section 2.2.3 and 2.2.4. Similarly, in ALI 
systems, cells were cultured as described in section 2.2.1.4 and 2.2.1.5. However, an 
aliquot of the viral particle for the TG2 mutant was added to inserts on the first day and 
re-infected on the second day during the initial 4 days prior to exposure of cells to air. 
The viral containing medium was discarded aseptically and cells were cultured at ALI 
with Western blotting carried out on lysates as described in section 2.2.4.     
 
2.2.20 Co-immunoprecipitation of TG2 and αV/β6 integrin in 
submerged medium 
 
Co-immunoprecipitation is a technique used to capture protein-protein interaction by 
indirectly using protein specific antibody to detect proteins that are bound to them. 
Briefly, 5x 105 IB3 and C38 cells were cultured in 60mm petri dish in full AEM for 48 h. 
Cells were then washed with 1X PBS, pH 7.4 twice. The cells were lysed using 50mls 
of lysis buffer; 0.25%(w/v) sodium deoxycholate, 150mM NaCl, 0.1mM PMSF, 1%(v/v) 
benzonase 1%(v/v) protein inhibitor cocktail and 500µM, R283 TG2 inhibitor in 50mM 
Tris-Cl, pH 7.4. The cells were then scraped into eppendorf tubes and allowed to stand 
on ice for 30min. The cells were centrifuged at 300g for 5min and supernatant was 
collected. Protein was quantified using the Lowry method. 200µg of IB3 and C38 
protein were placed into tubes and made up with lysis buffer (20µl). Correspondingly, 
50µl of beads: Protein A beads for Rabbit Ab and Protein G beads for Mouse Ab were 
pre-washed with 25µl of 1x PBS, pH 7.4 twice spinning at 1000g for 1 min and 
discarding supernatant. Finally, the beads were suspended in 25µl of 1x PBS, pH 7.4. 
To beads, all the cell lysates were added to corresponding beads with the initial protein 
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complex to be detected (Mouse or Rabbit); αV (Mouse), β6 (rabbit) and TG2 (Rabbit). 
This was left on shaker for 90min at 4oC (pre-clearing). The mixture was spun down at 
1000g for 1min and supernatant was collected into new tubes. 0.5µg of antibody 
(200µg/ml) was added to supernatants and placed on a shaker for 90min at 4oC. Again, 
beads corresponding to the “pull-down” protein were washed as described above and 
the mixture of antibody and proteins were added to the beads and allowed to incubate 
on shaker for 2 h at 4oC. This was spun at 1000g for 1 min and lysates were collected 
and 30µl of 2x sample buffer was added and heated for 3min prior to running a 
Western blot. Pull-down antibodies were used in detection. 8%(w/v) gels were made 
and SDS-PAGE/Western blotting was performed as described in section 2.2.3 and 
2.2.4.  
 
2.2.21 Statistical analysis 
 
All statistical analysis was carried out using either the One-way or Two-way Anova 
method with data presented as mean and standard deviations. Analysis was performed 
with the Graph pad Prism® software.  
 
!!
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TG2 expression and activity in 
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3.1 Introduction: 
!
The catalytic mechanism of TGases is common amongst all members and involves a 
transamidation reaction resulting in the formation of Nε-(γ-glutamyl) lysine bonds 
between proteins leading to high molecular weight complexes, resistant to proteolytic 
degradation (Griffin et al., 2002). As a consequence, this important effect of TGases on 
their substrate proteins can account for a number of human pathologies including 
various fibrotic and neurological diseases, illustrating the significance of this family of 
enzymes in disease progression.   
Tissue transglutaminase (TG2) is the most ubiquitous member of this family of 
compounds and the most studied in the group. Studies have shown its involvement in 
the pathogenesis of many diseases with underlying fibrosis where a depletion of 
energy levels, destabilisation of calcium homeostasis and elevation of reactive oxygen 
species lead to TG2 activation (Grosso and Mouradian, 2012). The normal 
physiological level of calcium within the cell is about 100-200nM, at which, TG2 ceases 
to function either due to the presence of inhibitory levels of GTPase (50-300µM) or 
other regulatory processes. This suggests that the activation of intracellular TG2 
requires an immense distortion of physiological conditions which in turn promotes the 
covalent Ca2+-mediated crosslinking by TG2 of glutamine containing protein and 
peptide substrates to lysine containing peptides or to primary amines (Folk and 
Finlayson, 1977, Greenberg et al., 1991, Griffin et al., 2002, Siegel and Khosla, 2007). 
This reaction however occurs at the catalytic domain of the enzyme (Beninati and 
Piacentini, 2004). Hence, TG2 assumes an active, open (Ca2+-bound) or an inactive 
closed (GTP bound) conformation, which regulates its activity intracellularly or 
extracellularly when secreted through an unknown mechanism. Studies have shown 
that this secretory pathway obviates the ER/Golgi pathway due to the lack of a signal 
sequence however its trafficking to the cell surface requires an intact N-terminal β-
sandwich domain (Balklava et al., 2002, Gaudry et al., 1999a, Gaudry et al., 1999b) 
and its interaction with the cell surface heparan sulphate proteoglycan syndecan-4 
(Wang et al., 2012).  
As studies unfold about the importance of TG2 activity in inflammation, evolving 
studies have shown the TG2 gene to be activated by various factors. With the TG2 
protein having a half-life of around 11 h, the sustainability of its activity would depend 
on either a constitutive or non-constitutive activation of its gene. Retinoid and steroid 
hormones have been shown to increase TG2 transcription (Verderio et al., 1998, 
Melino et al., 1988, Piacentini et al., 1988). Various cytokines and inflammatory factors 
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like TGFβ1 via a TGFβ response element and TNF-α via IκB phosphorylation have 
been shown to increase TG2 gene expression by acting directly on the TG2 promoter 
site (Ritter and Davies, 1998, Kuncio et al., 1998). This suggests that with an increase 
in co-factors that increase TG2 gene expression in pathological conditions, a 
consequential progression of inflammation followed by fibrosis might ensue in a 
number of diverse diseases where TG2 is implicated. 
TG2 and TGFβ1 have been shown to interact in a vicious circular relationship in 
various fibrotic diseases and this association has been characterised by the elevation 
of both activities (Kojima et al., 1993, Nunes et al., 1997, Akimov and Belkin, 2001b, 
Telci et al., 2009). In addition, this relationship promotes TG2 externalisation to the cell 
surface and deposition into the matrix via a cell heparan sulphate- dependent 
mechanism where active cell surface and matrix bound TG2 cause an increase in 
TGFβ1 activation via its crosslinking of the large latent TGFβ binding protein (Akimov 
and Belkin, 2001b, Verderio et al., 1999, Verderio et al., 1998). In CF, lung remodelling 
and fibrosis has been linked to an increase in TGFβ1 where elevation of TGFβ1 has 
been shown to down regulate the expression of the CFTR channel (Bremer et al., 
2008, Pruliere-Escabasse et al., 2005, Snodgrass et al., 2013). Studies by Olsen et al. 
(2011) have linked elevated TG2 expression in the lungs with an increase in fibrosis 
where elevation of TGFβ1 increases externalisation and activity of TG2 on the cell 
surface. It was further investigated and shown by Olsen et al. (2013) that TG2 activity 
was inhibited using electrophilic molecules that abrogate fibrosis in Idiopathic 
Pulmonary Fibrosis (IPF).   
Recent studies have correlated the progression of fibrosis in CF with an increase in 
TG2 expression. Maiuri et al. (2008) and Luciani et al. (2009) showed that SUMOylated 
TG2 prevents enzyme degradation but elevates activity which in turn increases 
reactive oxygen species (ROS), down regulates PPAR-γ and activates the NFκB 
inflammatory pathway with sustained inflammation in the lungs. They further extended 
the work to show that a defect in cellular autophagy occurred due to an increase in 
sequestration of beclin 1 and its associate partner, phosphatidylinositol-3-Kinase (PI(3-
)K), as a consequence of TG2 SUMOylation, thus sustaining the unremitting 
inflammation in CF.  
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3.2 Aims: 
In this chapter, work will be undertaken to determine if in CF cell models; 
! The elevation of TG2 protein levels can be correlated with an increase in TG2 
activity.  
! To determine the levels of TGFβ1 in CF cells. This will include the mutant CF 
cell line, IB3 and its corrected “add-back” cell, C38 as well as primary human 
bronchial epithelial cells, (HBEC) cultured in submerged conditions. 
! Also, to evaluate the effect of TG2 cell-permeable and impermeable inhibitors 
on TG2 activity on whole cell lysates and on cell surface.  
! In addition, to evaluate the effect of TG2 inhibition on TGFβ1 secretion and 
activity.     
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3.3 Methods:  
3.3.1 RNA purified from IB3 and C38 cells cultured in submerged 
medium 
 
To purify RNA from IB3 and C38 cells, 5 x105 cells were cultured in 10mm petri dishes 
to a confluency of 80-90%. RNA was extracted using the TRIzol® method as described 
in chapter 2.2.12. The RNA levels in samples were quantified using the Nanodrop® 
spectrophotometer. 
3.3.2 IB3 and C38 RNA reverse transcribed to cDNA 
 
Using the Qiagen® RT2 First Strand Kit, RNA fragments from IB3 and C38 cells were 
transcribed into cDNA as described in chapter 2.2.13. cDNA obtained from the cells 
was then used for PCR. 
 
3.3.3 TG1-4 and FX III gene expression determined using PCR 
  
The PCR was performed using annealing temperatures derived from primers for 
Transglutaminases (TG); TG1-4 & Factor 13, FX III. The PCR was performed as 
described in chapter 2.2.14. PCR was run for 35 cycles and cDNA amplicons were 
separated on agarose gel (2%w/v) and gel pictures taken on a G:BOX UV 
transilluminator.  
 
3.3.4 SDS-PAGE/Western Blotting to determine whole cell and cell 
surface protein expression of TG2 
 
8%(w/v) polyacrylamide gels were made and protein samples (50µg of protein per 
lane) separated as described in chapter 2.2.3. Western blotting as described in chapter 
2.2.4 using TG2 antibody was used to immunoblot membranes and bands detected 
using luminescence obtained using ECL reagent (1:1) and images captured using the 
G:Box (Syngene®). 
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3.3.5 Surface proteins biotinylation to determine cell surface TG2 in 
IB3 and C38 cells 
 
The biotinylation assay was carried out on IB3 and C38 cells cultured in submerged 
culture to determine cell surface TG2 as described in chapter 2.2.8. Western blotting 
as described in chapter 2.2.4 was carried out using biotinylated protein samples. 
 
3.3.6 TG2 activity determined on whole cell lysates and cell surface 
proteins using the Biotin Cadaverine incorporation assay 
 
5 x105 IB3 and C38 cells were cultured in 6-well plates for 6 h to allow attachment and 
medium was changed and replaced for treated groups supplemented with TG2 cell-
permeable inhibitor, R283 (500µM). Whole cell lysates from IB3 and C38 cells, were 
obtained as described in chapter 2.2.2.1 were used for TG2 activity assay as described 
in chapter 2.2.6.1. For cell surface TG2 activity, IB3 and C38 cells were treated with 
TG2 cell-permeable inhibitors; R283 (500µM) and Z-Don (50µM) and cell impermeable 
inhibitors; R292 (250µM) and R294 (250µM) in the presence of 0.1mM biotin 
cadaverine in fibronectin (5µg/ml) coated plates. Assays were carried out as described 
in chapter 2.2.6.2.  
 
3.3.7 Determination of Total TGFβ1 Assay using Human/Mouse 
TGFβ1 ELISA Ready-SET-Go!® (2nd Generation) 
  
2.5 x 105 IB3 and C38 cells were cultured in 400µl per well complete AEM in 12 well 
plates. The cells were cultured for 6 h to allow attachment in complete medium. The 
cells were then treated with TG2 inhibitors; R292 (500µM), R294 (500µM), R283 
(500µM), (50µM) and Z-Don (100µM) in serum free medium supplemented with 1x ITS 
supplement and incubated for 24 h. The medium was collected and centrifuged at 300g 
for 5min to remove cell debris. The ELISA for TGFβ1 was performed as per the 
manufacturer’s instructions (eBiosciences). All experiments were carried out in 
triplicate as described in chapter 2.2.9.  
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3.4 Results: 
3.4.1 Differential TGases expression in CF cells 
 
Previous studies have not elaborated on the differential gene expression of 
transglutaminases in the lung. Although a myriad of findings have been made on the 
gene expressional levels of TG1 and TG2 in the lungs. Studies have shown in human 
bronchial epithelial cells (HBEC), that mRNA levels of TG1 and TG2 are elevated by 
the presence of the pro-fibrotic cytokine, TGFβ1(Vollberg et al., 1992). Schittny et al., 
(1997) described the presence of TG2 mRNA and protein in whole lung homogenates 
from Wistar rats obtained one day before term. Also Hiiralgi et al., (1999) showed using 
mouse lungs, liver and kidney that TG1 was distributed in these tissues with the 
kidneys and liver expressing higher amount than the lungs. Here, an attempt is made 
to show the differential gene expression of TGases in CF cells using the CF cell line, 
IB3 and its “add-back” cell, C38 in submerged culture. Results show that TG1 and TG2 
genes were expressed in IB3 and C38 cells compared to the control. No gene 
expression was observed for TG3 and FX III in either cell line (Figure 3.1A). Comparing 
TG1 and TG2 gene expression using RT-PCR (Figure 3.1B) showed that IB3 cells 
expressed higher gene levels of TG1 over C38 cells whilst for TG2, a similar increase 
in gene expression was observed between C38 cells and IB3 cells. IB3 and C38 cells 
expressed more TG2 than TG1 with IB3 cells significantly showing more TG2 
expression. This result supports earlier studies of TGases gene expression in the lung 
and further suggests that an increase in TG1 and TG2 genes in CF cells occurs either 
in a reparative or pathological manner. 
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Figure 3.1A: TG gene expression in IB3 and C38 cells. cDNA products of IB3 and 
C38 cells were run on 2% agarose gel. Lanes are labelled with marker, M, TG1-3 and 
FXIII for IB3-1 and C38 cDNA. Recombinant TG1-3 and FXIII were used as positive 
controls (labelled recombinant plasmid). Gels were stained with ethidium bromide and 
images were taken using the G:Box. Experiments were carried out twice. Result shows 
gene expression of TG1 (172bp) and TG2 (167bp) in IB3 and C38 cells. 
 
Figure 3.1B: Relative TG1 and TG2 expression in IB3 and C38 cells cultured in 
submerged culture. RNA was extracted from IB3 and C38 cells and RT-PCR was 
carried out with primers for TG1 and TG2. CT values were analysed using ΔΔCt method 
using GAPDH as house keeping gene. Values indicate mean and standard deviation of 
two independent experiments carried out in triplicates. Results show high TG1 and 
TG2 expression in IB3 cells compared to C38 cells however the TG2 expression was 
shown to be higher than TG1 expression in both cell lines.  
!
A#
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3.4.2: CF phenotype correlates with elevated TG2 protein expression 
levels 
 
Elevated TG2 protein expression has been associated with the progression of various 
fibrotic conditions as mentioned in chapter 1. At the epicentre of the discussion in 
chapter 1, studies have linked high TG2 protein expression in CF with the sequestering 
of peroxisome proliferator activated receptor gamma (PPAR-γ) (Maiuri et al., 2008), 
SUMOylation (Luciani et al., 2009b) and defective autophagy (Luciani et al., 2010b, 
Luciani et al., 2012). To demonstrate the protein levels of TG2 expressed in CF, IB3, a 
CF cell line and the corrected “add-back” cell, C38 were used for this study. Results 
show elevated TG2 protein expression in whole cell lysates of IB3 cells compared to 
C38 cells. C38 cells showed a 5-fold decrease in TG2 expression compared to IB3 
cells (Figure 3.2B). These observations concur with the results shown by Maiuri et al. 
(2008) where TG2 protein expression in IB3 cells was higher compared to protein 
expression in C38 cells.         
 
                        
 
Figure 3.2A-B: TG2 expression in whole cell lysates of IB3 and C38 cells. IB3 and 
C38 cells were cultured in submerge culture for 48h. Cells were lysed and 50µg of 
protein was used for SDS/PAGE and Western blotting (WB) was carried out as 
described in methods. The WB represents a typical result of three independent 
repeats. Densitometry analysis shows the mean values and standard deviation of 3 
experiments normalised to GAPDH expression and indicates that IB3 cells express 
higher TG2 protein compared to C38 cells. A 5-fold increase in TG2 expression was 
observed in IB3 cells compared to C38 cells.    
 
A# B#
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Studies have implicated cell surface TG2 in fibronectin assembly where they crosslink 
these matrix proteins and form high molecular weight complexes (Jones et al., 1997, 
Verderio et al., 1998). Also Martinez et al. (1994) demonstrated using hepatocytes and 
endothelial cells that TG2 crosslinks fibronectin forming high molecular weight 
complexes. Here an attempt is made to evaluate cell surface TG2 protein expression in 
IB3 and C38 cells in submerged culture. The results observed in Figure 3.3A shows an 
elevation of TG2 cell surface protein expression in IB3 cells compared to C38 cells. 
TG2 expression in IB3 cells was >5 fold more than protein expression observed in C38 
cells. This is in concert with what was observed in whole cell lysates in Figure 3.2. This 
suggests an involvement of cell surface TG2 in orchestrating the effect of TG2 in these 
cells.  
 
           
Figure 3.3A&B: TG2 expression on the surface of IB3 and C38 cells. IB3 and C38 
cells were cultured in 60mm petri dishes and cell surface TG2 was captured using 
biotinylated Sulfo NHS biotin to label cell surface proteins as described in methods. 
500µg of biotinylated proteins were loaded on 8% (w/v) gels for Western blotting as 
described in methods. GAPDH was used to check for cytosolic protein contamination. 
The image represents a typical result from three independent repeats. Densitometry 
analysis show high TG2 cell surface protein in the total biotylated protein of IB3 
compared to C38 cells with a >5-fold decrease in TG2 cell surface expression was 
observed in C38 cells. Data represent mean values and standard deviation of 3 
independent experiments normalised to total TG2 expressed.  
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Using normal primary human bronchial epithelial cells, HBEC, TG2 protein expression 
was compared with IB3 cells to demonstrate the pathological variation of TG2 protein, 
expressed in CF and non-CF cells, cultured in submerged medium. Cell culturing and 
Western blotting was carried out as described chapter 2.2.1.2 and 2.2.4. Results show 
HBEC protein blots from passage 2 cells. It was observed that HBEC cells express 
very low levels of TG2 compared to IB3 cells (Figure 3.4 A&B). Densitometry shows an 
increase in TG2 protein expression in IB3 cells compared to normal HBEC cells. 
Luciani et al. (2009, 2010) suggested TG2 SUMOylation to be responsible for the 
elevated TG2 observed in the disease linking that to ER stress and an increase in 
reactive oxygen species (ROS) levels, which results from the effect of the mutated 
CFTR channel. Although, the results showed here are preliminary, this is indicative of 
TG2s involvement in the disease.  
                     
 
Figure 3.4A&B: TG2 expression in whole cell lysates of IB3 cells compared to 
primary human bronchial epithelial cell (HBEC) cells. IB3 and HBEC cells were 
cultured in 6-well plates for 48h prior to cell lysis and 50µg of protein used for Western 
blotting as previously described in chapter 2.2.4. GAPDH was used to normalise 
protein loading. A: The blot image is a characteristic result from two independent 
repeats. B: Densitometry represents the mean values and standard deviation of 2 
independent experiments normalised to GAPDH intensity. Results suggest relatively 
high TG2 protein expression in IB3 cells compared to HBEC cells. This suggests there 
is more TG2 protein expressed in CF cells than normal cells.   
 
 
 
 
A# B#
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3.4.3: Elevated TG2 activity concurs with increased TG2 protein 
expressed in CF cells 
 
A number of airway diseases where TG2 has been implicated have demonstrated the 
activity of the TG2 in these diseases to be directly linked to the presence of the protein. 
Olsen et al. (2011) showed that an elevation of TG2 protein in IPF correlated with an 
increase in TG2 activity, which was further augmented in the presence of TGFβ1. As 
observed in CF IB3 cells, TG2 protein levels were shown to be markedly elevated. 
Here, using IB3 and C38 cells, TG2 activity is determined to observe the correlation 
between protein expression and activity. Whole cell lysates and intact cells (for cell 
surface activity) were obtained and an assay was carried out to determine TG2 activity 
as described in chapter 2.2.6.1 and 2.2.6.2. The results from Figure 3.5A&B show 
elevated TG2 activity in IB3 cells compared to C38 cells for both whole cell lysates and 
cell surface TG2. However, in the presence of R283, a cell-permeable TG2 inhibitor 
(Skill et al., 2004, Harrison et al., 2007), a 2-fold inhibition in activity in IB3 and C38 
cells was observed in whole cell lysates. This was however mirrored with cell surface 
TG2 activity showing a 2-fold increase in TG2 activity in IB3 cells compared to C38 
cells. However in the presence of both TG2 cell-permeable (R283, Z-Don) and 
impermeable inhibitors (R292 and R294), a significant inhibition was observed in cell 
surface TG2 activity in IB3 cells but only marginally observed in C38 cells. Compared 
to the negative control where activity was abolished with 10mM EDTA (not shown), 
C38 cells showed no significant surface activity. 
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Figure 3.5A: TG2 activity in whole cell lysates of IB3 and C38 cells. IB3 and C38 
cells were cultured under submerged conditions in 6 well plates for 48 h. Cell lysates 
were collected and incubated with TG2 cell-permeable inhibitor; R283 (500µm). 
Results show significantly higher expression of TG2 in untreated IB3 cells compared to 
untreated C38 cells. However, in the presence of R283, TG2 expression was 
significantly inhibited in both cell lines with a >2-fold inhibition in IB3 cells and an 
estimated 2-fold inhibition in C38 cells. The results represent means and standard 
deviation of three independent experiments carried out in triplicates. Two-way Anova 
with Bonferroni post-tests: **p<0.01, ***p<001. 
                        
Figure 3.5B: TG2 cell surface activity in IB3 and C38 cells. IB3 and C38 cells 
cultured for 48 h and cells detached from matrix using 0.5mM EDTA in 1x PBS, pH 7.4. 
The cells were plated on fibronectin coated plates and incubated with TG2 inhibitors; 
impermeable {R292 (500µm), R294 (500µm)} and permeable {R283 (500µm) and Z-
Don (50µm)}. Cell surface TG2 expression is higher in IB3 cells compared to C38 cells 
however, in the presence of both cell permeable and impermeable inhibitors, TG2 
expression was inhibited 2-fold in IB3 cells. Results represents mean values and 
standard deviation of 3 independent experiments carried out in triplicates. One-way 
Anova with Dunnett’s multiple comparison tests: ***p<0.0001, n.s p>0.05.
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3.4.4: TG2 is involved in the activation of TGFβ1 in CF cells. 
 
Previous studies have shown a link between TG2 activity and TGFβ1 activation in 
various cells. In bovine aortic endothelial cell (BAEC), an elevation of TG2 levels by 
retinoids correlated with an increase in activation of TGFβ1 from its latent form (Kojima 
et al., 1993). In addition, an inhibition of TG2 activity via TG2 inhibitors or neutralising 
antibody abolished this process. Similarly, Nunes et al. (1997) demonstrated that both 
latent TGFβ1 binding protein (LTBP-1) and large latent complex are TG2 substrates, 
which are covalently cross-linked into the matrix serving as intermediates for the 
activation of TGFβ1. To show that TGFβ1 receptors play a role in TG2 activation of 
TGFβ1, the serine-threonine kinase receptors of TGFβ1, RI and RII protein expression 
was determined. Results in Figure 3.6A show expression of TGFβ RI and RII in IB3 
and C38 cells with expression of TGFβ RI shown to be higher in both cells compared 
with RII. These results show that CF cells express TGFβ receptors and suggest the 
possible involvement of TGFβ1 in CF disease in these cells. 
 
                                             
 
Figure 3.6A: TGFβ receptor 1 and 2 (RI and RII) expression in IB3 and C38 cells. 
Cells were cultured for 48h in complete medium before lysis and 50µg of protein used 
for Western blotting (WB). The WB images represent a characteristic result of 2 
independent experiments. GAPDH was used to normalise protein loading. Results 
show expression of TGFβ RI and RII in both cell lines with relatively more TGFβ RI 
expressed in both IB3 and C38 cells.  
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To evaluate the level of TGFβ1 in the CF cells, TGFβ1 gene expression and levels 
were measured. To determine gene expressional levels, cDNA from IB3 and C38 cells 
were used with specific TGFβ1 primers as listed in table 2.2. The ΔΔCT method was 
used with GAPDH serving as housekeeping gene. Results shown in Figure 3.6B 
indicate that TGFβ1 gene expression is higher in IB3 cells compared with C38 cells. 
C38 cells showed similar expressional levels to negative control, which indicates 
marginal TGFβ1 gene expression in these cells. Further replicates will determine if the 
observations made are significant.  Also secreted TGFβ1 levels were evaluated in 
serum free medium collected from IB3 and C38 cells cultured in submerged conditions. 
To quantify soluble TGFβ1, standard curves were first constructed using recombinant 
human TGFβ1 protein and TGFβ1 levels in cell culture samples were determined 
relative to the standard values. 
 
                         
Figure 3.6B: TGFβ1 gene expression in IB3 and C38 cells. The cells were cultured 
for 48 h and RNA was extracted using the TRIzol method. cDNA was used for the RT-
PCR. GAPDH was used as housekeeping gene and RNAse free water (H20) as 
negative control. Results show high TGFβ1 expression in IB3 cells and negligible 
expression in C38 cells. Results represent mean values and standard deviation of two 
independent experiments carried out in triplicates. 
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The results shown in section Figure 3.6B with TGFβ1 gene expression was confirmed 
when TGFβ1 levels were determined in serum free medium. The results (Figure 3.6C) 
show that minute TGFβ1 cytokine was secreted by C38 and HBEC. However, TGFβ1 
levels found in the culture medium of IB3 cells was significantly elevated (p<0.002) as 
a 4-fold increase was observed compared to C38 cells. These observations correlate 
with TG2 gene and protein expression and could reflect a hypothetical link between the 
expression of TG2 and TGFβ1.##
                      
Figure 3.6C: TGFβ1 levels in IB3, C38 and HBEC cells. The cells were cultured in 
serum free medium for 24h before supernatants were collected and TGFβ1 levels 
measured by ELISA. AEM was used as the negative control (not shown). Results show 
a 4-fold increase in TGFβ1 levels secreted by IB3 cells compared to C38 or HBEC 
cells. HBEC and C38 cells secrete very low levels of TGFβ1. Results represent mean 
values and standard deviation of three independent experiments carried out in 
triplicates. One way Anova analysis with Bonferroni’s Multiple comparison test; 
***p<0.002.    
 
Consequently, since this study hypothesises an activation of TGFβ1 from its latent 
forms by TG2, an inhibition of TG2 by TG2 inhibitors should consequentially block that 
activation thus impeding the release of TGFβ1 from its latent complex. Hence, IB3 and 
C38 cells were treated with cell permeable and impermeable TG2 inhibitors. Results 
show a significant decrease in TGFβ1 levels in IB3 cells in the presence of TG2 
inhibitors. As shown in Figure 3.6D, a > 2-fold decrease in TGFβ1 levels was observed 
between IB3 and the control CF cell, C38 cells, which expresses marginal TGFβ1 gene 
expression and mirrors TGFβ1 levels in the presence of TG2 inhibitors which show 
similar low levels of TGFβ1. This result suggests that TG2 is involved in the activation 
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of TGFβ1 from its latent forms and proposes a direct link between TG2 and TGFβ1, 
where TG2 drives TGFβ1 activation.  
                     
Figure 3.6D: TGFβ1 levels in IB3 and C38 cells incubated with TG2 cell-
permeable and impermeable inhibitors. The cells were cultured in serum free 
medium for 24 h. Media was collected and TGFβ1 levels were determined. AEM 
medium was used as negative control (not shown). It was observed that for IB3 cells in 
the presence of TG2 cell permeable and impermeable inhibitors, soluble TGFβ1 was 
significantly inhibited. The inhibition observed to be >2-fold compared to untreated 
cells. C38 cells produced low levels of TGFβ1 and did not change in the presence of 
inhibitors. Results represent mean values and standard deviation of three independent 
experiments carried out in triplicates. One- way Anova with Dunnett’s multiple 
comparison test: ***p<0.0001, n.s p>0.05.  
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3.5 Discussion:  
!
The previously elucidated role for TG2 in CF was centred on increased protein 
expression and transamidation activity with recent studies attributing this to a faulty 
degradation mechanism involving TG2 SUMOylation and its ability to obviate the 
ubiquitin-proteosomal system (Luciani et al., 2009b). The main mechanism of 
accomplishing this role relies on the transamidation activity of TG2. Here the results 
show that in CF cell lines, TG2 expression is driven by its intricate regulation by 
TGFβ1, the pro-fibrotic cytokine highly secreted and activated in CF. Although, studies 
have shown its relationship in other respiratory diseases, this is the first account of 
TG2 shown to be activating TGFβ1 in CF cells. 
These studies have shown, using the CFTR mutant cell, IB3, that TG2 expression 
correlates with high TGFβ1 secreted from these cells (Figure 3.2 and 3.6D). Hence 
TG2 gene expression was shown to be elevated in contrast to its corrected cell, C38. 
Consequently, TG2 protein expression in IB3 cells was significantly increased which 
coincided with an elevated TG2 activity as measured by a TG2 incorporation assay in 
fibronectin (Figure 1.5A). Importantly, these results show that cell surface TG2 plays a 
vital role in orchestrating TG2 function in CF. Verderio et al., (1999) and Akimov et al., 
(2001a) reported on the role of cell surface TG2 and the effect of activating TGFβ1 in 
relation to matrix growth. Elevated active cell surface TG2 is present in IB3 cells, which 
is inhibited by both cell-permeable (R283 and Z-Don) and cell impermeable TG2 
inhibitors (R292 and R294) but is minimally expressed in C38 cells. These results show 
that the protein expression and activity of TG2 in whole cell lysates can be reversed 
significantly in the presence of inhibitors and demonstrates the importance of cell 
surface TG2 in the total TG2 activity of the cell. This also implies that TG2 is active in 
CF cells and suggests further that the activity observed in CF cells might be originating 
from the cell surface as calcium was augmented in whole cell lysates therefore a 
slightly elevated TG2 activity observed and the presence of cell-permeable inhibitors 
did not markedly change the inhibitory pattern observed on the cell surface. It therefore 
can be postulated in concert with literature that high TG2 protein in CF cells may 
account for elevated TG2 activity and cell surface TG2 activity might be responsible for 
the observed TG2 effects. 
 
In retrospect, the overarching role of TGFβ1 has been elucidated in various pulmonary 
diseases including asthma (Hackett et al., 2009, Drumm et al., 2005), IPF (Olsen et al., 
2011) and CF (Arkwright et al., 2000, Drumm et al., 2005) and remains an important 
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physiological driver of fibrosis in the lungs. This study has shown elevated levels of 
TGFβ1 in IB3 cells but interestingly TG2 inhibitors abrogate TGFβ1 secretion (Figure 
3.6D). Also, the inhibition was observed equally between all TG2 inhibitors, which 
suggest that cell surface TG2 might principally be involved in the secretion of TGFβ1 in 
CF. The study has showed that both IB3 and C38 cells bear TGFβ1 receptors RI and 
RII on their cell surface. This supports the hypothesis that TG2 is principally involved in 
the release of TGFβ1 from its latent complex and so might serve as a rate limiting step 
necessary in driving disease processes where TGFβ1 plays a major lead role.  In 
comparison, the study observed that HBEC cells show minimal TGFβ1 levels that are 
similar to C38 cells. This suggests that in normal bronchial epithelial cells, although 
TGFβ1 plays a role as a proinflammatory cytokine in normal wound healing, an 
unremitting TG2 in CF maximises its inflammatory characteristics leading to a pro-
fibrotic cascade. Also the marginal expression of TG2 in HBEC cells suggests that 
although TG2 might be present in normal lungs, its probable activity centres on TG2s 
pathological role, where it can drive or is driven to support the progression of airway 
diseases.  
 
3.6 Conclusion 
Although the findings are in their nascent stages, it can be hypothesised that since 
TG2 inhibitors reduce TGFβ1 levels, active TG2 in CF cells may be involved in the 
release and activation of TGFβ1 from its latent forms and might be involved in the 
pathology of CF. 
 
!!
 
 
 
Chapter 4 
 
The Role of TGFβ1 in CF: An 
outlook on EMT and the effect 
of TG2 inhibition and 
knockdown on EMT in CF cells 
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4.1 Introduction: 
!
A large number of studies have correlated the progression of pulmonary fibrosis with 
the pro-fibrotic cytokine, TGFβ1 (Bartram, 2004, Olsen et al., 2011, Frank et al., 2003, 
Sheppard, 2006b, Kwong et al., 2006). Evidence suggests that the increased growth 
and stabilisation of the matrix contributes significantly to the progression of fibrosis. 
However, Kaminski et al., (2000) hypothesised in a comprehensive review of genes 
regulating pulmonary fibrosis, that aside from elevated TGFβ1 and its cohort of 
inducible genes, other regulatory factors contribute to the progression of fibrosis. 
 
In CF, the insidious progression of fibrosis has been attributed to elevated levels of 
TGFβ1 (Snodgrass et al., 2013). Gene profiling has shown that amongst 10 important 
genetic modifiers of CF, the polymorphism carried on the TGFβ1 gene significantly 
accentuates pulmonary fibrosis in CF (Drumm et al., 2005). Arkwright et al., (2000) 
observed that the polymorphism in TGFβ1 on codon 10 accounts for the chronic 
pernicious fibrosis in CF airways. Later, Hilliard et al., (2007) observed in 
bronchoalveolar lavage (BALF) of children (< 17 yrs), a correlation between the 
elevated levels of TGFβ1 with the thickening of reticular basement membrane, 
primarily linked to airway remodelling in CF. This occurs due to the inhibition of matrix 
degradation by TGFβ1 thus decreasing metalloproteinases, collagenases and 
stromelysin production whilst the level of protease inhibitors like tissue inhibitor of 
metalloproteinases (TIMP) are elevated (Edwards et al., 1987). In contrast, TGFβ1 in 
normal lungs plays a vital role in regulating tissue remodelling in wound injury (Grande, 
1997), maintaining lung homeostasis and cell proliferation/differentiation (Bartram, 
2004).  
 
In relation to TG2, studies have shown that the large latent TGFβ1 binding protein 
(LTBP-1) is a substrate of TG2 and demonstrated that TG2 mediated crosslinking is 
important in TGFβ1 dissociation from the TGFβ pro-peptide, latency activated peptide 
(LAP), in the activation of TGFβ1 (Nunes et al., 1997). TG2, in its role at the cell 
surface/matrix is involved in crosslinking LTBP-1 to the matrix and hence can release 
the small latency complex, which on exposure to pH changes, heat or proteolysis 
releases active TGFβ1. This culminates in the activation of TGFβ1 by TG2 and this 
complex interaction has been shown to account for the increased activation of TG2 by 
TGFβ1 via the TGFβ response element on the TG2 promoter site (Kojima et al., 1993, 
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Ritter and Davies, 1998, Telci et al., 2009). Thus it can be hypothesised that in the 
presence of exogenous TG2 or TGFβ1, an elevation of TGFβ1 or TG2 can be 
observed. Munger et al. (1999) and Mu et al. (2002) described the activation of TGFβ1 
in epithelial cells to depend chiefly on the integrins, αV, where certain subsets, αVβ6 
and αVβ8 could bind directly to the RGD motif of LAP and in some cases induce 
conformational changes which exposes latent TGFβ1 to membrane type-1 MMP 
cleavage thus activating TGFβ1. A large number of studies have attempted to show the 
role αVβ6 integrin plays in the activation of TGFβ1 by ultimately linking its association 
with LAP via binding to the recognition sequence, RGD and activating the cytokine. 
This was shown with co-cultures of bovine aortic endothelial cell (Cho et al., 2007) or 
bovine aortic smooth muscle (BSM) which were β6 transfected expressing αVβ6 on the 
cell surface as well as Mink stably lung epithelial reporter cells transfected with the 
TGFβ responsive portion of the plasminogen activator inhibitor 1 promoter driving the 
expression of firefly luciferase (Abe et al., 1994), where an elevation in luciferase 
activity was measured. However, this was abrogated in the presence of TGFβ or αVβ6 
antibodies (Sheppard, 2005).  Research has also shown that the β6 integrin subunit 
exists only as αVβ6 as deletion of the β6 domain abrogated TGFβ1 activity without 
impairing adhesion to LAP (Busk et al., 1992, Sheppard, 2005). Although epithelial 
injury is associated with the increase of αVβ6 integrin, its paracrine effect depicts its 
peculiarity in activating TGFβ1 devoid of the release of the cytokine from its latent 
complexes (Breuss et al., 1995). This was depicted by the loss of TGFβ1 activity in 
mink TGFβ reporter cells plated across a microporous plate with β6-transfected cells. 
The result observed was attributed to the loss of direct cell-cell contact (Henderson and 
Sheppard, 2013). Together, this suggests that although αVβ6 might be involved in the 
activation of TGFβ1, other proteins/mechanisms may be involved.  
 
In fibrosis, the lung epithelial microenvironment has been shown to undergo 
extracellular reorganisation described as Epithelial to Mesenchymal Transition (EMT) 
chiefly orchestrated by TGFβ1 as part of its pro-fibrotic role (Kasai et al., 2005, Doerner 
and Zuraw, 2009). Here, TGFβ1 plays the central role of promoting fibrosis as a 
consequence of an exaggerated reparative cytokine, hence elevating fibroblast 
proliferation, increased synthesis of mesenchymal growth factors, suppression of 
matrix degradation, actin skeleton reorganisation, loss of cell polarity, down regulation 
of tight junction and adheren junction markers which ultimately leads to epithelial cell 
migration (Xu et al., 2009, Bartram, 2004, Leask and Abraham, 2004). This all 
culminates into changing the cell morphology and phenotype. Similarly, it has been 
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shown that TG2 promotes EMT in cancer with its elevation associated with increased 
cell invasiveness and cell survival (Kumar et al., 2010). Although, this study showed 
that TGFβ1 induces EMT via TG2 (Ritter and Davies, 1998) it failed to show that TG2 
orchestrated the progression of EMT via TGFβ1. However, Kasai et al. (2005) and 
Hackett et al. (2009) showed in their study of Idiopathic Pulmonary Fibrosis (IPF) and 
asthma that TGFβ1 induced EMT in these disease conditions via SMAD 2 and SMAD 3 
phosphorylation. Similarly, Camara and Jarai, (2010) showed using human bronchial 
epithelial cells (HBEC), an elevation in p-SMAD 2 expression in the presence of TGFβ1 
with cells losing cell-cell contact and assuming a morphology consistent with EMT. 
Interestingly, Munger et al. (1999) had described the importance of actin cytoskeleton 
in αVβ6 mediated activation of TGFβ1 where a blockade of actin polymerisation leads 
to the abrogation of TGFβ1 activation via αVβ6.  This suggests that as EMT involves 
active matrix deposition and thickening with adjacent cell migration leading to actin 
reorganisation, a hypothesis that an inhibition of TG2 activity by TG2 inhibitors will 
block EMT with TGFβ1 activity abolished independent of αVβ6. Noteworthy of 
mentioning is the recent work by Niger et al. (2013) where human bone marrow derived 
mesenchymal stem cells (hbMSCs) were cultured on collagen II pre-incubated with 
TG2 or TGFβ1 or both for 48 h and SMAD dependent luciferase activity was measured. 
A 4-fold increase in SMAD dependent luciferase expression was observed in the 
presence of collagen II pre-incubated with TG2. This suggests that the link between 
TG2 and TGFβ1 is SMAD dependent. This report is in concert with that of Olsen et al., 
(2011) who indicated that elevated TGFβ1 levels were associated with increased cell 
surface TG2 and that TG2 knockout mice showed a reduction of matrix protein 
production in the fibrotic lung. Also, TG2 was hypothesised as increasing TGFβ1 
activation thus promoting EMT in the lungs as shown in TG2 knockout mice (Shweke et 
al., 2008).   
 
CF is a disease associated with the loss of CFTR function due to diverse mutations of 
the gene. CFTR regulates epithelial channel activity maintaining the balance between 
airway surface liquid (ASL), cilia movement and ion transport. This ultimately controls 
broncho-alveolar integrity. TGFβ1 has been observed to be a negative regulator of 
CFTR (Snodgrass et al., 2013, Pruliere-Escabasse et al., 2005). Vij et al. (2009) 
described CFTR as a negative regulator of the inflammatory pathway involving NFκB 
via its effect on NFκB translocation. Also CFTR regulates the expression of the 
epithelial sodium channel (ENaC) where CFTR down regulates ENaC expression to 
maintain ASL (Schwiebert et al., 1999, Reddy et al., 1999). This suggests that the 
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down regulation of CFTR is associated with an up regulation of inflammatory pathways 
mediators/cytokines as well as an increase in ENaC channel activity, viscidity of mucus 
and loss of ciliary currents.  
In the previous chapter, it was observed that an elevation of TG2 and TGFβ1 in CF 
cells could culminate in supporting the inflammatory process in CF cells. TGFβ1 
induced EMT has been linked to fibrosis in various diseases in the lungs. TG2 
knockout in the mammary epithelial cell line, MCF-10A has been shown to inhibit 
TGFβ1 induced EMT (Kumar et al., 2010). Hence, the hypothesis is that in CF, where 
cells are in a continuous state of stress with elevated levels of various cytokines, TG2 
up regulation can promote EMT via TG2 dependent activation of TGFβ1. 
 
4.2 Aims: 
In this chapter, the aim is to show that in a CF bronchial epithelial cell, the progression 
of fibrosis is mediated through EMT, driven by TG2 via TGFβ1. Hence the objectives 
are to:  
! Evaluate TG2 and EMT marker gene expression in CF and control cells in the 
presence of TG2 inhibitors and TGFβ1.  
 
! To show that CF cells express more EMT markers compared to control and that in 
the presence of TG2 inhibitors this can be reversed.  
 
! To attempt to up regulate TG2 expression in control cells using rTGFβ1 to 
measure TG2 and EMT expression and use TG2 inhibitors to reverse this process.  
 
! To evaluate the involvement of αVβ6 subunit in EMT via a direct or indirect link 
with TG2. 
 
! To observe the role that SMAD 2 and 3 play as downstream mediators of TGFβ1 
in regulating EMT in relation to elevated TG2 levels. 
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4.3 Methods: 
 
4.2.1 Detection of gene expression using Real Time (RT)-PCR 
 
To determine gene expression of TG2, TGFβ1, EMT markers ie fibronectin and N-
cadherin, transcriptional repressors ie Slug, Twist and Zeb 2 and the adherens junction 
marker, E-cadherin, RT-PCR was used. 5 x 105 IB3 or C38 cells were cultured on 
60mm plates for 48 h in complete medium. RNA was extracted using the TRIzol® 
method as described in chapter 2.2.12. cDNA was made as described in chapter 
2.2.13 using 5ng of RNA per cell line. Gene expression was determined from cDNA 
using RT-PCR, performed as described in chapter 2.2.15. cDNA was amplified in 40 
cycles. The housekeeping gene was GAPDH. Relative levels of expression of genes 
were determined by normalising mean expression to GAPDH. ΔΔCT method was used 
in determining gene expression relative to GAPDH.  
 
4.2.2 Evaluation of TG2 and TGFβ1 inhibition on gene expression 
 
To investigate the involvement of TG2 and TGFβ1 on the expression of EMT markers, 
transcriptional repressors and adherens junction marker, the TG2 cell-permeable 
inhibitor, R283 (500µM) or rTGFβ1 (3ng/ml) were incubated with IB3 or C38 cells 
respectively and gene expression determined using RT-PCR. 5 x 105 of IB3 and C38 
cells were cultured in submerged culture for 48 h, within which cells were treated with 
R283 and rTGFβ1 respectively prior to RNA extraction and cDNA production as 
described in chapter 2.2.12 and 2.2.13. Subsequently, using TGFβ1 primers, RT-PCR 
was carried out as described in chapter 2.2.15. 
 
4.2.3 Expression of EMT markers and/or transcriptional repressor in 
IB3 and C38 cells 
 
To investigate the protein expression of EMT markers ie fibronectin and N-cadherin 
and transcriptional repressors ie Slug, Western blotting was used as well as 
immunofluorescent staining. 5 x105 cells of IB3 and C38 cells were cultured in 60mm 
petri dishes for 48 h in complete medium and protein was extracted using lysis buffer 
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after washing the cells with 1x PBS, pH 7.4 twice as described in chapter 2.2.2.1. 
Western blotting was carried out as described in chapter 2.2.4. The membrane was 
blotted with TG2 (MA5-12989) (1:1000) in 5%(w/v) skimmed milk in 1x TBS-Tween 
(1M), pH 7.4 as described in section 2.2.4. 
4.2.4 Immunostaining of IB3, C38 and HBEC cells  
 
5 x 105 of IB3 and C38 cells were sub-cultured on 60mm petri dishes. The cells were 
cultured to confluency of 70-80%. The cells were washed three times with 1x PBS, pH 
7.4 for 3 min each. Immunostaining was carried out as described in chapter 2.2.16.1. 
Antibodies to TG2, fibronectin (F3648) or N-cadherin (13A9) (1:100) were used to blot 
cells. 
 
4.2.5 Inhibition of TG2 expression in IB3 and C38 cells 
 
The presence of TG2 both on the cell surface and intracellularly suggests that the 
observed effect of the enzyme might be due to its activity in either compartment. To 
determine this, cell-permeable TG2 inhibitors ie R283 (500µM), 1-155(200nM), Z-Don 
(50µM) and cell-impermeable TG2 inhibitors ie R292 (500µM), R294 (500µM) and 1-
133 (100µM) were used.  5 x105 cells of IB3 and C38 cells were incubated with 
inhibitors for 48 h where after fresh medium was added together with aliquots of the 
inhibitor compounds every 24 h. To determine cellular and matrix protein expression, 
cells were collected using 2mM EDTA in 1x PBS, pH 7.4 and matrix collected into 2x 
Laemmli buffer and boiled to denature protein. For whole cell lysates, the cells were 
lysed as described in chapter 2.2.2.1. Western blotting was performed for cell lysates 
and matrix proteins as described in chapter 2.2.4 of methods. Antibodies to TG2, 
fibronectin, N-cadherin and Slug (1:1000) were used to blot membrane using GAPDH 
staining as loading control.  
 
4.2.6 Migration assay of IB3 and C38 cells in submerged culture 
 
1 x 105 of IB3 and C38 cells were cultured in complete medium for 16h at 37oC. The 
migration assay was carried out in serum free medium supplemented with 1 x ITS and 
in the presence of TG2 cell-permeable inhibitor R283 (500µM). Migration assays were 
carried out as described in chapter 2.2.7.  
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4.2.7 Effect of TGFβ1 inhibition in IB3 cells using TGFβ1 neutralizing 
antibody on EMT markers 
!
5 x 105 of IB3 cells was cultured in 6-well plates for 48 h at 37oC. The cells were 
incubated with TGFβ neutralizing inhibitor, Nab, (20µg/ml). The cells were rinsed with 
1x PBS, pH 7.4 twice and cells were lysed as described in chapter 2.2.2.1. Western 
blotting was carried out as described in chapter 2.2.4. Antibodies to TG2, fibronectin, 
N-cadherin and Slug were used at 1:1000 dilution. 
 
4.2.8 Co-immunoprecipitation of TG2 and αV/ β6 integrins 
 
To determine TG2 and αV/ β6 integrins protein interaction in IB3 and C38 cells, 
proteins were immunoprecipitated. 5x 105 of IB3 and C38 cells were cultured in 60mm 
petri dish in complete AEM for 48 h. IB3 cells were treated with TG2 cell-permeable 
inhibitor, R283 (500µM) and C38 cells were treated with rTGFβ1 (3ng/ml). Cells were 
then washed with 1X PBS, pH 7.4 twice. Co-immunoprecipitation assay was carried out 
as described in chapter 2.2.20. The lysates collected from the assay were used for 
SDS/PAGE and Western blotting as described in chapters’ 2.2.3 and 2.2.4 
respectively.  
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4.3 Results:  
 
4.3.1: TG2 inhibitors reverse EMT gene expression in CF 
 
4.3.1.1: Inhibition of TG2 gene expression in IB3 cells impedes fibronectin, N-
cadherin, Twist, Slug and Zeb2 expression. 
 
Previous results from chapter 3 have shown high TG2 expression in IB3 cells 
compared to C38 cells. This was linked to the high TGFβ1 levels in this cell. This study 
further seeks to assess the correlation between elevated TGFβ1 expression and EMT 
in IB3 cells. Figure 4.1 shows that elevated TG2 gene expression in IB3 cells is 
commensurate with an increase in fibronectin, N-cadherin, Twist and Slug gene 
expression. However, in the presence of R283, there was < 2-fold inhibition of TG2 
expression. N-cadherin expression was slightly inhibited in the presence of R283 but 
was significant (p<0.001) compared to untreated cells along with a 2-fold inhibition in 
fibronectin, Twist and Slug expression. The expression of Zeb 2 remained unperturbed 
in the presence of R283. From these results, it can be suggested that an inhibition of 
TG2 gene expression correlates with the blockade of EMT marker expression. This 
however does not show whether the activity of TG2 is involved as TG2 binds to 
fibronectin independent of its transamidating activity. However, it suggests that in IB3 
cells, the fibrotic process may involve a cascade of processes where TG2 plays a role. 
 
 
 
 
 
 
 
Chapter!Four:!
!
! 107!
Relative TG2 expression in IB3 cells
using RT-PCR
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Figure 4.1: TG2 inhibition corresponds with a decrease in gene expression of 
EMT markers in IB3 cells. RT-PCR was performed using cDNA from IB3 cells to 
determine the gene expression of TG2 (left panel) and EMT markers, fibronectin, N-
cadherin, Twist, Slug and Zeb 2 (right panel) in the presence of R283 (500µM). Gene 
expression was determined using the ∆∆CT method with GAPDH used as house 
keeping gene to normalise gene expression. Results show an inhibition of TG2 gene 
expression in the presence of R283 compared to untreated IB3 cells, which 
corresponded to a decrease in fibronectin, Twist and Slug gene expression in these 
cells. N-cadherin expression was slightly reduced in the presence of the inhibitor 
however, E-cadherin and Zeb 2 showed no change in gene expression in the presence 
of R283. Experiments were carried out in triplicates and results represent mean values 
and standard deviation of 3 independent experiments carried out in duplicates Two-
way Anova analysis with Bonferronni’s Posttests; *** p<0.001, n.s. p>0.05.  
 
4.3.1.2: TGFβ1 promotes EMT progression via TG2 in C38 cells 
!
Considering the effect of TGFβ1 on TG2, experiments were undertaken using the CF 
“corrected add-back” cell line, C38 in determining whether TGFβ1 can reversibly 
increase TG2 and markers of EMT expression. The results show low TG2 expression 
in C38 cells unlike IB3 with a corresponding marginal expression of fibronectin, Twist, 
Slug and Zeb2 expression in C38 cells (Figure 4.2). Interestingly, N-cadherin 
expression was slightly elevated compared with other EMT markers and E-cadherin 
expression was shown to be significantly lower than the expression in IB3 cells. In the 
presence of rTGFβ1, a 6-fold increase in fibronectin expression as well as a 2-fold 
increase in N-cadherin expression was observed. Expression of Twist and Zeb 2 
remained unaltered. This concurs with the observation of Ritter and Davies (1998) who 
observed an up regulation of TG2 expression due to the TGFβ1 response element on 
the TG2 gene promoter site. Hence, it can be postulated that TGFβ1 serves as a 
mediator of EMT with TG2 positioned as the driver of the process, however, it cannot 
be ruled out that this relationship might be co-dependent. 
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Figure 4.2: Elevated TG2 gene expression correlates with the increase in EMT 
markers expressed by C38 cells. cDNA from C38 was analysed for the effects of 
rTGFβ1 (3ng/ml) on the expression of TG2 and the EMT markers, fibronectin, N-
cadherin, Twist, Slug and Zeb 2. Gene expression was determined using the ∆∆CT 
method. Results show a significant increase in TG2 gene expression in the presence of 
rTGFβ1 (left panel). In concert, an increase in N-cadherin and fibronectin expression 
was observed although there was only marginal gene expression of E-cadherin, Twist, 
Slug and Zeb 2 gene  (right panel). Data represents the mean and standard deviation 
of 3 independent experiments carried out in triplicates. Two-way Anova analysis with 
Bonferronni’s Posttests;*** p<0.001, n.s. p>0.05. 
 
 
4.3.2: IB3 cells express higher protein levels of fibronectin, N-
cadherin and Slug than C38 cells 
 
In order to verify the results obtained from gene expression studies, protein analysis 
was carried out on IB3 and C38 cells using Western blotting. IB3 and C38 cells were 
cultured in submerged medium as described in chapter 2.2.1.2. The results show 
elevated levels of fibronectin and N-cadherin in IB3 and C38 cells as shown by 
densitometry. Comparatively, in Figure 4.3A&B, a 2 and 7-fold increase in expression 
in fibronectin and N-cadherin respectively was observed in IB3 cells compared to C38 
cells. However, the expression of Slug was different in both cells with IB3 cells showing 
slightly higher expression compared to C38 cells (Figure 4.3C). These results verify the 
hypothesis that elevated levels of TG2 correlate with the elevated levels of fibronectin, 
N-cadherin and Slug expression. Also, this concurs with previous results in section 4.1 
with elevated gene expression of EMT markers as well as elevated expression of TG2 
in CF cells compared to C38 cells.  
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Figure 4.3 A,B&C: IB3 cells express higher protein levels of fibronectin, N-
cadherin and Slug than C38 cells. Western blotting showing A fibronectin, B, N-
cadherin, and C, Slug protein expression in IB3 and C38 cells. 50µg of protein was 
used loaded on 6% (w/v) and 8% (w/v) gels. GAPDH was used as loading control to 
normalise protein expression. Results show elevated TG2, fibronectin and Slug 
expression in IB3 cells compared to C38 cells. Densitometry results represent the 
mean and standard deviation of 3 independent experiments.   
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Similarly, using immunostaining, TG2, fibronectin and N-cadherin protein levels were 
determined in IB3 and C38 cells as well as the localisation of these proteins in the 
cells. Figure 4.4 shows that in IB3 cells, an increase in TG2 expression was followed 
with an up-regulated fibronectin and N-cadherin expression around the cell surface. 
Results further showed a network of fibronectin fibres, which together with elevated 
expression of N-cadherin demonstrates the disorientation of the cellular matrix of IB3 
cells compared to C38 cells. Likewise, the level of TG2 expressed concurred with that 
of fibronectin and N-cadherin in IB3 cells, which was shown to co-localise around the 
cells. The expression in C38 cells appeared in a similar pattern around the cell surface 
but was lower than the expression observed in IB3 cells. This reflects the consistent 
results observed with an increase in TG2 gene expression corresponding to an 
increase in protein expression as shown with Western blots and immunocytochemistry.  
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Figure 4.4A-D: IB3 cells express TG2, fibronectin and N-cadherin proteins when 
cultured in submerged conditions. Immunofluorescence staining of IB3 cells was 
carried out to detect TG2 (A), fibronectin (A) and N-cadherin (B) expression. TG2 
[monoclonal (mouse) and polyclonal (rabbit)], fibronectin [polyclonal (rabbit)] and N-
cadherin [monoclonal (mouse)] antibody (1:100) were used. Mouse IgG (C) and Rabbit 
IgG (D) were used as control in the cell. The cells were visualised using the Leica® SP5 
confocal microscope. Results show high expression of TG2 and fibronectin co-
localising with each other in IB3 cells (A), with N-cadherin expression shown to be high 
as well (B). Scale bar represents 50µm.  Images are representative of 2 independent 
experiments.   
 
A!
C!
D!
B!
Chapter!Four:!
!
! 112!
 
 
 
 
Figure 4.4E-I: C38 cells show marginal expression of TG2, fibronectin and N-
cadherin proteins when cultured in submerged conditions. Immunofluorescence 
staining of C38 cells carried out to detect TG2 (E), fibronectin (F) and N-cadherin (G) 
expression. TG2 [monoclonal (mouse) and polyclonal (rabbit)], fibronectin [polyclonal 
(rabbit)] and N-cadherin [monoclonal (mouse)] antibody (1:100) were used. Mouse IgG 
(H) and Rabbit IgG (I) were used as controls. The cells were visualised the Leica® SP5 
confocal microscope. Results show low expression of TG2, fibronectin and N-cadherin. 
Scale bar represents 50µm. Images are representative of 2 independent experiments.  
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4.3.3: Inhibition of TG2 protein expression reverses the development 
of EMT in CF. 
4.3.3.1: Inhibition of cellular and matrix TG2 reduces the expression of EMT 
markers in IB3 cells. 
 
To investigate the role played by intracellular and cell surface TG2 in promoting EMT, 
cellular and extracellular proteins were extracted from IB3 cells treated with TG2 cell-
permeable and impermeable inhibitors and examined for fibronectin, N-cadherin, E-
cadherin, Slug and TG2 expression using Western blotting. Results show that TG2 
inhibition caused an elevation of cellular TG2 levels corresponding with low levels of E-
cadherin (Figure 4.5A). This concurs with earlier results that showed low E-cadherin 
gene expression in wild type IB3 cells (Figure 4.1). In the presence of the cell-
permeable TG2 inhibitor, Z-DON, a significant inhibition of TG2 expression (>4-fold: 
p<0.001) was observed compared to control. This was associated with a 2-fold 
increase in E-cadherin expression in the presence of Z-DON. Interestingly, it was 
observed that incubating the cells with a cell impermeable TG2 inhibitor, R294 
significantly inhibited (p<0.001) the expression of TG2 as well as elevating the levels of 
E-cadherin expressed in this cell. Similar results were observed for fibronectin 
expression. Results show that elevated matrix fibronectin levels coincided with 
increased TG2 expression and TG2 inhibitors significantly (p<0.001) reversed 
fibronectin expression however, R294 was slightly less inhibitory compared to the 
others. Using new in-house synthesised peptido-mimetic TG2 specific inhibitors, 
attempts were made to distinguish whether the observed results were due to cell 
surface or intracellular TG2 activity. The TG2 inhibitors were; 1-133, which is cell 
impermeable and 1-155, a cell-permeable TG2 inhibitor. The observed results (Figure 
4.5B) shows that in the presence of these inhibitors, TG2, fibronectin, N-cadherin and 
Slug expression were significantly reversed (p<0.001) with 1-133 showing enhanced 
inhibitory characteristic compared to 1-155 (Figure 4.5B). Overall, the findings suggest 
TG2 expression to be involved in EMT where increased TG2 externalisation accounts 
for high levels of active TG2, which increasingly binds to fibronectin and other matrix 
proteins and is accountable for the gradual establishment of EMT in CF.   
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Figure 4.5A: Inhibition of cellular or matrix TG2 reduces EMT marker expression, 
but enhances matrix fibronectin deposition in IB3 cells. Western blotting showing 
cellular TG2 and E-cadherin expression (bottom panel) and matrix fibronectin 
expression (top panel) in IB3 cells incubated with cell-permeable TG2 inhibitors {Z-
DON (100µm) and R283 (500µM)} and impermeable inhibitor, R294 (500µM). 50µg of 
protein was used for the Western blot assay. Monoclonal mouse anti-TG2 and anti-E-
cadherin antibodies as well as polyclonal rabbit anti-fibronectin antibody (1:1000) were 
used to probe blots. Results show a significant inhibition of cellular TG2 and matrix 
fibronectin expression in IB3 cells in the presence of R283 and Z-Don as well as with 
the cell impermeable TG2 inhibitor, R294. However, E-cadherin expression was 
significantly increased in the presence of all TG2 inhibitors compared to untreated 
control. Western blotting is characteristic of 3 independent experiments with equal 
number of cells used at all times. Densitometry represents the mean values and 
standard deviation of 3 independent experiments adjusted relative to GAPDH staining 
intensity. One-way Anova analysis with Dunnett’s Multiple comparison test; *** 
p<0.0001 
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Figure 4.5B: Inhibition of cellular or matrix TG2 activity reduces EMT marker 
protein expression in IB3 cells. Western blotting showing cellular TG2, N-cadherin, 
Slug and fibronectin expression as well as matrix fibronectin expression in IB3 cells 
incubated with the peptido-mimetic cell-permeable TG2 inhibitor, 1-155 (200ng/ml) and 
the equivalent cell impermeable TG2 inhibitor, 1-133 (100µM). 50µg of protein was 
used for the Western blot assay. Monoclonal mouse anti-TG2, anti-Slug and anti-E-
cadherin antibodies as well as polyclonal rabbit anti-fibronectin antibody (1:1000) were 
used to probe blots. Results show that both 1-155 and 1-133 inhibitors significantly 
block cellular N-cadherin, TG2, Slug and both cellular and matrix fibronectin expression 
compared to control. GAPDH was used as a loading control to normalise cellular 
protein expression. The blot image is representative of 3 independent experiments with 
equal number of cells used at all times. Densitometry represents the mean values and 
standard deviation of 3 independent experiments. One-way Anova analysis with 
Dunnett’s multiple comparison tests; *** p<0.0001, **<p0.0029, .  
 
4.3.3.2: Abrogation of TG2 expression impedes cell migration 
!
TG2 has been termed a “cell adhesion” protein because of its involvement in wound 
healing and matrix deposition (Telci and Griffin, 2006). The key role of cell surface TG2 
in cell migration has been linked to the binding of active TG2 to matrix fibronectin (TG2-
FN) which depends somewhat on its transamidating activity (Verderio et al., 1998). 
Here, the effect of active cell surface TG2 on the migration of CF cells is demonstrated. 
The migration assay was carried out as described in chapter 2.2.7.  
Cell viability assays were used to show that IB3 cells proliferate faster than C38 cells 
with non-proliferative rates observed to be within 16h (Figure 4.6A). Migratory profiles 
of IB3 and C38 cells were therefore carried out within this time frame. The results here 
show that in IB3 and C38 cells, rapid wound closure was observed with IB3 cells 
B!
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migrating at a faster rate compared to C38 cells (Figure 4.6B). The relative wound 
closure shows around a 13% increase in migratory rate between IB3 and C38 cells. In 
the presence of R283, migration was inhibited more in IB3 cells with around 10% 
decrease in migratory rates compared to C38 cells, which showed a lower migratory 
rate at approximately 3%. Together, it can be can be hypothesised that, in both IB3 and 
C38 cells, due to the levels of TG2, TGFβ1 and EMT markers expressed, the migratory 
profile of both cells reflects their phenotypic traits and shows the effect of TG2 on 
matrix organisation in CF cells.         
 
                
              
Figure 4.6A: IB3 cells have accelerated doubling times compared to C38 cells. 
IB3 and C38 cells were cultured in submerged medium and viable cell numbers 
quantified for up to 48 h using the XTT assay with reagents added and incubated for 4 
h before absorbance was read at 490nm. Results represent mean values and standard 
deviation of 3 independent assays carried out in duplicates. Results show that in both 
IB3 and C38 cells, doubling of cell number was observed above 20 h and the 
absorbance values were consistently higher for IB3 cells compared to C38 cells 
suggesting greater proliferation of IB3 cells.   
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Figure 4.6 B,C&D: TG2 inhibitors impede migration rates of IB3 and C38 cells. 
Scratch assay was performed showing the migratory profile, of IB3, C and C38, D, cells 
cultured in submerged culture in the presence of the TG2 cell-permeable inhibitor, 
R283 (500µM). Migration was monitored for 16 h post wounding. Images (B) represent 
the plots of 2 independent experiments carried out in triplicates and graph shows mean 
values of wound closure in untreated and treated groups. The graph shows the % 
relative wound density (closure) against time. Results show that IB3 cells migrate faster 
than C38 cells with an inhibition in wound closure rate in the presence of R283 for both 
cell types 
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4.3.4: Induction of TG2 expression correlates with the elevation of 
EMT markers in CF 
4.3.4.1: Reversal of TG2 expression restores epithelial phenotype in IB3 cells  
 
In the presence of TGFβ1, airway epithelial cells lose their phenotypic traits and 
assume an undesirable morphology, which consequently leads to the loss of cell 
polarity and cell-cell adhesion (Xu et al., 2009). In continuation of the previous work on 
the link between TG2 and EMT, this study is aimed at correlating the outcomes of 
TGFβ1 exposure on gene expression in C38 cells, to the effect of TGFβ1 on TG2, 
fibronectin and N-cadherin at protein levels. Phase-contrast images show that treating 
C38 cells with TGFβ1 changes the phenotype from a cobblestone like structure to a 
fibroblast-like morphology (Figure. 4.7A). Similarly, as cells were stained with TG2 and 
the myofibroblast marker, α-SMA, images illustrates that the change in cell morphology 
correlated with an increase in TG2 and α-SMA expression as shown in Figure. 4.7B. 
This ultimately verifies that an up regulation of TG2 expression in the presence of 
TGFβ1 drives EMT as an increase in α-SMA expression defines a transformation of 
epithelial cells to myofibroblasts, which supports the findings as shown by Zhang et al., 
(2009).  
 
As C38 cells were treated with R283, a reversal of the EMT process was observed in 
Figure.4.8A. Using Western blotting, an increase in fibronectin expression was 
observed in the presence of rTGFβ1 in C38 cells, which was significantly inhibited 
(p<0.001) in the presence of R283 (Figure. 4.8B). TG2 expression was marginally 
inhibited which might be due to the overarching presence of active TGFβ1 on the cell 
surface thus causing the overproduction and then down regulation of TG2 which limits 
the amount present on the cell surface (Johnson et al., 2007). Comparatively, using a 
cell-permeable inhibitor for TG2, 1-155 as opposed to the cell impermeable TG2 
inhibitor, 1-133, results show that elevated TG2 expression was reduced in the 
presence of the former compared to the latter (Figure. 4.8C). 1-155 showed higher 
potency at blocking both cell surface and intracellular TG2 compared to 1-133, which is 
impermeable and blocked cell surface TG2 only. Differing IC50 of these inhibitors might 
be responsible for the inhibition shown. However, the results showed an enhanced 
inhibition of fibronectin and N-cadherin expression with 1-155 compared to 1-133. This 
suggests an involvement of cell surface TG2 in the EMT process.  
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Figure 4.7A&B: Elevation of TG2 levels drives C38 cells into EMT. Phase contrast 
images, (A) and immunofluorescent staining, (B), of C38 cells treated with rTGFβ1 
(3ng/ml) in serum free medium for 48h. Images were taken from a Nikkon camera 
mounted on a microscope. Results show a change in the cobblestone-like structure of 
the cells in the presence of rTGFβ1, with cells assuming a fibroblast-like morphology. 
C38 cells were then stained with polyclonal anti-TG2 (rabbit) or monoclonal anti-α-SMA 
(mouse) antibodies. Scale bar represents 25µm. Images were taken using the Leica® 
SP5 confocal microscope. Mouse and Rabbit IgG were used as control (data shown in 
figure 4.4F&I). Images are representative of 2 independent experiments. Images show 
an increase in TG2 staining in C38 cells in the presence of rTGFβ1 corresponding to 
an increase in α-SMA expression as the cells become fibroblast-like in morphology.  
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Figure 4.8A-C: TG2 induced EMT is reversed in the presence of TG2 inhibitors. 
Phase contrast images, A and Western blotting, B&C of C38 cells treated with cell-
permeable, R283 (500µM) and 1-155 (200nM) and cell impermeable TG2 inhibitors, 1-
133 (50µM) in submerged culture. The images were taken with a Zeiss camera (A) 
showing the change in C38 cell morphology in the presence of rTGFβ1 and this is 
inhibited in the presence of R283. 50µg of protein was used for the Western blot assay. 
Monoclonal mouse anti-TG2 and anti-N-cadherin antibodies as well as polyclonal rabbit 
anti-fibronectin antibody (1:1000) were used to probe blots. Results show a significant 
increase in TG2 and fibronectin expression in the presence of rTGFβ1 (B), which was 
inhibited in the presence of R283. Also in the presence of 1-133 and 1-155 (C), the 
rTGFβ1-dependent increase in expression of TG2, fibronectin and N-cadherin was 
inhibited. Western blotting images are representative of characteristic results of 3 
independent experiments. Densitometry represents mean and standard deviation of 3 
independent experiments. GAPDH was used a loading control to normalise protein 
expression. Magnification of images (x200). One-way Anova analysis with Dunnett’s 
multiple test: *** p<0.0001,*p<0.0323, n.s. p>0.05. 
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Using the same hypothesis, human bronchial primary epithelial cells (HBEC) 
possessing similar phenotypic characteristics as in vivo bronchial cells were evaluated 
to determine the effect of rTGFβ1 on TG2, fibronectin, N-cadherin and E-cadherin 
expression. The aim was to illustrate that in normal physiological conditions, an up 
regulation of TG2 in bronchial epithelial cells can provoke the initiation of EMT. The 
results here show a change from the tight cobblestone-like structure to a distorted 
organisation of cells characterized by a loss in cell cohesiveness and with cells 
assuming a fibroblast –like morphology in the presence of TGFβ1 after 48 h (Figure. 
4.9A). The presence of R283 impedes the process with HBEC regaining cell cohesion. 
Western blot analysis shows that at baseline, HBEC display a typical epithelial 
phenotype with diminished TG2, fibronectin and N-cadherin expression with high E-
cadherin expression. A decrease in E-cadherin expression was observed in the 
presence of TGFβ1 in HBEC cells, which in turn increases TG2 and fibronectin 
expression whilst N-cadherin expression was marginal (Fig. 4.9B). In the presence of 
R283, TG2 expression was shown to decline to basal levels in untreated cells. The 
expression of fibronectin and N-cadherin was slightly changed in the presence of R283, 
with protein levels marginally elevated. In concert, E-cadherin was also shown to 
increase slightly compared to levels in the presence of TGFβ1. These results suggest 
that although TGFβ1 increases TG2 and EMT marker expression, the amelioration of 
EMT is a relatively gradual process, where TG2 inhibition restores epithelial integrity 
progressively. 
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Figure 4.9A&B: Inhibition of TG2 in HBEC primary cells reduces the expression 
of EMT markers. Phase contrast images (A) and Western blot analysis (B) of TG2, 
fibronectin, N-cadherin and E-cadherin expression by HBEC cells treated with rTGFβ1 
(3ng/ml) or R283 (500µM). Cells were imaged with a Zeiss camera. 50µg of protein 
was used for the Western blot assay. Monoclonal mouse anti-TG2, anti-N-cadherin and 
anti-E-cadherin antibodies as well as polyclonal rabbit anti-fibronectin antibody 
(1:1000) were used to probe blots. GAPDH was used as loading control to normalise 
protein levels. Results show an increase in TG2 level in HBEC cells in the presence of 
rTGFβ1, with increase in fibronectin and N-cadherin expression. However, E-cadherin 
expression is decreased. The presence of R283 inhibits the increase in EMT marker 
expression but does not increase E-cadherin. Magnification of images (x400).  
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4.3.4.2: Inhibition of TGFβ1 ameliorates EMT in CF 
!
In the preceding chapter, results showed IB3 and C38 cells possessing TGFβ 
receptors, RI and RII. Studies have shown the importance of TGFβ receptors in the 
downstream signalling of TGFβ (Bartram, 2004). Within the ambits of this chapter, 
attempts have been made to observe the importance of the interaction of TGFβ1 with 
its receptors as well as how it relates to active cell surface TG2 in EMT in IB3 cells. 
Here result shows that in the presence of TGFβ neutralizing antibody (Nab), TG2, N-
cadherin and fibronectin expression were significantly inhibited (p<0.01 or p<0.001) 
compared to untreated cells whilst E-cadherin was marginally up regulated (Figure 
4.10). TG2, fibronectin and N-cadherin expression were inhibited about 4-fold 
compared to untreated control. The reduction in TG2 expression in the presence of 
Nab antibody shows a link between inhibition of TGFβ1/TGFβ receptors interaction and 
activation of TG2. It also shows the importance of TGFβ1 in promoting EMT expression 
as well as providing the link between TG2 and TGFβ1 activation.  
         
Figure 4.10: Blocking TGFβ1 impedes TG2, E-cadherin and EMT marker 
expression in submerged culture. IB3 cells were treated with the TGFβ neutralizing 
inhibitor (Nab) (20µg/ml) in submerged culture prior to analysis for TG2 and EMT 
markers using monoclonal mouse anti-TG2, anti-N-cadherin and anti-E-cadherin 
antibodies as well as polyclonal rabbit anti-fibronectin antibody (1:1000). 50µg of 
protein was used for the Western blot assay. GAPDH was used as loading control to 
normalize protein loading. Western blot image represents a characteristic result of 3 
independent experiments. Densitometry represents mean and standard deviation of 3 
independent experiments. Results show a decrease in TG2 expression corresponding 
to a significant decrease in fibronectin and N-cadherin expression compared to 
untreated control, however, E-cadherin expression was shown to be slightly elevated in 
the presence of the TGFβ neutralizing inhibitor (Nab). Two-way Anova analysis with 
Bonferroni’s post-tests; *** p<0.001, ** p<0.01, n.s. p>0.05.  
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4.3.5: TG2 involvement in the activation of TGFβ1 by the integrin, 
αVβ6. 
 
Studies have shown that αVβ6 activation of TGFβ1 occurs via the known RGD 
sequence present on the Latency Associated Protein (LAP), which is a propeptide 
directly bound by disulphide linkages to TGFβ1 (Munger et al., 1999) . However, the 
Latency TGFβ binding protein 1, LTBP-1, was shown to be required for the activation 
of latent TGFβ1 by αVβ6 (Annes et al., 2004). TG2 has also been associated with the 
activation of TGFβ1, with LTBP-1 and large latent complex shown to be substrates of 
TG2 where TG2 covalently crosslinks LTBP-1 to the matrix (Nunes et al., 1997). When 
binding integrins to ligands via their RGD sites, studies have observed that only α8β1, 
αVβ1, αVβ3 and αVβ5 could bind to LAP coated dishes with avidity dependent on high 
concentrations of substrate (Sheppard, 2005). However, αVβ6 was shown to bind at 
low concentrations with high avidity. In line with this studies, it was hypothesised as 
shown below in Figure 4.11 that since TG2 binds to LTBP-1 and covalently crosslinks it 
to matrix and studies by Fontana et al. (2005) have shown that fibronectin is required 
for the activation of TGFβ1 by αVβ6, the activation of TGFβ1 would involve a TG2- 
αVβ6 interaction. 
         
 
Figure 4.11: Schematic representation of a proposed mechanism of interaction 
between TG2, αV and β6 integrin in epithelial cells. This might be involved in the 
activation of TGFβ1. The interaction between TG2 and fibronectin aids in crosslinking 
LLC to the matrix and thus is involved in the activation of TGFβ1. However, αVβ6 also 
has been shown to activate TGFβ1. Hence a direct interaction between TG2 and αVβ6 
might exist driving the activation of TGFβ1.  
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To investigate this correlation between TG2 and αVβ6, Western blotting analysis was 
carried out on IB3 and C38 cells cultured in submerged culture. Co-
immunoprecipitation was carried out as described in chapter 2.2.20.  
 
      
 
Figure 4.12: TG2 expressed in CF cells interacts with integrins. To determine TG2 
interactions with integrins, Western blot analysis of TG2, αV, β6, β1 and β3 in IB3 and 
C38 cells was carried out. 50µg of protein was used for the Western blot assay. The 
membranes were blotted with antibodies for TG2, αV, β6, β1 and β3 (1:1000). GAPDH 
was used to normalise loaded protein. Results show increased TG2 expression in IB3 
cells compared to C38 corresponding to elevated levels of αV protein. β6, β1 and β3 
expression was shown to remain unchanged between cells. WB represents a 
characteristic result of 3 independent experiments. Results represent mean and 
standard deviation of 3 independent experiments. Two-way Anova analysis with 
Bonferroni post-tests; ***p<0.001, *p<0.05, n.s. p>0.05 
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The results have shown that αV protein expression corresponds with TG2 expression 
as IB3 cells were shown to express high levels of αV protein. β6, β1 and β3 expression 
was shown to remain unchanged between both cell lines. These data suggest that 
elevated levels of TG2 in IB3 cells which correlates with the activation of TGFβ1 might 
be related to the high levels of αV observed in these cells. Since LTBP-1 has been 
shown to interact with TG2 and its interaction involves crosslinking with fibronectin 
covalently, it suggests that TG2’s involvement in the activation of TGFβ1 might be 
through αV interaction with LAP (Verderio et al., 1999). To demonstrate the possible 
interaction between TG2, αV and β6 in IB3 and C38 cells, co-immunoprecipitation 
studies were carried out on these cells. Results show in Figure 4.13A1 that basal levels 
of TG2 immnoprecipitated αV or β6 in IB3 and C38 cells showed an elevated TG2-αV 
complex in IB3 cells compared with C38 cells and no change in expression of TG2 
between cells in TG2 immunoprecipitated β6. These results were similar for TG2 
expressions in both cells for αV but not β6. However, as TG2 expression was inhibited 
by R283 in IB3 cells and elevated by rTGFβ1 in C38 cells, TG2 immunoprecipitated αV 
showed an inhibition of TG2 levels in IB3 cells and an up regulation in C38 cells 
(Figure. 4.13A2). Interestingly, it was observed that with TG2 immunoprecipitated β6, 
TG2 expression were inhibited in IB3 cells and elevated in C38 cells. These results 
might have been due to the quiescent nature of αVβ6 in normal bronchial epithelial 
cells (where C38 cells are a model) where low levels are expressed however injury 
leads to a dramatic up regulation of the integrin (Breuss et al., 1995, Breuss et al., 
1993). On evaluating αV immunoprecipitating β6, under control conditions, there was 
equal expression of αV in IB3 and C38 cells. This transformed when IB3 cells were 
treated with R283 and C38 cells with rTGFβ1, with an inhibition or elevation in αV 
levels in the cells respectively (Figure. 4.13B1&2).  
This study shows an exaggerated response as TGFβ1 and consequently TG2 levels 
are up regulated. Conversely, results show no increase in basal expression of β6 in IB3 
and C38 cells for β6 immunoprecipitating αV as well as β6 marginal inhibition in IB3 
cells in the presence of R283 as oppose to C38 cells where rTGFβ1 failed to elevate 
β6 expression (Figure. 4.13C). This is in concert with results as shown in Figure 4.13 
where basal levels of β6 were shown to remain unchanged in both cells. Together, 
these results demonstrate some interaction between TG2 and αV as well as β6 in the 
cells following TGFβ1 activation.  
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Figure 4.13A,B&C: TG2 interaction with integrins is blocked in the presence of 
TG2 inhibitors. Co-immunoprecipitation (Co-IP) analysis of TG2, A αV, B and β6, C  
expression in IB3 and C38 cells treated with the cell-permeable TG2 inhibitor, R283 
(500µM) or rTGFβ1 (3ng/ml). 200µg of protein was loaded on 8%(w/v) gels for Western 
blot assay. Western blots images represent a characteristic result of 3 independent 
experiments. Densitometry represents mean and standard deviation of 3 independent 
experiments. Results show TG2 interacting with αV and β6 control at basal levels, A1 
as well as αV and β6 interaction with each other (B1 and C1). However, in the 
presence of R283 or rTGFβ1, IB3 and C38 cells decrease and increase TG2 and αV 
interaction respectively (A2 and B2) with no change in β6 and αV interaction (C2).  
Two way Anova analysis with Bonferroni’s post-tests; * p<0.05, n.s. p>0.05. 
A1#
B1#
A2#
B2#
C2#
C1#
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4.3.6: TG2-TGFβ1 induced EMT is SMAD dependent 
 
Studies have correlated the induction of EMT in bronchial epithelial cells to elevated 
levels of TGFβ1 (Doerner and Zuraw, 2009, Kasai et al., 2005). As TGFβ1 functions 
via different mechanistic pathways, its SMAD dependent pathway has been shown to 
be involved in the induction of EMT in airway pathologies (Hackett et al., 2009, 
Yanagisawa et al., 1998, Camara and Jarai, 2010). Here, it is hypothesised that as 
TG2 induces the activation of TGFβ1 and TGFβ1 functions via its receptors and down 
signalling partners, SMAD 2&3, blockade of TG2 activity with cell-permeable and cell 
impermeable TG2 inhibitors would show whether the progression of EMT driven by 
TG2 is SMAD dependent and illustrate the involvement of cell surface or intracellular 
TG2 in this process. Results show an elevation of phosphorylated-SMAD 2 and 3 
expression (p-SMAD) commensurate with TG2 expression in untreated IB3 cells 
(Figure. 4.14A). However, expression of p-SMAD 2 was higher than p-SMAD 3. In the 
presence of 1-133, R283 and R294, expression of p-SMAD 2 was inhibited compared 
to untreated control. Similarly, p-SMAD 3 and TG2 expression were inhibited compared 
to untreated control. Total SMAD 2 and 3, T-SMADs, had equal protein expression in 
the presence of 1-133, R283 and R294. However, in C38 cells, an up regulation of TG2 
was shown to correspond with an elevation of p-SMAD 2 and an elevation in p-SMAD 3 
expression in the presence of rTGFβ1 (Fig. 4.14B). In the presence of 1-133, R283 and 
R294, p-SMAD 2 and 3 expression was observed be inhibited. In all cases, no basal p-
SMAD expression was observed in untreated C38 cells. Comparing the results with 
that from IB3 cells, T-SMAD 2 and 3 levels remained unchanged in the presence of 
inhibitors in C38 cells. These results show no difference in inhibition of p-SMADs for 
cell impermeable inhibitors, 1-133 and R294 and R283. The non-differential inhibition 
of TG2 in the cell or on the cell surface by TG2 cell permeable or impermeable 
inhibitors suggests that cell surface TG2 might be involved in the SMAD related effect 
observed via its activation of TGFβ1 in CF cells.  
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Figure 4.14A&B: SMAD 2 and 3 regulate TGFβ1 downstream signaling in CF 
cells. Western blot analysis to determine SMAD expression in IB3 and C38 cells 
treated with cell-permeable and impermeable TG2 inhibitors; 1-133 (100uM), R283 
(500uM) and R294 (500uM). 50µg of protein was used for the Western blot assay. 
GAPDH was used to normalise protein loading for densitometry analysis. Both cell 
permeable and impermeable TG2 inhibitors inhibited P-SMAD 2 and 3 expressions in 
IB3 cells, without affecting T-SMAD levels.  
A#
B#
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4.4 Discussion: 
 
The requisite for the progression of EMT in CF cells is the elevation of TG2, which 
increases the activation of TGFβ1 and through its downstream partner proteins, 
sustains the fibrotic process. Previously in chapter 3, results showed that raised levels 
of TG2 corresponded with elevated expression of TGFβ1. Here elevated levels of TG2 
correlates with an increase in EMT markers whilst TG2 inhibitors impede the EMT 
process via the inhibition of active TGFβ1. This study also shows that inhibiting TGFβ1 
activation blocks SMAD-dependent regulation of EMT.  
 
This study has observed that high levels of TG2, corresponds with elevated expression 
of EMT markers in IB3 cells. It was shown that as gene expression of EMT markers 
was raised, the level of TGFβ1 was also elevated. This was inhibited in the presence of 
TG2 inhibitors. Preliminary results show that the comparative inhibition between TG2 
cell-permeable and impermeable inhibitors suggest that active cell surface TG2 was 
more likely to be involved in regulating TG2 activity in IB3 cells. Pinkas et al., (2007) 
observed that the open conformation of TG2 corresponds with the inhibitor bound 
structure of the enzyme suggesting that the inhibitors would function only with an open 
active structure of TG2 unless mutated. Furthermore, Siegel et al., (2008) showed that 
activation of extracellular TG2 depended on tissue injury which was hypothesised to be 
commensurate with increased matrix deposition and stabilisation leading to elevated 
levels of fibronectin and collagen 1 thus enhancing the fibrotic process. This can be 
suggested to correlate with the progression of certain diseases, in which TG2 is 
involved.  
 
In a related study, using 3T3 Swiss fibroblast cells, it was demonstrated that in the 
presence of the TG2 monoclonal antibody, CUB7402, cell migration was reduced in a 
dose dependent manner (Balklava et al., 2002). Verderio et al.(1998) also observed 
that when cells were incubated with CUB7402, there was a reduction in cell 
attachment. In addition, Akimov and Belkin, (2001b) showed in a study of monocytes 
that elevated levels of cell surface TG2 and integrin-bound TG2 were observed during 
the conversion of monocytes to macrophages which aids in macrophage adhesion. 
This further characterises the role of TG2 as a migration and adhesion mediator for 
fibronectin. This agrees with the results obtained where IB3 cells were shown to 
migrate more rapidly than C38 cells, with reduced migration of cells observed in the 
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presence of R283 inhibitor supporting the hypothesis that active cell surface TG2 might 
be involved in cellular migration in IB3 cells.  
 
Studies have shown that TGFβ1 plays a role in wound healing which involves 
expediting wound contraction, increasing matrix synthesis, repressing MMP production 
and elevating TG2 expression (Leask and Abraham, 2004, Ritter and Davies, 1998). 
Interestingly, this study observed that in the presence of TGFβ1 in C38 cells, TG2 
protein levels were markedly increased and that this was analogous to elevated EMT 
marker expression. The elevation of TG2 was in line with a change in cell morphology 
and an elevation of the myofibroblast marker, α-SMA. Again, TG2 inhibitors reversed 
this process. Noteworthy, is the morphological change in C38 cells in the presence of 
TGFβ1, which was blocked by TG2 inhibitor, R283. This illustrated a conventional 
phenomenon characterised by epithelial cells undergoing EMT in the presence TGFβ1. 
Doerner and Zuraw (2009) and Hackett et al., (2009) discovered in two separate 
studies that in the presence of TGFβ1, epithelial cells undergo morphological 
transformation where they lose their cell-cell contact and exhibit decreased expression 
of tight junction markers like E-cadherin and zonular occludin-1 and increase 
expression of myofibroblast markers like α-smooth muscle actin (α-SMA). This is 
concomitant with induction of the transcriptional marker, Slug and assumption of an 
EMT phenotype associated with an increase in fibronectin and collagen 1 deposition. 
Subsequently, when HBEC cells were treated with rTGFβ1 and R283, a loss of E-
caherin was observed (Figure 4.9A&B). In order to show TGFβ1 activation was linked 
directly with TG2 expression, TG2, fibronectin and N-cadherin expression was inhibited 
with TGFβ neutralizing antibody (Nab). It was observed that TG2 levels were markedly 
decreased compared to untreated control cells. Also, fibronectin and N-cadherin 
expression were significantly inhibited. A commensurate elevation of E-cadherin 
expression in IB3 cells was observed, which was similar to the results using TG2 
inhibitors (Figure 4.10). This suggests that as TGFβ1 is blocked from interacting with its 
receptors, this impedes the activation of TG2 gene expression by TGFβ on TG2 
promoter site, which might lead to a decrease in gene and protein expression of TG2.  
 
Lauzier et al., (2012) demonstrated using fibroblast-like synoviocytes (FLSs) obtained 
from control rats (C-FLS) that the invadopodia formation of cells deposited on gelatin 
matrix induced by TG2 was significantly inhibited in the presence of Nab. This 
proposes together with the results from this study that activation of TGFβ1 depends on 
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TG2 and that EMT ensues as a downstream event mediated by TGFβ1. Consequently, 
observing the effect of TG2 inhibitors on matrix proteins with the TG2 inhibitor, R283, 
showed that TG2 inhibitors reduce TG2 expression in IB3 cells thus impeding migration 
of the cells. Additionally, the comparative inhibition of matrix fibronectin deposition by 
1-133 and 1-155 in IB3 cells was shown to illustrate the role of cell surface TG2 in 
matrix deposition and EMT.  
 
A myriad of studies have linked αVβ6 expression to the activation of TGFβ1 as well 
shown the involvement of this integrin in TGFβ1 induced EMT (Mamuya and Duncan, 
2012, Katoh et al., 2013, Henderson and Sheppard, 2013). This study has highlighted 
possible interactions between TG2 and the αV subunit and suggested that this 
interaction might be involved in the activation of TGFβ1.The results showed an 
elevated αV protein expression in IB3 cells which was inhibited in the presence of TG2 
inhibitor, R283. The protein-protein interaction as shown using co-IP suggests a direct 
inhibition of αV expression as a consequence of TG2 inhibition. 
 
SMADs are downstream regulators of TGFβ1 signaling. The intricate cascades of 
interactions involved in the activation of SMADs are managed through TGFβ receptors, 
RI &RII. Previous results from chapter 3 have shown that the CF cell line IB3 express 
both RI and RII receptors and secrete high TGFβ1 levels compared to the corrected 
cell line, C38. These results show that IB3 cells express high levels of phosphorylated 
SMAD 2 and 3 compared to C38 cells. However, in the presence of TG2 inhibitors; 1-
133, R283 and R294, p-SMAD 2&3 were inhibited. In C38 cells, treatment with rTGFβ1 
increased p-SMAD 2 & 3 expression. However, this was inhibited in the presence of 
TG2 inhibitors. Notably, these results demonstrate that 1-133 and R294, which are cell 
impermeable inhibitors, show comparable inhibition to the cell-permeable inhibitor, 
R283. These suggest that cell surface TG2 might play a major role in the progression 
of EMT as inhibition of cell surface TG2 blocks the downstream signaling of TG2 via 
TGFβ1. 
4.5 Conclusion 
Although, the role shown by cellular TG2 remains resolute in the fibrotic process, the 
evidence presented in this chapter suggests that active extracellular TG2 might play a 
central role in the EMT process occurring in CF cells. The pathway for this occurrence 
seemingly might be through the activation of TGFβ1 and its downstream signalling 
pathways.  
!!
 
 
 
 
Chapter 5 
 
The effect of TG2 knockdown/ 
overexpression on the 
development of EMT in CF 
cells 
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5.1 Introduction:  
 
Generally, studies have linked the ubiquitous nature of TG2 to its involvement in 
various diseases where the transamidation reaction catalyzed by TG2 has been linked 
to its matrix deposition/pro-fibrotic function. The Ca2+ dependence of TG2 plays a vital 
role in determining its enzymatic activity and its ability to cross-link multiple substrates, 
leading to the progression of a number of different human diseases (Gundemir et al., 
2012, Smethurst and Griffin, 1996). 
Once activated, TG2 plays an essential role in either a reparative or pathological 
manner in tissue injury by stabilising matrix fibronectin or collagen deposition thus 
enhancing cell migration and stimulating wound healing (Nicholas et al., 2003, Telci 
and Griffin, 2006, Wang et al., 2012). Studies have established the importance of 
extracellular TG2 in stabilising matrix proteins in differentiating cartilages (Aeschlimann 
et al., 1995) and by using TG2 transfected cells, it has been shown that the role 
extracellular TG2 plays is important in increasing cell adhesiveness (Johnson et al., 
1994). Jones et al. (1997) demonstrated in the study using the human endothelial-like 
cell, ECV304, that cell spreading on fibronectin which normally depends on the 
crosslinking activity of TG2, could be impeded using the monoclonal mouse anti-TG2 
antibody, CUB7402. Also, Heath et al., (2002) revealed in a study on human 
osteoblasts cells that cell adhesion and spreading depended on a TG2-fibronectin 
heterocomplex. This was further confirmed by the study of Verderio et al. (2003) which 
showed that this interaction was resilient and withstands the effect of Arg-Gly-Asp 
(RGD) peptides thus maintaining cell adhesion. Taken together, this TG2 effect was 
attributed to extracellular TG2 interacting with the ECM protein, fibronectin and cell 
surface sulphates, which was independent of the formation of ε-(γ-glutamyl) lysine 
bonds.  
Intracellularly, TG2 assumes a closed inactive GTP-bound conformation where activity 
is sequestered due to high levels of GTP and low levels of calcium in approximately a 
150µM/100nM ratio (Smethurst and Griffin, 1996). This however, is reversed in 
diseased conditions where the cellular milieu is distorted and calcium levels can be 
elevated up to 100µM or above (Achyuthan and Greenberg, 1987). Here TG2 assumes 
an open conformation, exposing the active catalytic triad to substrates and crosslinks 
peptidyl glutamine residues acting as acyl donors to suitable primary amines, to form 
isopeptide bonds (Griffin et al., 2002). Studies have shown that certain domains are 
involved in modulating TG2 activity as mutations of such domains interferes with the 
multi-functionality of the enzyme. The C227S mutant is a cysteine to serine mutation at 
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position 227, which leads to a loss in transamidating activity and defective GTP binding 
capacity (Liu et al., 2002). The W241A and R580A mutants are TG2 constructs where 
tryptophan and arginine respectively are mutated and replaced by alanine. The former 
mutant is devoid of transamidating activity with little effect on its GTP binding capacity 
whilst on the contrary the R580A mutant is devoid of GTP binding with complete 
transamidating activity (Ruan et al., 2008, Murthy et al., 2002). These TG2 mutants 
have recently been used extensively to illustrate the importance of TG2 activity in 
diseases, hence proffering answers to whether TG2 is a “cause” or an “effect” in these 
diseases. 
In concert with TG2 mutations, studies have employed the use of TG2 inhibitors to 
demonstrate the importance of TG2s active spatial conformation on its enzymatic 
activity as well as the elasticity of the enzyme to respond to extracellular and 
intracellular levels of GTP/GDP and calcium. Consequently, Pinkas et al. (2007) 
demonstrated that the inhibitor-bound TG2 complex assumed an open conformation 
comparable to that in the presence of calcium-activated TG2. This suggests a 
hypothesis that an active site directed TG2 inhibitor could mainly function when TG2 is 
in an open active TG2 state. However, the different classes of TG2 inhibitors further 
aids in determining the location of TG2 as the inhibitors juggle between intracellular 
and extracellular compartments of the cell. Such inhibitors include the cell-permeable ie 
Cystamine, R283, Z-Don and the peptidomimetic inhibitors EB1-155, EB1-133 and the 
competitive substrate ie Monodansylcadaverine (MDC) and cell impermeable peptidic 
inhibitors eg R292, R294 and R281 (Griffin et al., 2008, Badarau et al., 2013, Telci et 
al., 2009, Aeschlimann et al., 1995). Recent studies have shown an upward rise in the 
potential use of compounds with TG2 inhibitory activity as part of a treatment cocktail in 
cancer (Kumar et al., 2010, Antonyak et al., 2004, Jones et al., 2006), coeliac disease 
(Maiuri et al., 2005), neurodegenerative diseases (Junn et al., 2003, Bailey and 
Johnson, 2006, Karpuj et al., 2002, Wakshlag et al., 2006), chronic kidney disease 
(Johnson et al., 2007, Johnson et al., 1999) and cystic fibrosis (Maiuri et al., 2008, 
Luciani et al., 2010a). 
The use of gene transduction has had broad applicability in research and gene therapy 
where genes of interest are efficiently transferred into target cells. For this purpose, 
development of viral and non-viral vectors have aimed at efficient transduction and the 
continual expression of the transduced gene whilst maintaining high levels of safety 
(Miyoshi et al., 1998). Consequently, retroviruses were developed with wide use of 
onco-retroviruses ie Murine Leukaemia Virus (MLV) which was marred by the requisite 
for cells to be proliferating thus limiting their use. This lead to the development of the 
second generation vesicular stomatitis virus glycoprotein (VSV-G) pseudotyped Human 
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Immunodeficiency virus type-1 (HIV-1) based vector with high efficiency in transducing 
non-dividing cells in-vitro and in-vivo as well as a broad range of other tissues with high 
titres (Naldini et al., 1996). Interestingly, Lewis at al. (1992) had previously shown that 
HIV infection of non dividing cells produces more viral particles than infection with 
onco-retroviral MLV.  
Also, eliminating the virulent genes in the viral genome further enhances the efficiency 
of the viral transduction. Furthermore, on developing a self-inactivating lentiviral (SIN) 
vector, Miyoshi et al. (1998) was able to replace the U3 region of the 5’ long terminal 
repeat (LTR) with a CMV promoter, obviating the need for the trans-activator of 
transcription protein, tat, encoded for by the tat gene in HIV-1, thus transcription occurs 
independent of tat. This produces high expression levels as the deletion of 133 base 
pairs from the U3 of 3’ LTR was transferred to the 5’ LTR after reverse transcription 
yielding the SIN which gets integrated into the host cell inactivating transcription of LTR 
in proviruses. Thus, as the vector construct is transfected into the packaging HEK 293T 
cells together with VSV-G plasmid, transcription ensues at the U3/R border of the 
5’LTR through to the R/U5 border of 3’LTR. On infection, the U3 regions of both LTRs 
are derived from the U3 region of the 3’LTR that serves as the template for reverse 
transcription to form double stranded DNA. Hence, both LTRs have a copy of the U3 
region of the 3’ LTR in the proviruses (Miyoshi et al., 1998). This third generation SIN 
forms the basis for the FIGB plasmid used in this study as shown below.  
 
 
 
Figure 5.1: Structure of FIG B plasmid carrying the TG2 gene.  The schematic 
shows the CMV promoter/enhancer replacing the tat promoter of the HIV-1 gene on the 
5’ LTR region with a flap region. The TG2 gene has an UBiC promoter, an ubiquitous 
promoter allowing TG2 to be expressed in various cells as well as the GFP region. The 
triangles represent U3 deleted regions. Viral transcription of TG2 begins from the 
5’LTR to the 3’LTR with GFP gene expression as the hallmark of TG2 expression in the 
cell.   
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The plasmid utilises the CMV promoter/enhancer making the plasmid tat independent 
as well as the UbiC and IRES 2 promoter to increase the ubiquitous expression of TG2 
gene in various tissues. Inclusion of GFP allows assessment of successful transduction 
via expression of the fluorescent green protein seen in cells under the microscope 
(Schorpp et al., 1996). Since the toxicity of the first generation HIV-1 derived vectors 
depended on the tat and rev proteins as well as the accessory factors, gag and pol 
genes in cis acting sequences, replacement of tat with an active promoter in trans with 
rev, produces high titre vectors when HIV-1 derived vectors are transduced with 
packaging vectors with gag and pol (Berkowitz et al., 1995, Zufferey et al., 1998, Dull et 
al., 1998). The Flap promotes nuclear importation of the viral genome and the 
woodchuck hepatitis posttranscriptional regulatory element (WRE) increases RNA 
processing and averts polyadenylation site read-through (Zufferey et al., 1999, Zennou 
et al., 2000). 
  
                     
Figure 5.2: Schematic representation of lentiviral production of TG2 plasmids. 
TG2 mutants (TG2-WT, shRNA, W124A and R580A) were transfected into packaging 
HEK293T cells in submerged culture. The packaging mix in a ratio of pPAX, envelop 
plasmid, VSV-G and DNA of interest; TG2 WT, R580A, W241A, scramble and empty 
plasmid transfected into HEK293T cells, a. The plasmid is integrated, undergoes 
transcription to form viral particles, b. The packaging proteins recognise the packaging 
sequence on the viral RNA, c. The viral particles are assembled and transported to the 
cytoplasm, d. VSV-G envelopes the viral particles and this buds out of the cell, e. The 
medium is collected and viral particles are harvested on centrifuging.   
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Limited studies have been performed using TG2 shRNA knockdown in airway cells. 
Recently, Olsen et al., (2011) showed in a study of Idiopathic Pulmonary Fibrosis (IPF) 
using human lung fibroblasts deficient in TG2 that further knockdown of TG2 prevented 
TGFβ1 mediated elevation of TG2 protein levels and a consequent impedance of 
fibroblast migration following a scratch assay. In the same study, extracellular TG2 
protein and activity was increased in the presence of TGFβ1 as human lung fibroblasts 
were treated for 72h. This suggests the correlation between TG2 protein and activity 
levels and the effects of its knockdown on disease progression.  
The work in this chapter is centered around transducing TG2 mutants into CF cells, IB3 
and C38 and the human primary epithelial cell, HBEC and observing the effect of these 
mutations on the pattern of expression of EMT markers as well as on TG2 activity. The 
work will examine the effect of over-expressing and knocking down TG2, transiently or 
stably in the cells on EMT.   
 
5.2 Aims: 
In this chapter, TG2 functional mutants are used to determine TG2s involvement in 
normal and CF cells by:  
! Transducing cells with Lenti-viral vectors containing wild type (WT) and TG2 
mutants. The mutants to be used include the GTP binding mutant, R580A, and 
the transamidating deficient mutant, W241A. This is carried out employing IB3, 
C38 and HBEC. 
! Determining TGFβ1 levels in the stably transduced TG2 shRNA IB3 cells.  
! Investigating the effect of elevated TG2 levels in C38 and HBEC cells on EMT 
marker expression.  
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5.3 Methods: 
5.3.1 siRNA Transfection of TG2 plasmids in IB3 cells 
 
To investigate the effect of TG2 silencing on EMT marker expression in IB3 cells, 
Qiagen® TG2 siRNAs were employed; TGM2_1, TGM2_5, TGM2_6 and TGM2_7. 5 X 
105 cells were seeded in complete medium overnight for 18-24 h. siRNA transfection 
was carried out as described in chapter 2.2.11. The cells were subsequently washed 
with 1x PBS, pH 7.4 twice and lysed as described in chapter 2.2.2.1 with SDS/PAGE 
and Western blotting carried out on lysates as described in chapter 2.2.3 and 2.2.4 
respectively.  
 
5.3.2 Western blotting of IB3, C38 and HBEC cells 
 
Using lysates from IB3, C38 or HBEC, 50µg of protein was added to pre-cast 6%(w/v), 
8%(w/v) or 12%(w/v) polyacrylamide gels and SDS/PAGE carried out as described in 
chapter 2.2.3. Western blotting was then performed for the detection of TG2, 
fibronectin, N-cadherin, Slug, E-cadherin and CFTR as described in chapter 2.2.4. 
 
5.3.3 TG2 activity determined using the Biotin Cadaverine assay 
 
TG2 activity was measured in lysates of IB3, C38 and HBEC cultured in full medium. 
The assay was carried out on 96-well plates coated with fibronectin (5µg/ml) 
suspended in 50mM Tris-Cl, pH 7.5. The assay was performed as described in chapter 
2.2.6.1.  
 
5.5.4 Lentiviral transduction of IB3, C38 and HBEC cells   
 
To produce viral particles for the different plasmids, HEK293FT packaging cells were 
cultured as described in chapter 2.2.19.1. HEK293FT packaging cells were transfected 
with packaging plasmids in a packaging mix as described in chapter 2.2.19.2. The viral 
particles were harvested and concentrated as described in chapter 2.2.19.3 and viral 
Chapter!Five:!
!
! 141!
titre determined as described in chapter 2.2.19.4. To 700µl of complete medium on 
IB3, C38 or HBEC, aliquots of viral particles of interest were added and transduction 
was carried out as described in chapter 2.2.19.5. The cells were rinsed aseptically with 
1 x PBS, pH 7.5 twice and cells were lysed and SDS-PAGE/Western blotting were 
carried out on lysates from the cells as described in chapter 2.2.3 and 2.2.4 
respectively.  
 
5.5.6 TGFβ1 activity assay in IB3 wild type and shRNA transduced 
cells  
 
To determine TGFβ1 levels in IB3 wild type and transduced cells, 4x105 of IB3 wild 
type or shRNA-transduced cells were cultured in 12 well plates in complete medium for 
6 h to allow cell attachment. The cells were then cultured overnight for 18-24 h in 1x 
ITS supplement without serum. Medium was collected and centrifuged and the TGFβ1 
assay carried out as described in chapter 2.2.9.  
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5.4 Results: 
5.4.1:  TG2 knockdown abrogates Epithelial to Mesenchymal (EMT) 
progression in CF cells. 
5.4.1.1: N-cadherin expression is transiently abolished in the presence of 
siRNAs. 
 
A myriad of TG2 studies have demonstrated the effect of TG2 inhibition or knockdown 
on disease progression. Recent studies by Nadalutti et al. (2011) showed that using 
TG2 siRNA, transient TG2-induced cell adhesion was impeded and apoptosis was 
induced, however, this was partially reversed in the presence of exogenous TG2. 
Previous results in chapter 4 have shown that in the presence of TG2 cell-permeable 
and impermeable inhibitors, EMT markers expression was significantly repressed. 
Here, first using siRNA, TG2 expression is reduced in order to observe changes in cell 
phenotype, which would affirm whether the observations on its effect on EMT, are 
directly related to TG2 expression. Using 4 different TG2 siRNA plasmids, TG2 siRNA 
silencing in IB3 cells was carried out as described in chapter 2.2.11. From the results 
as shown in Figure 5.3, it was observed that TG2 siRNA #6 significantly (p<0.0001) 
silenced TG2 expression (≥2-fold) compared to untreated groups. TG2 siRNAs #1,5 
and 7 slightly inhibited TG2 expression. Similarly, it was observed that the silencing of 
TG2 was commensurate to the inhibition observed in N-cadherin expression with 
siRNA #6. Hence, it could be suggested as previous results have shown in chapters 3 
and 4 that inhibition of TG2 expression concurs with the silencing of TG2 protein 
leading to loss of N-cadherin expression.  
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Figure 5.3: N-cadherin expression is reduced in the presence of TG2 siRNA. Left 
panel images showing representative Western blot of IB3 cell expression of TG2 and 
N-cadherin after transfection with TG2 siRNA plasmids #1,5,6,and 7. Iut indicates 
untreated cells and (-) indicates global negative control. 50µg of protein was used for 
the Western blot assay. Monoclonal mouse anti-TG2 and anti-N-cadherin antibodies 
(1:1000) were used to probe blots. The images represents a characteristic blot from 3 
independent experiments with equal number of cells used at all times. GAPDH was 
used to normalise protein loading. Densitometry represents the mean value and 
standard deviation of 3 independents experiments. Results show a significant inhibition 
of TG2 expression in the presence of siRNA #6 and reduced N-cadherin expression in 
the presence of TG2 siRNA #1 and #6. One-way Anova analysis with Dunnett’s 
multiple test; **p<0.0125, **p<0.0572, n.s. p>0.05.   
 
As observed with TG2 protein expression, Figure 5.4 shows an inhibition of TG2 
activity with the knockdown of TG2 expression. This illustrates in concert with earlier 
results in chapter four that in the presence of TG2 siRNA #6, there was a 2-fold 
inhibition of TG2 enzymatic activity. However, TG2 siRNA#1 inhibited N-cadherin 
expression (Figure 5.3) as well as enzymatic activity with siRNA#5, 6 and 7 inhibiting 
TG2 activity as well (Figure 5.4). Interestingly, the inhibition of TG2 activity by TG2 
specific siRNA silencing corresponds with inhibition of TG2 activity using TG2 
inhibitors. Although, the mechanism may remain different with an introduction of a 
silencing strand of RNA into the host genome as supposed to the interference of the 
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transamidating activity at the catalytic triad site, together they show that the 
knockdown/inhibition of TG2 is responsible for the abrogation of N-cadherin expression 
and this phenomenon might be occurring due to TG2 transamidating activity.   
 
                     
Figure 5.4: TG2 siRNA inhibits TG2 activity in IB3 cells. TG2 activity assay in IB3 
cells transfected with TG2 siRNA #1,5,6 and 7 was assayed using the Biotin 
Cadaverine assay. Global control plasmid was used as negative control (-). Results 
represent mean and standard deviation of 3 independent experiments carried out in 
triplicates. Results show a significant inhibition of TG2 activity in IB3 cells transfected 
with TG2 siRNA #1,5,6 and 7 compared to untreated control. One Anova analysis with 
Dunnetts’s Multiple tests; ***p<0.0001.  
 
5.4.1.2: Stable knockdown of TG2 mimics TG2 inhibition and abrogates EMT 
 
Evidence as shown by Wang et al.(2013) indicates that stable knockdown of TG2 in 
HUVEC cells inhibits tubule formation and cell migration and this result was 
comparable to that shown with TG2 inhibition achieved via site directed irreversible 
TG2 inhibitors. This suggests that the results observed in Figure 3.5 & 4.5 with TG2 
protein/activity inhibition using TG2 inhibitors can be confirmed using TG2 knockdown. 
Initially, using TG2 siRNAs was a pilot study to observe the effect of TG2 knockdown 
on EMT. With the results obtained, further attempts were made to knockdown TG2 
using TG2 shRNA containing virions, transduced into IB3 cells to recreate this 
observed trait. The TG2 shRNA plasmid was purified and propagated using Maxipreps. 
The purified TG2 shRNA plasmids were then transfected into packaging cells using 
Lipofectamine® 2000 as previously described in chapter 2.2.19.5. The TG2 shRNA viral 
particles were subsequently transduced into IB3 cells. The cells were then carefully 
lysed and TG2, fibronectin, N-cadherin and Slug protein expression was determined 
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using Western blotting as described in chapter 2.2.2.1 and 2.2.4 respectively. TG2 
activity was measured in whole cell lysates using fibronectin- coated plates, measuring 
the incorporation of biotin cadaverine into fibronectin. Results show in Figure 5.5A&B 
that knocking down TG2 protein expression with TG2-shRNA significantly inhibited 
TG2 expression in IB3 cells. Also, fibronectin, N-cadherin and Slug expression were 
significantly inhibited. The transduction of IB3 cells was shown not to affect the 
expression of TG2 and EMT markers as scrambled shRNA transduced IB3 cells 
showed no significant change in expression compared to IB3 wild type cells. Figure 
5.5C demonstrates that a knockdown of TG2 protein expression significantly inhibits 
(p<0.001) TG2 activity >6-fold in IB3 shRNA transduced cells. These results verify the 
link between TG2 expression and activity and suggest a link between progression of 
EMT and inhibition of TG2 activity in IB3 cells.  
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Figure 5.5A-C: TG2 knockdown impedes expression of EMT markers and inhibits 
TG2 activity. A. Western blot analysis of protein expression, B. Densitometry analysis 
and C, TG2 activity in lysates of IB3 cells using the biotin cadaverine assay. 50µg of 
protein was loaded on 6%(w/v), 8%(w/v) and 12%(w/v) gels for Western blot assay. IB3 
cells in submerged culture were transduced TG2 shRNA or control scramble plasmid. 
Monoclonal mouse anti-TG2, anti-Slug and anti-N-cadherin antibodies as well as 
polyclonal rabbit anti-fibronectin antibody (1:1000) were used to probe blots. GAPDH 
was used to normalise protein loading. Blot image is characteristic of 3 independent 
experiments with equal number of cells used at all times. Densitometry represents 
mean values and standard deviation of 3 independent experiments. Results show that 
as TG2 protein is knocked down with shRNA, fibronectin, N-cadherin and Slug 
expression is significantly inhibited compared to control. Similarly, TG2 activity is 
significantly inhibited in the presence of TG2 shRNA.  Two-way Anova analysis with 
Bonferroni post-tests; **p<0.001, n.s. p>0.05.    
 
These results have shown that the knockdown of TG2 protein expression using shRNA 
provides a reduction of TG2 expression. Consequently, it also shows a consistent 
inhibition of fibronectin, N-cadherin and Slug protein expression corresponding to TG2 
B#
C#
A#
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knockdown in IB3 cells. Comparatively, it can be deduced from these results that the 
observations from TG2 inhibition either via protein expression or activity reveals a role 
for TG2 in regulating the expression of EMT markers in IB3 cells.  
 
Using medium collected from these cells, TGFβ1 levels were analysed as shown in 
Figure 5.6. The IB3 wild type and shRNA cells were cultured in serum free medium 
supplemented with 1 x ITS medium to avoid growth factors present in serum. The 
medium was analysed for TGFβ1 levels as described in chapter 2.2.9.  
                            
Figure 5.6: TG2 knockdown in IB3  cells transduced with TG2 shRNA decreases 
TGFβ1 levels. TGFβ1 levels in medium collected from IB3 cells transduced with TG2 
shRNA cultured in submerged conditions in serum free medium (AEM). AEM used as 
negative control. Result represents mean values and standard deviation of 3 
independent repeats using the same number of cells. Results show a significant 
decrease in TGFβ1 levels from IB3 cells transduced with TG2 shRNA compared to 
untreated cells (IB3 wild type). One-way Anova  analysis of variance post-test; 
***p<0.0001. 
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5.4.2: Mutation at the TG2 transamidation active site and the GTPase 
site unveils the function of TG2 in EMT. 
 
5.4.2.1: TG2 transamidating activity plays an important function in EMT 
progression. 
 
Studies have highlighted the importance of various TG2 functional mutants driving 
various disease processes ie cancer (Kumar et al., 2012). Gundemir and Johnson, 
(2009)  showed whilst examining the role of TG2 in cell death in HEK293A that the 
GTP binding deficient mutant, R580A facilitates the pro-death characteristic of TG2 as 
observed. Also, Wang et al. (2013) demonstrated using the transamidation deficient 
GTP binding mutant, W241A, that the transamidating activity of TG2 was vital for 
endothelial tubule formation as transduction of the mutant into TG2 knockdown HUVEC 
cells failed to restore tubule formation hence inhibiting angiogenesis in these cells. 
Here, an attempt was made using the CFTR “add-back” cell, C38, to observe whether 
transducing the TG2 mutants into these cells, can dissect out the role TG2 plays in the 
fibrotic process in CF disease.   
Initially, C38 cells were transduced with wild type TG2 (TG2-WT) plasmid to observe 
the effects of TG2 overexpression in C38 cells. In addition by transducing the TG2 
Cys277Ser and R580A TG2 mutants, the role of transamidation and GTP binding was 
assessed in the progression of this disease. Western blotting was carried out as earlier 
described in chapter 2.2.19.5 and 2.2.4 respectively. 
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Figure 5.7: Phase contrast images of C38 cells transduced with TG2 WT plasmid. 
Images were taken using the Leica® Fluorescent microscope. The experiment was 
repeated 3 times. Scale bar present 100 µm. Transfection efficiency was shown by the 
presence of GFP-fluorescence in the cells and C38 cells transduced with TG2-WT 
plasmid (BF-Bright field, GFP-Green Fluorescent Protein).  
 
 
This study has observed together with other studies the importance of TG2 mutants in 
analysing the role of TG2 in diseases. Here, this study has demonstrated that the 
mutation, W241A does not alter the EMT phenotype however, the R580A mutant, 
though devoid of GTP binding but with transamidating activity showed a change in 
phenotype as expected with an increase in TG2 protein expression. This suggests that 
the TG2 GTP binding activity is not essential but its crosslinking activity is required for 
EMT progression. Furthermore, it shows that overexpression of TG2 supports EMT 
progression as transduction of TG2-WT increased TG2 and EMT marker expression in 
C38 cells. 
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Figure 5.8A,B&C: TG2 conformation determines phenotype in transduced C38 
cells. Using Lentiviral transduction, C38 cells were infected with viral particles carrying 
TG2-WT, W241A and R580 mutants. For W241A and R580 transfected cells, both cells 
and matrix were collected. 50µg of protein was used for the Western blot assay. 
Monoclonal mouse anti-TG2, anti-Slug and anti-N-cadherin antibodies as well as 
polyclonal rabbit anti-fibronectin antibody (1:1000) were used to probe blots. GAPDH 
was used to normalise protein loading. A. Results show elevated TG2 expression in 
C38 cells in the presence of TG2-WT plasmid, which corresponds with an elevation in 
fibronectin, N-cadherin and Slug expression. Similarly, in the presence of R580 
transduced cells, cellular and matrix, EMT markers were shown to be elevated as TG2 
expression increased however, W241A transduced cells did not show any change in 
the levels of expression both in the cells or matrix. Images represent characteristic 
blots from 3 independent experiments with equal number of cells used at all times. 
Densitometry represents mean values and standard deviation of 3 independent 
experiments One-way Anova analysis with Dunnett’s multiple comparison test; 
**p<0.0014, Ψ =*p<0.0080, n.s p>0.05, B, and One-way Anova analysis with Dunnett’s 
multiple comparison test; **p<0.0023, n.s p>0.05, C.    
  
B# C#
A#
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Figure 5.9: Transduction of wild type or R580A mutant increases TG2 activity in 
C38 cells. TG2 activity assay in C38 cells transduced with wild type TG2 (TG2-WT), 
mutant TG2 (R580A) and empty vector using the Biotin cadaverine assay using whole 
cell lysates. 50µg of protein was used for the Western blot assay. Results represent 
mean and standard deviation of 3 independent experiments. Results indicate that 
transduction of C38 cells with wild type TG2 significantly increases TG2 activity as well 
as with R580A mutant. However, TG2 activity in R580A transduced cells was slightly 
less than in C38 cells with TG2-WT mutants. One-way Anova analysis with Dunnett’s 
Multiple comparison test; ***p<0.0001, n.s p>0.05.   
 
This study shows that the elevation in transamidation activity corresponds with TG2 
protein levels in these cells (Figure 5.8). Its also confirms that the R580A mutant 
possess transamidation activity (Figure 5.9) which accounts for certain TG2 traits ie 
cellular pro-death function (Gundemir and Johnson, 2009) and EMT as observed in this 
study.  
 
5.4.2.2: Up-regulation of EMT expression in HBEC negatively regulates the CFTR 
channel.  
 
Previous studies shown in chapters three and four, have demonstrated that in the CF 
cell line, IB3 , TG2 protein and activity levels are elevated together with EMT markers. 
It also demonstrated that in CF “add-back” cell, C38, the occurrence of EMT could be 
augumented by an elevation of TG2 in the cell. Noteworthy of mentioning is that these 
cells are transformed cells which for in vitro purposes aid in understanding the 
underlying mechanism involved in diseases. However, although their cell proliferative 
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characters have been exploited in research, their loss of certain differentiation functions 
neccesitates the need to obtain primary cell lines with epithelial origin (Gruenert et al., 
1995). Hence, primary human bronchial epithelial cells were used in demonstrating the 
phenotypic traits associated with the normal, non-CF bronchial cells, thus providing 
relevant evidence likened to in vivo conditions.  
HBEC were employed to validate earlier results with IB3 and C38 cells thus showing 
the reproducibility of the results in in vitro cell culture conditions. HBEC were 
transduced with TG2-WT plasmid to investigate whether an elevation of TG2 in these 
cells corresponds with an increase in EMT markers expressions. Consequently, in 
order to show the effect of elevated TG2 on the expression of the epithelial adhesion 
maker, E-cadherin and the CFTR chloride channel, protein expression was determined 
for these two proteins.  
HBEC in submerged culture were transduced for 48 h with TG2-WT particles with re-
infection carried out once every 24 h. The cells were subsequently rinsed carefully with 
1x PBS, pH 7.4 and Western blotting carried out as described in chapter 2.2.4 to 
determine TG2, fibronectin, N-cadherin, Slug, E-cadherin and CFTR expression.  
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Figure 5.10A&B: Transducing TG2 to elevate TG2 levels induces a change in cell 
morphology in HBEC. A. Phase contrast images of HBEC wild type, HBEC-WT and 
cells transduced with TG2-WT plasmid, HBEC-T, showing a change in cell morphology 
from cobblestone-shaped to a spindle fibroblast-like morphology with higher TG2 levels 
after transduction with TG2-WT plasmid. B shows images of HBEC-T cells with GFP 
indicating transduction efficiency. Images were taken under the electron microscope 
and Leica® Fluorescence microscope respectively. Magnification of images (x100). 
Images are characteristic of 2 independent repeats.   
 
           
 
          
 
Figure 5.10C1-2: TG2 and fibronectin co-localise in HBEC-T cells. Cellular 
localisation analysis of TG2 and fibronectin expression in HBEC transduced with TG2 
viral particles, HBEC-T in submerged culture.  The cells were stained for polyclonal 
anti-TG2 (1:100), C1 and polyclonal anti-fibronectin (1:100), C2 in submerged culture. 
Scale bar represents 25µm. GFP indicates successful transduction of TG2-WT. Images 
were taken using a Leica® Fluorescence microscope. Results show an increase in TG2 
and fibronectin expression following transduction with TG2-WT viral particles. An 
elevation of TG2 and fibronectin expression corresponds to the increase in GFP 
expression (Figure 5.10B) showing that only the transduced cells express the high 
levels of the proteins. The increase in deposition of fibronectin fibrils, C2, around the 
cell suggests an increase in matrix deposition around these cells.  
A# B#
C2#
C1#
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The change in morphology of HBEC-T cells suggests that TG2 possibly plays a role in 
inducing cell matrix reorganization leading to EMT. As observed previously in chapter 
3, elevated levels of TG2 in IB3 cells is associated with an increase in matrix protein 
expression notably fibronectin. Hence, the implication is that TG2 expression leads to 
an elevation of EMT marker expression and a change in the matrix deposition. 
Consequently, in the HBEC-T cell, elevation in TG2, which was shown by the co-
localisation of fluorescent GFP and TG2 protein (Figure 5.10) accounts for the increase 
in fibronectin expression and deposition. Thus Figure 5.10C shows the matrix proteins 
that might be involved in EMT and the effect of matrix reorganisation after elevation of 
TG2 expression takes place. Further experiments need to be performed with HBEC 
transduced with empty vector as control to verify the results.   
 
 
                                                                                            
 
Figure 5.11A&B: Down regulation of CFTR and EMT markers corresponds to the 
elevation of TG2 after TG2 transduction. Western blots, A, of HBEC cells 
transduced with TG2-WT, HBEC-T, cultured in submerged medium. 50µg of protein 
was used for the Western blot assay. Monoclonal mouse anti-TG2, anti-CFTR, anti-
Slug, anti-N&E-cadherin antibodies as well as polyclonal rabbit anti-fibronectin antibody 
(1:1000) were used to probe blots. GAPDH was used to normalise protein loading. 
Western blot represents 2 independent experiments with equal numbers of cells used 
at all times. B. Densitometry shows the mean values of 2 independent experiments 
normalised to GAPDH. Results indicate that an elevation of TG2 protein levels (HBEC-
T) results in a decrease in CFTR and E-cadherin expression. However, fibronectin, N-
cadherin and Slug expression was shown to be elevated. 
 
These results show that an increase in TG2 expression down regulates CFTR and E-
cadherin expression whilst increasing fibronectin, N-cadherin and Slug expression. 
This importantly points to the study by Snodgrass et al. (2013) which shows the 
CFTR 
TG2 
N-CADHERIN 
FIBRONECTIN 
GAPDH 
HBEC    HBEC-T 
E-CADHERIN  
SLUG 
A! B!
Chapter!Five:!
!
! 155!
inhibition of CFTR protein expression by TGFβ1. In addition, regarding EMT, it was 
once more observed that HBEC-T cells have marginal expression of E-cadherin. This 
observation demonstrates that as TG2 levels increase and more matrix proteins are 
deposited, a consequent crosslinking and stabilisation of these proteins leads to matrix 
reorganisation with the loss of cell junctions as well as an increase in cell migration. 
Hence, cells assume the mesenchymal phenotype.  It can be inferred here that since 
TGFβ1 levels increases in HBEC-T cells (results not shown) and CFTR is down 
regulated and Figure 5.11 shows that elevated TG2 down regulates CFTR, it can be 
suggested that TG2 via TGFβ1 regulates CFTR in a negative manner.      
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5.5 Discussion 
 
The versatility of TG2 as an intracellular and extracellular protein together with its pro-
fibrotic traits depicts the robust innate role it plays in various disease processes. Here, 
this study shows that the intricate developments preceding the initiation of fibrosis in 
CF can be construed to intrinsically involve a need for consistently elevated levels of 
TG2. This in turn drives the activation of other pro-fibrotic proteins, notably TGFβ1 
while TG2 transient knockdown by siRNA or stable knockdown with shRNA reverses 
the EMT process. Consequently, these results postulate that the outcome of this 
knockdown might be related to a regain of cell-cell contact.   
Considering the results observed in chapter 4 where elevated TG2 correlated with an 
increase in TGFβ1 level and the use of cell-permeable and impermeable TG2 inhibitors 
demonstrated a comparable effect of TG2 inhibition on fibronectin, N-cadherin, E-
cadherin and Slug expression, the focus here was then centred on TG2 knockdown 
and its effects on EMT marker expression. Results showed that by transiently knocking 
down TG2, N-cadherin expression was inhibited (Figure 5.3). However, TG2 siRNA 
#1,5 and #7 showed marginal TG2 inhibition, both TG2 siRNA #1 and 6 demonstrated 
significant inhibition of N-cadherin expression. This differs with all siRNAs inhibiting 
TG2 activity (Figure. 5.4).  Verma et al. (2008) showed that in pancreatic cancer cells, 
silencing TG2 with siRNA reduces metastatic cell invasion, which might have 
therapeutic implications. In continuance, TG2 shRNA was transduced into IB3 cells in 
order to produce stable knockdown cell lines with reproducibility of similar traits. The 
TG2 knockdown further confirmed TG2 involvement in EMT with the knockdown 
producing a markedly significant inhibition of fibronectin, N-cadherin and Slug protein 
expression compared to scrambled shRNA and untreated. The reduction of TGFβ1 
levels showed again the involvement of TG2 in the activation of TGFβ1 in these cells. 
This confirms the link between TG2 and EMT where inhibition of its transamidating 
activity is comparable to the reversal of cell mesenchymal transition. Park et al., (2013) 
described the relationship between TG2 and N-cadherin expression in EMT using A549 
lung cancer cells. It was observed that silencing of TG2 using shRNA or elevation of 
TG2 via TG2-wild type plasmid down-regulated or increased TG2 expression 
respectively, thus suppressing or supporting EMT progression in this cell.   
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On establishing this involvement of TG2 in EMT, it became imperative to dissect out 
the mechanism by which TG2 carried out this function. Using different mutational 
variants of TG2 virally transduced into the control CF “add-back” cell, C38, TG2 
function was investigated. The results show that in the presence of TG-WT plasmid, 
TG2 protein expression was significantly increased compared to untreated control. This 
increase corresponded with the increase in fibronectin, N-cadherin and Slug 
expression as well as an increase in transamidating activity (Figure 5.8). This justifies 
previous results in chapter three and four where elevated TG2 protein expression in 
IB3 cells was shown to correlate with increased TG2 activity. On further evaluating 
other TG2 variants, it was observed that W241A, which is devoid of transamidating 
activity, showed no changes to the phenotype. However, R580A, the GTP binding 
mutant with transamidating activity drove epithelial cells into EMT with an increase in 
fibronectin, N-cadherin and Slug as well as an increase in TG2 protein expression and 
activity (Figure 5.8 & 5.9). Against the observations by Kumar et al., (2010), these 
results suggest that GTP binding might not be involved in TG2 dependent increase in 
EMT marker expression in IB3 cells. This together shows that in the presence of TG2 
transamidation deficient mutant, W241A, the abrogation of TG2 activity mimics the 
inhibition observed with TG2 inhibitors. Hence, it can be suggested here that the 
transamidation activity of TG2 might be important in the pathological functioning of the 
enzyme in CF cells.  
Using HBEC primary epithelial cells transduced with TG WT plasmid, results show a 
morphological change in transduced cells with the loss of the cobblestone-like 
structure, assuming a fibroblast-like morphology similar to an elevation of TGFβ1. 
Furthermore, this change in morphology was accompanied with an elevation of TG2, 
fibronectin, N-cadherin and Slug protein expression. On staining HBEC for fibronectin, 
it was observed that an increase in fibronectin deposition occurred around the cell 
indicating an up regulation of expression, which can be linked to elevated TG2 
expression. On investigating the effect of active TG2 elevation in HBEC-T cells on E-
cadherin and CFTR protein expression, the level were shown to be reduced probably 
due to enhanced levels of TGFβ1 hence driving the progression of EMT. Although 
Snodgrass et al. (2013) indicated that TGFβ1 negatively regulated CFTR, the results 
here suggest that the effect seen with TGFβ1 might be due to its activation by TG2. 
These results are preliminary findings and further studies might delineate the proposed 
mechanism.    
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5.6 Conclusion:  
 
This study has for the first time defined the role and mechanism by which knockdown 
of active elevated TG2 levels in CF could abolish the progression of fibrosis and 
conversely showed that an elevation of TG2 drives the increase in fibronectin, N-
cadherin and Slug whilst abolishing E-cadherin and CFTR expression. This leads to the 
conclusion that TG2 might be playing a major role in the progression of the EMT 
process in CF cells and its inhibition/knockdown might be a useful therapeutic tool in 
treating diseases where it has been implicated. However, further studies need to be 
carried out in in vivo or “near physiological conditions” to show whether these results 
can be translated to biological systems.   
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6.1 Introduction: 
!
Amongst the 6 classes of CFTR mutations, over 1900 mutations of the disease have 
been shown to exist which centres on the functionality of the channel (Bobadilla et al., 
2002). The phenotypic variation between the mutants alters from high sodium in sweat, 
chronic pulmonary disease, pancreatic insufficiency and infertility amongst both sexes 
(all associated with classes I and II) to specific phenotypes associated with certain 
mutations i.e. pancreatic sufficiency (class IV and V) (Levy et al., 2010, de Gracia et 
al., 2005). However, the symptoms associated with these phenotypes are worsened in 
heterozygote patients carrying class I-II mutations in which the other allele is either a 
class IV or V mutation. Such patients have lower survival rates. The most common 
alteration which accounts for 70% of the worldwide mutational variants was described 
by Kerem et al. (1989) and is the loss of 3 base pairs on exon 10 of the gene coding for 
CFTR, resulting in the absence at position 508 of the amino acid, phenylalanine, thus 
inducing a processing defect. Although there exists a vast heterogeneity of mutations, 
studies have attempted to define the peculiarity of each mutant, which ultimately guides 
research approaches towards therapeutic outcomes.  
Recent studies have been evaluating lead chemical compounds for “protein repair 
therapy”, aimed at repairing production, processing, regulation and conductance 
mutations and ultimately focuses on ensuring CFTR channel trafficking to the apical 
membrane and its functionality in situ (MacDonald et al., 2007). From the early 
successes of the aminoglycoside, tobramycin and the recombinant human 
deoxyribonuclease, Dornase alfa, a premature termination codon (PTC) modulator and 
an enzyme that cleaves extracellular DNA reducing sputum viscosity respectively, 
researchers have explored other lead compounds, which are now targeted at 
maturation/processional and regulation defects (Konstan and Ratjen, 2012, Chuchalin 
et al., 2009, Altamura et al., 2013, Lai et al., 2004). Hence, Ivacaftor (VX-770), a CFTR 
channel “potentiator” has demonstrated therapeutic success as it has been shown to 
be capable of increasing the gating activity of CFTR in patients with G551D mutation 
(Ramsey et al., 2011b, Accurso et al., 2010, Van Goor et al., 2009).  Other channel 
modifiers include ataluren (PTC124), an orally bioavailable compound used in the 
treatment of Duchenne muscular dystrophy (DMD) and CF where its capable of 
inducing ribosomes to read through nonsense stop mutations (Kerem et al., 2008) and 
lumecaftor (VX-880), another bioavailable CFTR “corrector” aimed at selectively 
correcting the ΔF508 mutation (Kerem et al., 2008, Van Goor et al., 2011, Clancy et al., 
2012). In the UK, Ivacaftor is currently available as an orally bioavailable tablet for 
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people with G551D mutation of 6 years and older. Lumecaftor is currently on clinical 
trials in combination with Ivacaftor for people homozygous or heterozygous for the 
ΔF508 mutation (Rowe and Verkman, 2013, Boyle et al., 2014). These compounds and 
other CFTR therapeutic agents in the pipeline demonstrate the advancement made in 
CF therapy and the impact on the quality of life (QOL) and life expectancy (Ashlock and 
Olson, 2011). Therefore, the forward approach would be to target CFTR mutational 
correction by using combination therapy, which synergistically or additively can 
enhance CFTR trafficking and conductance. 
The use of TG2 inhibitors as therapeutic targets have increased the possibility of better 
prognosis in various diseases e.g. chronic kidney disease (Johnson et al., 2007) and 
neurodegenerative diseases (Ruan and Johnson, 2007). Recently, TG2 has been 
implicated in the hyper-inflammatory responses typical to CF. Maiuri et al. (2008) 
described how in CF cells defective CFTR up-regulates intracellular TG2 activity that 
down regulates expression of the anti-inflammatory peroxisome proliferated activated 
receptor gamma (PPAR-γ). This was related to increased TG2-SUMOylation, which 
reduces ubiquitination and prevents TG2 degradation. Sustained intracellular TG2 
activity may therefore provide the link between increased inflammation and defective 
CFTR. 
Elevated TG2 levels were further shown to lead to defective beclin-1 mediated 
autophagy, a cell regulated process in which lysozymes degrade unwanted or 
dysfunctional cellular components. This was shown to be counteracted using TG2 
inhibitors as proteostasis regulators. This was illustrated to restore ΔF508 mutation 
stability prior to treating with CFTR potentiators, which maintain protein homeostasis 
whilst synergistically regulating CFTR channel maturation and trafficking to the apical 
surface ie VX-770, VX-532 (Luciani et al., 2010a, Luciani et al., 2012).   
The recurring conundrum in respiratory cell biology revolves around the development 
of robust representative tissue or cell systems that depicts inherent physiological 
conditions with flexibility of replication and maintenance of intricate respiratory traits. 
Studies continue to be sought to occlude this lacuna, which bridges the transfer of 
observable outcomes from research in in-vitro systems to outcomes in normal human 
physiological conditions.  
In respiratory medicine, the normal statutory lung milieu maintains cellular and matrix 
integrity and maintains tissue repair following insult caused by airborne particles and 
other injurious agents. Consequently, it is imperative to discern the mechanism through 
which this reparative process tips over into remodelling and fibrosis and develop 
Chapter!Six:!
!
! 162!
methods to abrogate faults in repair which ultimately leads to disease progression 
(Berube et al., 2010). The use of animal models, in vitro and ex vivo systems illustrates 
the need to undertake research within models that are easy to use, reproduce and 
maintain certain basic characteristics (Balharry et al., 2008, Coffman and Hessel, 
2005). To this end, animal models have been widely used as their size negates the 
laborious use of large population for drug toxicology studies, low acquisition cost and 
provides direct evidence of transferable traits observed in in-vitro cell systems (Berube 
et al., 2010). However, the lack of not mimicking human respiratory systems wholly in 
certain conditions opposes their use. 
Traditional 2-D cell culturing remains the resolute method used in culturing airway 
epithelial cells. This allows for culturing cells under submerged conditions in petri 
dishes or flasks with the ease of manipulation and allowing the cells to proliferate in 
single monolayers whilst changing medium (Yankaskas et al., 1985). Its also helps 
carrying out rapid, reproducible and rather simple experiments with the use of 
immortalised transformed or primary epithelial cells. However, with airway epithelial 
cells, a distortion of native cellular milieu by their removal from their native environment 
induces complex changes in the cells (Griffith and Swartz, 2006). Although, these 2D 
systems are robust, these changes have to be compensated for by developing models 
recreating the original native environment. Noteworthy of mentioning is the loss of tight 
junctions and polarity in 2-D systems. The importance of these tight junctions is 
depicted by their ability to control movement of ions and solute across the cell-matrix 
bed. Carterson et al. (2005) described whilst culturing A549 human lung epithelial cells 
on both cell culture flasks and Rotating Wall Vessel (RWV) bioreactors that cell polarity 
and tight junction was lower in 2-D submerged cultures than 3-D cultures and this 
impacts on the response of the cells to Pseudomonas aeruginosa, where infected 
submerged cells detached from their culture beds more easily than 3-D cultures.        
The elaborate airway epithelial traits shown by cells cultured at Air-Liquid Interface 
(ALI) recapitulate the salient phenotypic characteristics in comparison to submerged 
cultures. The ALI structure presents airway epithelial cells in culture inserts with 
micronized pore membranes coated (e.g. with collagen IV), upon which cells are 
cultured. The inserts are placed in companion plates with basal medium from which the 
cells feed. Grainger et al., (2006) showed in a comparative study using Calu-3 cells 
cultured in liquid covered culture (LCC) and at ALI that aside from the elevated trans-
epithelial-electrical resistance (TEER) measured in ALI compared to LLC, the 
expression level of zona occludens 1 (ZO-1), a tight junction protein, was raised in ALI 
thus indicating that cells cultured at ALI assume a morphological status representative 
of airway epithelium. This thus brings to the fore the studies by Gruenert et al. (1995) 
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that described the culturing of airway epithelial cells at ALI to generate increased cilia, 
serous cell differentiation and mucus production under appropriate conditions as 
mentioned by Robinson and Wu. (1993), which includes appropriate medium, substrate 
(e.g. collagen IV) and exposure to air. This supports the growth of cells in a pseudo-
stratified structure with exchange of cellular waste and nutrients across membrane.   
 
In the preceding chapters using IB3 as the CF cell and the corrected “add-back “ cell, 
C38 and human primary bronchial epithelial cell, HBEC, studies were carried out 
exclusively in submerged medium. The phenotypes in these cells were characterised 
under different conditions and treatments. This chapter attempts to undertake crucial 
experiments in an effort to recapture the phenotypes under ALI conditions. This would 
be confirmatory supporting our earlier results and prognosis. In addition, using cell-
permeable and cell impermeable TG2 inhibitors as well as CFTR correctors and 
potentiators, an attempt is made to combine these compounds together in other to 
determine the effect of TG2 inhibition and CFTR correction on CFTR Cl- channel 
rescue and via ion conductivity, thus directly examining the link between TG2 activity 
and CFTR functionality.   
 
6.2 Aims: 
This chapter is aimed at repeating the definitive experiments carried out in submerged 
medium, using the same cells but here cultured at ALI. Also, the study is aimed at 
showing the effect of combinational therapy involving TG2 inhibition on CFTR 
trafficking and conductivity. Here, IB3, C38, IB3-shRNA, HBEC and HBEC-T cells 
would be cultured in Transwells® at ALI for at least 28 days. During this period: 
! TEER readings will be taken aimed at determining cell-cell tightness and barrier 
integrity. 
! The effect of TG2 protein knockdown and TG2 up regulation on TG2 activity, 
TGFβ1 activity and TEER maintenance will be determined.  
! Using immunofluorescent staining, the expression and localisation of EMT 
markers relative to TG2 protein in TG2 knockdown cells will be determined.  
!  Following pre-treatment of IB3 cells with TG2 inhibitors and CFTR 
correctors/inhibitors, determine CFTR maturation and trafficking using Western 
blot analysis of membrane fractions.  
! Determine Cl- conductance through mature CFTR channels using the Cl- 
sensitive indicator, MQAE.     
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6.3 Methods: 
6.3.1 Culturing of airway epithelial cells using the ALI model 
 
3 x 104 of IB3, C38 or HBEC in 300µl of AEM were seeded on Transwell® insert 
membranes of 0.33cm2 area and 0.4µm pore size, previously coated with 33 µl of 
100µg/ml human placental Collagen IV in 3%(v/v) acetic acid.  These inserts were 
placed in companion plates with 600µl of medium in basal compartment. The cells 
were cultured as described in chapter 2.2.1.4. TEER was measured in cells after 
culturing for 14 days, using a voltohmmeter as described in chapter 2.2.1.5.   
 
6.3.2 Western blots of lysates of IB3, C38 and HBEC and their 
transduced variants 
 
The cells cultured on inserts were gently rinsed twice with 1x PBS, pH 7.4, removed 
from companion plates and placed on dry tissue paper. Using a sterile scalpel, the 
membrane was cut out carefully and placed into pre-cooled eppendorf tubes with lysis 
buffer and lysed as described in chapter 2.2.2.2. The lysates were dissolved in sample 
buffer and loaded onto 6%(w/v), 8%(w/v) or 12%(w/v) polyacrylamide gels for 
SDS/PAGE as described in chapter 2.2.3. The percentage of acrylamide used was 
altered in order to get effective separation of the proteins different proteins to be 
detected ie fibronectin and N-cadherin [6%(w/v)], TG2 [8%(w/v)] and Slug [12%(w/v)]. 
Western blotting was carried out on the separated proteins as described in chapter 
2.2.4. The membrane was stained with specific primary antibodies (1:1000) i.e. anti-
TG2, anti-fibronectin, anti-N-cadherin, anti-Slug, anti-CFTR, anti-E-cadherin and anti-
GAPDH (used as loading control).  
 
6.3.3 Immunocytochemistry of cells cultured at ALI 
 
After 28 days at ALI, the membranes were carefully cut out of the inserts and placed 
with cells uppermost in 12-well plates. Using, 200µl of 1x PBS, pH 7.4 cells were rinsed 
twice. Immunocytochemistry was carried out as described in chapter 2.2.16.1 using 
150µl primary antibody (Ab) (1:100) in complete medium ie anti-TG2, anti-fibronectin, 
anti-N-cadherin or anti-CFTR followed by 200µl of either Fluorescein isothiocyanate, 
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FITC (green) or Tetramethylrhodamine, TRITC (red) conjugated secondary antibody 
(1:200). 
6.3.4 TG2 activity of whole cell lysates of IB3, C38, HBEC and their 
transduced variants using the Biotin cadaverine incorporation assay 
 
The TG2 activity assay was carried out on protein lysates of IB3, IB3-shRNA, C38, 
HBEC and HBEC-TG epithelial cells cultured in AEM. Initially, cells were cultured at 
ALI as described in chapter 2.2.1.4. The cells were carefully rinsed in 1x PBS, pH 7.4 
twice. The membrane was cut out cells were lysed as described in chapter 2.2.2.2 and 
protein content quantified. The activity assay was carried out on 96-well plates pre-
coated with fibronectin (5µg/ml) using 50µg of cell lysate protein per well as described 
in chapter 2.2.6.1. 
 
6.3.4 Determination of plasma membrane proteins in IB3 cells using 
membrane fractionation 
!
6.3.4.1: Submerged culture 
5 x 105
 
of IB3 cells were sub cultured into 60mm petri dishes and allowed to attach for 
4 h. Medium was discarded and replaced with treated medium containing VX-809 
(Selleckchem®) (10µM), R283 (500µM), a combination of VX-809 and R283 or with 
DMSO (1:1000) as a control. The cells were cultured for 72 h with medium changed 
every 24 h. Cells were washed with ice cold 1x PBS, p.H 7.4 twice and membrane 
fractionation was carried out as described in chapter 2.2.17.1. Western blotting was 
carried out on membrane fractions as described in section 2.2.4.  
 
6.3.4.2: ALI culture 
3 x 104
 
of IB3 cells were sub-cultured into 0.33µm Transwell® insert membranes coated 
with collagen IV as described in chapter 2.2.1.4. The cells were allowed to attach for 6-
8 h. The medium was removed from Transwell® inserts (i.e. apically) as well as in the 
companion plates (i.e. basally). 300µl of complete medium was inserted into the 
Transwell® inserts with 600µl added to the companion plates. Medium was 
supplemented with VX-809 (10µM), R283 (500µM), a combination of VX- 809 and 
R283 or with DMSO as vehicle control (1:1000). Basal medium was changed daily for 
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the first 4 days i.e. This is the time required to attain relevant physiological features 
typical of ALI cultures. The cells were cultured as described in chapter 2.2.1.4 
supplementing medium with chemical compounds. Membrane fractionation was carried 
out on lysates as described in chapter 2.2.17.2. and Western blotting carried out on 
membrane fractions as described in chapter 2.2.4. 
 
6.3.5 Chloride channel activity assay in IB3 cells in the presence of a 
chloride sensitive indicator, MQAE 
 
1 x 105 IB3 cells were sub cultured into 100µl in 96-well plates and allowed to attach for 
6 h. The medium was changed and replaced with medium supplemented with TG2 
inhibitors with or without the CFTR corrector, VX-809 (10µM). The TG2 inhibitors used 
were R283 (500µM) and cystamine (250 µM). In order to load the cells with a chloride 
sensitive indicator, 10 mM MQAE in medium was added at 100µl/well according to the 
previously published method (West and Molloy, 1996) and cells were incubated at 
37oC for 16-18 h. The chloride conductance assay was then carried out as described in 
chapter 2.2.18.  
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6.4 Results: 
6.4.1 EMT marker and TG2 expression in CF cells cultured at ALI 
mimics expression in submerged culture: 
6.4.1.1: TG2, fibronectin and N-cadherin protein expression in IB3 and C38 cells 
is unchanged at ALI. 
 
As earlier described, the ALI model attempts to mimic in vivo physiological conditions 
with cells assuming the pseudo-stratified ultrastructure seen in the lungs. Studies have 
confirmed that this model produces airway epithelial cells showing electrical resistance, 
increased ciliogenesis and mucus production consistent with the airways in-vivo and 
the features required for maintaining the integrity of the airways (Grainger et al., 2006). 
Here, in concert with the results shown in chapter 3 and 4, an attempt is made to 
determine the expression of TG2 and EMT markers in IB3 and C38 cells cultured at 
ALI. The cells were cultured and Western blotting was performed as described in 
chapter 2.2.1.4 and 2.2.4 respectively. TEER was measured every other day to 
observe and estimate the appropriate epithelial resistance for cells to be harvested. 
Preliminary results have shown that from the 28th day (4 days in submerged and 24 
days at ALI) cells attain TEER values of ≥300Ω cm2, which was appropriate for the 
experiments (data not shown). Figure 6.1 shows Western blot analysis of TG2, 
fibronectin and N-cadherin expression by IB3 and C38 cells after 28 days at ALI. Here, 
TG2 and N-cadherin expression in IB3 cells were higher than C38 cells at ALI. Also, 
the expression of fibronectin was higher in IB3 cells compared with C38 cells. Previous 
studies have shown that the presence of collagen IV does not alter the protein 
expression of TG2 in these cells (results not shown). This was proven as TG2 levels 
were observed to be diminished in C38 cells compared to IB3 cells. This observation 
supports earlier results from submerged culture where expression patterns of TG2 and 
EMT markers were similar to that in ALI conditions (Figure 3.2 and 4.3).  
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Figure 6.1A,B,C&D: Elevated TG2 and EMT marker expression in CF cells 
cultured at ALI corresponds with expression in submerged conditions.  Western 
blots TG2, A fibronectin, B and N-cadherin, C expression in IB3 and C38 cells cultured 
at ALI. Cells were cultured for 28 days. 50µg of protein was used for the Western blot 
assay. Membranes were probed with monoclonal anti-TG2 and anti N-cadherin or 
polyclonal anti-fibronectin antibodies. GAPDH was used as the loading control to 
normalize protein expression. Densitometry, D, represents mean values of 2 
independent experiments. Blot images represent a characteristic blot of 2 independent 
experiments with equal number of cells used at all times. Results show higher TG2 and 
N-cadherin expression in IB3 cells more than C38 cells. Fibronectin expression in IB3 
cells was shown to be slightly higher than in C38 cells. The results observed above of 
TG2 and EMT markers expressed in IB3 and C38 cells show similarity with results 
observed in submerged cultures.  
 
6.4.1.2: TG2 co-localises with N-cadherin and fibronectin in CF cells at ALI. 
 
In previous chapters, the interaction between TG2 and EMT markers has been shown 
only in submerged culture. The results in Figure 6.1 suggest that protein expression of 
TG2 correlates to that of EMT markers in the ALI model in the same manner as was 
shown for submerged cultures. Here, emphasis has been made on determining the 
localisation of TG2 relative to that of the EMT markers when cultured at ALI. Figure 6.2 
shows that TG2, N-cadherin and fibronectin expression in IB3 cells was higher than in 
C38 cells and that these were co-localised. In IB3 cells, fibronectin and N-cadherin 
A# B# C#
D#
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were expressed consistently around the cell membrane with distinct expression within 
the extracellular matrix. Very little fibrous fibronectin was found around the periphery of 
C38 cells. Together, the results show that with respect to cells cultured in submerged 
models, TG2 and EMT markers are expressed to similar levels in ALI culture for both 
cell types. 
       
 
 
Figure 6.2A&B: TG2 co-localises with fibronectin and N-cadherin in IB3 and C38 
cells at ALI. Immunofluorescent images showing the expression of TG2, fibronectin 
and N-cadherin in IB3, A, and C38, B, cells cultured at ALI. Polyclonal rabbit anti-TG2 
and anti-fibronectin or monoclonal mouse anti-N-cadherin antibodies were used to 
stain cells with TRITC (red) or FITC (green), used as secondary conjugated antibody. 
Images are representative of 2 independent experiments carried out under comparable 
conditions. Mouse and Rabbit IgG were used as control (Figure 4.4). DAPI was used to 
stain nuclei. Images were visualised on the Leica® SP5 confocal microscope. Scale bar 
represents 7.5µm. Results show TG2 co-localising with fibronectin and N-cadherin in 
IB3 cells and C38 cells. However, the expression of TG2 and EMT markers were 
higher in IB3 cells than C38 cells.  
A#
B#
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6.4.2: TG2 inhibitors abrogate TG2 activity in CF cells cultured at 
ALI. 
!
As previously observed from Figure 3.5, TG2 inhibitors play a major role in abrogating 
TG2 activity thus impeding the progression of EMT. Furthermore, it was observed that 
TG2 inhibitors inhibit TGFβ1 secretion and activity in IB3 cells cultured in submerged 
culture (Figure 3.6D) as well as blocking the effect of elevated TG2 in C38 cells treated 
with rTGFβ1, thus impeding an increase in EMT marker expression as shown in HBEC 
(Figure 4.9).  Importantly, these results illustrate the link between TG2 and EMT with 
TGFβ1 playing a vital role in the process. Here, an attempt is made to use the cell-
permeable and cell impermeable TG2 inhibitors, R283 and R281 respectively, to 
abolish TG2 activity in cells cultured at ALI. The cells were cultured in the presence of 
R283 and R281 (500µM each) basally for 28 days at ALI before lysis. The cell lysates 
were used in the TG2 activity assay to determine total cell TG2 activity measured by 
the incorporation of biotinylated cadaverine into fibronectin by TG2. The results show a 
3-fold increase in total TG2 activity in untreated IB3 cells compared to C38 cells. It was 
demonstrated (Figure 6.3) that the presence of R283 and R281 completely abolished 
TG2 activity in both cell lines with a decrease in TG2 activity in R283 and R281 treated 
IB3 cells compared to negative control (with 10mM EDTA not shown). It was also 
observed that C38 cells showed little or no TG2 activity compared to IB3 cells, in 
agreement with data from submerged culture. This is in concert with the TG2 
expression observed with the Western blots conducted and data from submerged 
culture (Figure 3.5) where R283 was shown to inhibit TG2 activity both in lysates and at 
the cell surface. It can be deduced here that culture at ALI maintains the characteristics 
of each cell type with IB3 cells retaining their high TG2 activity and C38 cells showing 
marginal TG2 activity, which suggests that normal airway epithelial cells have little or 
no TG2 expression or activity and the ALI model is a useful model depicting in vivo 
conditions. Also due to the non-differential inhibition of TG2 activity by TG2 cell-
permeable and impermeable inhibitors, it can be hypothesised that cell surface TG2 
might be playing a role in the mechanism that induces promotion of EMT in IB3 cells.    
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Figure 6.3: Cell permeable and impermeable TG2 inhibitors in IB3 cells at ALI 
inhibit TG2 activity. Biotin cadaverine TG2 activity assay was carried out on lysates of 
IB3 and C38 cells cultured at ALI under control conditions (no inhibitors) and in the 
presence of cell-permeable and cell impermeable TG2 inhibitors, R283 (500µM) and 
R281 (500µM) respectively. Results represent mean and standard deviation values of 
2 independent experiments. Results show high TG2 basal activity in IB3 cells 
(untreated), which was inhibited by R283 and R281 equally. C38 cells showed marginal 
TG2 activity under control conditions (untreated) with little effect observed in the 
presence of either TG2 inhibitor.  
 
6.4.3: Knockdown of TG2 restores airway integrity in a reparative 
manner. 
 
6.4.3.1: TG2 shRNA transduction abolishes TG2 induced EMT progression in the 
IB3 cell line. 
 
The abrogation of TG2 activity as observed in section 6.2 has demonstrated that 
culturing IB3 and C38 cells at ALI retains vital characteristics of the cells in terms of 
differential TG2 activity. Studies have shown that TG2 levels are elevated in wound 
healing where cellular migration/ invasion holds a reparative role in collagen deposition 
and re-epithelialisation and that active cell surface TG2 activity is involved (Telci and 
Griffin, 2006, Verderio et al., 2004). Here, the ALI model is used to evaluate how TG2 
knockdown could reverse EMT in IB3 cells. Using IB3 cells transduced with TG2 
shRNA as described in chapter 2.2.19.5, cells were cultured at ALI to observe the 
effect of TG2 knockdown in IB3 cells on EMT marker expression. The results suggest a 
lowering of TG2 expression in the IB3 cells transduced with TG2-shRNA. The link 
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between high TG2 expression and EMT was further illustrated by the decrease in 
fibronectin, N-cadherin and Slug expression in TG2-shRNA IB3 cells compared to wild 
type IB3 cells (Figure 6.4). This shows a possible interaction between TG2 and 
fibronectin expression, which studies have shown to be both RGD and RGD 
independent (Verderio et al., 2003, Telci et al., 2008) and TG2 and N-cadherin, a 
cadherin cell adhesion protein which TG2 has been shown to up regulate in EMT and 
whose expression illustrates EMT progression in epithelial cells (Park et al., 2013, Kim 
et al., 2000).  
 
                 
Figure 6.4 A&B: TG2 knockdown impedes fibronectin, N-cadherin and Slug 
expression in IB3 cells at ALI. Western blot analysis of fibronectin, N-cadherin and 
Slug expression in IB3 cells cultured at ALI and transduced with TG2 shRNA. IB3 cells 
were cultured at ALI for 28 days, within which cells were transduced. 50µg of protein 
was used for the Western blot assay. Monoclonal antibodies (anti-TG2, anti-N-cadherin 
and anti-Slug) and polyclonal anti-fibronectin antibody were used to probe blots. 
GAPDH was used to normalise protein loading. The blot image is characteristic of two 
independent repeats. Densitometry represents mean values of two independent 
experiments. Results show that as IB3 cells are transduced with TG2 shRNA, 
fibronectin, N-cadherin and Slug expression was inhibited.  
 
6.4.4:  Abrogation of TG2 activity restores tight junction cohesion 
 
Previous experiments have shown that inhibition of TG2 activity reverses the 
progression of EMT as shown by reduced expression of EMT markers and also 
restores junction integrity with the up regulation of junction proteins i.e. adherin junction 
proteins like E-cadherin (Figure 5.9). Conversely, it was observed that an elevation of 
B#A#
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TG2 expression and activity possibly reinstates the expression of EMT markers in 
airway epithelial cells (Figure 4.9 & 5.8). This suggests that TG2 might play a vital role 
in the regulation of EMT. Here, using the ALI model, abolishment of TG2 expression 
with TG2-shRNA is shown to inhibit TG2 activity. From the results in Figure 6.5, it was 
observed that in TG2 shRNA transduced cells, there was a reduction of TG2 activity in 
IB3 shRNA-transduced cells compared to wild type cells. This indicates referring back 
to Figure 6.3 that TG2 activity inhibited by TG2 inhibitors mimics the knockdown of 
TG2. This suggests that the effect observed might be solely related to the regulation of 
TG2 activity and hence implies that TG2 activity plays a vital role in promoting the 
expression of EMT markers.   
                                
 
Figure 6.5: TG2 shRNA inhibits TG2 activity in IB3 cells cultured at ALI. TG2 
activity in lysates of IB3 cells transduced with TG2 shRNA and cultured at ALI using the 
Biotin cadaverine assay. The cells were cultured at ALI for 28 days. 50µg of guinea pig 
liver TG2 (gplTG2) was used a positive control (+) with the substitution of calcium for 
10 mM EDTA in the negative control (-). Results represent mean values of triplicates of 
two independent experiments. Results show that high TG2 activity in untreated IB3 
cells is inhibited to marginal levels, compared to the negative control after transduction 
with TG2 shRNA.    
 
Whilst demonstrating the importance of TG2 knockdown in abrogating EMT, it was 
hypothesised that the abolishment of TG2 activity, which ultimately impedes cell 
detachment and migration as well as matrix growth, should reestablish cell-cell 
adhesion thus restoring epithelial integrity. To demonstrate this, TEER of IB3 TG2 
shRNA transduced cells cultured at ALI were measured.  
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Results show (Figure 6.6) a 2-fold increase in epithelial cell resistance in IB3 TG2 
shRNA transduced cells compared to wild type cells, when cultured at ALI. The 
increase in electrical tightness, correlates with TG2 knockdown and inhibition of 
fibronectin, N-cadherin and Slug expression. However, C38 cells were observed to 
have similar TEER values to untreated IB3 cells. This might be due to the fact that C38 
cells are “corrected” IB3 cells and so retain some phenotypes of IB3 cells. This 
illustrates that inhibiting TG2 can enhance electrical resistance in CF cells. Alongside, it 
can be postulated that abrogation of TG2-induced EMT, which is analogous to TG2 
inhibition by TG2 inhibitors, restores epithelial cadherin and tight junction expression, 
thus restoring epithelial integrity.   
               
Figure 6.6: Epithelial “tightness” is restored in the presence of TG2 shRNA. 
TEER measurements of IB3, C38 and TG2 shRNA transduced IB3 cells cultured at 
ALI. The cells were cultured for 28 days at ALI. TEER measurements were carried out 
from 14 days at ALI. Resistance was measured on a voltohmmeter in ohms. Triplicate 
readings were carried out from each well. TEER values represent means and standard 
deviation from triplicates taken from 3 independent readings. Results show a significant 
increase in epithelial resistance in the presence of TG2 shRNA in IB3 transduced cells 
compared to untreated IB3 cells. C38 cells showed similar TEER values to untreated 
IB3 cells One-way Anova analysis with Bonferroni’s Multiple comparison test: *p<0.05, 
**p<0.01, n.s. p>0.05.       
 
The results presented here have shown that the TG2 expressional pattern in IB3 cells 
cultured at ALI correlates with that in submerged culture. These data also illustrate the 
link between TG2 knockdown, restoration of epithelial tightness and reversal of EMT 
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marker expression. To further support these findings, immunostaining to illustrate TG2 
co-localisation with EMT markers at ALI was carried out with the aim of determining the 
effect of knockdown of TG2 in situ on expression of these proteins. Using IB3 cells 
transduced with TG2 shRNA, immunostaining was performed on cells cultured at ALI. 
Cells were cultured and immunocytochemistry was carried out as described in chapter 
2.2.1.4 and 2.2.16.2 respectively. Results in Figure 6.7 depict TG2 and fibronectin 
localised outside the cells in both wildtype and TG2 shRNA transduced IB3 cells with 
DAPI staining the nucleus (blue). However, it was observed that expression was 
reduced in transduced cells compared to wild type with a reduction of the staining 
(TRITC-red) for both TG2 and fibronectin. This concurs with the Western blot results in 
Figure 6.4 where TG2 and fibronectin expression were reduced in transduced cells 
compared to wild type. Furthermore, this supports the hypothesis that TG2 regulates 
EMT progression in IB3 cells.  
 
                            
           
Figure 6.7A&B: TG2 shRNA reduces fibronectin expression by IB3 cells at ALI. 
Immunofluorescent confocal microscopy for TG2 (A) and fibronectin (B) in wild type 
IB3 cells (IB3) and in IB3 cells transduced with TG2 shRNA (IB3+ shRNA) cultured at 
ALI for 28 days. Polyclonal rabbit anti-TG2 and anti-fibronectin antibodies were used to 
stain cells. Images were taken using a Leica® SP5 confocal microscope. Mouse and 
Rabbit IgG were used as control (Figure 4.4). DAPI was used to stain nuclei. Images 
are representative of 2 independent experiments. Scale bar represents 10µm. Images 
show an inhibition of TG2 expression by TG2 shRNA indicating that blocking TG2 
expression (with shRNA) reduces expression. Similarly, as TG2 expression was 
inhibited (in the presence of shRNA), fibronectin expression was reduced, B. 
A# B#
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6.4.5: Up regulation of TG2 in HBEC cultured at ALI mimics the IB3 
submerged phenotype. 
 
Studies have suggested that whilst culturing primary bronchial epithelial cells at ALI, 
certain characteristic phenotypes of in vivo physiological airway can be recreated, 
which has aided research in understanding the potential mechanisms involved in 
airway pathologies (Stewart et al., 2012). Albeit, because of the complexity of using this 
model and cost of primary cells, its use in this study has been limited to evaluating and 
confirming previous experiment carried out in submerged culture. Here TG2 wild type 
plasmid was transduced into human primary bronchial epithelial cells, HBEC, in order 
to observe whether an elevation of TG2 levels will induce or increase expression of 
EMT markers in the cell at ALI. HBEC (HBEC) and TG2 transduced cells (HBEC-T) 
were cultured at ALI for 28 days as previously described in chapter 2.2.1.4. Phase 
contrast images of the cells were captured using a Nikon camera mounted on a 
compound microscope. Figure 6.8 shows the cobblestone-like structures of HBEC cells 
with tight convoluted cell-cell adhesion compared to HBEC-T cells where cells have 
assumed a disoriented morphology and are seen to lose their adhesion and are rather 
migrating away from each other and assuming a morphology corresponding to an EMT 
phenotype. This relates with our observation in chapter four where HBEC were 
incubated with rTGFβ-1 protein and cells change their morphology with a decline in E-
cadherin expression and an elevation of TG2, fibronectin and N-cadherin levels. Also 
this confirms the role of TG2 in the restoration of epithelial integrity in TG2 shRNA 
knockdown cells IB3 cells (Figure 6.4). 
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Figure 6.8: Up regulation of TG2 in HBEC alters epithelial morphology. Phase 
contrast images of untreated HBEC and TG2 transduced (HBEC-T) cells cultured at 
ALI. Cells were cultured for 28 days and images were taken in situ in Transwell® plates 
using a Nikon camera mounted on a microscope (magnification of x200 and x400 for 
left and right panels, respectively). Images are representative of 2 independent 
experiments. Images show a change in cell morphology from the characteristic 
epithelial cobblestone-like morphology in untreated HBEC to a disoriented fibroblast-
like morphology seen in HBEC-T.  
 
In furtherance to the observation of a change in cell morphology with TG2 wild type 
transduction, protein expression and immunostaining of the primary cells at ALI was 
carried out. The expression levels of TG2, fibronectin, N-cadherin and Slug were 
determined using Western blotting. The results again show that there is an increase in 
TG2 expression in HBEC-T cells compared to untreated HBEC and that this appears to 
associate with an increase in fibronectin and N-cadherin expression (Figure 6.9). The 
expression of Slug wasn’t significantly different between untreated and transduced 
HBEC. TEER values were shown to slightly decrease in HBEC-T cells however, it was 
observed that values were higher than TEER in IB3 wild type cells cultured at ALI 
(Figure 6.6). These changes in EMT marker expression are in concert with the results 
in submerged culture but however show that although the cells might be going through 
EMT, the slight increase with Slug added to the decrease in TEER values in HBEC-T 
cells suggests that HBEC primary cells retain residual cell-cell adhesion compared to 
IB3 cells. This might be attributed to the inherent continuous feed back mechanism via 
TGFβ1 in IB3 cells, where TG2 remains elevated.   
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Figure 6.9A&B: Transduced TG2 protein expression in HBEC at ALI increases 
EMT marker expression and reduces TEER. Western blot, A analysis and TEER, B 
measurements for HBEC and HBEC-T cells cultured at ALI. The cells were cultured for 
28 days during which TEER values were measured from the 14 days post ALI. 50µg of 
protein was used for the Western blot assay. Monoclonal (anti-TG2, anti-N-cadherin 
and anti-Slug) and polyclonal anti-fibronectin antibodies were used to probe blots. 
GAPDH was used to normalise protein loading. Densitometry represents protein 
expression normalised to GAPDH expression. TEER values represent the means of 
triplicate readings from 2 inserts at 3 different time points. Results show that an 
elevation of TG2 in HBEC-T cells induces an increase in fibronectin, N-cadherin and 
Slug expression. TEER values showed a reduction in resistance in untreated HBEC 
compared to HBEC-T cells.     
 
Using immunostaining (Figure 6.10), it was apparent that elevated TG2 levels (green) 
found in HBEC-T cells were commensurate with raised fibronectin expression (red) (in 
agreement with observations from Western blots in Figure 6.9). Here, it was observed 
that deposits of fibronectin were distributed around the cells surface in concert with 
where TG2 was localised on the cell and across the cell matrix. Together, these 
suggest that elevation of TG2 expression in HBEC drives similar EMT marker 
expression to that observed in IB3 cells and supports the hypothesis that elevated TG2 
levels increases the expression of fibronectin and N-cadherin and drives EMT in IB3 
cells.      
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Figure 6.10A: TG2 induced expression increases TG2 fluorescence in HBEC-T 
cells. Immunofluorescent images showing TG2 expression in HBEC cells transduced 
with TG2-WT plasmid cultured at ALI. The cells were cultured for 28 days and stained 
with monoclonal mouse anti-TG2 antibody and secondary FITC anti-mouse antibody 
(green). Images were taken using the Leica® SP5 confocal microscope. DAPI was 
used to stain nuclei. Scale bar represents 25 µm. Images show an increase in 
fluorescence in HBEC-T cells as a consequence of increased TG2 expression. 
 
           
Figure 6.10B: TG2 induced expression increases fibronectin expression in 
HBEC-T cells. Immunofluorescent images of fibronectin expression in HBEC cells 
transduced with TG2-WT plasmid cultured at ALI. The cells were cultured for 28 days 
and stained with polyclonal anti-fibronectin antibody (rabbit) and secondary FITC anti-
rabbit antibody (green). Images were taken using the Leica® SP5 confocal microscope. 
DAPI was used to stain nuclei. Scale bar represents 25 µm. Images show an elevation 
of fibronectin expression around the HBEC-T cells. 
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6.4.6: TG2 is a negative regulator of the CFTR chloride channel 
expression and activity. 
6.4.6.1: Synergism between TG2 inhibition and CFTR correction elevates CFTR 
expression. 
The recent milestone approval of Ivacaftor, VX-770, a CFTR potentiator for the 
treatment of heterozygote CF patients with the G551D mutation, signalled the opening 
of a range of novel classes of drugs used in the treatment of CF aimed at ameliorating 
CFTR protein mutations (Ramsey et al., 2011a, Harrison et al., 2013). The 
conventional therapy was aimed at alleviating patient symptoms but with the advent of 
these new compounds, treatment is centred on correcting the default in chloride 
conductance. This current study has primarily suggested the involvement of TG2 in the 
pathogenesis of the disease with insight into new therapeutical goals. Luciani et al. 
(2012) demonstrated using the CFTR potentiators, VX-325 or Corr-4a, that an increase 
in CFTR function in ΔF508-homozygous epithelial cells was not enough to sustain an 
increase in chloride conductance. Hence, the presence of a mature channel in the 
plasma membrane requires an increase in stability of the protein, which prevents 
premature proteosomal degradation so reducing the copies of the CFTR channel in the 
apical membrane. However, in the presence of the non–specific TG2 inhibitor or 
“proteostasis regulator”, cystamine, the membrane status of the channel was 
maintained 12 h after washout of cystamine and cycloheximide treatment (Luciani et 
al., 2012). Nonetheless, due to the ubiquitous nature of cystamine as a TG2 and 
caspase inhibitor, its function cannot be solely related to its inhibition of TGases (Lesort 
et al., 2003). With that background, this study is aimed at using the TG specific 
inhibitor, R283 in the presence of the CFTR corrector, VX-809 and determining the 
combined effect of these compounds in alleviating protein degradation, thus elevating 
the expression of mature CFTR in the apical surface of IB3 cells. Figure 6.11 shows 
Western blots of TG2 and CFTR protein expression (band C) in the presence of VX-
809 (10µM) and R283 (500µM) in IB3 cells in submerged culture. Results show 
elevated TG2 expression in VX-809 treated groups compared to DMSO control. R283 
inhibited TG2 expression slightly compared to untreated cells and in the presence of 
both R283 and VX-809, TG2 expression was significantly inhibited (p<0.001) compared 
to the DMSO control. Conversely, CFTR was marginally expressed at the membrane in 
untreated wild type cells, however in the presence of VX-809, expression was 
significantly elevated (p<0.001) compared to the DMSO control. Figure 6.11 shows that 
following treatment of IB3 cells with R283, membrane expression of CFTR increased 
significantly (p<0.01) above untreated groups however slightly below the VX-809 
treated group compared with DMSO. CFTR expression in the presence of VX-
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809/R283 was not significantly higher than VX-809 alone. The effects of R283 on 
CFTR expression suggest a novel role for TG2 in CF disease pathophysiology whereby 
TG2 activity is directly linked with CFTR maturation and indicates a potential future 
input of TG2 inhibitors as therapeutic compounds in patients with ΔF508 or W1282X 
mutation.        
   
 Figure 6.11: Partial correction of ΔF508 CFTR mutation by VX-809 and R283 
augment CFTR protein copies on cell membrane.  Left panel. Western blots 
showing TG2 and CFTR expression in IB3 cells under submerged culture treated with 
the TG2 inhibitor, R283 (500µM) or CFTR corrector, VX-809 (10µM). 250µg of protein 
was used for the Western blot assay. Monoclonal anti-TG2 and anti-CFTR antibodies 
were used to detect protein with Na+-K+-ATPase detection used as protein loading 
control. Blot image represents a characteristic blot of 3 independent experiments 
carried out with the same number of cells. Right panel. Densitometry represents mean 
and standard deviation of 3 independent experiments with protein expression 
normalised to Na+-K+-ATPase. Results show no change in TG2 expression in the 
presence of VX-809 compared to DMSO control however, the combination of VX-809 
with R283 significantly inhibited TG2 expression. A reduction in TG2 expression was 
shown in the presence of R283 compared to untreated control. However, CFTR 
expression was shown to increase significantly in the presence of R283 compared to 
untreated control and markedly elevated in the presence of VX-809 and VX-809/R283 
compared to DMSO control. Two-way Anova analysis with Bonferroni post-tests:  *** 
p<0.001, **p<0.01, * p<0.05, n.s. p>0.05. 
 
6.4.6.2: Conformational correction induced by VX-809 salvages CFTR from early 
proteosomal degradation 
 
Studies have shown that patients carrying the ΔF508 mutation, which is confined to the 
nuclear binding domain 1 (NBD-1) of the CFTR protein, acquire 15% of normal lung 
function when treated with the CFTR corrector, VX-809 (Van Goor et al., 2011). Albeit, 
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the amelioration of lung function in the presence of VX-809 has been demonstrated to 
be due to the conformational modifications induced by the compound in the membrane-
spanning domain 1 of the protein which enhances the interaction between NBD-1 and 
MSD-1 and 2 (Ren et al., 2013). This brings to the fore the importance of the stability of 
the NBD-1 hence suggesting that compounds can synergistically improve CFTR 
expression by stabilising this domain interaction with MSD-1, which suppresses folding 
defects of ΔF508 mutation and forges the processing of mature CFTR which is 
trafficked to the plasma membrane. Here, IB3 cells were treated with VX-809 and R283 
prior to immunocytochemical staining of the cells with antibodies to TG2 or CFTR to 
ascertain the effect of the compounds on CFTR expression and TG2 expression. 
Figure 6.12A shows that in untreated IB3 cells, expression of TG2 was high but 
expression of CFTR was marginal. In the presence of VX-809, high elevation of CFTR 
expression was observed with TG2 expression remaining unchanged. DAPI (blue) was 
used to stain nuclei. Expression of CFTR was shown as “glowing green dots” 
distributed around the cell (Figure 6.12B). Likewise, in the presence of R283 treatment, 
CFTR expression was highly expressed however slightly less than was expressed in 
VX-809 group but higher than untreated groups (Figure 6.12C). Figure 6.12D shows a 
combination of R283 and VX-809; here elevated expression of CFTR was marked with 
large widespread distribution across the cell whilst TG2 expression (red) was reduced. 
TG2 expression was shown to reduce in the presence of both R283 and VX-809/R283 
(Figure 6.12 C and D).  These results suggest that whilst the R283 inhibitor blocks TG2 
expression, VX-809 corrects the conformational default of the ΔF508 mutation, thus 
allowing the channel to be processed properly, avoiding early degradation and 
presumably allowing glycosylated matured channel to be trafficked to the cell surface. 
Although, the functionality of the channels has not been tested, the prognosis is that 
this synergistic/additive effect can be construed as a merger of an abolished TG2 
induced EMT and CFTR mutational correction.  
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Figure 6.12A: Low CFTR expression in untreated IB3 cells in submerged culture. 
Immunofluorescent images of TG2 and CFTR expression in IB3 cells in submerged 
culture. Polyclonal rabbit anti-TG2 and monoclonal mouse anti-CFTR antibodies were 
used to stain cells. Images were taken under a Leica® SP5 confocal microscope. 
Mouse and Rabbit IgG were used as control (Figure 4.4). DAPI was used to stain 
nuclei. Images represent characteristic staining of 2 repeat experiments. Scale bar 
represents 10 µm. Images show marginal CFTR expression and high TG2 expression 
in IB3 cells. 
                   
Figure 6.12B: VX-809 increases CFTR expression in IB3 cells. Immunofluorescent 
images showing TG2 and CFTR expression in IB3 cells in submerged culture. Cells 
were treated with the CFTR corrector, VX-809 (10µM) for 48 h prior to staining. 
Polyclonal rabbit anti-TG2 and monoclonal mouse anti-CFTR antibodies were used to 
stain cells. Images were taken under a Leica® SP5 confocal microscope. Mouse and 
Rabbit IgG were used as control (Figure 4.4). DAPI was used to stain nuclei. Images 
represent characteristic staining of 2 repeat experiments. Scale bar represents 10 µm. 
Images show an elevation of CFTR expression in IB3 cells in the presence of the 
CFTR corrector, VX-809 with no change in TG2 expression. 
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Figure 6.12C: R283 inhibits TG2 expression but up regulates CFTR expression in 
IB3 cells.  Immunofluorescent images showing TG2 and CFTR expression, in the 
presence of cell permeable TG2 inhibitor, R283 (500µM).  Polyclonal rabbit anti-TG2 
and monoclonal mouse anti-CFTR antibodies were used to stain cells. Images were 
taken under a Leica® SP5 confocal microscope. Mouse and Rabbit IgG were used as 
control (Figure 4.4). DAPI was used to stain nuclei. Images represent characteristic 
staining of 2 repeat experiments. Scale bar represents 10 µm. Images show an 
inhibition of TG2 expression after incubating with R283 and that this corresponds with 
an increase in CFTR expression. 
 
 
                
 
Figure 6.12D: VX-809 and R283 synergistically elevate CFTR levels in IB3 cells. 
Immunofluorescent images showing TG2 and CFTR in IB3 cells in submerged culture 
incubated with VX-809 (10µM) and R283 (500µM). Polyclonal rabbit anti-TG2 (red) and 
monoclonal mouse anti-CFTR (green) antibodies were used to stain cells. Images were 
taken under a Leica® SP5 confocal microscope. Mouse and Rabbit IgG were used as 
control (Figure 4.4). DAPI was used to stain nuclei. Images represent characteristic 
staining of 2 repeat experiments. Scale bar represents 10 µm. Images show marked 
elevation of CFTR expression in IB3 cells treated with VX-809 and R283 while TG2 
expression is inhibited under these conditions. 
 
 
!
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6.4.6.3: Ivacaftor, VX-770, increases CFTR expression in IB3 cells. 
 
In a recent study, Yu et al. (2012) showed that the CFTR potentiator, VX-770 could 
potentiate chloride conductivity in a variety of CFTR gating mutations ie G551D, 
G178R, G551S, S549N, S549R, G1244E, S1251N, S1255P and G1329D. In relation to 
this, the FDA recently approved that VX-770 can be used for these mutations 
mentioned above as well (De Boeck et al., 2014). However, VX-770 has also been 
demonstrated to improve chloride-gating activity in temperature corrected ΔF508 
homozygous mutations or heterozygous mutations with at least one G551D allele (Van 
Goor et al., 2009). The hypothesis suggests that VX-770 in combination with TG2 
inhibitors might improve the trafficking of the channel to the plasma membrane as well 
as potentiate the conductance of chlorine. To support this hypothesis, IB3 cells in 
submerged culture were treated with VX-770 (10µM) alone and in combination with 
VX-809 (10µM) and R283 (500µM). Results from Figure 6.13 show that compared to 
cells treated with VX-770 alone, the combination of VX-770 with VX-809 elevated 
CFTR expression on the cells surface by 2-fold. On treating cells with VX-770 and 
R283, CFTR expression increased significantly (p<0.05) above the VX-770 alone 
treated groups but slightly less than that observed in the presence of VX-770/VX-809. 
These observations support previous results where R283 combination with the CFTR 
corrector, VX-809 improved CFTR expression by presumably stabilising the thermo 
unstable NBD-1 thus increasing the turnover of the protein on the plasma membrane.  
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Figure 6.13A&B: Combinations of VX-770 with VX-809 or R283 ameliorates CFTR 
levels in IB3 cells. A. Western blots showing CFTR expression in IB3 cells cultured in 
submerged culture and treated with CFTR potentiator, VX-770 (10µM) and TG2 
inhibitor, R283 (500µM). 250µg of protein was used for the Western blot assay. 
Monoclonal anti-mouse CFTR antibody was used with anti-Na+-K+-ATPase used as 
loading control. B. Densitometry represents means and standard deviation of 3 
independent experiments normalised to Na+-K+-ATPase expressed. Blot image 
represents a characteristic blot of 3 independent experiments carried out with the same 
number of cells. Results show an increase in CFTR expression in the presence of 
either the combination of VX-770/VX-809 or VX-770/R283 with the former showing 
higher levels of CFTR expression. One way Anova with Bonferroni’s multiple 
comparison test; **p<0.005, *p<0.05, n.s. p>0.05.  
   
In concert with these findings above, IB3 cells treated with both VX-770 and R283 were 
evaluated to determine co-localisation of cell surface TG2 and CFTR and to observe 
the distribution of CFTR trafficked to the cell surface. Compared to results from VX-
809, VX-770 improved CFTR expression (Figure 6.14A) with well distributed “glowing 
green dots” interspaced across the surface of cells, which was subsequently enhanced 
slightly in the presence of R283 (Figure 6.14B). TG2 expression was inhibited in the 
presence of R283 (Figure 6.14B). Together, this report concurs with previous studies 
suggesting that VX-770 can increase CFTR expression and inhibition of TG2 
seemingly aids in stabilising mutated CFTR protein hence ameliorating channel 
trafficking.   
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Figure 6.14A: VX-770 ameliorates CFTR expression in IB3 cells. 
Immunofluorescent staining for TG2 and CFTR in IB3 cells cultured in medium 
supplemented with VX-770 (10µM). Polyclonal rabbit anti-TG2 and monoclonal mouse 
anti-CFTR antibodies were used to stain cells. Images were taken under a Leica® SP5 
confocal microscope. Mouse and Rabbit IgG were used as control (Figure 4.4). DAPI 
was used to stain nuclei. Images represent characteristic staining of 2 repeat 
experiments. Scale bar represents 10 µm. Results show an increase in CFTR 
expression in the presence of VX-770 in IB3 cells. 
                 
 
Figure 6.14B: CFTR expression is up regulated by a combination of VX-770 and 
R283. Immunofluorescent images showing IB3 cells in submerged culture stained with 
polyclonal rabbit anti-TG2 and monoclonal mouse anti-CFTR antibodies following 
treatment with VX-770 (10µM) and R283 (500µM). Images were taken under a Leica® 
SP5 confocal microscope. Mouse and Rabbit IgG were used as control (Figure 4.4). 
DAPI was used to stain nuclei. Images represent characteristic staining of 2 repeat 
experiments. Scale bar represents 10 µm. Images show a highly elevated CFTR 
expressed in IB3 cells in the presence of VX-770 and R283 with TG2 expression 
inhibited under these conditions. 
 
6.4.6.4: Recapitulation of augmented CFTR expression with VX809 and R283 
treatment in the ALI model 
 
The robustness of the ALI model in depicting in vivo airway architecture was observed 
earlier when IB3, C38 and HBEC were cultured at ALI and TG2 and EMT marker 
expression determined (Figure 6.1 and 6.9). The results obtained illustrated similar 
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findings as observed in submerged medium. Therefore, using this model showed IB3 
cells expressing high TG2 levels corresponding to elevated EMT markers and the 
effects of knockdown or up regulation of TG2 on EMT progression. Here, in order to 
confirm the recent findings of an elevation of CFTR expression in monolayer cell 
culture model where the correlation between CFTR and EMT marker expression has 
been established, IB3 cells were cultured at ALI for 28 days, treated with VX-809 and 
R283 and then TG2 and CFTR expression were determined. As observed in 
submerged culture, CFTR expression was shown to be elevated in the presence of VX-
809 compared to control however, TG2 expression remains unaltered. On addition of 
R283, it is observed that CFTR expression is slightly elevated, beyond that seen in 
untreated cells and not as significantly elevated as observed in VX-809 treated cells 
(Figure 6.15A-C). CFTR expression was shown in IB3 cells to increase when cells 
were incubated with both VX-809 and R283. These results support the findings from 
submerged culture however, further investigation using 3-D images confirms from the 
cross-sectional image an increase in CFTR expression (green) shown to traffic from 
the basal cells to the cell surface in the presence of VX-809. DMSO controls need to be 
assessed to further confirm the results obtained. These images further show that in the 
presence of R283, CFTR levels were shown to increase with increased expression 
closer to the apical surface, however expression was less compared to VX-809 alone 
(Figure 6.14D). Together, these results culminate in illustrating that VX-809 treatment 
might be correcting processional CFTR defects (such as the ΔF508 mutation) in IB3 
cells, which is further stabilised byTG2 inhibition with R283 hence allowing matured 
CFTR protein to be trafficked to the plasma membrane as suggested in the results 
presented.   
                
Figure 6.15A: Low CFTR expression in untreated IB3 cells cultured at ALI. Images 
showing TG2 and CFTR expression in untreated IB3 cells cultured at ALI. The cells 
were cultured for 28 days and stained with polyclonal rabbit anti-TG2 and monoclonal 
mouse anti-CFTR antibodies. Images were taken under a Leica® SP5 confocal 
microscope. Mouse and Rabbit IgG were used as control (Figure 4.4). DAPI was used 
to stain nuclei. Images represent characteristic staining of 2 repeat experiments. Scale 
bar represents 10 µm. Results show marginal CFTR and high TG2 expression in IB3 
cells cultured at ALI.   
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Figure 6.15B: Elevated CFTR expression in the presence of VX-809. 
Immunofluorescent images of TG2 and CFTR expression in IB3 cells cultured at ALI 
and treated with the CFTR corrector, VX-809 (10µM) and cultured at ALI. The cells 
were cultured for 28 days and polyclonal rabbit anti-TG2 and monoclonal mouse anti-
CFTR antibodies were used to stain cells. Images were taken under a Leica® SP5 
confocal microscope. Mouse and Rabbit IgG were used as control (Figure 4.4). DAPI 
was used to stain nuclei. Images represent characteristic staining of 2 repeat 
experiments. Scale bar represents 10 µm. Results show an elevation in CFTR 
expression in IB3 cells cultured in the presence of VX-809 with no change in TG2 
expression.  
 
                
 
Figure 6.15C: TG2 inhibition up regulates CFTR expression in IB3 cells. 
Immunofluorescent images of TG2 and CFTR expression in IB3 cells cultured at ALI, in 
the presence of the cell-permeable TG2 inhibitor, R283 (500µM). The cells were 
cultured for 28 days and polyclonal rabbit anti-TG2 and monoclonal mouse anti-CFTR 
antibodies were used to stain cells. Images were taken under a Leica® SP5 confocal 
microscope. Mouse and Rabbit IgG were used as control (Figure 4.4). DAPI was used 
to stain nuclei. Images represent characteristic staining of 2 repeat experiments. Scale 
bar represents 10 µm. R283 inhibits TG2 expression and slightly increases CFTR 
expression in IB3 cells at ALI. 
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Figure 6.15D: VX-809 and R283 markedly increase CFTR expression in IB3 cells 
at ALI. Immunofluorescent staining of TG2 and CFTR protein expressed in IB3 cells 
cultured at ALI and treated with CFTR corrector, VX-809 (10µM) and TG2 inhibitor, 
R283 (500µM). The cells were cultured for 28 days and polyclonal rabbit anti-TG2 and 
monoclonal mouse anti-CFTR antibodies were used to stain cells. Images were taken 
under a Leica® SP5 confocal microscope. Mouse and Rabbit IgG were used as control 
(Figure 4.4). DAPI was used to stain nuclei. Images represent characteristic staining of 
2 repeat experiments. Scale bar represents 10 µm. CFTR expression was markedly 
increased and TG2 expressed was reduced in IB3 cells cultured at ALI in the presence 
of VX-809 and R283. 
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Figure 6.15E: VX-809 and R283 augment CFTR expression on the apical surface 
of IB3 cells at ALI. 3-D cross sections of TG2 (red) and CFTR (green) expression in 
untreated IB3 cells cultured at ALI, E1, IB3 cells cultured in medium supplemented with 
VX-809 (10µM), E2, and IB3 cells cultured in medium supplemented with R283 
(500µM), E3.  Cells were cultured for 28 days at ALI before staining with polyclonal 
rabbit anti-TG2 (red) or monoclonal mouse anti-CFTR (green) antibodies. Images were 
taken using the Leica® SP5 confocal microscope using 3-D projections where a cross 
section of the membrane with IB3 cells were visualised from the apical side, A to the 
basal, B using the z-stack acquisition panel. DAPI (blue) was used stain nuclei. Mouse 
and Rabbit IgG were used as control (Figure 4.4). Images represent characteristic 
staining of 2 repeat experiments. Images show z-stack from IB3 untreated and VX-809-
treated cells having high TG2 expression whilst R283 treated cells have marginal TG2 
levels. However, although CFTR expression is low in untreated IB3 cells, treatment 
with VX-809 or R283 produces an increase in apical CFTR expression with the former 
showing higher expression.  
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6.4.7: Chloride conductance rescued with CFTR corrector and TG2 
inhibitors. 
 
The underlying pathology of CF is centred on the low or absolute loss of chloride 
conductance within the airways. This maligning defect defines the disease prognosis 
and therapy has been palliative with treatment aimed at alleviating symptoms of the 
disease. However, with the milestone discovery of channel potentiators and recently 
correctors, the treatment regimen has been reformed with affirmative prognosis for 
patients. The results presented in this chapter have illustrated the vital role TG2 
inhibition plays in ameliorating the disease as well as the combinatorial approach by 
TG2 inhibitors and CFTR correctors in forging an elevation in the CFTR turnover and 
trafficking to the plasma membrane. Here using both TG2 inhibitors, chloride 
conductance is been evaluated to provide an insight of the impact of elevated CFTR 
expression and trafficking on CFTR function. Results show (Figure 6.16) that when 
untreated IB3 cells were incubated in chloride free buffer, there was no increase in 
chloride conduction across CFTR channels. This suggests no change in the state of 
chloride dependent channels and consequently no efflux of MQAE bound intracellular 
chloride in the presence of chloride free buffer. Anderson and Welsh, (1991) described 
calcium dependent chloride secretion to be independent of the cAMP dependent 
chloride regulation, which is defective in CF. Their results showed that although cAMP 
regulates chloride secretion differently, they could ultimately produce an additive 
chloride secretion. Consequently, using chloride free containing buffer, IB3 cells were 
treated with dibutyryl cyclic adenosine monophosphate (db-cAMP) (1mM). The aim 
was to increase intracellular cAMP levels via increase in adenylate cyclase or mimic 
cAMP activity with db-cAMP. In addition, db-cAMP is a phosphodiesterase inhibitor 
(PDI), which inhibits the activity of phosphodiesterases involved in the breakdown of 
cAMP. The cells were excited at 350nm and emission was measured at 450nm. CFTR 
is cAMP dependent channel hence in the absence of cAMP, CFTR regulatory (R) 
domain is not phosphorylated and the channel is not open. As cAMP levels are 
elevated, the R-domain is phosphorylated, adenosine triphosphate (ATP) is hydrolysed 
in NDB, which in turn causes the MSD of the channel to open.  In the presence of db-
cAMP supplemented buffer (Figure 6.16), R283 was shown to significantly elevate 
CFTR conductance about 4-fold. However, CFTR conductance was highly elevated in 
the presence of the non-specific TG2 inhibitor cystamine, where conductance was 
stabilised at 270 mins. In line with these, in the presence of chloride free buffer (i.e. in 
the presence of a driving force for chloride movement), a significant elevation of 
chloride conductance in foskolin treated cells was observed (results not shown) which 
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was further elevated in the presence of db-cAMP. Interestingly, the elevated chloride 
movement observed illustrates targeted cAMP-mediated CFTR activation for both 
foskolin and db-cAMP groups, obviating chloride quenching with chloride free medium 
and in db-cAMP chloride free groups, enhanced chloride movement depicts added in-
situ Phosphodiesterase inhibitor (PDI) function. Together, these results demonstrate a 
marginal increase in chloride conductance in IB3 cells attributed to the presence of 
residual functional CFTR copies found in the apical plasma membrane as shown in 
Figure 6.11.      
          
 
Figure 6.16: R283 and Cystamine augment chloride conductance in IB3 cells. 
Chloride conductance in IB3 cells in submerged culture incubated in chloride free 
buffer with Dibutyryl cAMP (db-cAMP) (1mM) in combination with the cell permeable 
TG2 inhibitors; R283 (500µM) or Cystamine (250 µM). The chloride indicator dye, 
MQAE (10 mM) was added to measure intracellular chloride levels. Results represent 
mean of 2 independent experiments each carried out in triplicates. Results show 
marginal chloride conductance in untreated IB3 cells (closed circles) with a slight 
increase in the presence of db-cAMP (closed squares). However, incubation with R283 
or Cystamine markedly increased db-cAMP-dependent chloride conductance through 
the CFTR channel with the latter producing a higher effect.  
 
As previously shown (Figure 6.11 and 6.15), the inhibition of TG2 activity in 
combination with conformational correction of MSD-1 of CFTR protein to sustain a 
stable NBD-1, in turn salvages ΔF508 mutation from proteosomal degradation, thus 
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enhancing functional CFTR protein trafficking to the plasma surface. Results from 
Western blotting and immunostaining have also shown that CFTR protein is well 
distributed on the plasma membrane after treating IB3 cells with VX-809, VX-770 and 
R283 and further increased after combination treatments (Figures 6.12, 6.13 and 6.14). 
The increase in chloride conductance observed in the presence of cystamine or R283 
indicates that as channels open in the presence of db-cAMP, these cell-permeable 
TG2 inhibitors augment channel activity in IB3 cells. This suggests importantly that 
inhibition of cell surface TG2 in addition to a correction in ΔF508 CFTR protein 
increases both turn over and conductance of CFTR and chloride respectively. It can be 
inferred here that TG2 inhibition impedes EMT progression via TGFβ1, which in turn 
retards CFTR degradation induced by TGFβ1 consequently, reverting the CFTR 
mutational phenotype. This in concert with CFTR correctors, which stabilises NBD-1, 
ultimately leads to an enhanced CFTR maturation and trafficking to the plasma 
membrane. This augments chloride conductance.      
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6.5: Discussion: 
!
The invasiveness of using human subjects in drug design has forged the design of 
culture models that mimic the in vivo environment. The burgeoning evidence from 
studies on the robustness of ALI models for modelling the respiratory tract and its use 
in determining salient functions of the respiratory system serves as a useful resource 
and remains a vital tool in obviating the cost and laborious constraints involved in using 
human samples. Over time, research into various CF mutations including the ΔF508 
mutation and the recent discovery of the CFTR potentiator, VX-770, which is orally 
bioavailable and used in patients with G551D CFTR mutation and other gating 
mutations, unravelled an episode of research into other lead compounds capable of 
altering the phenotype of CFTR patients with other mutations (Kerem et al., 1989, Van 
Goor et al., 2006). However, the conundrum surrounds the non-availability of lead 
compounds to treat the most prevalent mutation, ΔF508, which accounts for about 70% 
of the world’s population (Bobadilla et al., 2002) . 
This study has shown the vital role TG2 plays in CF disease pathophysiology. The 
nascent results obtained from the previous chapters leading up to this chapter have 
suggested the link between TG2 and EMT progression and have related this to 
elevated levels of the pro-fibrotic cytokine, TGFβ1 which studies have shown to inhibit 
CFTR biogenesis (Snodgrass et al., 2013) and suggested the remission of fibrosis in 
the disease due to TG2 inhibition/knockdown. In this chapter, using ALI models, results 
suggest some comparability to the results observed in submerged cultures where TG2 
and EMT marker expression have been shown to be elevated in IB3 cells compared to 
C38 cells (Figure 6.1). They have also shown that knockdown of TG2 protein induces a 
restoration of cell-cell integrity with a 2-fold elevation of TEER values in TG2 shRNA 
transduced IB3 cells compared to untreated cells (Figure 6.4). On the contrary, it was 
observed using primary HBEC-T cells that an increase in TG2 expression, which 
mimicked CF phenotype, suggests a change in cell morphology and reduced TEER 
values as shown (Figure 6.8 and 6.9B). This demonstrates that elevation of TG2 
supports the promotion of EMT, which progresses with an increase in cell migration. 
This also might be responsible for the loss of E-cadherin expression in HBEC-T cell 
transduced with TG2 wild type plasmid (Figure 5.11) in submerged culture. These 
results are in concert with similar studies using MCF-10A breast cancer cells, where 
EMT was shown to be promoted in TG2 transduced cells with an elevation of TG2, 
fibronectin, N-cadherin, Vimentin and β-catenin whilst E-cadherin expression was 
inhibited (Kumar et al., 2010). Also in a related study, increased TG2 expression in the 
presence of TGFβ1 in A549 lung cancer cells initiated an E-cadherin to N-cadherin 
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switch attributed to a down regulation of protein phosphatase 2A (PP2A) which 
activates C-Jun N-terminal Kinase (JNK) inducing EMT (Park et al., 2013). The A549 
wild type cells, A549WT, migrated across Transwells® in the presence of TGFβ1 
(100pg/ml) as well as A549 cells transduced with TG2 plasmid, A549TG2. Migration was 
reduced in A549 cells transduced with TG2 shRNA, A549shTG2 even when treated with 
TGFβ1 (100pg/ml). This infers that TG2 is involved in migration, which leads to an 
induction of EMT in epithelial cells. The results presented in this chapter represent for 
the first time where CF cells are cultured at ALI to determine the correlation between 
TG2 expression and ΔF508 mutation. 
Luciani et al. (2012) showed using IB3 and CFBE41o- cells carrying heterozygous and 
homozygous ΔF508 mutations (ΔF508/W1282X and ΔF508/ΔF508 respectively) that 
pre-treatment with the TG2 inhibitor/proteostasis regulator, cystamine prior to the use 
of CFTR potentiators (VX-770, VX-532, Corr-4a) restored and sustained CFTR 
expression at the plasma membrane compared to the use of potentiators alone. Based 
on this approach, TG2 inhibitors were combined with the CFTR corrector, VX-809, 
since studies have also shown that VX-809 corrects the mutation defect in CF ΔF508 
mutation similar to compounds like the transcriptional regulator, 4-phenyl-butyrate (4-
PBA) (Rubenstein et al., 1997, Van Goor et al., 2011). This was carried out on the 
premise that ΔF508 mutation is a class II processing mutation where immature proteins 
are produced due to the deletion of phenylalanine at position 508. Hence, 
stabilising/correcting this defect with TG2 inhibitors/ CFTR corrector possibly by 
increased stabilisation of the MSD-1, increases interaction between the NBD-1 and 
intracellular loop 1 (ICL-1), involved in connecting the transmembrane segments of the 
MSD and thus priming ΔF508 for further correction by TG2 inhibitors. This may 
enhance CFTR read-through and production of matured protein from the endoplasmic 
reticulum (ER) thus obviating the proteosomal degradation or endosomal recycling 
(Okiyoneda et al., 2010, Lukacs and Verkman, 2012, Ren et al., 2013). Results show 
that both in submerged culture and at ALI, VX-809 significantly increases CFTR 
presence at the plasma membrane. However, in combination with R283, CFTR 
presence is significantly elevated for VX-809. Intriguingly, it was observed in the 
presence of VX-770, mature CFTR protein expression was further elevated in the 
presence of VX-809. R283 showed remarkable effects on CFTR alone further 
supporting its role as TG2 inhibitor involved in stabilizing the thermo unstable NBD-1 of 
the protein. CFTR membrane expression was high with VX-770/R283 combination but 
wasn’t as high as with VX-809. It was further illustrated using immunocytochemistry 
that the observed elevation of CFTR matched with staining of the protein with CFTR 
and TG2 shown to co-localise around the cell. Interestingly, culturing IB3 cells at ALI 
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and applying the same treatment not only mimicked submerged culture results but also 
illustrated that the elevated CFTR observed at the plasma membrane was a synopsis 
of the distribution of CFTR from the apical membrane to the basal membrane. Figure 
6.14D shows a high distribution of CFTR in VX-809 treated groups of cells cultured at 
ALI compared with untreated groups as well as a slightly elevated CFTR in R283 
groups. It can be deduced here that an inhibition of TG2 supports an increase in CFTR 
maturation and trafficking and in combination with VX-809, additional CFTR proteins 
can be trafficked to the plasma membrane. No effect was observed of VX-809 on EMT 
reversal in IB3 cells (results not shown). This further supports the hypothesis that 
fibrosis in CF is an effect based on elevated TG2 levels and is an indirect rather than a 
direct consequence of the mutation. 
Furthermore, increased CFTR-dependent chloride conductance was observed in the 
presence of both TG2 inhibitors and VX-809. Because of the non-selectivity of 
cystamine as a TG2 inhibitor, in-house synthesised cell-permeable and impermeable 
TG2 inhibitors were used. Chloride movement was observed in chloride free buffers as 
intracellular chloride bound to MQAE dye diffused out of the cell through chloride 
channels either via CFTR or CaCCs. The use of db-cAMP showed that the diffusion of 
chloride ions was due to the opening of cAMP activated channels. However, chloride 
conductance was shown to significantly increase with R283 but much more with 
cystamine, which again was attributed to its non-selectivity for TG2 and caspases. 
From these results, it can be hypothesised that targeting TG2/CFTR mutation with 
chemical compounds (TG2 inhibitors/CFTR correctors) can be used as combinatorial 
therapeutic agents in CF treatment.    
The results presented in this chapter have suggested that CFTR maturation and 
trafficking in patients carrying the ΔF508 mutation can be alleviated by TG2 inhibitors 
and CFTR correctors. The potency of this synergism is suggested to be surrounded by 
the stabilisation of the NBD-1 and conformational correction of MSD-1 of the protein 
which ultimately leads to the production of mature and functional CFTR protein on the 
apical surface of CF airway epithelia.  
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6.6 Conclusion: 
Together, this study suggests that TG2 inhibition in combination with CFTR mutational 
correction supports a sustained CFTR maturation and trafficking to the plasma surface, 
which maintains chloride conductance characteristics. Further experiments using 
DMSO control will help to delineate if the effect observed is due to the 
corrector/potentiator exclusively. Certain experiments need to be performed thrice in 
other to make statistically affirmative conclusions.  
 
 
 
 
 
 
 
 
 
!!
 
 
 
 
Chapter 7 
 
Discussion 
 
 
Chapter!Seven!
! 200!
7.0 Discussion 
 
The overarching challenge surrounding CF therapy has been the degenerative nature 
of the disease, which impacts on both the quality and number of years of life of the 
patient. Hence therapies have been targeted at increasing the life years of patients 
through rigorous palliative therapy centred on alleviating the untoward effects of the 
disease and more recently on corrective therapy targeted at the CFTR mutational 
defects. The current outlook for patients living with the disease has increased over the 
past decade with an increase in life expectancy from 31 years to 37 years in the US 
and a predicted increase of up to 50 years in the UK (O'Sullivan and Freedman, 2009, 
Dodge et al., 2007). The common cause of mortality in CF is respiratory complications. 
In a cross-sectional study on the causes of death in CF patients in Canada, Mitchell et 
al. (2000) showed that more than 40% of patients presented with respiratory 
complication with most patients carrying Pseudomonas aeruginosa, Staphylococcus 
aureus or Burkholderia cepacia in their sputum and 75% of the total population dying 
due to this and other complications.  
 
Albeit, successful therapeutic approaches have been used like dornase alfa, the 
recombinant human deoxyribonuclease and the inhaled aminoglycoside, Tobramycin, 
as chronic respiratory treatment together with other therapeutic strategies to combat 
disease symptoms like pulmonary exacerbations, the past decade heralded the advent 
of mutational specific therapies aimed at further improving CFTR protein read-through 
and restoring functionality to the channel at the apical surface. Though, these emerging 
therapies are at their nascent stages and are CFTR mutation class specific, their 
prognosis has been affirmative. Ataluren (PTC124), a bioavailable molecule that aids 
the read through of premature stop codons during mRNA translation has been used in 
class 1 mutation (Kerem et al., 2008, Kerem et al., 2014) where an increase in nasal 
chloride hyperpolarization was observed due to an increase in expression of apical full-
length CFTR protein (Sermet-Gaudelus et al., 2010). Also, Ivacaftor, (VX-770), another 
bioavailable drug has been shown to improve CFTR conductance as a “potentiator” in 
patients carrying the G551D mutation and other CFTR mutations with gating defects 
(Van Goor et al., 2006, Yu et al., 2012). Recently, CFTR correctors were introduced 
which studies have shown to ultimately correct the processing of CFTR protein in 
patients with ΔF508 mutation and one of such correctors is VX-809, which has been 
shown to stabilise MSD-1 thus increasing NBD-1 interaction with intracellular loops 
(ICL) on MSD-1, leading to an improvement in folding and thermodynamic stability of 
the CFTR protein (Van Goor et al., 2011, Ren et al., 2013). In all, although the recent 
therapies have improved disease prognosis, the fibrotic process and lung remodelling 
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involved as the disease progresses remains unresolved and lingers which ultimately 
debilitates and often leads to early mortality.        
 
The ubiquitous nature of TG2 and disease modifying role of the pro-fibrotic cytokine, 
TGFβ1 have been linked to various diseases from cancer (Cao et al., 2012), diabetic 
nephropathy (Huang et al., 2010), idiopathic pulmonary fibrosis (Olsen et al., 2011) and 
other diseases and TG2 has been suggested to drive the activation of TGFβ1 in these 
diseases. In CF, it has been shown that the recurring activation of TG2 via its possible 
SUMOylation has been linked to abnormal expression of TG2 in the disease and been 
suggested to drive fibrosis in the disease via the activation of the NFκB pathway as 
well as defective autophagy (Luciani et al., 2009a, Maiuri et al., 2008, Luciani et al., 
2010b). However, the use of the TG2 inhibitor and competitive amine, cystamine, was 
shown to remarkably halt disease progression in CF mutant human cell via the 
abrogation of TG2 activity, restoration of beclin1, a tumour suppressor gene and the 
involvement of autophagy, ultimately restoring CFTR trafficking (Luciani et al., 2010b). 
Furthermore, pre-treating ΔF508 CFTR mutated cells with a proteostasis regulator like 
cystamine was suggested to aid in sustaining the stability of CFTR on the plasma 
membrane beyond drug withdrawal and has also been implied to aid CFTR 
potentiators, genistein or VX-770 in fresh isolated nasal brushings from homozygous 
ΔF508 CFTR patients (Villella et al., 2013, Luciani et al., 2012). Similarly, Snodgrass et 
al. (2013) demonstrated that TGFβ1 could functionally inhibit the biogenesis of CFTR 
both at mRNA and protein levels as well as induce an increase in N-cadherin 
expression in Human bronchial epithelial cells (HBEC) cultured for 24 h which was 
suggested not to match a reduction in E-cadherin levels corresponding to a 
mesenchymal phenotype. This report is refuted by Camara and Jarai (2010) where 
HBEC cells were cultured for 72 h and an increase in N-cadherin, α-SMA and vimentin 
and a corresponding decrease in E-cadherin expression was observed in the presence 
of TGFβ1. Also, TG2 has been demonstrated to be involved in the activation of TGFβ1 
and likewise TGFβ1 involved in the regulation of TG2 (Nunes et al., 1997, Kojima et al., 
1993, Ritter and Davies, 1998). These relationships suggest that TG2 is involved in 
inducing a mesenchymal phenotype in cells via TGFβ1. Park et al. (2013)  showed that 
in A549 lung cancer cells, TG2 induced EMT via TGFβ1 with an elevation of N-
cadherin expression in the cells.  These results suggest that TG2, via increasing 
TGFβ1 levels is involved in the fibrotic process in the lungs and in CF might be 
involved in the down regulation of the CFTR channel. 
  
This study centred on understanding the role TG2 plays in the development of fibrosis 
in CF, evaluating the involvement of TG2 in the disease. It was shown that aberrant 
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TG2 expression activates TGFβ1 via an increase in TGFβ1 gene expression and cell 
medium levels observed in IB3 cells. This coincided with the study, which showed 
latent TGFβ1 released from latent TGFβ binding protein (LTBP-1) in bronchial epithelial 
cells was reported by Nunes et al. (1997) but using endothelial cells. Interestingly, in 
the current study, activation of TGFβ1 was equally blocked in the presence of TG2 cell 
impermeable (R292 and R294) and permeable inhibitors (R283 and Z-DON) (Figure 
3.6D), irrespective of the site of action of the inhibitor. This suggests together with the 
high TG2 cell surface protein expressed in IB3 cells, that the observed effect of TG2 in 
CF cells might also be attributed to its presence on the cell surface where it is active as 
shown in Figure 3.5B where it has been shown to be involved in matrix and other 
crosslinking reactions (Verderio et al., 1999, Verderio et al., 1998). 
  
Abnormal regulation of TG2 correlates with the elevation of expression of some 
markers of EMT, a phenomenon where epithelial cells undergo morphological changes 
losing their cell-cell adhesion and polarity as well as cobblestone-like structure in order 
to assume a fibroblast-like morphology (Kumar et al., 2010, Cao et al., 2012). The 
highlight of this process is the acquisition of a mesenchymal phenotype with an 
elevation in expression of EMT markers including fibronectin, N-cadherin and the 
transcriptional marker, Slug. This study has attributed the high expression of these 
markers to an up-regulation of the inflammatory cytokine, TGFβ1 in IB3 cells. This 
ultimately leads to an increase in cell migration, loss of cell-cell adhesion, polarity and 
morphological modification as shown in the study. Figures 4.1 to 4.4 show the increase 
in expression of EMT markers, at both gene and protein level in high TG2 expressing 
IB3 cells. This further suggests that an up regulation of TG2 levels drives EMT marker 
expression in IB3 cells. Similarly, a corresponding up regulation of TG2 and EMT 
marker expression in HBEC cells transfected with a TG2 overexpression plasmid, 
HBEC-T (Figure 5.11) and rTGFβ1 (Figure 4.9) was observed. Again, in the presence 
of the TG2 inhibitor, R283, the expression of the EMT marker was inhibited in HBEC 
and C38 cells where a change in cell morphology was impeded (Figure 4.8A-C and 
4.9A&B). This suggests that an inhibition of TG2 in the CF cells supports a reversal of 
the mesenchymal phenotype and a possible introduction of a mesenchymal to 
epithelial transition.  
  
In the lungs, TGFβ1 has been found to be the main regulator of EMT evidenced by 
fibrotic diseases such as in asthma and IPF (Olsen et al., 2011, Doerner and Zuraw, 
2009, Sheppard, 2006a).   In CF, studies have shown that polymorphism of TGFβ1 is 
associated with virulent pulmonary fibrosis, which remains the major cause of mortality 
in CF patients (Arkwright et al., 2000, Drumm et al., 2005). This work has shown 
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marginal TG2 and TGFβ1 levels in C38 cells, while elevated levels of TGFβ1 activated 
by TG2 in IB3 cells are likely to occur via the crosslinking of LTBP-1 to the ECM 
(Nunes et al., 1997). Also, active TGFβ1 might in turn through the phosphorylation of 
its receptors, RI and RII promote a downward intracellular SMAD dependent signalling 
via SMAD 2 and 3 to an increase in TG2 expression (Figure 4.14). This coincides with 
the role TGFβ1 plays in up-regulating TG2 gene expression. Conversely, inhibition of 
TGFβ1 receptor binding in IB3 cells with a TGFβ neutralizing antibody reverses TG2 
and EMT marker expression (Figure  
4.10). This shows that inhibition of active TGFβ1 binding to its receptors abolishes the 
downstream transduction signalling, which impedes TG2 activation and hence blocks 
the EMT process. 
 
The loss of the adhesion protein, E-cadherin and an increase in N-cadherin truncates 
cell anchorage and re-organization of the actin cytoskeleton (Wheelock and Johnson, 
2003). This is the hallmark of the EMT process. TGFβ1 has been shown to play a key 
role in driving EMT in the lungs, kidney and pancreas (Rastaldi et al., 2002, Willis and 
Borok, 2007) and this function involves nuclear restructuring via transcriptional 
repressors ie Snail Slug and Twist (Heldin et al., 2012, Kawata et al., 2012). In the 
presence of 3ng/ml of rTGFβ1, it was observed that an increase in TG2 expression 
corresponded to a decrease in E-cadherin expression in HBEC (Figure 4.9). Similarly, 
in order to confirm that this effect is TG2 related, HBEC transduced with TG2 
overexpressing plasmid, HBEC-T cells were evaluated for the expression of EMT 
markers (Figure 5.11). Again, it was observed that with an increase in TG2 expression, 
E-cadherin expression was inhibited. Interestingly, CFTR expression was shown to 
decrease in HBEC-T cells. This is in concert with the study by Snodgrass et al. (2013) 
where TGFβ1 was linked to an inhibition of CFTR biogenesis in HBEC cells. This was 
shown to be due to the activation of the TGFβ1 canonical pathway, which includes its 
activity on TG2 promoter site. In concert with this study, it can be suggested that TG2 
activated TGFβ1 in IB3 cells drives EMT that results in the down regulation of CFTR 
expression levels and a consequent elevation in EMT markers.   
 
This study has shown high levels of TG2 and EMT marker expression in IB3 cells 
compared to C38 cells (Figure 4.3), which coincided with an increase in the migration 
profile shown between the cells (Figure 4.6). Also, in the presence of R283, migration 
was impeded in both cell types. With TGFβ1 implicated in cell migration by its role in 
down regulating cell adhesion, cell surface TG2 was suspected to be involved in 
activating TGFβ1 from its latent forms in the extracellular matrix. Additionally, in the 
presence of TGFβ1, TG2 and EMT markers was shown to be elevated both at gene 
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and protein level. Again, the TG2 inhibitors, R283, 1-133 and 1-155 (the latter two are 
highly specific to TG2) were shown to inhibit the levels of these proteins. This is in 
agreement with results from Ritter and Davies (1998) where it was shown that TG2 
gene expression is regulated by TGFβ1 via a TGFβ1 Response Element (TRE) on the 
promoter site of the TG2 gene and suggests further the extent of TG2 involvement in 
activation of this cytokine. 
       
The development and stabilisation of the ECM is an important phenomenon in 
reparative wound repair however altered turnover of the ECM plays a major role in 
orchestrating a fibrotic cascade associated with various diseases. TGFβ1 has been 
implicated as an important ECM protein favouring increased ECM deposition and 
resistance to proteases (Bartram, 2004). In the lungs, TGFβ1 functions both as a pro- 
and anti-fibrotic cytokine where its role has been linked to EMT progression in various 
lung pathologies (Hackett et al., 2009, Doerner and Zuraw, 2009). Thus, activation of 
TGFβ1 by TG2 has been shown to correlate with enhancement of EMT (Kumar et al., 
2010). Studies have importantly shown TG2 involved in crosslinking of matrix proteins 
via its transamidating activity hence promoting ECM stabilisation (Aeschlimann and 
Thomazy, 2000). Consequently with an increase in fibronectin deposition in C38 cells 
treated with TGFβ1, the untoward change in morphology observed was retarded in the 
presence of R283 (Figure 4.8A). It can therefore be hypothesised that a slowdown of 
the EMT process corresponds to an inhibition of TG2 activity. Knocking down TG2 with 
shRNA via Lentiviral transduction inhibited TG2 expression and activity in IB3 cells 
(Figure 5.5), which was followed by a significant reduction in fibronectin, N-cadherin, 
Slug expression and TGFβ1 activity. This was in concert with TG2 inhibition using TG2 
inhibitors shown in Figure 4.5. This work reveals for the first time the direct link 
between TG2 activity and EMT expression in CF cells. 
 
TG2 activity and conformational variants overtly showed TG2 alignment alters TG2 
induced EMT in IB3 cells. The GTPase binding mutant, R580A showed that cell 
surface TG2 activity and not GTP binding might play a vital role in the progression of 
TG2-driven EMT with a significant increase in TG2 expression, matrix fibronectin 
deposition and other EMT markers (Figure 5.8). This was shown to be similar with cells 
transduced with the WT TG2 overexpressing plasmid with elevated TG2, fibronectin, N-
cadherin and Slug expression. This further shows the involvement of TG2 
transamidating activity as the transamidating mutant with a conserved GTPase binding 
activity, W241A showed significant knockdown of TG2 and reduced fibronectin, N-
cadherin and Slug expression (Figure 5.8). This confirms that the transamidating 
activity is imperative for the TG2 related phenotype in IB3 cells and the GTPase 
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conformation does not play a role in TG2 related EMT progression in IB3 cells. Again, 
these results mimic the TGFβ1 related increase in TG2 as shown in control C38 cells 
and blockage of TG2 activity with TG2 inhibitors in IB3 cells.  
 
In accordance with the study by Pruliere-Escabasse et al. (2005), where TGFβ1 was 
associated with a down regulation of CFTR mRNA and protein level in non-CF human 
nasal polyps, this study further observed that in the presence of TGFβ1, TG2, 
fibronectin and N-cadherin expression were elevated in C38 “CFTR corrected” 
bronchial epithelial cells. This shows the resilient dynamic processes existing between 
TG2 and TGFβ1 in regulating their expression concurrently. Nonetheless, this 
observable evidence was replicated at air liquid interface (ALI) where IB3, C38 and 
HBEC cells demonstrated similar epithelial characteristics to similar cells cultured in 
submerged culture. TG2 activity was suggested to increase in the presence of TG2 
wild type transduced cells, HBEC-T and reversed in the presence of TG2 shRNA in IB3 
cells (Figure 6.3 and 6.4). Importantly, the reduction of TG2 expression was matched 
with an increase in TEER and the up regulation of TG2 increased cell disorientation 
and reduced TEER values (Figure 6.6 and 6.9B). Conversely, an up regulation of TG2 
expression in HBEC cells caused an increase in the expression of TG2 and EMT 
markers similar to the observations shown in submerged culture. This demonstrates 
the robustness of the ALI system in depicting in vivo conditions as well as linking TG2 
expression with cell-cell interactions, migration and ultimately EMT.  
 
The activation of TGFβ1 is associated with the up regulation of the integrin, αVβ6 in the 
fibrotic lung (Sheppard, 2005, Sheppard, 2006b, Henderson and Sheppard, 2013). This 
association has been linked with the binding of αVβ6 and αVβ8 to the RGD motif of 
LAP on the LLC of TGFβ1 (Munger et al., 1999). This study shows a correlation 
between TG2 up regulation and elevation of αV expression in CF model, IB3 cell. Also 
co-immunoprecipation of αV and β6 with antibodies to TG2 showed an increase in TG2 
“immunoprecipated” αV levels compared with β6. Similarly, αV levels were shown to be 
elevated in C38 cells in the presence of TGFβ1 (Figure 4.13 A2 and B2). Interestingly, 
R283 also inhibited the expression of αV “immunoprecipitated” β6 levels in IB3 cells 
indicating that the down regulation of TG2 directly influenced the expression of the αV 
protein. Since R283 has been shown earlier to inhibit TGFβ1 expression, it can be 
suggested, as illustrated in Figure 4.12, that TG2 might be interacting directly with 
αVβ6 integrin in CF in co-activating TGFβ1 from its latent form.       
 
The advent of novel therapeutic strategies in CF therapy heralded the use of small 
chemical compounds used to increase CFTR channel read through and thus enhance 
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chloride conductance. The use of CFTR potentiators and correctors has been deemed 
as the recent breakthrough in CF therapy (Van Goor et al., 2011, Van Goor et al., 
2009, Ramsey et al., 2011b). Using both R283 and VX-809, it was observed that CFTR 
expression significantly increased with a decrease in TG2 expression in IB3 cells 
(Figure 6.11). Although, VX-809 has no effect on EMT markers (not shown), the effect 
of R283 on EMT process, which could be suggested to be related to TG2 inhibition. 
Similarly it was observed that the copies of CFTR trafficked to the plasma membrane 
increased in the presence of VX-809 compared to R283, however, together, a high 
number of CFTR copies were observed on the plasma membrane both in submerged 
culture and at ALI (Figure 6.12D and 6.15D). As VX-809 has been described to 
function by stabilizing MSD-1 on the CFTR gene (Ren et al., 2013), a 3-D cross 
sectional analysis suggested that the CFTR channel was located at the apical channel 
in the presence of VX-809 and R283 compared to untreated cells (Figure 6.15E). This 
reaffirms the elevated CFTR protein levels observed and shows TG2 negatively 
regulating CFTR expression via TGFβ1 (Figure 5.11). Similarly, CFTR channel 
conductance was elevated in IB3 cells treated with R283 and Cystamine (Figure 6.16). 
The increase was attributed to an inhibition of TG2, which caused an increase in CFTR 
copies on the apical surface as well as an increase in conductance of the rescued 
CFTR channel. Luciani et al., (2012) observed in CFBE41o- cells transfected with 
ΔF508 CFTR that cystamine reduced the CFTR recycling and sustained the channel at 
the apical membrane compared to CFTR correctors, VX-325 or Corr-4a as well as 
significantly increasing the activity at the channel beyond the activity with CFTR 
corrector alone. This study supports the study carried out in chapter 6 suggesting that 
TG2 inhibitors prime ΔF508 CFTR and together with the CFTR corrector, VX-809 
stabilize and increase NBD-1:ICL interactions. This in turn allows the read through of 
ΔF508 CFTR copies whilst precluding their proteosomal degradation, hence, 
increasing stable and mature CFTR copies trafficked to the plasma membrane.         
 
Altogether, this study shows a link between TG2 expression and EMT in CF cells 
where TG2 activates TGFβ1, which plays a major role in orchestrating the downstream 
signalling involved in driving EMT. This phenomenon as illustrated in Figure 7.1 
suggests a ΔF508 CFTR induced activation of TG2 due to the dysregulation of calcium 
levels in CF (Tabary et al., 2006, Ribeiro et al., 2005) inducing cell stress and a 
calcium-mediated activation of TG2. Once up regulated, TG2 is ultimately externalized 
by an unknown mechanism and remains active due to decreased GTPase inhibition 
and an increase in extracellular calcium stores, hence supporting the activation of 
TGFβ1 from their latent forms by TG2 mediated crosslinking of LLC to the matrix. 
Active TGFβ1 via its receptors, RI and RII signals the downstream transduction of 
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SMAD and non-SMAD pathways. Phosphorylation of SMADs 2 and 3 recruits recycling 
SMAD 4, where the heterocomplex formed is involved in activating TG2 on its promoter 
site via the TG2 response element (TRE). Increased TG2 activation supports the 
vicious cycle fuelling the continuous externalisation and activation of TGFβ1-TG2 in 
CF. Albeit, this is associated with a consequent loss of epithelial phenotype and 
acquisition of relatively high levels of EMT markers and transcriptional repressors 
which mechanistically drive the fibrosis in the disease. Concurrently, the ΔF508 
mutation prevents the maturation and trafficking of matured CFTR from the 
endoplasmic reticulum to the plasma membrane due to premature denaturation. This 
study has demonstrated the “swiss-army knife” approach of TG2 in CF, where its 
inhibition blocks both intracellular and extracellular activation thus preventing the 
activation of TGFβ1 and its effects on the SMAD/non-SMAD pathways. Also, a synergy 
between TG2 inhibitors and CFTR correctors was shown to block a TG2 induced 
TGFβ1 mediated down regulation of CFTR, increase CFTR protein read through and 
maturation and its trafficking to the apical surface to function as a chloride conducting 
channel. Although other studies have attempted to relate EMT in alveoli cells to an 
aberration of TGFβ1, this study has provided the interrelationship between TG2 and 
TGFβ1 in a bronchial epithelial model of CF and for the first time shows fibrosis to be 
mediated via a TG2-TGFβ1-EMT driven pathway.  
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Figure 7.1: Schematic representation of TG2 regulated EMT via TGFβ1 and the 
reparative effect of TG2 inhibitors/CFTR correctors in CF. The ΔF508 mutation 
induces cell stress, A which distorts cellular milieu increasing intracellular TG2 levels. 
Externalisation of TG2 activates TGFβ1 from its latent forms, B thus orchestrating a down 
stream activation of SMAD pathway via SMADS 2,3 and 4, C. TG2 gene activation via its 
response element, TRE, further elevates TG2 synthesis, D. Similarly, ΔF508 mutation 
impedes trafficking of matured CFTR to the apical surface. The use of TG2 
inhibitors/CFTR corrector stabilizes and supports the trafficking of matured CFTR copies 
to the apical surface deluding proteosomal degradation, E.  
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8.1 Future Work 
In other to continue the work carried out in this study, further investigation can be 
undertaken as follows: 
! Determine the apical expression of CFTR in IB3, IB3-TG2 shRNA, C38 and 
HBEC cells using a robust membrane fractionation kit in both ALI and 
submerged medium as well as using Zona Occludens-1/E-cadherin as a 
membrane marker.   
! Using primary human bronchial epithelial cells, HBEC with wild type and mutant 
CFTR transduced into these cells to determine the CFTR phenotype with 
regards to EMT markers expression in submerged and at ALI. 
!  Following culture of cells at ALI, histological analysis of CF mutant cell, IB3 
cells and CFTR mutant transfected human bronchial epithelial cell ie HBEC-
ΔF508CFTR and control HBEC treated with CFTR correctors ie VX-809, VX-
532 or Corr-4A and the TG2 cell-permeable/impermeable inhibitors ie 1-133/1-
155. Then determine apical surface TG2/CFTR expression as well as EMT 
expression in these cells.  
! Determine the intracellular Ca2+ ion levels in IB3 cells and mutant CFTR cells 
transduced HBEC in order to predict active intracellular/extracellular TG2 
activation in-situ in CF. 
! Investigate the use of Human bronchial epithelial cells from CF patients for the 
effect of TG2 inhibitors/CFTR correctors on CFTR maturation and trafficking  
! Demonstrate using chloride dye, CFTR conductance in IB3 cells, C38 cells 
HBEC and HBEC transduced with mutant CFTR in the presence of TG2 cell-
permeable/impermeable inhibitors and CFTR correctors. 
! Use cDNA of the 3 different domains of the CFTR channel to investigate the 
effect of TG2 inhibitors on the stability and interactions of the domains towards 
enhancing CFTR channel read-through. 
! Undertake animal studies, where TG2 inhibitors can be used in CFTR wild type 
and deficient mice and in combination with CFTR correctors to observe their in-
vivo effect on CFTR maturation. 
References!
!
! 211!
References 
!
Anonymous,!1993. Correlation between genotype and phenotype in patients with cystic 
fibrosis. The Cystic Fibrosis Genotype-Phenotype Consortium. N Engl J Med, 
329, 1308-13. 
Abe, M., Harpel, J. G., Metz, C. N., Nunes, I., Loskutoff, D. J. & Rifkin, D. B. 1994. An 
assay for transforming growth factor-beta using cells transfected with a 
plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem, 
216, 276-84. 
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M. P., Dunitz, J. M., Durie, P. R., 
Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., Moss, R. B., 
Pilewski, J. M., Rubenstein, R. C., Uluer, A. Z., Aitken, M. L., Freedman, S. D., 
Rose, L. M., Mayer-Hamblett, N., Dong, Q., Zha, J., Stone, A. J., Olson, E. R., 
Ordonez, C. L., Campbell, P. W., Ashlock, M. A. & Ramsey, B. W. 2010. Effect 
of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl 
J Med, 363, 1991-2003. 
Achyuthan, K. E. & Greenberg, C. S. 1987. Identification of a guanosine triphosphate-
binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions 
in modulating activity. J Biol Chem, 262, 1901-6. 
Aeschlimann, D., Kaupp, O. & Paulsson, M. 1995. Transglutaminase-catalyzed matrix 
crosslinking in differentiating cartilage: identification of osteonectin as a major 
glutaminyl substrate. J Cell Biol, 129, 881-92. 
Aeschlimann, D. & Thomazy, V. 2000. Protein crosslinking in assembly and 
remodelling of extracellular matrices: the role of transglutaminases. Connect 
Tissue Res, 41, 1-27. 
Aeschlimann, D., Wetterwald, A., Fleisch, H. & Paulsson, M. 1993. Expression of 
tissue transglutaminase in skeletal tissues correlates with events of terminal 
differentiation of chondrocytes. J Cell Biol, 120, 1461-70. 
Akimov, S. S. & Belkin, A. M. 2001a. Cell surface tissue transglutaminase is involved in 
adhesion and migration of monocytic cells on fibronectin. Blood, 98, 1567-76. 
Akimov, S. S. & Belkin, A. M. 2001b. Cell-surface transglutaminase promotes 
fibronectin assembly via interaction with the gelatin-binding domain of 
fibronectin: a role in TGFbeta-dependent matrix deposition. J Cell Sci, 114, 
2989-3000. 
Altamura, N., Castaldo, R., Finotti, A., Breveglieri, G., Salvatori, F., Zuccato, C., 
Gambari, R., Panin, G. C. & Borgatti, M. 2013. Tobramycin is a suppressor of 
premature termination codons. J Cyst Fibros, 12, 806-11. 
References!
!
! 212!
Amaral, M. D., Pacheco, P., Beck, S., Farinha, C. M., Penque, D., Nogueira, P., 
Barreto, C., Lopes, B., Casals, T., Dapena, J., Gartner, S., Vasquez, C., Perez-
Frias, J., Olveira, C., Cabanas, R., Estivill, X., Tzetis, M., Kanavakis, E., 
Doudounakis, S., Dork, T., Tummler, B., Girodon-Boulandet, E., Cazeneuve, 
C., Goossens, M., Blayau, M., Verlingue, C., Vieira, I., Ferec, C., Claustres, M., 
Des Georges, M., Clavel, C., Birembaut, P., Hubert, D., Bienvenu, T., Adoun, 
M., Chomel, J. C., De Boeck, K., Cuppens, H. & Lavinha, J. 2001. Cystic 
fibrosis patients with the 3272-26A>G splicing mutation have milder disease 
than F508del homozygotes: a large European study. J Med Genet, 38, 777-83. 
Anderson, M. P. & Welsh, M. J. 1991. Calcium and cAMP activate different chloride 
channels in the apical membrane of normal and cystic fibrosis epithelia. Proc 
Natl Acad Sci U S A, 88, 6003-7. 
Ann, D. K., Wu, M. M., Huang, T., Carlson, D. M. & Wu, R. 1988. Retinol-regulated 
gene expression in human tracheobronchial epithelial cells. Enhanced 
expression of elongation factor EF-1 alpha. J Biol Chem, 263, 3546-9. 
Annes, J. P., Chen, Y., Munger, J. S. & Rifkin, D. B. 2004. Integrin alphaVbeta6-
mediated activation of latent TGF-beta requires the latent TGF-beta binding 
protein-1. J Cell Biol, 165, 723-34. 
Antonyak, M. A., Miller, A. M., Jansen, J. M., Boehm, J. E., Balkman, C. E., Wakshlag, 
J. J., Page, R. L. & Cerione, R. A. 2004. Augmentation of tissue 
transglutaminase expression and activation by epidermal growth factor inhibit 
doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem, 279, 
41461-7. 
Arentz-Hansen, H., Korner, R., Molberg, O., Quarsten, H., Vader, W., Kooy, Y. M., 
Lundin, K. E., Koning, F., Roepstorff, P., Sollid, L. M. & Mcadam, S. N. 2000. 
The intestinal T cell response to alpha-gliadin in adult celiac disease is focused 
on a single deamidated glutamine targeted by tissue transglutaminase. J Exp 
Med, 191, 603-12. 
Arkwright, P. D., Laurie, S., Super, M., Pravica, V., Schwarz, M. J., Webb, A. K. & 
Hutchinson, I. V. 2000. TGF-beta(1) genotype and accelerated decline in lung 
function of patients with cystic fibrosis. Thorax, 55, 459-62. 
Ashlock, M. A. & Olson, E. R. 2011. Therapeutics development for cystic fibrosis: a 
successful model for a multisystem genetic disease. Annu Rev Med, 62, 107-
25. 
Assemat, E., Bazellieres, E., Pallesi-Pocachard, E., Le Bivic, A. & Massey-Harroche, 
D. 2008. Polarity complex proteins. Biochim Biophys Acta, 1778, 614-30. 
References!
!
! 213!
Badarau, E., Mongeot, A., Collighan, R., Rathbone, D. & Griffin, M. 2013. Imidazolium-
based warheads strongly influence activity of water-soluble peptidic 
transglutaminase inhibitors. Eur J Med Chem, 66, 526-30. 
Bailey, C. D. & Johnson, G. V. 2006. The protective effects of cystamine in the R6/2 
Huntington's disease mouse involve mechanisms other than the inhibition of 
tissue transglutaminase. Neurobiol Aging, 27, 871-9. 
Bakin, A. V., Tomlinson, A. K., Bhowmick, N. A., Moses, H. L. & Arteaga, C. L. 2000. 
Phosphatidylinositol 3-kinase function is required for transforming growth factor 
beta-mediated epithelial to mesenchymal transition and cell migration. J Biol 
Chem, 275, 36803-10. 
Balharry, D., Sexton, K. & Berube, K. A. 2008. An in vitro approach to assess the 
toxicity of inhaled tobacco smoke components: nicotine, cadmium, 
formaldehyde and urethane. Toxicology, 244, 66-76. 
Balklava, Z., Verderio, E., Collighan, R., Gross, S., Adams, J. & Griffin, M. 2002. 
Analysis of tissue transglutaminase function in the migration of Swiss 3T3 
fibroblasts: the active-state conformation of the enzyme does not affect cell 
motility but is important for its secretion. J Biol Chem, 277, 16567-75. 
Barrallo-Gimeno, A. & Nieto, M. A. 2005. The Snail genes as inducers of cell 
movement and survival: implications in development and cancer. Development, 
132, 3151-61. 
Bartram, U. 2004. The Role of Transforming Growth Factor   in Lung Development and 
Disease. Chest, 125, 754-765. 
Belkin, A. M. 2011. Extracellular TG2: emerging functions and regulation. FEBS J, 278, 
4704-16. 
Beninati, S. & Piacentini, M. 2004. The transglutaminase family: an overview: 
minireview article. Amino Acids, 26, 367-72. 
Bergamini, C. M. 1988. GTP modulates calcium binding and cation-induced 
conformational changes in erythrocyte transglutaminase. FEBS Lett, 239, 255-
8. 
Bergamini, C. M. & Signorini, M. 1993. Studies on tissue transglutaminases: interaction 
of erythrocyte type-2 transglutaminase with GTP. Biochem J, 291 ( Pt 1), 37-9. 
Berkowitz, R. D., Hammarskjold, M. L., Helga-Maria, C., Rekosh, D. & Goff, S. P. 1995. 
5' regions of HIV-1 RNAs are not sufficient for encapsidation: implications for 
the HIV-1 packaging signal. Virology, 212, 718-23. 
Berube, K., Aufderheide, M., Breheny, D., Clothier, R., Combes, R., Duffin, R., Forbes, 
B., Gaca, M., Gray, A., Hall, I., Kelly, M., Lethem, M., Liebsch, M., Merolla, L., 
Morin, J. P., Seagrave, J., Swartz, M. A., Tetley, T. D. & Umachandran, M. 
References!
!
! 214!
2009. In vitro models of inhalation toxicity and disease. The report of a FRAME 
workshop. Altern Lab Anim, 37, 89-141. 
Berube, K., Prytherch, Z., Job, C. & Hughes, T. 2010. Human primary bronchial lung 
cell constructs: the new respiratory models. Toxicology, 278, 311-8. 
Bobadilla, J. L., Macek, M., Fine, J. P. & Farrell, P. M. 2002. Cystic fibrosis: A 
worldwide analysis ofCFTR mutations?correlation with incidence data and 
application to screening. Human Mutation, 19, 575-606. 
Bombieri, C., Claustres, M., De Boeck, K., Derichs, N., Dodge, J., Girodon, E., Sermet, 
I., Schwarz, M., Tzetis, M., Wilschanski, M., Bareil, C., Bilton, D., Castellani, C., 
Cuppens, H., Cutting, G. R., Drevinek, P., Farrell, P., Elborn, J. S., Jarvi, K., 
Kerem, B., Kerem, E., Knowles, M., Macek, M., Jr., Munck, A., Radojkovic, D., 
Seia, M., Sheppard, D. N., Southern, K. W., Stuhrmann, M., Tullis, E., Zielenski, 
J., Pignatti, P. F. & Ferec, C. 2011. Recommendations for the classification of 
diseases as CFTR-related disorders. J Cyst Fibros, 10 Suppl 2, S86-102. 
Bompadre, S. G., Sohma, Y., Li, M. & Hwang, T. C. 2007. G551D and G1349D, two 
CF-associated mutations in the signature sequences of CFTR, exhibit distinct 
gating defects. J Gen Physiol, 129, 285-98. 
Bonfield, T. L., Konstan, M. W. & Berger, M. 1999. Altered respiratory epithelial cell 
cytokine production in cystic fibrosis. J Allergy Clin Immunol, 104, 72-8. 
Boyer, A. S., Erickson, C. P. & Runyan, R. B. 1999. Epithelial-mesenchymal 
transformation in the embryonic heart is mediated through distinct pertussis 
toxin-sensitive and TGFbeta signal transduction mechanisms. Dev Dyn, 214, 
81-91. 
Boyle, M. P., Bell, S. C., Konstan, M. W., Mccolley, S. A., Rowe, S. M., Rietschel, E., 
Huang, X., Waltz, D., Patel, N. R. & Rodman, D. 2014. A CFTR corrector 
(lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with 
cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised 
controlled trial. Lancet Respir Med, 2, 527-38. 
Bremer, L. A., Blackman, S. M., Vanscoy, L. L., Mcdougal, K. E., Bowers, A., 
Naughton, K. M., Cutler, D. J. & Cutting, G. R. 2008. Interaction between a 
novel TGFB1 haplotype and CFTR genotype is associated with improved lung 
function in cystic fibrosis. Hum Mol Genet, 17, 2228-37. 
Breuss, J. M., Gallo, J., Delisser, H. M., Klimanskaya, I. V., Folkesson, H. G., Pittet, J. 
F., Nishimura, S. L., Aldape, K., Landers, D. V., Carpenter, W. & Et Al. 1995. 
Expression of the beta 6 integrin subunit in development, neoplasia and tissue 
repair suggests a role in epithelial remodeling. J Cell Sci, 108 ( Pt 6), 2241-51. 
References!
!
! 215!
Breuss, J. M., Gillett, N., Lu, L., Sheppard, D. & Pytela, R. 1993. Restricted distribution 
of integrin beta 6 mRNA in primate epithelial tissues. J Histochem Cytochem, 
41, 1521-7. 
Busk, M., Pytela, R. & Sheppard, D. 1992. Characterization of the integrin alpha v beta 
6 as a fibronectin-binding protein. J Biol Chem, 267, 5790-6. 
Camara, J. & Jarai, G. 2010. Epithelial-mesenchymal transition in primary human 
bronchial epithelial cells is Smad-dependent and enhanced by fibronectin and 
TNF-alpha. Fibrogenesis Tissue Repair, 3, 2. 
Candi, E., Oddi, S., Terrinoni, A., Paradisi, A., Ranalli, M., Finazzi-Agro, A. & Melino, 
G. 2001. Transglutaminase 5 cross-links loricrin, involucrin, and small proline-
rich proteins in vitro. J Biol Chem, 276, 35014-23. 
Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., Del Barrio, M. 
G., Portillo, F. & Nieto, M. A. 2000. The transcription factor snail controls 
epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat 
Cell Biol, 2, 76-83. 
Cao, L., Shao, M., Schilder, J., Guise, T., Mohammad, K. S. & Matei, D. 2012. Tissue 
transglutaminase links TGF-beta, epithelial to mesenchymal transition and a 
stem cell phenotype in ovarian cancer. Oncogene, 31, 2521-34. 
Carterson, A. J., Honer Zu Bentrup, K., Ott, C. M., Clarke, M. S., Pierson, D. L., 
Vanderburg, C. R., Buchanan, K. L., Nickerson, C. A. & Schurr, M. J. 2005. 
A549 lung epithelial cells grown as three-dimensional aggregates: alternative 
tissue culture model for Pseudomonas aeruginosa pathogenesis. Infect Immun, 
73, 1129-40. 
Casadio, R., Polverini, E., Mariani, P., Spinozzi, F., Carsughi, F., Fontana, A., 
Polverino De Laureto, P., Matteucci, G. & Bergamini, C. M. 1999. The structural 
basis for the regulation of tissue transglutaminase by calcium ions. Eur J 
Biochem, 262, 672-9. 
Castellani, C., Bonizzato, A., Pradal, U., Filicori, M., Foresta, C., La Sala, G. B. & 
Mastella, G. 1999. Evidence of mild respiratory disease in men with congenital 
absence of the vas deferens. Respir Med, 93, 869-75. 
Chacko, B. M., Qin, B. Y., Tiwari, A., Shi, G., Lam, S., Hayward, L. J., De Caestecker, 
M. & Lin, K. 2004. Structural basis of heteromeric smad protein assembly in 
TGF-beta signaling. Mol Cell, 15, 813-23. 
Chmiel, J. F. & Davis, P. B. 2003. State of the art: why do the lungs of patients with 
cystic fibrosis become infected and why can't they clear the infection? Respir 
Res, 4, 8. 
Cho, H. J., Baek, K. E., Saika, S., Jeong, M. J. & Yoo, J. 2007. Snail is required for 
transforming growth factor-beta-induced epithelial-mesenchymal transition by 
References!
!
! 216!
activating PI3 kinase/Akt signal pathway. Biochem Biophys Res Commun, 353, 
337-43. 
Cho, S. Y., Jeon, J. H., Kim, C. W., Shin, D. M., Jang, G. Y., Jeong, E. M., Lee, S. E., 
Song, K. Y. & Kim, I. G. 2010. Monoclonal antibodies to human 
transglutaminase 4. Hybridoma (Larchmt), 29, 263-7. 
Choo-Kang, L. R. & Zeitlin, P. L. 2001. Induction of HSP70 promotes DeltaF508 CFTR 
trafficking. Am J Physiol Lung Cell Mol Physiol, 281, L58-68. 
Chopra, D. P., Klinger, M. M. & Sullivan, J. K. 1989. Effects of vitamin A on growth and 
differentiation of human tracheobronchial epithelial cell cultures in serum-free 
medium. J Cell Sci, 93 ( Pt 1), 133-42. 
Chuchalin, A., Amelina, E. & Bianco, F. 2009. Tobramycin for inhalation in cystic 
fibrosis: Beyond respiratory improvements. Pulm Pharmacol Ther, 22, 526-32. 
Clancy, J. P., Rowe, S. M., Accurso, F. J., Aitken, M. L., Amin, R. S., Ashlock, M. A., 
Ballmann, M., Boyle, M. P., Bronsveld, I., Campbell, P. W., De Boeck, K., 
Donaldson, S. H., Dorkin, H. L., Dunitz, J. M., Durie, P. R., Jain, M., Leonard, 
A., Mccoy, K. S., Moss, R. B., Pilewski, J. M., Rosenbluth, D. B., Rubenstein, R. 
C., Schechter, M. S., Botfield, M., Ordonez, C. L., Spencer-Green, G. T., 
Vernillet, L., Wisseh, S., Yen, K. & Konstan, M. W. 2012. Results of a phase IIa 
study of VX-809, an investigational CFTR corrector compound, in subjects with 
cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax, 67, 12-8. 
Coffman, R. L. & Hessel, E. M. 2005. Nonhuman primate models of asthma. J Exp 
Med, 201, 1875-9. 
Colin, A. A., Sawyer, S. M., Mickle, J. E., Oates, R. D., Milunsky, A. & Amos, J. A. 
1996. Pulmonary function and clinical observations in men with congenital 
bilateral absence of the vas deferens. Chest, 110, 440-5. 
Collighan, R. J. & Griffin, M. 2009. Transglutaminase 2 crosslinking of matrix proteins: 
biological significance and medical applications. Amino Acids, 36, 659-70. 
Comer, D. M., Ennis, M., Mcdowell, C., Beattie, D., Rendall, J., Hall, V. & Elborn, J. S. 
2009. Clinical phenotype of cystic fibrosis patients with the G551D mutation. 
QJM, 102, 793-8. 
Comijn, J., Berx, G., Vermassen, P., Verschueren, K., Van Grunsven, L., Bruyneel, E., 
Mareel, M., Huylebroeck, D. & Van Roy, F. 2001. The two-handed E box 
binding zinc finger protein SIP1 downregulates E-cadherin and induces 
invasion. Mol Cell, 7, 1267-78. 
Cutting, G. R., Kasch, L. M., Rosenstein, B. J., Zielenski, J., Tsui, L. C., Antonarakis, S. 
E. & Kazazian, H. H., Jr. 1990. A cluster of cystic fibrosis mutations in the first 
nucleotide-binding fold of the cystic fibrosis conductance regulator protein. 
Nature, 346, 366-9. 
References!
!
! 217!
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Dott, K., Dreyer, D., Crystal, R. 
G., Pavirani, A., Lecocq, J. P. & Lazdunski, M. 1991. Altered chloride ion 
channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature, 
354, 526-8. 
Davis, P. & Di Sant'agnese, P. 1984. Diagnosis and treatment of cystic fibrosis. An 
update. Chest, 85, 802-809. 
De Boeck, K., Munck, A., Walker, S., Faro, A., Hiatt, P., Gilmartin, G. & Higgins, M. 
2014. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-
G551D gating mutation. J Cyst Fibros. 
De Gracia, J., Mata, F., Alvarez, A., Casals, T., Gatner, S., Vendrell, M., De La Rosa, 
D., Guarner, L. & Hermosilla, E. 2005. Genotype-phenotype correlation for 
pulmonary function in cystic fibrosis. Thorax, 60, 558-63. 
De Jong, P. M., Van Sterkenburg, M. A., Hesseling, S. C., Kempenaar, J. A., Mulder, 
A. A., Mommaas, A. M., Dijkman, J. H. & Ponec, M. 1994. Ciliogenesis in 
human bronchial epithelial cells cultured at the air-liquid interface. Am J Respir 
Cell Mol Biol, 10, 271-7. 
Derynck, R. & Zhang, Y. E. 2003. Smad-dependent and Smad-independent pathways 
in TGF-beta family signalling. Nature, 425, 577-84. 
Dimango, E., Ratner, A. J., Bryan, R., Tabibi, S. & Prince, A. 1998. Activation of NF-
kappaB by adherent Pseudomonas aeruginosa in normal and cystic fibrosis 
respiratory epithelial cells. J Clin Invest, 101, 2598-605. 
Dodge, J. A., Lewis, P. A., Stanton, M. & Wilsher, J. 2007. Cystic fibrosis mortality and 
survival in the UK: 1947-2003. Eur Respir J, 29, 522-6. 
Doerner, A. M. & Zuraw, B. L. 2009. TGF-beta1 induced epithelial to mesenchymal 
transition (EMT) in human bronchial epithelial cells is enhanced by IL-1beta but 
not abrogated by corticosteroids. Respir Res, 10, 100. 
Drumm, M. L., Konstan, M. W., Schluchter, M. D., Handler, A., Pace, R., Zou, F., 
Zariwala, M., Fargo, D., Xu, A., Dunn, J. M., Darrah, R. J., Dorfman, R., 
Sandford, A. J., Corey, M., Zielenski, J., Durie, P., Goddard, K., Yankaskas, J. 
R., Wright, F. A. & Knowles, M. R. 2005. Genetic modifiers of lung disease in 
cystic fibrosis. N Engl J Med, 353, 1443-53. 
Dubbink, H. J., De Waal, L., Van Haperen, R., Verkaik, N. S., Trapman, J. & Romijn, J. 
C. 1998. The human prostate-specific transglutaminase gene (TGM4): genomic 
organization, tissue-specific expression, and promoter characterization. 
Genomics, 51, 434-44. 
Dubbink, H. J., Verkaik, N. S., Faber, P. W., Trapman, J., Schroder, F. H. & Romijn, J. 
C. 1996. Tissue specific and androgen-regulated expression of human 
prostate-specific transglutaminase. Biochem J, 315 ( Pt 3), 901-8. 
References!
!
! 218!
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D. & Naldini, L. 
1998. A third-generation lentivirus vector with a conditional packaging system. J 
Virol, 72, 8463-71. 
Eckert, R. L. 1989. Structure, function, and differentiation of the keratinocyte. Physiol 
Rev, 69, 1316-46. 
Edwards, D. R., Murphy, G., Reynolds, J. J., Whitham, S. E., Docherty, A. J., Angel, P. 
& Heath, J. K. 1987. Transforming growth factor beta modulates the expression 
of collagenase and metalloproteinase inhibitor. EMBO J, 6, 1899-904. 
Eickmeier, O., Boom, L., Schreiner, F., Lentze, M. J., D, N. G., Schubert, R., Zielen, S. 
& Schmitt-Grohe, S. 2013. Transforming growth factor beta1 genotypes in 
relation to TGFbeta1, interleukin-8, and tumor necrosis factor alpha in induced 
sputum and blood in cystic fibrosis. Mediators Inflamm, 2013, 913135. 
Feingold, J. & Guilloud-Bataille, M. 1999. Genetic comparisons of patients with cystic 
fibrosis with or without meconium ileus. Clinical Centers of the French CF 
Registry. Ann Genet, 42, 147-50. 
Ferec, C. & Cutting, G. R. 2012. Assessing the Disease-Liability of Mutations in CFTR. 
Cold Spring Harb Perspect Med, 2, a009480. 
Fesus, L., Thomazy, V., Autuori, F., Ceru, M. P., Tarcsa, E. & Piacentini, M. 1989. 
Apoptotic hepatocytes become insoluble in detergents and chaotropic agents 
as a result of transglutaminase action. FEBS Lett, 245, 150-4. 
Folk, J. E. & Finlayson, J. S. 1977. The epsilon-(gamma-glutamyl)lysine crosslink and 
the catalytic role of transglutaminases. Adv Protein Chem, 31, 1-133. 
Fontana, L., Chen, Y., Prijatelj, P., Sakai, T., Fassler, R., Sakai, L. Y. & Rifkin, D. B. 
2005. Fibronectin is required for integrin alphavbeta6-mediated activation of 
latent TGF-beta complexes containing LTBP-1. FASEB J, 19, 1798-808. 
Frank, J., Roux, J., Kawakatsu, H., Su, G., Dagenais, A., Berthiaume, Y., Howard, M., 
Canessa, C. M., Fang, X., Sheppard, D., Matthay, M. A. & Pittet, J. F. 2003. 
Transforming growth factor-beta1 decreases expression of the epithelial sodium 
channel alphaENaC and alveolar epithelial vectorial sodium and fluid transport 
via an ERK1/2-dependent mechanism. J Biol Chem, 278, 43939-50. 
Frischmeyer, P. A. & Dietz, H. C. 1999. Nonsense-mediated mRNA decay in health 
and disease. Hum Mol Genet, 8, 1893-900. 
Fulmer, S. B., Schwiebert, E. M., Morales, M. M., Guggino, W. B. & Cutting, G. R. 
1995. Two cystic fibrosis transmembrane conductance regulator mutations 
have different effects on both pulmonary phenotype and regulation of outwardly 
rectified chloride currents. Proc Natl Acad Sci U S A, 92, 6832-6. 
Gaudry, C. A., Verderio, E., Aeschlimann, D., Cox, A., Smith, C. & Griffin, M. 1999a. 
Cell surface localisation of tissue transglutaminase is dependent on a 
References!
!
! 219!
fibronectin-binding site in its N-terminal beta-sandwich domain. J Biol Chem, 
274, 30707-14. 
Gaudry, C. A., Verderio, E., Jones, R. A., Smith, C. & Griffin, M. 1999b. Tissue 
transglutaminase is an important player at the surface of human endothelial 
cells: evidence for its externalisation and its colocalisation with the beta(1) 
integrin. Exp Cell Res, 252, 104-13. 
George, M. D., Vollberg, T. M., Floyd, E. E., Stein, J. P. & Jetten, A. M. 1990. 
Regulation of transglutaminase type II by transforming growth factor-beta 1 in 
normal and transformed human epidermal keratinocytes. J Biol Chem, 265, 
11098-104. 
Graff, J. M., Bansal, A. & Melton, D. A. 1996. Xenopus Mad proteins transduce distinct 
subsets of signals for the TGF beta superfamily. Cell, 85, 479-87. 
Grainger, C. I., Greenwell, L. L., Lockley, D. J., Martin, G. P. & Forbes, B. 2006. 
Culture of Calu-3 Cells at the Air Interface Provides a Representative Model of 
the Airway Epithelial Barrier. Pharmaceutical Research, 23, 1482-1490. 
Grande, J. P. 1997. Role of transforming growth factor-beta in tissue injury and repair. 
Proc Soc Exp Biol Med, 214, 27-40. 
Grande, M., Franzen, A., Karlsson, J. O., Ericson, L. E., Heldin, N. E. & Nilsson, M. 
2002. Transforming growth factor-beta and epidermal growth factor 
synergistically stimulate epithelial to mesenchymal transition (EMT) through a 
MEK-dependent mechanism in primary cultured pig thyrocytes. J Cell Sci, 115, 
4227-36. 
Greenberg, C. S., Birckbichler, P. J. & Rice, R. H. 1991. Transglutaminases: 
multifunctional crosslinking enzymes that stabilize tissues. FASEB J, 5, 3071-7. 
Griffin, M., Casadio, R. & Bergamini, C. M. 2002. Transglutaminases: nature's 
biological glues. Biochem J, 368, 377-96. 
Griffin, M., Mongeot, A., Collighan, R., Saint, R. E., Jones, R. A., Coutts, I. G. & 
Rathbone, D. L. 2008. Synthesis of potent water-soluble tissue 
transglutaminase inhibitors. Bioorg Med Chem Lett, 18, 5559-62. 
Griffin, M., Smith, L. L. & Wynne, J. 1979. Changes in transglutaminase activity in an 
experimental model of pulmonary fibrosis induced by paraquat. Br J Exp Pathol, 
60, 653-61. 
Griffith, L. G. & Swartz, M. A. 2006. Capturing complex 3D tissue physiology in vitro. 
Nat Rev Mol Cell Biol, 7, 211-24. 
Grosso, H. & Mouradian, M. M. 2012. Transglutaminase 2: biology, relevance to 
neurodegenerative diseases and therapeutic implications. Pharmacol Ther, 
133, 392-410. 
References!
!
! 220!
Grove, D. E., Rosser, M. F. N., Ren, H. Y., Naren, A. P. & Cyr, D. M. 2009. 
Mechanisms for Rescue of Correctable Folding Defects in CFTR F508. 
Molecular Biology of the Cell, 20, 4059-4069. 
Gruenert, D. C., Finkbeiner, W. E. & Widdicombe, J. H. 1995. Culture and 
transformation of human airway epithelial cells. Am J Physiol, 268, L347-60. 
Gundemir, S., Colak, G., Tucholski, J. & Johnson, G. V. 2012. Transglutaminase 2: a 
molecular Swiss army knife. Biochim Biophys Acta, 1823, 406-19. 
Gundemir, S. & Johnson, G. V. 2009. Intracellular localisation and conformational state 
of transglutaminase 2: implications for cell death. PLoS One, 4, e6123. 
Haardt, M., Benharouga, M., Lechardeur, D., Kartner, N. & Lukacs, G. L. 1999. C-
terminal truncations destabilize the cystic fibrosis transmembrane conductance 
regulator without impairing its biogenesis. A novel class of mutation. J Biol 
Chem, 274, 21873-7. 
Hackett, T. L., Warner, S. M., Stefanowicz, D., Shaheen, F., Pechkovsky, D. V., 
Murray, L. A., Argentieri, R., Kicic, A., Stick, S. M., Bai, T. R. & Knight, D. A. 
2009. Induction of epithelial-mesenchymal transition in primary airway epithelial 
cells from patients with asthma by transforming growth factor-beta1. Am J 
Respir Crit Care Med, 180, 122-33. 
Hamosh, A., Rosenstein, B. J. & Cutting, G. R. 1992. CFTR nonsense mutations 
G542X and W1282X associated with severe reduction of CFTR mRNA in nasal 
epithelial cells. Hum Mol Genet, 1, 542-4. 
Harrison, C. A., Layton, C. M., Hau, Z., Bullock, A. J., Johnson, T. S. & Macneil, S. 
2007. Transglutaminase inhibitors induce hyperproliferation and parakeratosis 
in tissue-engineered skin. Br J Dermatol, 156, 247-57. 
Harrison, M. J., Murphy, D. M. & Plant, B. J. 2013. Ivacaftor in a G551D homozygote 
with cystic fibrosis. N Engl J Med, 369, 1280-2. 
Hasegawa, G., Suwa, M., Ichikawa, Y., Ohtsuka, T., Kumagai, S., Kikuchi, M., Sato, Y. 
& Saito, Y. 2003. A novel function of tissue-type transglutaminase: protein 
disulphide isomerase. Biochem J, 373, 793-803. 
Hata, A., Lagna, G., Massague, J. & Hemmati-Brivanlou, A. 1998. Smad6 inhibits 
BMP/Smad1 signaling by specifically competing with the Smad4 tumor 
suppressor. Genes Dev, 12, 186-97. 
Hay, E. D. 1995. An overview of epithelio-mesenchymal transformation. Acta Anat 
(Basel), 154, 8-20. 
Heath, D. J., Christian, P. & Griffin, M. 2002. Involvement of tissue transglutaminase in 
the stabilisation of biomaterial/tissue interfaces important in medical devices. 
Biomaterials, 23, 1519-26. 
References!
!
! 221!
Hegedus, T., Aleksandrov, A., Mengos, A., Cui, L., Jensen, T. J. & Riordan, J. R. 2009. 
Role of individual R domain phosphorylation sites in CFTR regulation by protein 
kinase A. Biochim Biophys Acta, 1788, 1341-9. 
Heldin, C. H., Miyazono, K. & Ten Dijke, P. 1997. TGF-beta signalling from cell 
membrane to nucleus through SMAD proteins. Nature, 390, 465-71. 
Heldin, C. H., Vanlandewijck, M. & Moustakas, A. 2012. Regulation of EMT by 
TGFbeta in cancer. FEBS Lett, 586, 1959-70. 
Henderson, N. C. & Sheppard, D. 2013. Integrin-mediated regulation of TGFbeta in 
fibrosis. Biochim Biophys Acta, 1832, 891-6. 
Hiiragi, T., Sasaki, H., Nagafuchi, A., Sabe, H., Shen, S. C., Matsuki, M., Yamanishi, K. 
& Tsukita, S. 1999. Transglutaminase type 1 and its crosslinking activity are 
concentrated at adherens junctions in simple epithelial cells. J Biol Chem, 274, 
34148-54. 
Hilliard, T. N., Regamey, N., Shute, J. K., Nicholson, A. G., Alton, E. W., Bush, A. & 
Davies, J. C. 2007. Airway remodelling in children with cystic fibrosis. Thorax, 
62, 1074-80. 
Hoodless, P. A., Haerry, T., Abdollah, S., Stapleton, M., O'connor, M. B., Attisano, L. & 
Wrana, J. L. 1996. MADR1, a MAD-related protein that functions in BMP2 
signaling pathways. Cell, 85, 489-500. 
Hoot, K. E., Lighthall, J., Han, G., Lu, S. L., Li, A., Ju, W., Kulesz-Martin, M., Bottinger, 
E. & Wang, X. J. 2008. Keratinocyte-specific Smad2 ablation results in 
increased epithelial-mesenchymal transition during skin cancer formation and 
progression. J Clin Invest, 118, 2722-32. 
Huang, L., Haylor, J. L., Fisher, M., Hau, Z., El Nahas, A. M., Griffin, M. & Johnson, T. 
S. 2010. Do changes in transglutaminase activity alter latent transforming 
growth factor beta activation in experimental diabetic nephropathy? Nephrol 
Dial Transplant, 25, 3897-910. 
Ichinose, A. & Davie, E. W. 1988. Characterization of the gene for the a subunit of 
human factor XIII (plasma transglutaminase), a blood coagulation factor. Proc 
Natl Acad Sci U S A, 85, 5829-33. 
Iismaa, S. E. 2003. Evolutionary specialization of a tryptophan indole group for 
transition-state stabilisation by eukaryotic transglutaminases. Proceedings of 
the National Academy of Sciences, 100, 12636-12641. 
Iismaa, S. E., Mearns, B. M., Lorand, L. & Graham, R. M. 2009. Transglutaminases 
and disease: lessons from genetically engineered mouse models and inherited 
disorders. Physiol Rev, 89, 991-1023. 
References!
!
! 222!
Ikenouchi, J., Matsuda, M., Furuse, M. & Tsukita, S. 2003. Regulation of tight junctions 
during the epithelium-mesenchyme transition: direct repression of the gene 
expression of claudins/occludin by Snail. J Cell Sci, 116, 1959-67. 
Jacquot, J., Tabary, O., Le Rouzic, P. & Clement, A. 2008. Airway epithelial cell 
inflammatory signalling in cystic fibrosis. The International Journal of 
Biochemistry & Cell Biology, 40, 1703-1715. 
Jilling, T. & Kirk, K. L. 1997. The biogenesis, traffic, and function of the cystic fibrosis 
transmembrane conductance regulator. Int Rev Cytol, 172, 193-241. 
Johnson, G. V., Cox, T. M., Lockhart, J. P., Zinnerman, M. D., Miller, M. L. & Powers, 
R. E. 1997a. Transglutaminase activity is increased in Alzheimer's disease 
brain. Brain Res, 751, 323-9. 
Johnson, L. G., Dickman, K. G., Moore, K. L., Mandel, L. J. & Boucher, R. C. 1993. 
Enhanced Na+ transport in an air-liquid interface culture system. Am J Physiol, 
264, L560-5. 
Johnson, T. S., Fisher, M., Haylor, J. L., Hau, Z., Skill, N. J., Jones, R., Saint, R., 
Coutts, I., Vickers, M. E., El Nahas, A. M. & Griffin, M. 2007. Transglutaminase 
Inhibition Reduces Fibrosis and Preserves Function in Experimental Chronic 
Kidney Disease. Journal of the American Society of Nephrology, 18, 3078-
3088. 
Johnson, T. S., Griffin, M., Thomas, G. L., Skill, J., Cox, A., Yang, B., Nicholas, B., 
Birckbichler, P. J., Muchaneta-Kubara, C. & Meguid El Nahas, A. 1997b. The 
role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis. 
J Clin Invest, 99, 2950-60. 
Johnson, T. S., Knight, C. R., El-Alaoui, S., Mian, S., Rees, R. C., Gentile, V., Davies, 
P. J. & Griffin, M. 1994. Transfection of tissue transglutaminase into a highly 
malignant hamster fibrosarcoma leads to a reduced incidence of primary 
tumour growth. Oncogene, 9, 2935-42. 
Johnson, T. S., Skill, N. J., El Nahas, A. M., Oldroyd, S. D., Thomas, G. L., Douthwaite, 
J. A., Haylor, J. L. & Griffin, M. 1999. Transglutaminase transcription and 
antigen translocation in experimental renal scarring. J Am Soc Nephrol, 10, 
2146-57. 
Jones, R. A., Kotsakis, P., Johnson, T. S., Chau, D. Y., Ali, S., Melino, G. & Griffin, M. 
2006. Matrix changes induced by transglutaminase 2 lead to inhibition of 
angiogenesis and tumor growth. Cell Death Differ, 13, 1442-53. 
Jones, R. A., Nicholas, B., Mian, S., Davies, P. J. & Griffin, M. 1997. Reduced 
expression of tissue transglutaminase in a human endothelial cell line leads to 
changes in cell spreading, cell adhesion and reduced polymerisation of 
fibronectin. J Cell Sci, 110 ( Pt 19), 2461-72. 
References!
!
! 223!
Junn, E., Ronchetti, R. D., Quezado, M. M., Kim, S. Y. & Mouradian, M. M. 2003. 
Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications 
for Lewy body formation in Parkinson's disease and dementia with Lewy 
bodies. Proc Natl Acad Sci U S A, 100, 2047-52. 
Kalin, N., Claass, A., Sommer, M., Puchelle, E. & Tummler, B. 1999. DeltaF508 CFTR 
protein expression in tissues from patients with cystic fibrosis. J Clin Invest, 
103, 1379-89. 
Kalluri, R. & Neilson, E. G. 2003. Epithelial-mesenchymal transition and its implications 
for fibrosis. J Clin Invest, 112, 1776-84. 
Kaminski, N., Allard, J. D., Pittet, J. F., Zuo, F., Griffiths, M. J., Morris, D., Huang, X., 
Sheppard, D. & Heller, R. A. 2000. Global analysis of gene expression in 
pulmonary fibrosis reveals distinct programs regulating lung inflammation and 
fibrosis. Proc Natl Acad Sci U S A, 97, 1778-83. 
Karpuj, M. V., Becher, M. W., Springer, J. E., Chabas, D., Youssef, S., Pedotti, R., 
Mitchell, D. & Steinman, L. 2002. Prolonged survival and decreased abnormal 
movements in transgenic model of Huntington disease, with administration of 
the transglutaminase inhibitor cystamine. Nat Med, 8, 143-9. 
Kasai, H., Allen, J. T., Mason, R. M., Kamimura, T. & Zhang, Z. 2005. TGF-beta1 
induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir 
Res, 6, 56. 
Katoh, D., Nagaharu, K., Shimojo, N., Hanamura, N., Yamashita, M., Kozuka, Y., 
Imanaka-Yoshida, K. & Yoshida, T. 2013. Binding of alphavbeta1 and 
alphavbeta6 integrins to tenascin-C induces epithelial-mesenchymal transition-
like change of breast cancer cells. Oncogenesis, 2, e65. 
Katona, E., Nagy, B., Kappelmayer, J., Baktai, G., Kovacs, L., Marialigeti, T., Dezso, B. 
& Muszbek, L. 2005. Factor XIII in bronchoalveolar lavage fluid from children 
with chronic bronchoalveolar inflammation. J Thromb Haemost, 3, 1407-13. 
Kawata, M., Koinuma, D., Ogami, T., Umezawa, K., Iwata, C., Watabe, T. & Miyazono, 
K. 2012. TGF-beta-induced epithelial-mesenchymal transition of A549 lung 
adenocarcinoma cells is enhanced by pro-inflammatory cytokines derived from 
RAW 264.7 macrophage cells. J Biochem, 151, 205-16. 
Kelley, J., Fabisiak, J. P., Hawes, K. & Absher, M. 1991. Cytokine signaling in lung: 
transforming growth factor-beta secretion by lung fibroblasts. Am J Physiol, 
260, L123-8. 
Kerem, B., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, 
A., Buchwald, M. & Tsui, L. C. 1989. Identification of the cystic fibrosis gene: 
genetic analysis. Science, 245, 1073-80. 
References!
!
! 224!
Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M., Nissim-
Rafinia, M., Blau, H., Rivlin, J., Aviram, M., Elfring, G. L., Northcutt, V. J., Miller, 
L. L., Kerem, B. & Wilschanski, M. 2008. Effectiveness of PTC124 treatment of 
cystic fibrosis caused by nonsense mutations: a prospective phase II trial. 
Lancet, 372, 719-27. 
Kerem, E., Konstan, M. W., De Boeck, K., Accurso, F. J., Sermet-Gaudelus, I., 
Wilschanski, M., Elborn, J. S., Melotti, P., Bronsveld, I., Fajac, I., Malfroot, A., 
Rosenbluth, D. B., Walker, P. A., Mccolley, S. A., Knoop, C., Quattrucci, S., 
Rietschel, E., Zeitlin, P. L., Barth, J., Elfring, G. L., Welch, E. M., Branstrom, A., 
Spiegel, R. J., Peltz, S. W., Ajayi, T. & Rowe, S. M. 2014. Ataluren for the 
treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, 
placebo-controlled phase 3 trial. Lancet Respir Med. 
Kim, D. S., Park, S. S., Nam, B. H., Kim, I. H. & Kim, S. Y. 2006. Reversal of Drug 
Resistance in Breast Cancer Cells by Transglutaminase 2 Inhibition and 
Nuclear Factor- B Inactivation. Cancer Research, 66, 10936-10943. 
Kim, H. 2001. Crystallization and Preliminary X-Ray Analysis of Human 
Transglutaminase 3 from Zymogen to Active Form. Journal of Structural 
Biology, 135, 73-77. 
Kim, J. B., Islam, S., Kim, Y. J., Prudoff, R. S., Sass, K. M., Wheelock, M. J. & 
Johnson, K. R. 2000. N-Cadherin extracellular repeat 4 mediates epithelial to 
mesenchymal transition and increased motility. J Cell Biol, 151, 1193-206. 
Kim, S. Y., Grant, P., Lee, J. H., Pant, H. C. & Steinert, P. M. 1999. Differential 
expression of multiple transglutaminases in human brain. Increased expression 
and crosslinking by transglutaminases 1 and 2 in Alzheimer's disease. J Biol 
Chem, 274, 30715-21. 
Kojima, S., Nara, K. & Rifkin, D. B. 1993. Requirement for transglutaminase in the 
activation of latent transforming growth factor-beta in bovine endothelial cells. J 
Cell Biol, 121, 439-48. 
Komaromi, I., Bagoly, Z. & Muszbek, L. 2011. Factor XIII: novel structural and 
functional aspects. J Thromb Haemost, 9, 9-20. 
Konstan, M. W., Hilliard, K. A., Norvell, T. M. & Berger, M. 1994. Bronchoalveolar 
lavage findings in cystic fibrosis patients with stable, clinically mild lung disease 
suggest ongoing infection and inflammation. Am J Respir Crit Care Med, 150, 
448-54. 
Konstan, M. W. & Ratjen, F. 2012. Effect of dornase alfa on inflammation and lung 
function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros, 11, 
78-83. 
References!
!
! 225!
Kretzschmar, M. & Massague, J. 1998. SMADs: mediators and regulators of TGF-beta 
signaling. Curr Opin Genet Dev, 8, 103-11. 
Kumar, A., Xu, J., Brady, S., Gao, H., Yu, D., Reuben, J. & Mehta, K. 2010. Tissue 
transglutaminase promotes drug resistance and invasion by inducing 
mesenchymal transition in mammary epithelial cells. PLoS ONE, 5, e13390. 
Kumar, A., Xu, J., Sung, B., Kumar, S., Yu, D., Aggarwal, B. B. & Mehta, K. 2012. 
Evidence that GTP-binding domain but not catalytic domain of transglutaminase 
2 is essential for epithelial-to-mesenchymal transition in mammary epithelial 
cells. Breast Cancer Res, 14, R4. 
Kuncio, G. S., Tsyganskaya, M., Zhu, J., Liu, S. L., Nagy, L., Thomazy, V., Davies, P. 
J. & Zern, M. A. 1998. TNF-alpha modulates expression of the tissue 
transglutaminase gene in liver cells. Am J Physiol, 274, G240-5. 
Kwong, K., Niang, S., Literat, A., Zhu, N., Ramanathan, R., Jones, C. & Minoo, P. 
2006. Expression of transforming growth factor beta (TGF-b1) by human 
preterm lung inflammatory cells☆. Life Sciences, 79, 2349-2356. 
Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head 
of bacteriophage T4. Nature, 227, 680-5. 
Lai, C. H., Chun, H. H., Nahas, S. A., Mitui, M., Gamo, K. M., Du, L. & Gatti, R. A. 
2004. Correction of ATM gene function by aminoglycoside-induced read-
through of premature termination codons. Proc Natl Acad Sci U S A, 101, 
15676-81. 
Lai, T. S., Slaughter, T. F., Koropchak, C. M., Haroon, Z. A. & Greenberg, C. S. 1996. 
C-terminal deletion of human tissue transglutaminase enhances magnesium-
dependent GTP/ATPase activity. J Biol Chem, 271, 31191-5. 
Lauzier, A., Charbonneau, M., Paquette, M., Harper, K. & Dubois, C. M. 2012. 
Transglutaminase 2 crosslinking activity is linked to invadopodia formation and 
cartilage breakdown in arthritis. Arthritis Res Ther, 14, R159. 
Leask, A. & Abraham, D. J. 2004. TGF-beta signaling and the fibrotic response. 
FASEB J, 18, 816-27. 
Lee, J. H., Jang, S. I., Yang, J. M., Markova, N. G. & Steinert, P. M. 1996. The 
proximal promoter of the human transglutaminase 3 gene. Stratified squamous 
epithelial-specific expression in cultured cells is mediated by binding of Sp1 and 
ets transcription factors to a proximal promoter element. J Biol Chem, 271, 
4561-8. 
Lee, J. M., Dedhar, S., Kalluri, R. & Thompson, E. W. 2006. The epithelial-
mesenchymal transition: new insights in signaling, development, and disease. J 
Cell Biol, 172, 973-81. 
References!
!
! 226!
Lee, K. N., Arnold, S. A., Birckbichler, P. J., Patterson, M. K., Jr., Fraij, B. M., Takeuchi, 
Y. & Carter, H. A. 1993. Site-directed mutagenesis of human tissue 
transglutaminase: Cys-277 is essential for transglutaminase activity but not for 
GTPase activity. Biochim Biophys Acta, 1202, 1-6. 
Lesort, M., Lee, M., Tucholski, J. & Johnson, G. V. 2003. Cystamine inhibits caspase 
activity. Implications for the treatment of polyglutamine disorders. J Biol Chem, 
278, 3825-30. 
Levy, H., Cannon, C. L., Asher, D., Garcia, C., Cleveland, R. H., Pier, G. B., Knowles, 
M. R. & Colin, A. A. 2010. Lack of correlation between pulmonary disease and 
cystic fibrosis transmembrane conductance regulator dysfunction in cystic 
fibrosis: a case report. J Med Case Rep, 4, 117. 
Lewis, P., Hensel, M. & Emerman, M. 1992. Human immunodeficiency virus infection 
of cells arrested in the cell cycle. EMBO J, 11, 3053-8. 
Lilja, H. & Laurell, C. B. 1985. The predominant protein in human seminal coagulate. 
Scand J Clin Lab Invest, 45, 635-41. 
Liu, S., Cerione, R. A. & Clardy, J. 2002. Structural basis for the guanine nucleotide-
binding activity of tissue transglutaminase and its regulation of transamidation 
activity. Proc Natl Acad Sci U S A, 99, 2743-7. 
Lowry, O. H., Rosebrough, N. J., Farr, A. L. & Randall, R. J. 1951. Protein 
measurement with the Folin phenol reagent. J Biol Chem, 193, 265-75. 
Luciani, A., Villella, V. R., Esposito, S., Brunetti-Pierri, N., Medina, D., Settembre, C., 
Gavina, M., Pulze, L., Giardino, I., Pettoello-Mantovani, M., D'apolito, M., 
Guido, S., Masliah, E., Spencer, B., Quaratino, S., Raia, V., Ballabio, A. & 
Maiuri, L. 2010a. Defective CFTR induces aggresome formation and lung 
inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat 
Cell Biol, 12, 863-75. 
Luciani, A., Villella, V. R., Esposito, S., Brunetti-Pierri, N., Medina, D., Settembre, C., 
Gavina, M., Pulze, L., Giardino, I., Pettoello-Mantovani, M., D'apolito, M., 
Guido, S., Masliah, E., Spencer, B., Quaratino, S., Raia, V., Ballabio, A. & 
Maiuri, L. 2010b. Defective CFTR induces aggresome formation and lung 
inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. 
Nature Cell Biology, 12, 863-875. 
Luciani, A., Villella, V. R., Esposito, S., Gavina, M., Russo, I., Silano, M., Guido, S., 
Pettoello-Mantovani, M., Carnuccio, R., Scholte, B., De Matteis, A., Maiuri, M. 
C., Raia, V., Luini, A., Kroemer, G. & Maiuri, L. 2012. Targeting autophagy as a 
novel strategy for facilitating the therapeutic action of potentiators on DeltaF508 
cystic fibrosis transmembrane conductance regulator. Autophagy, 8. 
References!
!
! 227!
Luciani, A., Villella, V. R., Vasaturo, A., Giardino, I., Raia, V., Pettoello-Mantovani, M., 
D'apolito, M., Guido, S., Leal, T., Quaratino, S. & Maiuri, L. 2009a. 
SUMOylation of Tissue Transglutaminase as Link between Oxidative Stress 
and Inflammation. The Journal of Immunology, 183, 2775-2784. 
Luciani, A., Villella, V. R., Vasaturo, A., Giardino, I., Raia, V., Pettoello-Mantovani, M., 
D'apolito, M., Guido, S., Leal, T., Quaratino, S. & Maiuri, L. 2009b. 
SUMOylation of tissue transglutaminase as link between oxidative stress and 
inflammation. J Immunol, 183, 2775-84. 
Lukacs, G. L., Chang, X. B., Bear, C., Kartner, N., Mohamed, A., Riordan, J. R. & 
Grinstein, S. 1993. The delta F508 mutation decreases the stability of cystic 
fibrosis transmembrane conductance regulator in the plasma membrane. 
Determination of functional half-lives on transfected cells. J Biol Chem, 268, 
21592-8. 
Lukacs, G. L., Mohamed, A., Kartner, N., Chang, X. B., Riordan, J. R. & Grinstein, S. 
1994. Conformational maturation of CFTR but not its mutant counterpart (delta 
F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J, 13, 
6076-86. 
Lukacs, G. L. & Verkman, A. S. 2012. CFTR: folding, misfolding and correcting the 
DeltaF508 conformational defect. Trends Mol Med, 18, 81-91. 
Luo, J., Pato, M. D., Riordan, J. R. & Hanrahan, J. W. 1998. Differential regulation of 
single CFTR channels by PP2C, PP2A, and other phosphatases. Am J Physiol, 
274, C1397-410. 
Macdonald, K. D., Mckenzie, K. R. & Zeitlin, P. L. 2007. Cystic fibrosis transmembrane 
regulator protein mutations: 'class' opportunity for novel drug innovation. 
Paediatr Drugs, 9, 1-10. 
Maiuri, L., Ciacci, C., Ricciardelli, I., Vacca, L., Raia, V., Rispo, A., Griffin, M., Issekutz, 
T., Quaratino, S. & Londei, M. 2005. Unexpected role of surface 
transglutaminase type II in celiac disease. Gastroenterology, 129, 1400-13. 
Maiuri, L., Luciani, A., Giardino, I., Raia, V., Villella, V. R., D'apolito, M., Pettoello-
Mantovani, M., Guido, S., Ciacci, C., Cimmino, M., Cexus, O. N., Londei, M. & 
Quaratino, S. 2008. Tissue transglutaminase activation modulates inflammation 
in cystic fibrosis via PPARgamma down-regulation. J Immunol, 180, 7697-705. 
Mak, V., Zielenski, J., Tsui, L. C., Durie, P., Zini, A., Martin, S., Longley, T. B. & Jarvi, 
K. A. 2000. Cystic fibrosis gene mutations and infertile men with primary 
testicular failure. Hum Reprod, 15, 436-9. 
Mamuya, F. A. & Duncan, M. K. 2012. aV integrins and TGF-beta-induced EMT: a 
circle of regulation. J Cell Mol Med, 16, 445-55. 
References!
!
! 228!
Marchetti, A., Colletti, M., Cozzolino, A. M., Steindler, C., Lunadei, M., Mancone, C. & 
Tripodi, M. 2008. ERK5/MAPK is activated by TGFbeta in hepatocytes and 
required for the GSK-3beta-mediated Snail protein stabilisation. Cell Signal, 20, 
2113-8. 
Martinet, N. 2003. In Vivo Transglutaminase Type 1 Expression in Normal Lung, 
Preinvasive Bronchial Lesions, and Lung Cancer. American Journal of 
Respiratory Cell and Molecular Biology, 28, 428-435. 
Martinez, J., Chalupowicz, D. G., Roush, R. K., Sheth, A. & Barsigian, C. 1994. 
Transglutaminase-mediated processing of fibronectin by endothelial cell 
monolayers. Biochemistry, 33, 2538-45. 
Massague, J. 1996. TGFbeta signaling: receptors, transducers, and Mad proteins. Cell, 
85, 947-50. 
Massague, J., Seoane, J. & Wotton, D. 2005. Smad transcription factors. Genes Dev, 
19, 2783-810. 
Massaous, J. & Hata, A. 1997. TGF-beta signalling through the Smad pathway. Trends 
Cell Biol, 7, 187-92. 
Melino, G., Farrace, M. G., Ceru, M. P. & Piacentini, M. 1988. Correlation between 
transglutaminase activity and polyamine levels in human neuroblastoma cells. 
Effect of retinoic acid and alpha-difluoromethylornithine. Exp Cell Res, 179, 
429-45. 
Mian, S., El Alaoui, S., Lawry, J., Gentile, V., Davies, P. J. & Griffin, M. 1995. The 
importance of the GTP-binding protein tissue transglutaminase in the regulation 
of cell cycle progression. FEBS Lett, 370, 27-31. 
Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. 1994. TGF-beta induced 
transdifferentiation of mammary epithelial cells to mesenchymal cells: 
involvement of type I receptors. J Cell Biol, 127, 2021-36. 
Mirza, A., Liu, S. L., Frizell, E., Zhu, J., Maddukuri, S., Martinez, J., Davies, P., 
Schwarting, R., Norton, P. & Zern, M. A. 1997. A role for tissue 
transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-
kappaB. Am J Physiol, 272, G281-8. 
Mitchell, I., Nakielna, E., Tullis, E. & Adair, C. 2000. Cystic fibrosis. End-stage care in 
Canada. Chest, 118, 80-4. 
Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H. & Verma, I. M. 1998. Development 
of a self-inactivating lentivirus vector. J Virol, 72, 8150-7. 
Monsonego, A., Friedmann, I., Shani, Y., Eisenstein, M. & Schwartz, M. 1998. GTP-
dependent conformational changes associated with the functional switch 
between Galpha and crosslinking activities in brain-derived tissue 
transglutaminase. J Mol Biol, 282, 713-20. 
References!
!
! 229!
Moreno-Bueno, G., Cubillo, E., Sarrio, D., Peinado, H., Rodriguez-Pinilla, S. M., Villa, 
S., Bolos, V., Jorda, M., Fabra, A., Portillo, F., Palacios, J. & Cano, A. 2006. 
Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a 
distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal 
transition. Cancer Res, 66, 9543-56. 
Mu, D., Cambier, S., Fjellbirkeland, L., Baron, J. L., Munger, J. S., Kawakatsu, H., 
Sheppard, D., Broaddus, V. C. & Nishimura, S. L. 2002. The integrin 
alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent 
activation of TGF-beta1. J Cell Biol, 157, 493-507. 
Munger, J. S., Harpel, J. G., Giancotti, F. G. & Rifkin, D. B. 1998. Interactions between 
growth factors and integrins: latent forms of transforming growth factor-beta are 
ligands for the integrin alphavbeta1. Mol Biol Cell, 9, 2627-38. 
Munger, J. S., Harpel, J. G., Gleizes, P. E., Mazzieri, R., Nunes, I. & Rifkin, D. B. 1997. 
Latent transforming growth factor-beta: structural features and mechanisms of 
activation. Kidney Int, 51, 1376-82. 
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J., Dalton, S. L., Wu, J., Pittet, J. 
F., Kaminski, N., Garat, C., Matthay, M. A., Rifkin, D. B. & Sheppard, D. 1999. 
The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism 
for regulating pulmonary inflammation and fibrosis. Cell, 96, 319-28. 
Murthy, S. N., Iismaa, S., Begg, G., Freymann, D. M., Graham, R. M. & Lorand, L. 
2002. Conserved tryptophan in the core domain of transglutaminase is 
essential for catalytic activity. Proc Natl Acad Sci U S A, 99, 2738-42. 
Nadalutti, C., Viiri, K. M., Kaukinen, K., Maki, M. & Lindfors, K. 2011. Extracellular 
transglutaminase 2 has a role in cell adhesion, whereas intracellular 
transglutaminase 2 is involved in regulation of endothelial cell proliferation and 
apoptosis. Cell Prolif, 44, 49-58. 
Naldini, L., Blomer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M. & 
Trono, D. 1996. In vivo gene delivery and stable transduction of nondividing 
cells by a lentiviral vector. Science, 272, 263-7. 
Nicholas, B., Smethurst, P., Verderio, E., Jones, R. & Griffin, M. 2003. Crosslinking of 
cellular proteins by tissue transglutaminase during necrotic cell death: a 
mechanism for maintaining tissue integrity. Biochem J, 371, 413-22. 
Niger, C., Beazley, K. E. & Nurminskaya, M. 2013. Induction of chondrogenic 
differentiation in mesenchymal stem cells by TGF-beta cross-linked to collagen-
PLLA [poly(L-lactic acid)] scaffold by transglutaminase 2. Biotechnol Lett, 35, 
2193-9. 
Nunes, I., Gleizes, P. E., Metz, C. N. & Rifkin, D. B. 1997. Latent transforming growth 
factor-beta binding protein domains involved in activation and 
References!
!
! 230!
transglutaminase-dependent crosslinking of latent transforming growth factor-
beta. J Cell Biol, 136, 1151-63. 
O'sullivan, B. P. & Freedman, S. D. 2009. Cystic fibrosis. Lancet, 373, 1891-904. 
Okiyoneda, T., Barriere, H., Bagdany, M., Rabeh, W. M., Du, K., Hohfeld, J., Young, J. 
C. & Lukacs, G. L. 2010. Peripheral protein quality control removes unfolded 
CFTR from the plasma membrane. Science, 329, 805-10. 
Olsen, K. C., Epa, A. P., Kulkarni, A. A., Kottmann, R. M., Mccarthy, C. E., Johnson, G. 
V., Thatcher, T. H., Phipps, R. P. & Sime, P. J. 2013. Inhibition of 
Transglutaminase 2, a Novel Target for Pulmonary Fibrosis, by two Small 
Electrophilic Molecules. Am J Respir Cell Mol Biol. 
Olsen, K. C., Sapinoro, R. E., Kottmann, R. M., Kulkarni, A. A., Iismaa, S. E., Johnson, 
G. V., Thatcher, T. H., Phipps, R. P. & Sime, P. J. 2011. Transglutaminase 2 
and its role in pulmonary fibrosis. Am J Respir Crit Care Med, 184, 699-707. 
Osika, E., Cavaillon, J. M., Chadelat, K., Boule, M., Fitting, C., Tournier, G. & Clement, 
A. 1999. Distinct sputum cytokine profiles in cystic fibrosis and other chronic 
inflammatory airway disease. Eur Respir J, 14, 339-46. 
Ozdamar, B., Bose, R., Barrios-Rodiles, M., Wang, H. R., Zhang, Y. & Wrana, J. L. 
2005. Regulation of the polarity protein Par6 by TGFbeta receptors controls 
epithelial cell plasticity. Science, 307, 1603-9. 
Park, M. K., You, H. J., Lee, H. J., Kang, J. H., Oh, S. H., Kim, S. Y. & Lee, C. H. 2013. 
Transglutaminase-2 induces N-cadherin expression in TGF-beta1-induced 
epithelial mesenchymal transition via c-Jun-N-terminal kinase activation by 
protein phosphatase 2A down-regulation. Eur J Cancer, 49, 1692-705. 
Pasyk, S., Li, C., Ramjeesingh, M. & Bear, C. E. 2009. Direct interaction of a small-
molecule modulator with G551D-CFTR, a cystic fibrosis-causing mutation 
associated with severe disease. Biochem J, 418, 185-90. 
Pellegrin, S. & Mellor, H. 2007. Actin stress fibres. J Cell Sci, 120, 3491-9. 
Piacentini, M., Autuori, F., Dini, L., Farrace, M. G., Ghibelli, L., Piredda, L. & Fesus, L. 
1991. "Tissue" transglutaminase is specifically expressed in neonatal rat liver 
cells undergoing apoptosis upon epidermal growth factor-stimulation. Cell 
Tissue Res, 263, 227-35. 
Piacentini, M., Fesus, L., Sartori, C. & Ceru, M. P. 1988. Retinoic acid-induced 
modulation of rat liver transglutaminase and total polyamines in vivo. Biochem 
J, 253, 33-8. 
Piek, E., Moustakas, A., Kurisaki, A., Heldin, C. H. & Ten Dijke, P. 1999. TGF-(beta) 
type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal 
transdifferentiation in NMuMG breast epithelial cells. J Cell Sci, 112 ( Pt 24), 
4557-68. 
References!
!
! 231!
Pinkas, D. M., Strop, P., Brunger, A. T. & Khosla, C. 2007. Transglutaminase 2 
undergoes a large conformational change upon activation. PLoS Biol, 5, e327. 
Pittet, J. F., Griffiths, M. J., Geiser, T., Kaminski, N., Dalton, S. L., Huang, X., Brown, L. 
A., Gotwals, P. J., Koteliansky, V. E., Matthay, M. A. & Sheppard, D. 2001. 
TGF-beta is a critical mediator of acute lung injury. J Clin Invest, 107, 1537-44. 
Plenz, A., Fritz, P., Konig, G., Laschner, W. & Saal, J. G. 1996. Immunohistochemical 
detection of factor XIIIa and factor XIIIs in synovial membranes of patients with 
rheumatoid arthritis or osteoarthritis. Rheumatol Int, 16, 29-36. 
Porta, R., Esposito, C., De Santis, A., Fusco, A., Iannone, M. & Metafora, S. 1986. 
Sperm maturation in human semen: role of transglutaminase-mediated 
reactions. Biol Reprod, 35, 965-70. 
Postigo, A. A., Depp, J. L., Taylor, J. J. & Kroll, K. L. 2003. Regulation of Smad 
signaling through a differential recruitment of coactivators and corepressors by 
ZEB proteins. EMBO J, 22, 2453-62. 
Proesmans, M., Vermeulen, F. & De Boeck, K. 2008. What's new in cystic fibrosis? 
From treating symptoms to correction of the basic defect. Eur J Pediatr, 167, 
839-49. 
Pruliere-Escabasse, V., Fanen, P., Dazy, A. C., Lechapt-Zalcman, E., Rideau, D., 
Edelman, A., Escudier, E. & Coste, A. 2005. TGF-beta 1 downregulates CFTR 
expression and function in nasal polyps of non-CF patients. Am J Physiol Lung 
Cell Mol Physiol, 288, L77-83. 
Ramalho, A. S., Beck, S., Meyer, M., Penque, D., Cutting, G. R. & Amaral, M. D. 2002. 
Five percent of normal cystic fibrosis transmembrane conductance regulator 
mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J 
Respir Cell Mol Biol, 27, 619-27. 
Ramsey, B. W., Davies, J., Mcelvaney, N. G., Tullis, E., Bell, S. C., Drevinek, P., 
Griese, M., Mckone, E. F., Wainwright, C. E., Konstan, M. W., Moss, R., Ratjen, 
F., Sermet-Gaudelus, I., Rowe, S. M., Dong, Q., Rodriguez, S., Yen, K., 
Ordonez, C. & Elborn, J. S. 2011a. A CFTR potentiator in patients with cystic 
fibrosis and the G551D mutation. N Engl J Med, 365, 1663-72. 
Ramsey, B. W., Davies, J., Mcelvaney, N. G., Tullis, E., Bell, S. C., Drevinek, P., 
Griese, M., Mckone, E. F., Wainwright, C. E., Konstan, M. W., Moss, R., Ratjen, 
F., Sermet-Gaudelus, I., Rowe, S. M., Dong, Q., Rodriguez, S., Yen, K., 
Ordonez, C., Elborn, J. S. & Group, V. X. S. 2011b. A CFTR potentiator in 
patients with cystic fibrosis and the G551D mutation. N Engl J Med, 365, 1663-
72. 
Rastaldi, M. P., Ferrario, F., Giardino, L., Dell'antonio, G., Grillo, C., Grillo, P., Strutz, 
F., Muller, G. A., Colasanti, G. & D'amico, G. 2002. Epithelial-mesenchymal 
References!
!
! 232!
transition of tubular epithelial cells in human renal biopsies. Kidney Int, 62, 137-
46. 
Ratjen, F. & Doring, G. 2003. Cystic fibrosis. Lancet, 361, 681-9. 
Reddy, M. M., Light, M. J. & Quinton, P. M. 1999. Activation of the epithelial Na+ 
channel (ENaC) requires CFTR Cl- channel function. Nature, 402, 301-4. 
Ren, H. Y., Grove, D. E., De La Rosa, O., Houck, S. A., Sopha, P., Van Goor, F., 
Hoffman, B. J. & Cyr, D. M. 2013. VX-809 corrects folding defects in cystic 
fibrosis transmembrane conductance regulator protein through action on 
membrane-spanning domain 1. Mol Biol Cell, 24, 3016-24. 
Ribeiro, C. M., Paradiso, A. M., Carew, M. A., Shears, S. B. & Boucher, R. C. 2005. 
Cystic fibrosis airway epithelial Ca2+ i signaling: the mechanism for the larger 
agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia. J Biol 
Chem, 280, 10202-9. 
Richards, R. J., Masek, L. C. & Brown, R. F. 1991. Biochemical and cellular 
mechanisms of pulmonary fibrosis. Toxicol Pathol, 19, 526-39. 
Riordan, J. R., Rommens, J. M., Kerem, B., Alon, N., Rozmahel, R., Grzelczak, Z., 
Zielenski, J., Lok, S., Plavsic, N., Chou, J. L. & Et Al. 1989. Identification of the 
cystic fibrosis gene: cloning and characterization of complementary DNA. 
Science, 245, 1066-73. 
Ritter, S. J. & Davies, P. J. 1998. Identification of a transforming growth factor-
beta1/bone morphogenetic protein 4 (TGF-beta1/BMP4) response element 
within the mouse tissue transglutaminase gene promoter. J Biol Chem, 273, 
12798-806. 
Robinson, C. B. & Wu, R. 1993. Mucin synthesis and secretion by cultured tracheal 
cells: effects of collagen gel substratum thickness. In Vitro Cell Dev Biol Anim, 
29A, 469-77. 
Rosser, M. F., Grove, D. E., Chen, L. & Cyr, D. M. 2008. Assembly and misassembly 
of cystic fibrosis transmembrane conductance regulator: folding defects caused 
by deletion of F508 occur before and after the calnexin-dependent association 
of membrane spanning domain (MSD) 1 and MSD2. Mol Biol Cell, 19, 4570-9. 
Rowe, S. M. & Verkman, A. S. 2013. Cystic fibrosis transmembrane regulator 
correctors and potentiators. Cold Spring Harb Perspect Med, 3. 
Ruan, Q. & Johnson, G. V. 2007. Transglutaminase 2 in neurodegenerative disorders. 
Front Biosci, 12, 891-904. 
Ruan, Q., Tucholski, J., Gundemir, S. & Johnson Voll, G. V. 2008. The Differential 
Effects of R580A Mutation on Transamidation and GTP Binding Activity of Rat 
and Human Type 2 Transglutaminase. Int J Clin Exp Med, 1, 248-59. 
References!
!
! 233!
Rubenstein, R. C., Egan, M. E. & Zeitlin, P. L. 1997. In vitro pharmacologic restoration 
of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic 
fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest, 100, 2457-65. 
Sato, M., Muragaki, Y., Saika, S., Roberts, A. B. & Ooshima, A. 2003. Targeted 
disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial 
fibrosis induced by unilateral ureteral obstruction. J Clin Invest, 112, 1486-94. 
Schorpp, M., Jager, R., Schellander, K., Schenkel, J., Wagner, E. F., Weiher, H. & 
Angel, P. 1996. The human ubiquitin C promoter directs high ubiquitous 
expression of transgenes in mice. Nucleic Acids Res, 24, 1787-8. 
Schwiebert, E. M., Benos, D. J., Egan, M. E., Stutts, M. J. & Guggino, W. B. 1999. 
CFTR is a conductance regulator as well as a chloride channel. Physiol Rev, 
79, S145-66. 
Seissler, J., Schott, M., Boms, S., Wohlrab, U., Ostendorf, B., Morgenthaler, N. G. & 
Scherbaum, W. A. 1999. Autoantibodies to human tissue transgutaminase 
identify silent coeliac disease in Type I diabetes. Diabetologia, 42, 1440-1. 
Seitz, J., Keppler, C., Rausch, U. & Aumuller, G. 1990. Immunohistochemistry of 
secretory transglutaminase from rodent prostate. Histochemistry, 93, 525-30. 
Sermet-Gaudelus, I., Boeck, K. D., Casimir, G. J., Vermeulen, F., Leal, T., Mogenet, 
A., Roussel, D., Fritsch, J., Hanssens, L., Hirawat, S., Miller, N. L., Constantine, 
S., Reha, A., Ajayi, T., Elfring, G. L. & Miller, L. L. 2010. Ataluren (PTC124) 
induces cystic fibrosis transmembrane conductance regulator protein 
expression and activity in children with nonsense mutation cystic fibrosis. Am J 
Respir Crit Care Med, 182, 1262-72. 
Shah, M., Revis, D., Herrick, S., Baillie, R., Thorgeirson, S., Ferguson, M. & Roberts, 
A. 1999. Role of elevated plasma transforming growth factor-beta1 levels in 
wound healing. Am J Pathol, 154, 1115-24. 
Sharma, M., Pampinella, F., Nemes, C., Benharouga, M., So, J., Du, K., Bache, K. G., 
Papsin, B., Zerangue, N., Stenmark, H. & Lukacs, G. L. 2004. Misfolding diverts 
CFTR from recycling to degradation: quality control at early endosomes. J Cell 
Biol, 164, 923-33. 
Sheppard, D. 2005. Integrin-mediated activation of latent transforming growth factor 
beta. Cancer Metastasis Rev, 24, 395-402. 
Sheppard, D. 2006a. Transforming Growth Factor  : A Central Modulator of Pulmonary 
and Airway Inflammation and Fibrosis. Proceedings of the American Thoracic 
Society, 3, 413-417. 
Sheppard, D. 2006b. Transforming growth factor beta: a central modulator of 
pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc, 3, 413-
7. 
References!
!
! 234!
Shoshani, T., Augarten, A., Gazit, E., Bashan, N., Yahav, Y., Rivlin, Y., Tal, A., Seret, 
H., Yaar, L., Kerem, E. & Et Al. 1992. Association of a nonsense mutation 
(W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis 
patients in Israel, with presentation of severe disease. Am J Hum Genet, 50, 
222-8. 
Shweke, N., Boulos, N., Jouanneau, C., Vandermeersch, S., Melino, G., Dussaule, J.-
C., Chatziantoniou, C., Ronco, P. & Boffa, J.-J. 2008. Tissue Transglutaminase 
Contributes to Interstitial Renal Fibrosis by Favoring Accumulation of Fibrillar 
Collagen through TGF-β Activation and Cell Infiltration. The American Journal 
of Pathology, 173, 631-642. 
Siegel, M. & Khosla, C. 2007. Transglutaminase 2 inhibitors and their therapeutic role 
in disease states. Pharmacology & Therapeutics, 115, 232-245. 
Siegel, M., Strnad, P., Watts, R. E., Choi, K., Jabri, B., Omary, M. B. & Khosla, C. 
2008. Extracellular transglutaminase 2 is catalytically inactive, but is transiently 
activated upon tissue injury. PLoS One, 3, e1861. 
Skill, N. J., Johnson, T. S., Coutts, I. G., Saint, R. E., Fisher, M., Huang, L., El Nahas, 
A. M., Collighan, R. J. & Griffin, M. 2004. Inhibition of transglutaminase activity 
reduces extracellular matrix accumulation induced by high glucose levels in 
proximal tubular epithelial cells. J Biol Chem, 279, 47754-62. 
Small, K., Feng, J. F., Lorenz, J., Donnelly, E. T., Yu, A., Im, M. J., Dorn, G. W., 2nd & 
Liggett, S. B. 1999. Cardiac specific overexpression of transglutaminase II 
(G(h)) results in a unique hypertrophy phenotype independent of phospholipase 
C activation. J Biol Chem, 274, 21291-6. 
Smethurst, P. A. & Griffin, M. 1996. Measurement of tissue transglutaminase activity in 
a permeabilized cell system: its regulation by Ca2+ and nucleotides. Biochem J, 
313 ( Pt 3), 803-8. 
Snodgrass, S. M., Cihil, K. M., Cornuet, P. K., Myerburg, M. M. & Swiatecka-Urban, A. 
2013. Tgf-beta1 inhibits Cftr biogenesis and prevents functional rescue of 
DeltaF508-Cftr in primary differentiated human bronchial epithelial cells. PLoS 
ONE, 8, e63167. 
Sparbel, K. J. & Tluczek, A. 2011. Patient and family issues regarding genetic testing 
for cystic fibrosis: a review of prenatal carrier testing and newborn screening. 
Annu Rev Nurs Res, 29, 303-29. 
Stewart, C. E., Torr, E. E., Mohd Jamili, N. H., Bosquillon, C. & Sayers, I. 2012. 
Evaluation of differentiated human bronchial epithelial cell culture systems for 
asthma research. J Allergy (Cairo), 2012, 943982. 
References!
!
! 235!
Sturniolo, M. T., Chandraratna, R. A. & Eckert, R. L. 2005. A novel transglutaminase 
activator forms a complex with type 1 transglutaminase. Oncogene, 24, 2963-
72. 
Sun, F., Mi, Z., Condliffe, S. B., Bertrand, C. A., Gong, X., Lu, X., Zhang, R., Latoche, 
J. D., Pilewski, J. M., Robbins, P. D. & Frizzell, R. A. 2008. Chaperone 
displacement from mutant cystic fibrosis transmembrane conductance regulator 
restores its function in human airway epithelia. FASEB J, 22, 3255-63. 
Tabary, O., Boncoeur, E., De Martin, R., Pepperkok, R., Clément, A., Schultz, C. & 
Jacquot, J. 2006. Calcium-dependent regulation of NF-κB activation in cystic 
fibrosis airway epithelial cells. Cellular Signalling, 18, 652-660. 
Tanfani, F., Bertoli, E., Signorini, M. & Bergamini, C. M. 1993. Structural investigation 
of transglutaminase by Fourier transform infrared spectroscopy. Eur J Biochem, 
218, 499-505. 
Telci, D., Collighan, R. J., Basaga, H. & Griffin, M. 2009. Increased TG2 expression 
can result in induction of transforming growth factor beta1, causing increased 
synthesis and deposition of matrix proteins, which can be regulated by nitric 
oxide. J Biol Chem, 284, 29547-58. 
Telci, D. & Griffin, M. 2006. Tissue transglutaminase (TG2)--a wound response 
enzyme. Front Biosci, 11, 867-82. 
Telci, D., Wang, Z., Li, X., Verderio, E. A., Humphries, M. J., Baccarini, M., Basaga, H. 
& Griffin, M. 2008. Fibronectin-tissue transglutaminase matrix rescues RGD-
impaired cell adhesion through syndecan-4 and beta1 integrin co-signaling. J 
Biol Chem, 283, 20937-47. 
Thibaut, S., Cavusoglu, N., De Becker, E., Zerbib, F., Bednarczyk, A., Schaeffer, C., 
Van Dorsselaer, A. & Bernard, B. A. 2008. Transglutaminase-3 Enzyme: A 
Putative Actor in Human Hair Shaft Scaffolding? Journal of Investigative 
Dermatology, 129, 449-459. 
Thiery, J. P. 2002. Epithelial-mesenchymal transitions in tumour progression. Nat Rev 
Cancer, 2, 442-54. 
Thomas, P. J., Shenbagamurthi, P., Ysern, X. & Pedersen, P. L. 1991. Cystic fibrosis 
transmembrane conductance regulator: nucleotide binding to a synthetic 
peptide. Science, 251, 555-7. 
Tovar-Vidales, T., Clark, A. F. & Wordinger, R. J. 2011. Transforming growth factor-
beta2 utilizes the canonical Smad-signaling pathway to regulate tissue 
transglutaminase expression in human trabecular meshwork cells. Exp Eye 
Res, 93, 442-51. 
References!
!
! 236!
Towbin, H., Staehelin, T. & Gordon, J. 1979. Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 
Proc Natl Acad Sci U S A, 76, 4350-4. 
Travis, S. M., Berger, H. A. & Welsh, M. J. 1997. Protein phosphatase 2C 
dephosphorylates and inactivates cystic fibrosis transmembrane conductance 
regulator. Proc Natl Acad Sci U S A, 94, 11055-60. 
Trezise, A. E. & Buchwald, M. 1991. In vivo cell-specific expression of the cystic 
fibrosis transmembrane conductance regulator. Nature, 353, 434-7. 
Tsukita, S., Furuse, M. & Itoh, M. 2001. Multifunctional strands in tight junctions. Nat 
Rev Mol Cell Biol, 2, 285-93. 
Upchurch, H. F., Conway, E., Patterson, M. K., Jr. & Maxwell, M. D. 1991. Localisation 
of cellular transglutaminase on the extracellular matrix after wounding: 
characteristics of the matrix bound enzyme. J Cell Physiol, 149, 375-82. 
Uttamsingh, S., Bao, X., Nguyen, K. T., Bhanot, M., Gong, J., Chan, J. L., Liu, F., Chu, 
T. T. & Wang, L. H. 2008. Synergistic effect between EGF and TGF-beta1 in 
inducing oncogenic properties of intestinal epithelial cells. Oncogene, 27, 2626-
34. 
Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Cao, D., Neuberger, T., 
Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., Zhou, J., Mccartney, J., 
Arumugam, V., Decker, C., Yang, J., Young, C., Olson, E. R., Wine, J. J., 
Frizzell, R. A., Ashlock, M. & Negulescu, P. 2009. Rescue of CF airway 
epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad 
Sci U S A, 106, 18825-30. 
Van Goor, F., Hadida, S., Grootenhuis, P. D., Burton, B., Stack, J. H., Straley, K. S., 
Decker, C. J., Miller, M., Mccartney, J., Olson, E. R., Wine, J. J., Frizzell, R. A., 
Ashlock, M. & Negulescu, P. A. 2011. Correction of the F508del-CFTR protein 
processing defect in vitro by the investigational drug VX-809. Proc Natl Acad 
Sci U S A, 108, 18843-8. 
Van Goor, F., Straley, K. S., Cao, D., Gonzalez, J., Hadida, S., Hazlewood, A., 
Joubran, J., Knapp, T., Makings, L. R., Miller, M., Neuberger, T., Olson, E., 
Panchenko, V., Rader, J., Singh, A., Stack, J. H., Tung, R., Grootenhuis, P. D. 
& Negulescu, P. 2006. Rescue of DeltaF508-CFTR trafficking and gating in 
human cystic fibrosis airway primary cultures by small molecules. Am J Physiol 
Lung Cell Mol Physiol, 290, L1117-30. 
Vankeerberghen, A., Cuppens, H. & Cassiman, J. J. 2002. The cystic fibrosis 
transmembrane conductance regulator: an intriguing protein with pleiotropic 
functions. J Cyst Fibros, 1, 13-29. 
References!
!
! 237!
Varga, K., Jurkuvenaite, A., Wakefield, J., Hong, J. S., Guimbellot, J. S., Venglarik, C. 
J., Niraj, A., Mazur, M., Sorscher, E. J., Collawn, J. F. & Bebok, Z. 2004. 
Efficient intracellular processing of the endogenous cystic fibrosis 
transmembrane conductance regulator in epithelial cell lines. J Biol Chem, 279, 
22578-84. 
Venkatakrishnan, A., Stecenko, A. A., King, G., Blackwell, T. R., Brigham, K. L., 
Christman, J. W. & Blackwell, T. S. 2000. Exaggerated activation of nuclear 
factor-kappaB and altered IkappaB-beta processing in cystic fibrosis bronchial 
epithelial cells. Am J Respir Cell Mol Biol, 23, 396-403. 
Verderio, E., Gaudry, C., Gross, S., Smith, C., Downes, S. & Griffin, M. 1999. 
Regulation of cell surface tissue transglutaminase: effects on matrix storage of 
latent transforming growth factor-beta binding protein-1. J Histochem 
Cytochem, 47, 1417-32. 
Verderio, E., Nicholas, B., Gross, S. & Griffin, M. 1998. Regulated expression of tissue 
transglutaminase in Swiss 3T3 fibroblasts: effects on the processing of 
fibronectin, cell attachment, and cell death. Exp Cell Res, 239, 119-38. 
Verderio, E. A., Johnson, T. & Griffin, M. 2004. Tissue transglutaminase in normal and 
abnormal wound healing: review article. Amino Acids, 26, 387-404. 
Verderio, E. A., Telci, D., Okoye, A., Melino, G. & Griffin, M. 2003. A novel RGD-
independent cel adhesion pathway mediated by fibronectin-bound tissue 
transglutaminase rescues cells from anoikis. J Biol Chem, 278, 42604-14. 
Vergani, P., Basso, C., Mense, M., Nairn, A. C. & Gadsby, D. C. 2005. Control of the 
CFTR channel's gates. Biochem Soc Trans, 33, 1003-7. 
Verma, A., Guha, S., Diagaradjane, P., Kunnumakkara, A. B., Sanguino, A. M., Lopez-
Berestein, G., Sood, A. K., Aggarwal, B. B., Krishnan, S., Gelovani, J. G. & 
Mehta, K. 2008. Therapeutic significance of elevated tissue transglutaminase 
expression in pancreatic cancer. Clin Cancer Res, 14, 2476-83. 
Vij, N., Mazur, S. & Zeitlin, P. L. 2009. CFTR is a negative regulator of NFkappaB 
mediated innate immune response. PLoS ONE, 4, e4664. 
Villalta, D., Bizzaro, N., Tonutti, E. & Tozzoli, R. 2002. IgG anti-transglutaminase 
autoantibodies in systemic lupus erythematosus and Sjogren syndrome. Clin 
Chem, 48, 1133. 
Villella, V. R., Esposito, S., Maiuri, M. C., Raia, V., Kroemer, G. & Maiuri, L. 2013. 
Towards a rational combination therapy of cystic fibrosis: How cystamine 
restores the stability of mutant CFTR. Autophagy, 9, 1431-4. 
Vollberg, T. M., George, M. D., Nervi, C. & Jetten, A. M. 1992. Regulation of type I and 
type II transglutaminase in normal human bronchial epithelial and lung 
carcinoma cells. Am J Respir Cell Mol Biol, 7, 10-8. 
References!
!
! 238!
Wakshlag, J. J., Antonyak, M. A., Boehm, J. E., Boehm, K. & Cerione, R. A. 2006. 
Effects of tissue transglutaminase on beta -amyloid1-42-induced apoptosis. 
Protein J, 25, 83-94. 
Wang, Z., Collighan, R. J., Gross, S. R., Danen, E. H., Orend, G., Telci, D. & Griffin, M. 
2010. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin 
matrix promotes fibronectin fibril deposition and requires syndecan-4/2 and 
{alpha}5{beta}1 integrin co-signaling. J Biol Chem, 285, 40212-29. 
Wang, Z., Collighan, R. J., Pytel, K., Rathbone, D. L., Li, X. & Griffin, M. 2012. 
Characterization of heparin-binding site of tissue transglutaminase: its 
importance in cell surface targeting, matrix deposition, and cell signaling. J Biol 
Chem, 287, 13063-83. 
Wang, Z., Perez, M., Caja, S., Melino, G., Johnson, T. S., Lindfors, K. & Griffin, M. 
2013. A novel extracellular role for tissue transglutaminase in matrix-bound 
VEGF-mediated angiogenesis. Cell Death Dis, 4, e808. 
Wang, Z., Wade, P., Mandell, K. J., Akyildiz, A., Parkos, C. A., Mrsny, R. J. & Nusrat, 
A. 2007. Raf 1 represses expression of the tight junction protein occludin via 
activation of the zinc-finger transcription factor slug. Oncogene, 26, 1222-30. 
Ward, C. L., Omura, S. & Kopito, R. R. 1995. Degradation of CFTR by the ubiquitin-
proteasome pathway. Cell, 83, 121-7. 
Weber, A. J., Soong, G., Bryan, R., Saba, S. & Prince, A. 2001. Activation of NF-
kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- 
channel function. Am J Physiol Lung Cell Mol Physiol, 281, L71-8. 
Welsh, M. J. & Smith, A. E. 1993. Molecular mechanisms of CFTR chloride channel 
dysfunction in cystic fibrosis. Cell, 73, 1251-4. 
West, M. R. & Molloy, C. R. 1996. A microplate assay measuring chloride ion channel 
activity. Anal Biochem, 241, 51-8. 
Wheelock, M. J. & Johnson, K. R. 2003. Cadherin-mediated cellular signaling. Curr 
Opin Cell Biol, 15, 509-14. 
Willis, B. C. & Borok, Z. 2007. TGF-beta-induced EMT: mechanisms and implications 
for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol, 293, L525-34. 
Wilschanski, M., Miller, L. L., Shoseyov, D., Blau, H., Rivlin, J., Aviram, M., Cohen, M., 
Armoni, S., Yaakov, Y., Pugatsch, T., Cohen-Cymberknoh, M., Miller, N. L., 
Reha, A., Northcutt, V. J., Hirawat, S., Donnelly, K., Elfring, G. L., Ajayi, T. & 
Kerem, E. 2011. Chronic ataluren (PTC124) treatment of nonsense mutation 
cystic fibrosis. Eur Respir J, 38, 59-69. 
Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J., Aviram, M., 
Bdolah-Abram, T., Bebok, Z., Shushi, L., Kerem, B. & Kerem, E. 2003. 
References!
!
! 239!
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis 
and CFTR stop mutations. N Engl J Med, 349, 1433-41. 
Winter, M. C. & Welsh, M. J. 1997. Stimulation of CFTR activity by its phosphorylated 
R domain. Nature, 389, 294-6. 
Wu, R., Martin, W. R., Robinson, C. B., St George, J. A., Plopper, C. G., Kurland, G., 
Last, J. A., Cross, C. E., Mcdonald, R. J. & Boucher, R. 1990. Expression of 
mucin synthesis and secretion in human tracheobronchial epithelial cells grown 
in culture. Am J Respir Cell Mol Biol, 3, 467-78. 
Wu, R., Yankaskas, J., Cheng, E., Knowles, M. R. & Boucher, R. 1985. Growth and 
differentiation of human nasal epithelial cells in culture. Serum-free, hormone-
supplemented medium and proteoglycan synthesis. Am Rev Respir Dis, 132, 
311-20. 
Xu, J., Lamouille, S. & Derynck, R. 2009. TGF-beta-induced epithelial to mesenchymal 
transition. Cell Res, 19, 156-72. 
Yamaya, M., Finkbeiner, W. E., Chun, S. Y. & Widdicombe, J. H. 1992. Differentiated 
structure and function of cultures from human tracheal epithelium. Am J 
Physiol, 262, L713-24. 
Yanagisawa, K., Osada, H., Masuda, A., Kondo, M., Saito, T., Yatabe, Y., Takagi, K. & 
Takahashi, T. 1998. Induction of apoptosis by Smad3 and down-regulation of 
Smad3 expression in response to TGF-beta in human normal lung epithelial 
cells. Oncogene, 17, 1743-7. 
Yang, J., Mani, S. A., Donaher, J. L., Ramaswamy, S., Itzykson, R. A., Come, C., 
Savagner, P., Gitelman, I., Richardson, A. & Weinberg, R. A. 2004. Twist, a 
master regulator of morphogenesis, plays an essential role in tumor metastasis. 
Cell, 117, 927-39. 
Yankaskas, J. R., Cotton, C. U., Knowles, M. R., Gatzy, J. T. & Boucher, R. C. 1985. 
Culture of human nasal epithelial cells on collagen matrix supports. A 
comparison of bioelectric properties of normal and cystic fibrosis epithelia. Am 
Rev Respir Dis, 132, 1281-7. 
Yi, J. Y., Shin, I. & Arteaga, C. L. 2005. Type I transforming growth factor beta receptor 
binds to and activates phosphatidylinositol 3-kinase. J Biol Chem, 280, 10870-
6. 
Yu, H., Burton, B., Huang, C. J., Worley, J., Cao, D., Johnson, J. P., Jr., Urrutia, A., 
Joubran, J., Seepersaud, S., Sussky, K., Hoffman, B. J. & Van Goor, F. 2012. 
Ivacaftor potentiation of multiple CFTR channels with gating mutations. J Cyst 
Fibros, 11, 237-45. 
Zavadil, J. & Bottinger, E. P. 2005. TGF-beta and epithelial-to-mesenchymal 
transitions. Oncogene, 24, 5764-74. 
References!
!
! 240!
Zennou, V., Petit, C., Guetard, D., Nerhbass, U., Montagnier, L. & Charneau, P. 2000. 
HIV-1 genome nuclear import is mediated by a central DNA flap. Cell, 101, 173-
85. 
Zhang, M., Zhang, Z., Pan, H. Y., Wang, D. X., Deng, Z. T. & Ye, X. L. 2009. TGF-
beta1 induces human bronchial epithelial cell-to-mesenchymal transition in 
vitro. Lung, 187, 187-94. 
Zhang, Y., Feng, X., We, R. & Derynck, R. 1996. Receptor-associated Mad 
homologues synergize as effectors of the TGF-beta response. Nature, 383, 
168-72. 
Zielenski, J. 2000. Genotype and phenotype in cystic fibrosis. Respiration, 67, 117-33. 
Zufferey, R., Donello, J. E., Trono, D. & Hope, T. J. 1999. Woodchuck hepatitis virus 
posttranscriptional regulatory element enhances expression of transgenes 
delivered by retroviral vectors. J Virol, 73, 2886-92. 
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L. & Trono, D. 
1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene 
delivery. J Virol, 72, 9873-80. 
 
 
